0001564590-22-008049.txt : 20220301 0001564590-22-008049.hdr.sgml : 20220301 20220301161940 ACCESSION NUMBER: 0001564590-22-008049 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 78 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220301 DATE AS OF CHANGE: 20220301 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Avidity Biosciences, Inc. CENTRAL INDEX KEY: 0001599901 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 461336960 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39321 FILM NUMBER: 22698326 BUSINESS ADDRESS: STREET 1: 10578 SCIENCE CENTER DRIVE STREET 2: SUITE 125 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-401-7900 MAIL ADDRESS: STREET 1: 10578 SCIENCE CENTER DRIVE STREET 2: SUITE 125 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: Avidity Biosciences LLC DATE OF NAME CHANGE: 20161227 FORMER COMPANY: FORMER CONFORMED NAME: Avidity NanoMedicines LLC DATE OF NAME CHANGE: 20140211 10-K 1 rna-10k_20211231.htm 10-K rna-10k_20211231.htm
false 2021 FY --12-31 0001599901 1 true true true true true 1 P5Y P5Y P4Y 0 0 http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember P8Y6M P8Y6M P7Y9M18D 0.005 0.003 0.014 0.86 0.88 0.84 P5Y6M P5Y4M24D P2Y 0.013 0.015 0.027 0.88 0.92 0.88 P6Y1M6D P6Y1M6D P6Y1M6D 0.001 0.69 0.75 P6M P6M 0.002 0.75 0.96 0001599901 2021-01-01 2021-12-31 xbrli:shares 0001599901 2022-02-07 iso4217:USD 0001599901 2021-06-30 0001599901 2021-12-31 0001599901 2020-12-31 iso4217:USD xbrli:shares 0001599901 2020-01-01 2020-12-31 0001599901 2019-01-01 2019-12-31 0001599901 rna:PreferredUnitsMember 2018-12-31 0001599901 rna:CommonUnitsMember 2018-12-31 0001599901 rna:PredecessorsDeficitMember 2018-12-31 0001599901 2018-12-31 0001599901 rna:PreferredUnitsMember 2019-01-01 2019-12-31 0001599901 rna:CommonUnitsMember 2019-01-01 2019-12-31 0001599901 rna:PredecessorsDeficitMember 2019-01-01 2019-12-31 0001599901 us-gaap:ConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001599901 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001599901 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001599901 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001599901 us-gaap:ConvertiblePreferredStockMember 2019-12-31 0001599901 us-gaap:CommonStockMember 2019-12-31 0001599901 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001599901 us-gaap:RetainedEarningsMember 2019-12-31 0001599901 2019-12-31 0001599901 us-gaap:ConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001599901 us-gaap:CommonStockMember us-gaap:IPOMember 2020-01-01 2020-12-31 0001599901 us-gaap:AdditionalPaidInCapitalMember us-gaap:IPOMember 2020-01-01 2020-12-31 0001599901 us-gaap:IPOMember 2020-01-01 2020-12-31 0001599901 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001599901 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001599901 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001599901 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001599901 us-gaap:CommonStockMember 2020-12-31 0001599901 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001599901 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001599901 us-gaap:RetainedEarningsMember 2020-12-31 0001599901 us-gaap:CommonStockMember us-gaap:IPOMember 2021-01-01 2021-12-31 0001599901 us-gaap:AdditionalPaidInCapitalMember us-gaap:IPOMember 2021-01-01 2021-12-31 0001599901 us-gaap:IPOMember 2021-01-01 2021-12-31 0001599901 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001599901 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001599901 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001599901 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001599901 us-gaap:CommonStockMember 2021-12-31 0001599901 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001599901 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001599901 us-gaap:RetainedEarningsMember 2021-12-31 0001599901 us-gaap:CommonStockMember 2019-04-01 2019-04-01 0001599901 rna:SeriesAConvertiblePreferredStockMember 2019-04-01 2019-04-01 0001599901 rna:SeriesBConvertiblePreferredStockMember 2019-04-01 2019-04-01 0001599901 us-gaap:IPOMember 2020-06-16 2020-06-16 0001599901 us-gaap:IPOMember 2020-06-16 0001599901 us-gaap:CommonStockMember us-gaap:IPOMember 2020-06-16 0001599901 rna:UndesignatedPreferredStockMember us-gaap:IPOMember 2020-06-16 xbrli:pure 0001599901 2020-06-04 2020-06-04 0001599901 rna:FollowOnPublicOfferingMember us-gaap:CommonStockMember 2021-08-06 2021-08-06 0001599901 rna:FollowOnPublicOfferingMember us-gaap:CommonStockMember 2021-08-06 0001599901 2021-07-02 2021-07-02 0001599901 srt:MinimumMember 2021-01-01 2021-12-31 0001599901 srt:MaximumMember 2021-01-01 2021-12-31 rna:Segment 0001599901 us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001599901 us-gaap:WarrantMember us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001599901 us-gaap:WarrantMember us-gaap:ConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001599901 us-gaap:WarrantMember us-gaap:ConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001599901 us-gaap:WarrantMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001599901 us-gaap:WarrantMember us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001599901 us-gaap:WarrantMember us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001599901 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001599901 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001599901 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001599901 rna:CommonStockSubjectToRepurchaseOrForfeitureMember 2021-01-01 2021-12-31 0001599901 rna:CommonStockSubjectToRepurchaseOrForfeitureMember 2020-01-01 2020-12-31 0001599901 rna:CommonStockSubjectToRepurchaseOrForfeitureMember 2019-01-01 2019-12-31 0001599901 rna:EmployeeStockPurchasePlanSharesPendingIssuanceMember 2021-01-01 2021-12-31 0001599901 rna:EmployeeStockPurchasePlanSharesPendingIssuanceMember 2020-01-01 2020-12-31 0001599901 rna:EmployeeStockPurchasePlanSharesPendingIssuanceMember 2019-01-01 2019-12-31 0001599901 us-gaap:AccountingStandardsUpdate202006Member 2021-12-31 0001599901 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:FairValueInputsLevel1Member us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:FairValueInputsLevel3Member us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001599901 us-gaap:FairValueInputsLevel1Member us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001599901 us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001599901 us-gaap:FairValueInputsLevel3Member us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001599901 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001599901 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001599901 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001599901 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001599901 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001599901 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001599901 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001599901 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001599901 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001599901 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-01-01 2019-12-31 0001599901 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001599901 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-01-01 2020-12-31 0001599901 rna:USTreasurySecuritiesOneYearOrLessMaturityMember 2021-12-31 0001599901 rna:NegotiableCertificatesOfDepositOneYearOrLessMaturityMember 2021-12-31 0001599901 rna:USTreasurySecuritiesWithOneToTwoYearsMaturityMember 2021-12-31 0001599901 rna:NegotiableCertificatesOfDepositWithOneToTwoYearsMaturityMember 2021-12-31 0001599901 rna:CorporateDebtSecuritiesWithOneToTwoYearsMaturityMember 2021-12-31 0001599901 rna:CorporateDebtSecuritiesOneYearOrLessMaturityMember 2020-12-31 0001599901 rna:CorporateDebtSecuritiesWithOneToTwoYearsMaturityMember 2020-12-31 rna:Product 0001599901 rna:ResearchCollaborationAndLicenseAgreementWithEliLillyAndCompanyMember srt:MaximumMember 2019-04-01 2019-04-30 0001599901 rna:ResearchCollaborationAndLicenseAgreementWithEliLillyAndCompanyMember 2019-04-01 2019-04-30 rna:Obligation 0001599901 rna:ResearchCollaborationAndLicenseAgreementWithEliLillyAndCompanyMember 2021-01-01 2021-12-31 0001599901 rna:ResearchCollaborationAndLicenseAgreementWithEliLillyAndCompanyMember 2020-01-01 2020-12-31 0001599901 rna:ResearchCollaborationAndLicenseAgreementWithEliLillyAndCompanyMember 2019-01-01 2019-12-31 0001599901 rna:ResearchCollaborationAndLicenseAgreementWithEliLillyAndCompanyMember 2021-12-31 0001599901 rna:ResearchCollaborationAndLicenseAgreementWithEliLillyAndCompanyMember 2020-12-31 0001599901 rna:ResearchCollaborationAndLicenseAgreementWithEliLillyAndCompanyMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2021-12-31 0001599901 rna:ResearchCollaborationAndLicenseAgreementWithEliLillyAndCompanyMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2020-12-31 0001599901 rna:ResearchCollaborationAndLicenseAgreementWithEliLillyAndCompanyMember 2019-12-31 0001599901 rna:LillyConvertiblePromissoryNotesMember rna:SeriesCConvertiblePreferredStockMember 2019-11-01 2019-11-30 0001599901 rna:ResearchCollaborationWithMyoKardiaIncMember 2021-01-01 2021-12-31 0001599901 rna:ResearchCollaborationWithMyoKardiaIncMember 2020-01-01 2020-12-31 0001599901 rna:LaboratoryEquipmentMember 2021-12-31 0001599901 rna:LaboratoryEquipmentMember 2020-12-31 0001599901 us-gaap:ComputerEquipmentMember 2021-12-31 0001599901 us-gaap:ComputerEquipmentMember 2020-12-31 0001599901 rna:OfficeFurnitureAndEquipmentMember 2021-12-31 0001599901 rna:OfficeFurnitureAndEquipmentMember 2020-12-31 0001599901 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001599901 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001599901 rna:SiliconValleyBankMember rna:LoanAndSecurityAgreementAmendmentMember 2017-06-30 0001599901 rna:SiliconValleyBankMember rna:TermCLoanMember rna:LoanAndSecurityAgreementAmendmentMember 2017-06-30 0001599901 rna:SiliconValleyBankMember rna:TermDLoanMember rna:LoanAndSecurityAgreementAmendmentMember 2017-06-30 0001599901 rna:SiliconValleyBankMember 2017-06-01 2017-06-30 0001599901 rna:SiliconValleyBankMember rna:LoanAndSecurityAgreementAmendmentMember rna:TermCLoanMember 2017-06-01 2017-06-30 0001599901 rna:SiliconValleyBankMember rna:LoanAndSecurityAgreementAmendmentMember rna:TermCLoanMember 2021-01-01 2021-12-31 rna:Installment 0001599901 rna:SiliconValleyBankMember rna:LoanAndSecurityAgreementAmendmentMember rna:TermCLoanMember 2019-07-01 2019-07-01 0001599901 rna:SiliconValleyBankMember rna:LoanAndSecurityAgreementSecondAmendmentMember rna:TermDLoanMember 2018-08-01 2018-08-31 0001599901 rna:SiliconValleyBankMember us-gaap:ConvertibleNotesPayableMember 2018-08-01 2018-08-31 0001599901 rna:SiliconValleyBankMember rna:AmendedAndRestatedLoanAndSecurityAgreementMember rna:TermCAndDLoansMember 2020-06-01 2020-06-30 0001599901 rna:SiliconValleyBankMember rna:TermAAndTermBLoansMember rna:SeriesAConvertiblePreferredStockMember srt:MaximumMember 2020-06-30 0001599901 rna:SiliconValleyBankMember rna:TermAAndTermBLoansMember rna:SeriesAConvertiblePreferredStockMember 2020-06-30 0001599901 rna:SiliconValleyBankMember rna:TermAAndTermBLoansMember rna:SeriesAConvertiblePreferredStockMember 2020-06-01 2020-06-30 0001599901 us-gaap:CommonStockMember 2020-06-30 0001599901 rna:SiliconValleyBankMember rna:TermCLoanMember us-gaap:CommonStockMember srt:MaximumMember 2020-06-30 0001599901 rna:SiliconValleyBankMember rna:TermCLoanMember us-gaap:CommonStockMember 2020-06-30 0001599901 rna:SiliconValleyBankMember rna:TermCLoanMember us-gaap:CommonStockMember 2020-06-01 2020-06-30 0001599901 us-gaap:CommonStockMember 2020-06-17 2020-06-17 0001599901 rna:TwoThousandAndEighteenConvertiblePromissoryNotesMember 2018-12-31 0001599901 rna:TwoThousandAndNineteenConvertiblePromissoryNotesMember 2019-12-31 0001599901 rna:TwoThousandAndEighteenConvertiblePromissoryNotesMember 2018-01-01 2018-12-31 0001599901 rna:TwoThousandAndNineteenConvertiblePromissoryNotesMember 2019-01-01 2019-12-31 0001599901 rna:LillyConvertiblePromissoryNotesMember 2019-04-01 2019-04-30 0001599901 us-gaap:ConvertibleNotesPayableMember rna:SeriesCConvertiblePreferredStockMember 2019-11-01 2019-11-30 0001599901 us-gaap:ConvertibleNotesPayableMember rna:SeriesCConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001599901 rna:LeaseTermThroughNovemberTwoThousandAndSeventeenMember rna:OfficeAndLaboratorySpaceMember 2021-01-01 2021-12-31 0001599901 rna:LeaseTermThroughDecemberTwoThousandAndTwentyOneMember rna:OfficeAndLaboratorySpaceMember 2021-01-01 2021-12-31 0001599901 rna:NewLeaseMember rna:OfficeAndLaboratorySpaceMember 2021-01-01 2021-12-31 0001599901 rna:OfficeAndLaboratorySpaceMember rna:NewLeaseMember 2020-12-18 2020-12-18 0001599901 rna:OfficeAndLaboratorySpaceMember rna:NewLeaseMember 2020-12-18 0001599901 rna:OfficeAndLaboratorySpaceMember rna:TemporaryLeaseMember 2020-12-18 2020-12-18 0001599901 2020-06-16 0001599901 2019-04-01 0001599901 rna:SeriesCConvertiblePreferredStockMember 2019-11-30 0001599901 rna:SeriesCConvertiblePreferredStockMember 2020-01-31 0001599901 rna:SeriesCConvertiblePreferredStockMember 2019-11-01 2019-11-30 0001599901 rna:SeriesCConvertiblePreferredStockMember 2020-01-01 2020-01-31 0001599901 us-gaap:IPOMember us-gaap:CommonStockMember 2020-06-01 2020-06-30 0001599901 rna:TwoThousandThirteenEquityIncentivePlanMember 2013-01-31 0001599901 rna:TwoThousandTwentyIncentiveAwardPlanMember 2020-06-30 0001599901 rna:TwoThousandTwentyIncentiveAwardPlanMember 2021-01-01 2021-12-31 0001599901 rna:TwoThousandThirteenEquityIncentivePlanMember srt:MaximumMember 2021-01-01 2021-12-31 0001599901 rna:TwoThousandTwentyIncentiveAwardPlanMember srt:MaximumMember 2021-01-01 2021-12-31 0001599901 rna:EmployeeStockPurchasePlanMember 2020-06-30 0001599901 rna:EmployeeStockPurchasePlanMember 2020-06-01 2020-06-30 0001599901 rna:EmployeeStockPurchasePlanMember 2021-12-31 0001599901 rna:EmployeeStockPurchasePlanMember 2021-01-01 2021-12-31 0001599901 rna:EmployeeStockPurchasePlanMember 2020-01-01 2020-12-31 0001599901 rna:EmployeeStockPurchasePlanMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2021-12-31 0001599901 srt:MinimumMember 2020-01-01 2020-12-31 0001599901 srt:MinimumMember 2019-01-01 2019-12-31 0001599901 srt:MaximumMember 2020-01-01 2020-12-31 0001599901 srt:MaximumMember 2019-01-01 2019-12-31 0001599901 rna:EmployeeStockPurchasePlanMember srt:MinimumMember 2021-01-01 2021-12-31 0001599901 rna:EmployeeStockPurchasePlanMember srt:MinimumMember 2020-01-01 2020-12-31 0001599901 rna:EmployeeStockPurchasePlanMember srt:MaximumMember 2021-01-01 2021-12-31 0001599901 rna:EmployeeStockPurchasePlanMember srt:MaximumMember 2020-01-01 2020-12-31 0001599901 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001599901 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001599901 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001599901 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001599901 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001599901 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001599901 rna:TimeBasedOptionsMember 2021-12-31 0001599901 rna:TimeBasedOptionsMember 2021-01-01 2021-12-31 0001599901 rna:CommonStockOptionIssuedAndOutstandingMember 2021-12-31 0001599901 rna:CommonStockOptionIssuedAndOutstandingMember 2020-12-31 0001599901 rna:EquityAwardsAvailableForFutureIssuanceUnderEquityPlansMember 2021-12-31 0001599901 rna:EquityAwardsAvailableForFutureIssuanceUnderEquityPlansMember 2020-12-31 0001599901 rna:CommonStockAuthorizedUnderESPPMember 2021-12-31 0001599901 rna:CommonStockAuthorizedUnderESPPMember 2020-12-31 0001599901 us-gaap:DomesticCountryMember 2021-12-31 0001599901 us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0001599901 us-gaap:DomesticCountryMember 2021-01-01 2021-12-31 0001599901 us-gaap:StateAndLocalJurisdictionMember 2021-01-01 2021-12-31 0001599901 us-gaap:DomesticCountryMember rna:OrphanDrugTaxCreditsMember 2021-12-31 0001599901 us-gaap:DomesticCountryMember rna:OrphanDrugTaxCreditsMember 2021-01-01 2021-12-31 0001599901 us-gaap:CommonStockMember us-gaap:SubsequentEventMember rna:SalesAgreementMember 2022-01-01 2022-03-01

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 10-K

 

 

(Mark One)

☒

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021

OR

 

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM                      TO                     

Commission file number: 001-39321

 

 

AVIDITY BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

46-1336960

(State or Other Jurisdiction of

Incorporation or Organization)

 

(I.R.S. Employer

Identification No.)

 

 

10578 Science Center Drive, Suite 125

San Diego, CA

 

92121

(Address of Principal Executive Offices)

 

(Zip Code)

(858) 401-7900

(Registrant’s Telephone Number, Including Area Code)

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

RNA

 

The Nasdaq Global Market

 

Securities registered pursuant to Section 12(g) of the Act: None

 

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ☒    No  ☐

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934.    Yes  ☐    No  ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer  ☒

 

Accelerated filer  ☐

 

 

 

Non-accelerated filer  ☐

 

Smaller reporting company  ☐

 

 

 

Emerging growth company  ☐

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes  ☐    No  ☒

As of June 30, 2021, the aggregate market value of the registrant’s common stock held by non-affiliates of the registrant was approximately $798.1 million, based on the closing price of the registrant’s common stock on the Nasdaq Global Market of $24.71 per share.

As of February 7, 2022, the registrant had 47,754,677 shares of common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

 

Certain sections of the registrant’s definitive proxy statement for the 2022 annual meeting of stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Form 10-K are incorporated by reference into Part III of this Form 10-K. 

 

 

 

 

AVIDITY BIOSCIENCES, INC.

TABLE OF CONTENTS

FORM 10-K

For the Year Ended December 31, 2021

INDEX

 

PART I

  

 

  

 

 

 

Item 1.

  

Business

  

 

 

1

Item 1A.

  

Risk Factors

  

 

 

32

Item 1B.

  

Unresolved Staff Comments

  

 

 

88

Item 2.

  

Properties

  

 

 

88

Item 3.

  

Legal Proceedings

  

 

 

89

Item 4.

  

Mine Safety Disclosures

  

 

 

89

 

 

 

PART II

  

 

  

 

 

 

Item 5.

  

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

  

 

 

90

Item 6.

  

[Reserved]

  

 

 

92

Item 7.

  

Management’s Discussion and Analysis of Financial Condition and Results of Operations

  

 

 

93

Item 7A.

  

Quantitative and Qualitative Disclosures About Market Risk

  

 

 

105

Item 8.

  

Financial Statements and Supplementary Data

  

 

 

105

Item 9.

  

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

  

 

 

105

Item 9A.

  

Controls and Procedures

  

 

 

105

Item 9B.

  

Other Information

  

 

 

109

Item 9C.

 

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

 

 

 

109

 

 

 

PART III

  

 

  

 

 

 

Item 10.

  

Directors, Executive Officers and Corporate Governance

 

 

 

110

Item 11.

  

Executive Compensation

  

 

 

110

Item 12.

  

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

  

 

 

110

Item 13.

  

Certain Relationships and Related Transactions, and Director Independence

  

 

 

110

Item 14.

  

Principal Accounting Fees and Services

  

 

 

110

 

 

 

PART IV

  

 

  

 

 

 

Item 15.

  

Exhibits, Financial Statement Schedules

  

 

 

111

Item 16.

 

Form 10-K Summary

 

 

 

111

 

 

 

 

 

PART I

Forward-Looking Statements and Market Data

This annual report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this annual report, including statements regarding our future results of operations and financial position, business strategies and plans, research and development plans, the anticipated timing, costs, design and conduct of our ongoing and planned preclinical studies and clinical trials for our product candidates, the timing and likelihood of regulatory filings and approvals for our product candidates, the impact of COVID-19 on our business, the timing and likelihood of success, plans and objectives of management for future operations and future results of anticipated product development efforts, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. This annual report on Form 10-K also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this annual report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this annual report and are subject to a number of risks, uncertainties and assumptions, including those described in Part I, Item 1A, “Risk Factors.” The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

This annual report includes trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, trademarks and tradenames referred to in this annual report appear without the ® and ™ symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and tradenames.

We maintain a website at www.aviditybiosciences.com, to which we regularly post copies of our press releases as well as additional information about us. Our filings with the Securities and Exchange Commission, or SEC, are available free of charge through our website as soon as reasonably practicable after being electronically filed with or furnished to the SEC. Information contained in our website does not constitute a part of this report or our other filings with the SEC.

ITEM 1.  Business

   

Avidity Biosciences (also referred to as Avidity, we, our or us) is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Our proprietary AOC platform is designed to combine the specificity of monoclonal antibodies, or mAbs, with the precision of RNA therapeutics to target the root cause of diseases previously untreatable

1

 

with such therapeutics. We are initially focused on muscle diseases to demonstrate the capabilities of our AOCs, and we expect to have three muscle programs in clinical development by the end of 2022. Our lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, or DM1, a rare monogenic muscle disease. In October 2021, we dosed the first patient in our Phase 1/2 MARINA clinical trial, a trial designed to evaluate the safety and tolerability of single and multiple ascending doses of AOC 1001 administered intravenously in adults with DM1. In the fourth quarter of 2022, we plan to conduct a preliminary assessment of safety, tolerability and key biomarkers in approximately half of the trial participants. The U.S. Food and Drug Administration, or FDA, and European Medicines Agency, or EMA, have granted Orphan Designation for AOC 1001. The FDA has also granted Fast Track Designation to AOC 1001 for the treatment of DM1.  

Our advancing and expanding pipeline also includes AOC 1044, the lead of three programs for the treatment of Duchenne Muscular Dystrophy, or DMD, and AOC 1020, designed to treat facioscapulohumeral muscular dystrophy, or FSHD. We anticipate that both AOC 1044 and AOC 1020 will enter the clinic by the end of 2022 following additional preparatory preclinical studies and regulatory clearance. In addition to our muscle franchise, we are also broadening the development of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships that are focused on immune cells, cardiac tissue and other cell types.

Our Strategy

 

Our vision is to profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics. We are executing on that vision by focusing on our three strategic pillars: a disruptive and broad AOC platform, an advancing and expanding pipeline and building an agile and diverse company. With this strategy, our goal is to discover, develop and commercialize novel AOC therapeutics that overcome current barriers to the delivery of oligonucleotides and unlock their potential to treat a wide range of serious diseases currently lacking adequate treatment options. The key elements of our strategy to achieve this goal are to:

 

 

•

Harness the power of our AOC platform to develop a new class of drugs. We are committed to delivering a new class of RNA therapeutics by utilizing decades of research on the power of oligonucleotides. Our deep experience with oligonucleotide therapeutics, modulation of RNA processes, antibody engineering and conjugation, and drug delivery techniques provide the foundation for our efforts to address the current limitations of oligonucleotide therapies. Our disruptive and broad AOC platform also affords us the option to deploy various types of oligonucleotides, including small interfering RNAs, or siRNAs, and phosphorodiamidate morpholino oligomers, or PMOs, whose specific mechanisms of action modify RNA function in different ways. This flexibility allows us to use oligonucleotides that are tailored to have the potential to modulate a given disease process. Potential mechanisms of action for these oligonucleotides can range from reducing the expression of disease-related RNA with siRNAs, to correction of aberrant processing of RNAs with splice modifying oligonucleotides. AOCs are designed to do the following:

 

o

Combine the proven technologies of approved mAbs and oligonucleotides

 

o

Deliver to tissues previously untreatable with RNA therapeutics, starting with muscle and broadening to other tissues and cell types

 

o

Scale with experienced manufacturers who are able to utilize well-established and scalable methods for manufacturing mAbs and oligonucleotides. We also have the ability to use a single mAb across multiple programs, providing significant leverage around development costs and timelines associated with each incremental muscle program.

 

 

•

Continue Advancing and Expanding Our Pipeline. We are advancing and expanding our innovative AOC pipeline to offer treatment options for people across a wide-range of therapeutic areas. Our first AOC programs are from our muscle disease franchise. We are also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships. We are progressing our pipeline in the following ways:

2

 

 

o

Advancing our lead product candidate, AOC 1001, through clinical trials to approval. AOC 1001 is designed to address the root cause of DM1 by reducing levels of a disease-related mRNA called dystrophy myotonic protein kinase, or DMPK. AOC 1001 consists of a proprietary mAb that binds to the transferrin receptor 1, or TfR1, receptor conjugated with a siRNA targeting DMPK mRNA. In October 2021, we dosed the first patient in our ongoing Phase 1/2 MARINA trial of AOC 1001 in adults with DM1. The FDA and EMA have granted Orphan Designation for AOC 1001 and the FDA has granted AOC 1001 Fast Track Designation for the treatment of DM1.

 

o

Progressing our FSHD and DMD programs into clinical development. We expect to initiate clinical trials for AOC 1044, targeting Exon 44 and the first of three DMD programs, and AOC 1020, our FSHD program, by the end of 2022 following additional preparatory preclinical studies and regulatory clearance. There are no therapies approved for mutations amenable to skipping Exon 44 and no therapies approved to treat FSHD.

 

o

Expanding our pipeline within and beyond muscle. Our expanding pipeline also includes two additional programs in DMD targeting Exons 51 and 45, as well as programs in muscle atrophy and Pompe disease. We continue to pursue additional programs that expand our AOC pipeline beyond muscle and into other indications including immune cells, cardiomyocytes and other cell types. Through internal discovery efforts and partnerships, our goal is to discover, develop and commercialize novel AOC therapeutics that overcome current barriers to the delivery of oligonucleotides and unlock their potential to treat a wide range of serious diseases currently lacking adequate treatment options.

 

 

 

•

Build an agile and diverse company. We have assembled a management team with deep experience in the discovery, development and commercialization of RNA therapeutics. The team also has extensive knowledge of oligonucleotide therapeutics, modulation of RNA processes, antibody engineering and conjugation, and drug delivery techniques. Our team also has broad experience in the discovery, development and commercialization of products for rare diseases, including building clinical and commercial organizations that support the unique needs of the rare disease community.

As we grow the company, we plan to continue to employ a disciplined strategy to maximize the value of our pipeline by retaining development and commercialization rights to those product candidates, indications and geographies that we believe we can ultimately commercialize successfully on our own if they are approved. We plan to collaborate on product candidates that we believe have promising utility in disease areas or patient populations that are better served by the resources or specific expertise of other biopharmaceutical companies. For example, we are collaborating with Eli Lilly and Company, or Lilly, initially on up to six mRNA targets in immunology and other select indications outside of muscle for the delivery, development and commercialization of AOCs. We entered into a collaboration with MyoKardia that will help us expand our therapeutic activities to include cardiac-specific indications. Through additional collaborations and our internal research, we plan to continue to invest our resources in our AOC platform to explore the full potential of our AOCs in additional previously inaccessible tissue and cell types.

Our AOC Product Platform

 

Overview

 

We are committed to delivering a new class of RNA therapeutics called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. We utilize our proprietary AOC platform to design, engineer and develop therapeutics that combine specificity of mAbs with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with such therapeutics. All of our oligonucleotides target disease-related RNA. RNA is a polymeric molecule essential in the coding, decoding, regulation and expression of genes. We have accumulated deep experience regarding oligonucleotide therapeutics, modulation of RNA processes, antibody engineering and conjugation, and drug delivery techniques. We collectively refer to the know-how

3

 

and proprietary technology born out of this experience, and their systematic application in the design and development of our product candidates, as our AOC platform.

 

Our Approach

 

Based on the data-driven hypothesis that the delivery of oligonucleotides can be greatly enhanced by using antibodies as conjugates, our scientists have established a framework for screening potential cell surface protein-mAb pairs to determine which pairs we believe are well suited to deliver active oligonucleotides to specific cell types. We have identified multiple cell surface protein-mAb pairs that can deliver oligonucleotides into various tissue and cell types to induce pharmacologic changes. For example, we have employed AOCs built on a scaffold of a mAb or mAb fragment that binds with high selectivity and affinity to TfR1 to deliver oligonucleotides to cell types outside of the liver, in particular to muscle.

Our AOC platform also affords us the option to deploy various types of oligonucleotides, including siRNAs and PMOs, whose specific mechanisms of action modify RNA function in different ways. This flexibility allows us to use oligonucleotides that are tailored to modulate a given disease process. Mechanisms of these oligonucleotides can range from reducing the expression of a disease-related RNA with siRNAs, to correction of aberrant processing of RNAs with splice modifying oligonucleotides.

In preclinical studies, our AOCs have demonstrated pharmacologic responses as measured by mRNA reduction in liver, skeletal muscle, cardiac muscle, activated B- and T-cells and lymphocyte subsets, as well as macrophages.

Our AOC Platform Proprietary Chemistry

 

Successfully engineering an active AOC requires a sophisticated understanding of the precise characteristics of each of the components of the AOC, as well as their behavior when acting in concert. We have deployed significant know-how towards optimizing our AOCs, beginning with their individual oligonucleotide and mAb components.

 

Optimization of the oligonucleotide. We have engineered our oligonucleotides to maximize their stability, potency and specificity. For many of our applications, the oligonucleotide we employ is a double-stranded siRNA, comprised of a passenger and guide strand. Modifications to the passenger strand are designed to reduce loading into the RNA Induced Silencing Complex, or RISC, decreasing inadvertent RNA interference activity from the passenger strand. In comparison, modifications to the guide strand, also known as the active strand, are designed to enhance RISC loading, increasing the potential for matching sequences in newly transcribed RNA. Following a match, enzymes in the RISC will cleave the targeted mRNA, thereby effectively destroying it and reducing disease-related RNA levels. Our siRNAs have been stabilized to withstand the nucleases in lysosomes, enhancing their ability to escape the lysosome after AOC internalization and antibody degradation.

In preclinical studies, we observed that AOCs in circulation were stable for at least seven days. The biologic activity of the AOC was independent of plasma circulation times because the AOCs were cleared from plasma more rapidly than tissues. Once delivered into cells, our oligonucleotide therapeutics were stabilized and, particularly when loaded into the RISC, had prolonged activity. In mice treated with our AOC, the half-life of siRNA in muscle tissue was approximately 12 days. In comparison, the half-life of siRNA in RISC had a projected half-life of approximately 80 days, suggesting that, once in tissues, the siRNA is stabilized in RISC, prolonging the duration of action.

We believe that chemical modifications to the siRNA drive their long-lived pharmacologic activity. We observed that a single dose of 3 mg/kg of a siRNA in an AOC administered to monkeys reduced the level of the mRNA for DMPK for eight months. We believe that these results suggest that AOCs for muscle diseases may be given as infrequent intravenous doses similar to those that are being used with other siRNA therapeutics in the liver.

 

4

 

 

Optimization of the mAb. Prior to choosing mAbs, we tried a number of delivery moieties including small molecule ligands, peptide fragments and antigen-binding fragments, or Fabs. For example, we conducted a study on plasma pharmacokinetics in nonhuman primates, where we compared a siRNA loaded onto a Fab fragment versus siRNA loaded onto a full-length mAb. The full-length mAb demonstrated superior pharmacokinetics. After conducting these preclinical experiments, we ultimately chose the proven technology of mAbs due to their well-established safety profiles, high specificity and affinity and more attractive plasma kinetics.

Because the mAb is the key delivery agent for our oligonucleotides, we are focused on identifying and tailoring mAbs to enhance their selectivity and minimize toxicity. For example, all our muscle programs employ our proprietary, effector function null, fully humanized IgG1 mAb targeting human TfR1. This antibody was selected to minimize interference with transferrin binding, minimizing alterations of iron uptake by the targeted cells. Further, our antibody is selective to TfR1 and does not cross-react with TfR2, which is widely expressed in the liver. Selectivity of our anti-transferrin receptor antibody for human and cynomolgus monkey TfR1 can be attributed to our antibody binding domain, to an epitope that is conserved between human TfR1 and cynomolgus monkey TfR1. To minimize antibody-dependent cell-mediated cytotoxicity, or ADCC, and complement fixation, we introduced mutations to eliminate effector functions. Reduction of ADCC has been shown for the lead clones. The final clone-expressing cell was selected based on high production yields and optimized physical and chemical properties. The selected mAb demonstrated good delivery into human skeletal muscle cells in vitro and favorable bioconjugation with a siRNA, and polyclonal versions of the mAb showed favorable delivery and pharmacodynamics in studies in cynomolgus monkeys.

Optimization of the antibody conjugate design. In addition to the oligonucleotide and the mAb, we have also optimized the conjugation of the two, including the linker. Our linkers are optimized for stability and durability, as evidenced by preclinical studies in which we observed enhanced stability of some linkers over others. In addition to optimizing our linker, we optimize several other key aspects including sites of conjugation and the ratio of oligonucleotides to antibodies.

 

Advantages of our AOC Product Platform

 

We believe that the product candidates derived from our AOC platform will have the potential to offer the following distinct advantages:

 

 

●

Expand scope of diseases addressable with oligonucleotides: (i) utilize identified cell surface protein-antibody pairs to design oligonucleotides in order to target the root cause of diseases  previously untreatable with RNA therapeutics; (ii) flexibility to deploy an appropriate oligonucleotide type for different diseases; and (iii) optimize all structural components of our AOCs for effective delivery—the oligonucleotide, the mAb and the antibody conjugate design.

 

 

●

Potential to mitigate toxicity by limiting drug exposure: (i) selection of the most potent oligonucleotide type; (ii) targeted delivery to tissues and cells; and (iii) infrequent administration.

 

●

Infrequent dosing: (i) ability to deliver oligonucleotides to tissues and cells at concentrations that produce pronounced and prolonged pharmacodynamic effects as observed in our preclinical models; and (ii) ability to select appropriate oligonucleotide mechanisms to maximize durability.

 

 

●

Readily reproducible and scalable: (i) AOCs synthesized using well-established and scalable methods for manufacturing mAbs and oligonucleotides; and (ii) ability to use a single mAb across multiple programs provides significant leverage around development costs and timelines associated with each incremental muscle program. For example, we use the same mAb targeting TfR1 across our current muscle franchise.

 

 

Our Development Programs

 

We are advancing and expanding our innovative AOC pipeline to develop potential treatment options for patients and their families across a wide-range of therapeutic areas. Our first AOC programs are from

5

 

our muscle disease franchise where we have leveraged our deep experience with oligonucleotide therapeutics, modulation of RNA processes, antibody engineering and conjugation and drug delivery techniques. The research and development chart below represents a summary of our wholly owned development programs, which are focused on muscle disease:

 

 

 

In addition to our wholly owned programs in muscle disease, we also have development efforts focused on immune and other cell types. Under the Research Collaboration and License Agreement with Lilly, or the Lilly Agreement, we are collaborating with Lilly for the discovery, development and commercialization of AOCs directed to up to six selected mRNA targets in immunology and other select indications outside of muscle. Through our research collaboration with Myokardia and our internal discovery efforts, we are expanding our development activities to include cardiac-specific indications.

 

Our Muscle Disease Franchise

 

We have selected muscle as the first tissue type in which to explore the potential of our AOCs. In our early screening efforts, we observed a 95% reduction of target gene expression in mouse skeletal muscle with the AOC we tested, which in part led us to focus on developing a deep pipeline of AOCs that are designed to address multiple muscle diseases including DM1, FSHD and DMD. We currently use the same proprietary mAb targeting TfR1 across our muscle programs, which we believe gives us significant leverage of development costs and timelines associated with each incremental muscle program.

 

Our Clinical Program

 

AOC 1001 for the Treatment of Myotonic Dystrophy Type 1 (DM1)

 

Our lead product candidate utilizing the AOC platform, AOC 1001, is designed to address the root cause of DM1 by reducing levels of a disease-related mRNA called DMPK. AOC 1001 consists of a proprietary mAb that binds to TfR1 conjugated with a siRNA targeting DMPK mRNA. The FDA and EMA have granted Orphan Designation for AOC 1001. In October, the FDA also granted Fast Track Designation to AOC 1001 for the treatment of DM1. 

 

 

Phase 1/2 MARINA clinical trial

In October 2021, we dosed the first patient in our Phase 1/2 MARINA clinical trial, a trial designed to evaluate the safety and tolerability of single and multiple ascending doses of AOC 1001 administered

6

 

intravenously in adults with DM1. The MARINA trial is a randomized, double-blind, placebo-controlled, Phase 1/2 clinical trial expected to enroll approximately 44 adults with DM1. The MARINA trial is assessing the activity of AOC 1001 across key biomarkers, including spliceopathy, an important biomarker for DM1, and knockdown of DMPK mRNA. Though the Phase 1/2 trial is not powered to assess functional benefit, it is exploring the clinical activity of AOC 1001 including measures of mobility and muscle strength as well as patient reported outcomes and quality of life measures. Patients will have the option to enroll in an open label extension study at the end of the post-treatment period. In the fourth quarter of 2022, Avidity plans to conduct a preliminary assessment of safety, tolerability and key biomarkers in approximately half of the study participants.

 

 

The sites participating in the MARINA trial are all part of the Myotonic Dystrophy Clinical Research Network, or DMCRN. The DMCRN is running a natural history study called Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1, or END-DM1. We have entered into a collaboration supporting END-DM1, a non-interventional study designed to advance the understanding of disease progression in approximately 700 people with DM1. With our collaboration, we are able to assess the data from END-DM1, which we believe will help to inform the clinical development of AOC 1001.

 

DM1 Disease Overview

 

DM1 is an underrecognized, progressive and often fatal neuromuscular disease with multiple organ involvement. DM1 is a monogenic, autosomal dominant disease caused by a triplet-repeat in the DMPK gene, resulting in a toxic gain of function mRNA. DM1 primarily affects skeletal and cardiac muscle and can be highly variable with respect to severity, presentation and age of onset. Patients can suffer from a constellation of manifestations including myotonia and muscle weakness, respiratory problems, fatigue, hypersomnia, cardiac abnormalities, gastrointestinal complications, and cognitive and behavioral impairment. DM1 is estimated to affect over 40,000 people in the United States and there are similar prevalence estimates for Europe. All forms, except the late-onset form, of DM1 are associated with high levels of disease burden and may cause premature mortality.

 

 

Current Treatment Landscape and Limitations

 

There are currently no approved therapies to treat DM1, and medical care is focused largely on symptom management. Due to the well-known challenges of delivery, a previous attempt at treating DM1 with an unconjugated antisense oligonucleotide was discontinued. Therefore, there remains a high unmet medical need for new disease modifying therapies.

 

Our Solution

 

7

 

 

AOC 1001 consists of a proprietary mAb that binds to TfR1 conjugated with a siRNA, siDMPK.19, targeted to DMPK RNA, and is designed to be administered to the patient as an intravenous infusion. We believe that the following specific characteristics of AOC 1001 position it to have advantages over historical and current efforts to develop an effective therapy for people with DM1:

 

 

•

Addresses the underlying cause of the disease—DM1 is caused by an increase in the number of CUG triplet repeats occurring in the DMPK gene product. AOC 1001 is designed to reduce the expression levels DMPK RNA, thereby reducing the CUG burden in the nucleus and thereby releasing muscle blind-like protein to allow for normal mRNA processing.

 

•

Efficient delivery of drug substance to diseased cells—In an effort to solve for challenges identified in prior unsuccessful efforts to deliver an unconjugated oligonucleotide into muscle cells, the TfR1 antibody component of AOC 1001 facilitates efficient delivery of AOC 1001 to skeletal and cardiac muscle cells. Once inside the muscle cells, the siRNA component of AOC 1001, siDMPK.19, acts to reduce levels of DMPK mRNA in both the nucleus and the cytoplasm. In preclinical studies in cynomolgus monkeys, we observed that treatment with an AOC containing siDMPK.19 produced a greater than 50% reduction of DMPK mRNA across a wide range of skeletal muscles at a concentration of 1 nM or less, approximately 1,000 fold more potent than has been reported for an unconjugated antisense oligonucleotide. We also observed reductions in DMPK mRNA in the gastrointestinal tract.

 

 

•

Reproducible and scalable therapeutic—As with all our AOCs, AOC 1001 is readily synthesized using well-established and scalable methods for manufacturing mAbs and oligonucleotides.

 

Preclinical Data supporting AOC 1001

In preclinical studies in mice and cynomolgus monkeys, AOC 1001 delivered siRNAs to muscle cells and reduce the levels of DMPK RNA across a broad range of muscles including skeletal, cardiac, and smooth. These data suggest that AOC 1001 has potential to be a potent and infrequently dosed therapy in DM1. In in vitro experiments in cells from patients with DM1, after treatment with siDMPK.19, we observed reductions in nuclear foci, and a return to more normal splicing patterns for key genes.

 

In muscle cells derived from patients with DM1, we observed that it is possible to reduce the number of muscle blind-like protein, or MBNL, or MBNL, -associated nuclear foci after incubation with siDMPK.19. Using fluorescence microscopy, we observed that incubation of DM1 patient cells with siDMPK.19 resulted in a release of the MBNL and quantifiable reductions in nuclear foci. In addition, we observed substantial improvements in disease-related biomarkers as measured by the splice score in the cells of patients with DM1following treatment with siDMPK.19. We used RNA-sequence analysis of the myotubes from patients with DM1 to create a splice score for control human subjects’ cells treated with siDMPK.19 or the inactive siRNA, siDMPK.29. When patient myotubes were analyzed, there was a marked improvement in the splice score of the myotubes treated with the siDMPK.19 compared to the inactive siDMPK.29. The splice signature approached that of control myotubes.

 

In cynomolgus monkeys, we observed that a single dose of 2 mg/kg of siDMPK.19 included in AOC 1001 produced an approximately 75% reduction of DMPK mRNA in skeletal muscles that was sustained up to 12 weeks after administration. We also observed that treatment with an AOC containing siDMPK.19 produced a greater than 50% reduction of DMPK mRNA across a wide range of skeletal muscles at a concentration of 1 nM or less and we also observed reductions in DMPK mRNA in the jejunum and ileum. Plasma profiles demonstrated no neutralizing antibodies to AOC 1001. In addition, AOC 1001 reduced muscle DMPK mRNA in a concentration responsive manner. We completed our IND-enabling good laboratory practice, or GLP, toxicology study of AOC 1001 in non-human primate. Results from the 13-week study showed that AOC 1001 was generally well tolerated and supported advancement into the clinic. The highest dose tested was the maximum feasible dose and was the no-observed adverse effect level, or NOAEL. We did not observe any treatment-related histopathologic toxicity or any changes in safety pharmacology parameters (cardiac, respiratory and neurological). All dose levels in the GLP toxicology study produced a greater than 80% reduction in the expression of DMPK across multiple skeletal muscles, suggesting that pharmacology was essentially saturated even at the lowest dose tested. These data taken together with the data from cells from DM1 patients demonstrate marked and prolonged reductions in levels of DMPK mRNA expression, nM potency, along with reductions in nuclear foci and a return to more

8

 

normal splicing patterns for key genes, suggesting that AOC 1001 has potential to be a potent, infrequently dosed therapy for people with DM1.

 

Our Pre-IND Programs:

 

AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

 

We are developing AOC 1020 to treat the underlying cause of FSHD, one of the most common forms of muscular dystrophy. Our therapeutic strategy in FSHD is to use an AOC based on our proprietary mAb that targets TfR1 to deliver a siRNA targeted to DUX4 mRNA. In preclinical models, we observed siRNA-mediated DUX4 silencing in muscle cells from patients with FSHD. Following regulatory clearance, we plan to advance AOC 1020 into a clinical trial by the end of 2022. Due to the lack of available therapies in this rare disease, should our trial be successful, we plan to explore the potential to advance this program into registrational trials in order to expedite making an AOC available for a patient population in severe need.

 

Disease Overview

 

FSHD is characterized by progressive and often asymmetric skeletal muscle loss that initially causes weakness in muscles in the face, shoulders, arms and trunk and progresses to weakness in muscles in lower body. FSHD is an autosomal dominant disease caused by the aberrant expression of the DUX4 gene in the skeletal muscle, which activates genes that are toxic to muscle cells and leads to a series of downstream events that result in skeletal muscle wasting and compromised muscle function. Skeletal muscle weakness results in physical limitations throughout the whole body, including an inability to lift arms for more than a few seconds, loss of ability to show facial expressions and serious speech impediments. These symptoms cause many people affected by FSHD to become dependent on the use of a wheelchair for mobility. FSHD affects both sexes equally, with onset typically in teenage and young adult years. The FSHD Society estimated FSHD affects approximately one in 20,000 people in the United States. A recent study conducted in the Netherlands reported a more frequent prevalence of one in 8,333 people. We believe that the patient population is between 16,000 to 38,000 in the United States. As is typical in diseases with no approved therapies, we believe that these patient population estimates are conservative.

 

Current Treatment Landscape and Limitations

 

Currently there is no treatments for FSHD, and there are no therapies to treat the underlying cause of FSHD. Current approaches are focused on support for activities of daily living and mobility, improved functioning and lowering the risk of complications. They include physical therapy, exercise, pain management and orthopedic interventions. Two approaches are currently in Phase 2 development to treat FSHD but do not directly target DUX4, the driver of the disease.

 

Our Solution

 

AOC 1020 consists of our proprietary mAb that is designed to bind to TfR1 conjugated with a siRNA targeted to DUX4 mRNA to be administered as an intravenous infusion. Our preclinical data support our hypotheses on the potential advantages of AOC 1020. We believe these data suggest that AOC 1020 targets the root cause of FSHD, and may have the potential advantage of infrequent administration.

 

We believe that the following specific characteristics of AOC 1020 position it to have advantages over historical and current efforts to develop an effective therapy for people with FSHD:

 

 

▪

Addresses the underlying cause of the disease—AOC 1020 is designed to reduce the expression of the DUX4 mRNA, thereby reducing the expression of the DUX4 protein resulting in reduced expression of the downstream genes that are believed to cause FSHD. We believe these downstream genes can be used as biomarkers to assess the disease state and therapeutic activity.

9

 

 

▪

Efficient delivery of drug substance to diseased cells— The TfR1 antibody component of the AOC is designed to facilitate efficient delivery to skeletal and cardiac muscle cells, an advantage over other companies previous unsuccessful efforts to deliver an unconjugated oligonucleotide into muscle cells. Once inside the muscle cells, the siRNA component of AOC 1020, siDUX4, acts to reduce levels of DUX4 mRNA. In preclinical models, we observed siRNA-mediated DUX4 silencing in muscle cells from patients with FSHD.

 

 

▪

Reproducible and scalable therapeutic—As with all our AOCs, AOC 1020 is readily synthesized using well-established and scalable methods for manufacturing mAbs and oligonucleotides.

 

Preclinical Data and Next Steps

 

Results from preclinical studies in FSHD patient myotubes and in an FSHD mouse disease model showed potent inhibition of DUX4-mediated gene signature in skeletal muscles. Results from a non-GLP, pharmacokinetic/pharmacodynamic study in NHP showed that AOC 1020 was well-tolerated at all doses tested following single and repeat dosing. We did not observe any dose-limiting toxicity at the highest dose tested based on in-life safety assessments. AOC 1020 produced a dose-dependent increase in siRNA plasma exposure following single doses, and AOC 1020 was observed to be stable in plasma with no evidence of degradation of the intact AOC. AOC 1020 also produced a dose-dependent increase in siRNA tissue exposure following single doses in a broad panel of muscle tissue. We believe these data support advancement of the AOC 1020 development program and potentially support an infrequent dosing regimen.

 

 

AOC 1020 is now in IND-enabling studies. Following regulatory clearance, we plan to advance AOC 1020 into a clinical trial by the end of 2022.

 

We have partnered with the FSHD clinical trial research network, or FSHD CTRN, on the ongoing natural history study called Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD). We are sponsoring the MOVE Plus, or MOVE+, study which is enrolling approximately 100 participants in the US. The goal of MOVE+ is to enhance the community's understanding of how to utilize whole-body MRI and other tools to identify specific biomarkers for FSHD that can accelerate and support future clinical trial design.

 

Our Duchenne Muscular Dystrophy (DMD) Program

 

We are developing AOCs to treat the underlying cause of DMD, a monogenic, X-linked, recessive, neuromuscular disease that almost exclusively occurs in males. DMD is caused by mutations in the gene that encodes for dystrophin, a protein critical for the normal function of muscle cells. The oligonucleotides in our AOCs are designed to promote the skipping of specific exons to allow the production of the dystrophin gene product. We are focusing our initial efforts on the development of AOCs for mutations amenable to skipping Exon 44, Exon 51 and Exon 45 and we intend to conjugate these individual oligonucleotides to our proprietary mAb targeting TfR1. We have three programs in development for DMD which target Exon 44, Exon 51 and Exon 45. Our first DMD program, AOC 1044 targeting Exon 44, is now in IND-enabling studies. Following additional preparatory preclinical studies and regulatory clearance, we plan to advance AOC 1044 into a clinical trial by the end of 2022.

 

Disease Overview

 

In people with DMD, mutations in the affected gene hinder the production of normal levels of dystrophin protein, which is needed to maintain the integrity of muscle fibers. The absence of functional dystrophin leads to stresses and tears of muscle cell membranes, resulting in muscle cell death and the progressive loss of muscle function. A global database analysis characterized over 7,000 genetic mutations that cause DMD. Exons 44, 51 and 45 represent approximately 30% of the total mutations observed in DMD that are amenable to skipping.

 

For people suffering from DMD, symptoms usually begin to manifest between three and five years of age. Affected people fail to reach developmental milestones or experience motor function challenges, such as difficulty walking or climbing stairs. Muscle wasting initially presents in the legs and pelvic area and later affects muscles of the shoulders, neck and arms, resulting in the inability to walk and dependence on a

10

 

wheelchair for mobility, and later becoming paralyzed from the neck down and requiring a ventilator to breathe. Though disease severity and life expectancy vary, a patient’s quality of life dramatically decreases over time, and death typically occurs by early adulthood from either cardiac or respiratory complications. DMD occurs in approximately one in every 3,500 to 5,000 live male births and is estimated to affect 10,000 to 15,000 people in the United States. The estimated prevalence of DMD in the European Union is similar to than that in the United States.

 

Current Treatment Landscape and Limitations

 

Currently people with DMD are treated with corticosteroids to manage the inflammatory component of the disease. There are three approved unconjugated PMO-based oligonucleotide therapies, each addressing a specific mutation. However, these drugs, in addition to requiring weekly intravenous infusions, have demonstrated a less than 6% mean increase in dystrophin in clinical trials. The FDA-approved labels for these drugs state that a clinical benefit has not yet been established and continued approval may be contingent upon the verification of such clinical benefit in confirmatory clinical trials. Additional approaches currently in clinical development include PPMOs and gene therapy. While there are therapies approved for Exon 51 and Exon 45 and multiple programs in clinical development for Exon 51, there are no therapies approved targeting Exon 44.

 

Our Solution

 

Our initial development efforts in DMD are focused on AOCs based on PMOs that can induce exon skipping specifically for Exons 44, 51 and 45 conjugated to our proprietary mAb targeting TfR1. AOC 1044 is our lead program in development for DMD and targets Exon 44. We believe that our AOCs have the potential to increase the production of dystrophin in people with DMD for two reasons. First, because of recent advances in the understanding of the splicing process and placement of skipping agents on pre-mRNA described in published literature and based on these advances, we have screened for and identified PMOs with optimized skipping activity. Second, the mAb targeting TfR1 allows for more efficient delivery to muscle cells, therefore allowing for better uptake of the PMO. In preclinical studies, we also observed that our TfR1-based AOCs induced exon skipping in cardiac muscle, which we believe may address some of the cardiomyopathies in people with DMD, a key complication of the disease. Based on their mechanism of action, we believe that our AOCs could have utility in several additional DMD mutations beyond these first three.

 

Preclinical Data and Next Steps

 

In preclinical studies, we observed that treatment of an mdx mouse with an AOC caused a greater than 50-fold increase in exon skipping compared to an equimolar dose of the unconjugated oligonucleotide. In an mdx mouse model of DMD, a widely accepted mouse model in DMD, we observed that conjugating an oligonucleotide designed to bind to a specific exon can induce exon skipping and production of dystrophin protein more efficiently than unconjugated oligonucleotides. Fourteen days following treatment with a single 8mg/kg dose of a mouse Exon 23-targeting PMO conjugated to a mouse-specific- mAb targeting TfR1, we observed an approximately 50-fold increase in the degree of splice switching as compared to an equimolar dose of the unconjugated PMO).

 

Our first DMD program, AOC 1044 targeting Exon 44, is now in IND-enabling studies and we have preclinical programs for Exons 45 and 51. Following additional preparatory preclinical studies and regulatory clearance, we plan to advance AOC 1044 into a clinical trial by the end of 2022.

 

Our Discovery Programs

 

 

Muscle Atrophy

 

Muscle atrophy is the loss of skeletal muscle mass that leads to muscle weakness and physical disability for patients. It is caused by a range of conditions spanning from rare genetic muscle diseases to common disorders like muscle wasting disease or cachexia.

 

11

 

 

Muscle atrophy is caused by a change in the balance between protein breakdown and protein synthesis signals. Muscle atrophy can be associated with the activation of pro-inflammatory cytokine pathways which induce protein degradation or inhibit growth factor pathways that promote protein synthesis. Genetic profiling of atrophic muscles has identified a group of ubiquitin ligases (E3 ligases) that are upregulated when muscle atrophy begins. In particular, muscle-specific E3 ligase muscle RING finger protein 1, or MuRF1, has been shown to be upregulated in muscle atrophy. Genetic ablation of MuRF1 in mice has been shown by third parties to render muscles partially resistant to various conditions of muscle atrophy. MuRF1 is a difficult target to address with traditional approaches like small molecules because of the gene family of E3 ligases, however, it may be able to benefit from the specificity of treatment achieved with a siRNA.

 

Our AOC for muscle atrophy is made up of our mAb targeting TfR1 and an oligonucleotide targeting MuRF1, and is designed to employ both the catabolic and anabolic pathways associated with the degradation of protein in muscle cells. We are focused on preclinical studies and identifying a muscle atrophy indication that we believe will be best suited for AOCs.

 

Pompe Disease

 

Pompe disease is a rare, autosomal recessive lysosomal storage disease that results in the toxic buildup of glycogen in the body’s cells, causing impairment of normal tissue and organ function. People with the infantile-onset form of the condition are most severely affected, suffering from progressive muscle weakness, respiratory deficiency, and heart problems. A late-onset form of Pompe disease can manifest in older patients and is generally associated with progressive weakness of the proximal muscles and varying degrees of respiratory weakness.

 

We are developing an AOC targeting the glycogen synthase 1, or GYS1, mRNA to diminish the toxic accumulation of glycogen in muscle. Reducing GYS1 in muscle will reduce the toxic accumulation of glycogen and we believe our approach may be complementary to enzyme replacement therapy, or ERT, which is currently the only approved treatment for Pompe disease. Preclinical studies are ongoing.

 

Opportunities in Immunology, Immune Disorders and Cardiomyopathies

 

We intend to pursue the development of AOCs in other tissue and cell types, including immune cells. In the field of immunology, we believe AOCs have the potential to target a broader set of cell types and diseases than traditional oligonucleotide therapies. We believe oligonucleotide therapies have the potential to address the challenges of immune responses at the RNA level; however, the ability to modulate immune responses has been hampered by the inappropriate delivery of these agents to immune cells. By identifying and optimizing antibodies for specific immune cells, our goal is to leverage our AOC platform to develop product candidates that can deliver siRNAs to disease-driving subsets of immune cells.

 

In studies designed to explore AOCs in immuno-oncology, we observed significant AOC-mediated mRNA reduction in CD8+ tumor infiltrating lymphocytes, or TILs, in vivo in the syngeneic CT-26 tumor model with an intravenous dose of 6 mg/kg siRNA. However, we observed that the AOCs had no effect on the mRNA levels in T or B cells in the spleen, suggesting that activity can be limited to only the cell populations involved in immune-responses to tumors without affecting lymphocytes outside the tumor. We believe this specificity was driven by the fact that the AOC employed our mAb targeting TfR1, and TfR1 is over expressed only on activated lymphocytes. We also observed significant AOC-mediated mRNA reduction in CD4+ TILs and T-regs from mice treated with an AOC comprised of a mAb targeting TfR1 and a siRNA targeting SHP2.

 

We have also identified a mAb that binds to macrophages specifically, and when conjugated with a siRNA, produces reduction in levels of the target mRNA in that cell both in vitro and in vivo. We believe this finding supports the development of AOCs for diseases where macrophages play a significant role, like immune disorders. We are in the process of generating data to demonstrate the pharmacologic effects of siRNA reduction in animal models of immune disorders, which will help inform our future development plans. Our internal efforts are focused on finding additional surface protein-mAb pairs and demonstrating reduction in the expression of key targets in subsets of immune cells. As we identify appropriate product

12

 

candidates in immunology, we may choose to advance these on our own or seek a strategic collaborator based on the nature of potential indications. Our findings in immunology served as one of the key bases of our collaboration with Lilly who has access to a defined set of up to six mRNA targets initially in immunology and other select indications on a worldwide basis.

Beyond immune cells, we plan to continue to invest in our AOC platform to explore the full potential of our AOCs in cardiomyopathies, as well as in additional previously inaccessible tissue and cell types. We entered into a collaboration with MyoKardia that, in combination with our internal discovery efforts, will help us expand our therapeutic activities to include cardiac-specific indications. Our goal is to discover, develop and commercialize novel AOC therapeutics that overcome current barriers to the delivery of oligonucleotides and unlock their potential to treat a wide range of serious diseases currently lacking adequate treatment options.

Manufacturing

 

We do not own or operate manufacturing facilities. We currently rely on third-party manufacturers and suppliers for the antibodies, oligonucleotides and linkers used to make our AOCs, and we expect to continue to do so to meet our preclinical, clinical and commercial activities. Our third-party manufacturers are required to manufacture our product candidates under current Good Manufacturing Practice, or cGMP, requirements and other applicable laws and regulations. We believe there are multiple sources for all of the materials required for the manufacture of our product candidates.

Competition

 

The biotechnology and biopharmaceutical industries are characterized by rapid technological advancement, significant competition and an emphasis on intellectual property. We face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with current therapies and new therapies that may become available in the future.

 

With respect to AOC 1001, there are currently no approved therapies to treat the underlying cause of DM1. Products currently in development to treat DM1 include: tideglusib, a GSK3-ß inhibitor in late-stage clinical development by AMO Pharma for the congenital phenotype of DM1; AT466, which is an AAV-antisense candidate in preclinical development by Astellas Gene Therapies; a Fab linked oligonucleotide in preclinical development by Dyne Therapeutics Inc.; gene editing treatments in preclinical development by Vertex Pharmaceuticals, Inc.; an RNA-targeting gene therapy in preclinical development by Locana, Inc.; and small molecules interacting with RNA in preclinical development by Expansion Therapeutics. There are a growing number of companies pursuing different paths to treat DM1 and we expect that the space will continue to evolve as additional candidates advance.

 

There are currently no therapies to treat the underlying cause of FSHD. Products currently in development to treat FSHD include: creatine monohydrate, a supplement that enhances muscle performance, which is being evaluated in a Phase 2 clinical trial by Murdoch Children’s Research Institute; losmapimod, a p38 MAPK inhibitor that may modulate DUX4 expression, which is being evaluated in a Phase 2 clinical trial by Fulcrum Therapeutics Inc; an antibody linked oligonucleotide in preclinical development by Dyne Therapeutics Inc.; and a ligand conjugated oligonucleotide in preclinical development by Arrowhead Therapeutics.

 

Currently people with DMD are treated with corticosteroids to manage the inflammatory component of the disease. Deflazacort is an FDA approved corticosteroid marketed by PTC Therapeutics, Inc. In addition, there are three FDA approved exon skipping drugs marketed by Sarepta Therapeutics, Inc.: Eteplirsen, an unconjugated PMO approved for people with DMD amenable to skipping Exon 51; golodirsen for the treatment of people with DMD amenable to skipping Exon 53; and casimersen for the treatment of DMD in patients with a confirmed mutation amenable to exon 45 skipping. There is an FDA-approved exon skipping drug marketed by Nippon Shinyaku Co., Inc.: viltolarsen, an unconjugated PMO approved for people with DMD amenable to skipping Exon 53. Companies focused on developing treatments for DMD that target dystrophin mechanisms, as does our DMD program, include Sarepta Therapeutics with SRP-

13

 

5051, a PPMO currently being evaluated in a Phase 2 clinical trial for patients amenable to Exon 51 skipping , and PTC Therapeutics with ataluren, a small molecule targeting nonsense mutations in a Phase 3 clinical trial. In addition, several companies are developing gene therapies, including Milo Biotechnology (AAV1-FS344), Pfizer (PF-06939926), Sarepta Therapeutics (SRP-9001 and Galgt2 gene therapy program), and Solid Biosciences Inc. (SGT-001). Dyne Therapeutics Inc. has submitted an IND to the FDA to initiate a clinical trial of DYNE-251, a PMO conjugated to a Fab for treatment of patients with DMD amendable to skipping exon 51. We are also aware of several companies targeting non-dystrophin mechanisms for the treatment of DMD.

Current treatments for muscle atrophy are primarily focused on nutritional intake and physical exercise. Other products in developments for muscle atrophy in cachexia include: adlumiz and AEZS-130, which are ghrelin agonists in a Phase 3 clinical trial by Helsinn Healthcare SA and a Phase 2 trial by Aeterna Zentaris Inc., respectively; GSK2881078, an androgen receptor modulator in Phase 2 clinical in development by GlaxoSmithKline plc; NGM120, a GSF15 inhibitor by NGM Biopharmaceuticals Inc.; and PF-06946860 in Phase 1 clinical development by Pfizer Inc.

 

The only approved therapies for Pompe disease are Lumizyme (known as Myozyme outside of the United States) and Nexviazyme, ERTs delivered by bi-weekly intravenous infusion, and marketed by Sanofi Genzyme. We are aware of multiple ERT therapies in clinical development, including AT-GAA, which uses a pharmacological chaperone, with a BLA under FDA review submitted by Amicus Therapeutics, Inc. In addition, several companies are developing gene therapies, including Actus Therapeutics, Inc. (ACTUS101), Asklepios BioPharmaceutical, Inc. (AAV2/8-LSPhGAA), Astellas Gene Therapies  (AT845) and Spark Therapeutics, Inc. (SPK-3006).

 

We will also compete more generally with other companies developing alternative scientific and technological approaches, including other companies working to develop conjugates with oligonucleotides for extra-hepatic delivery, including Alnylam Pharmaceuticals, Aro Biotherapeutics, Arrowhead Therapeutics, Dyne Therapeutics, Ionis Pharmaceuticals, Sarepta Therapeutics, DTx Pharma, Inc., PepGen, Inc., PeptiDream Inc. and Bicycle Therapeutics, as well as gene therapy and CRISPR approaches.

Many of our competitors, either alone or with strategic partners, have substantially greater financial, technical and human resources than we do. Accordingly, our competitors may be more successful than us in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining approval for treatments and achieving widespread market acceptance, rendering our treatments obsolete or non-competitive. Merger and acquisition activity in the biotechnology and biopharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. These companies also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials and acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Our commercial opportunity could be substantially limited if our competitors develop and commercialize products that are more effective, safer, less toxic, more convenient or less expensive than our comparable products. In geographies that are critical to our commercial success, competitors may also obtain regulatory approvals before us, resulting in our competitors building a strong market position in advance of the entry of our products. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of other drugs. The key competitive factors affecting the success of our programs are likely to be their efficacy, safety profile, convenience, level of promotional activity, intellectual property protection and availability of reimbursement.

Intellectual Property

We strive to protect our product candidates and our AOC product platform through a variety of methods, including seeking and maintaining patents intended to cover our AOC product platform, our products and compositions, their methods of use and processes for their manufacture, and any other inventions that are commercially important to the development of our business. We also rely on know-how, continuing technological innovation and in-licensing opportunities to develop and maintain our proprietary

14

 

position. We also rely on trade secrets and know-how that may be important to the development of our business. We seek to obtain domestic and international patent protection and endeavor to promptly file patent applications for new commercially valuable inventions to expand our intellectual property portfolio.

 

We believe that we have a significant global intellectual property position and substantial know-how relating to our AOC product candidates and our technology platform. As of December 31, 2021, our intellectual property portfolio consisted of 13 issued U.S. patents and 29 pending U.S. patent applications that we own. Collectively, these patent rights relate to various aspects of our AOC product candidates and technology platform. In addition, we have an exclusive option to an exclusive license to certain patent rights from the University of Alberta. In addition to filing and prosecuting patent applications in the United States, we often file counterpart patent applications in additional countries where we believe such foreign filing is likely to be beneficial, including Australia, Canada, China, Europe, Hong Kong, Israel, Japan, Mexico, Singapore, New Zealand, Taiwan, and South Korea. We also file patent applications pursuant to the Patent Cooperation Treaty, or PCT. Our PCT patent applications are in the first phase of the PCT process, which is the international phase, in which patent protection is pending under a single patent application filed with the United States Patent and Trademark Office, or USPTO, as a contracting state of the PCT. These PCT patent applications have not yet entered the second phase of the PCT process, which is the national and regional phase, in which rights are continued by filing necessary documents with the patent offices of separate contracting states of the PCT. The national phase of the PCT patent application process occurs 30 months after the earliest priority date of the PCT patent application.

 

We continually assess and refine our intellectual property strategy as we develop new product candidates and platform technologies. To that end, we are prepared to file additional patent applications in any appropriate fields if our intellectual property strategy requires such filings, or where we seek to adapt to competition or seize business opportunities. Further, we are prepared to file patent applications, as we consider appropriate under the circumstances, relating to the new technologies that we develop.

 

We cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications we may own or license in the future, nor can we be sure that any of our existing patents or any patents we may own or license in the future will be useful in protecting our technology. Please see “Risk Factors—Risks Related to Our Intellectual Property” for additional information on the risks associated with our intellectual property strategy and portfolio.

 

Intellectual Property Relating to AOC 1001

 

With regard to AOC 1001, as of December 31, 2021, we owned one issued U.S. patent,  nine pending U.S. patent applications, 11 pending patent applications in foreign jurisdictions, and one pending patent application filed pursuant to the PCT. These patent rights relate to AOC 1001 composition of matter, formulations containing AOC 1001, methods of manufacturing, and methods of treating diseases, using AOC 1001. Any patents issued from these applications are expected to expire in 2038-2041; however, a patent term extension may be available.

 

Intellectual Property Relating to Our FSHD AOC Product Candidate

 

With regard to our FSHD AOC product candidate, as of December 31, 2021 we owned three pending U.S. patent application. These patent rights relate to the FSHD AOC composition of matter, formulations containing the FSHD AOC, methods of manufacturing, and methods of treating diseases, using our FSHD AOC. Any patents issued from these applications are expected to expire in 2041-2042; however, a patent term extension may be available.

 

Intellectual Property Relating to Our DMD AOC Product Candidates

 

With regard to our DMD AOC product candidates, as of December 31, 2021, we owned two issued U.S. patents, five pending U.S. patent applications and 24 pending patent applications in various countries and regions including Australia, Canada, China, Europe, Hong Kong, Israel, Japan, Mexico, Singapore, and South Korea. These patent rights relate to the DMD AOCs composition of matter, formulations containing the DMD AOCs, methods of manufacturing, and methods of treating diseases, using our DMD AOCs. Any patents issued from these applications are expected to expire in 2038-2042; however, a patent term extension may be available.

15

 

 

Intellectual Property Relating to Our Muscle Atrophy AOC Product Candidate

 

With regard to our muscle atrophy AOC product candidate, as of December 31, 2021 we owned one issued U.S. patent, eight pending U.S. patent applications,  and 10 pending patent applications in various countries and regions including Australia, Canada, China, Europe, Hong Kong, Israel, Japan, Mexico, Singapore, and South Korea. These patent rights relate to the muscle atrophy AOC composition of matter, formulations containing the muscle atrophy AOC, methods of manufacturing, and methods of treating diseases, using our muscle atrophy AOC. Any patents issued from these applications are expected to expire in 2038; however, a patent term extension may be available.

 

Intellectual Property Relating to Our Pompe AOC Product Candidate

 

With regard to our Pompe AOC product candidate, as of December 31, 2021, we owned one pending patent application filed pursuant to the PCT. This application relates to the Pompe disease AOC composition of matter, formulations containing the Pompe disease AOC, methods of manufacturing, and method of treating diseases, using our Pompe disease AOC. Any patents issued from this application are expected to expire in 2041; however, a patent term extension may be available.

 

Intellectual Property Relating to Our AOC Product Platform

 

As of December 31, 2021, we owned 16 families of U.S. and foreign patents and patent applications generally covering our AOC product platform. These families include t11issued U.S. patents, 28 pending U.S. patent applications, three PCT patent applications and 79 foreign patent applications in the European Patent Office, Australia, Canada, China, Israel, Hong Kong, Japan, South Korea, Mexico, Singapore, New Zealand, and Taiwan, relating to key aspects and components of our AOC product platform systems. Our patent applications contain claims covering (i) proprietary antibodies; (ii) proprietary oligonucleotide chemical structures; (iii) proprietary oligonucleotide sequences;

 

(iv)proprietary AOC structures; and (v) methods for manufacturing and using our AOC technologies. Some of these AOC platform cases generically cover our various product candidates. The issued U.S. patents and any U.S. patents issuing from our pending U.S. patent applications are expected to expire between 2037 and 2042.

 

The term of individual patents depends upon the laws of the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing of a non-provisional patent application. However, the term of United States patents may be extended for delays incurred due to compliance with the FDA requirements or by delays encountered during prosecution that are caused by the USPTO. For example, for drugs that are regulated by the FDA under the Hatch-Waxman Act, it is permitted to extend the term of a patent that covers such drug for up to five years beyond the normal expiration date of the patent. In the future, if and when our biopharmaceutical product candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those product candidates. We intend to seek patent term extensions to any of our issued patents in any jurisdiction where these are available; however, there is no guarantee that the applicable authorities, including the USPTO and FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. If patents are issued on our pending patent applications, the resulting patents are projected to expire on dates ranging from 2038 to 2042, unless we receive patent term extension or patent term adjustment, or both.

 

However, the actual protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent.

 

The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in patents in the field of oligonucleotide therapy has emerged in the United States. The patent situation outside of the United States is even more uncertain. Changes in the patent laws and rules, either by legislation, judicial decisions, or regulatory interpretation in the United States and other countries may diminish our ability to protect our inventions and enforce our intellectual property rights, and more generally could affect the value of our

16

 

intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell, importing or otherwise commercializing any of our patented inventions, either directly or indirectly, will depend in part on our success in obtaining, defending and enforcing patent claims that cover our technology, inventions, and improvements. With respect to both licensed and company-owned intellectual property, we cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in protecting our platform and product candidates and the methods used to manufacture them. Moreover, our issued patents and those that may issue in the future may not guarantee us the right to practice our technology in relation to the commercialization of our platform’s product candidates. The area of patent and other intellectual property rights in biotechnology is an evolving one with many risks and uncertainties, and third parties may have blocking patents that could be used to prevent us from commercializing our AOC product platform and product candidates and practicing our proprietary technology. Our issued patents and those that may issue in the future may be challenged, narrowed, circumvented or invalidated, which could limit our ability to stop competitors from marketing related platforms or product candidates or limit the length of the term of patent protection that we may have for our AOC product platform and product candidates. In addition, the rights granted under any issued patents may not provide us with protection or competitive

 

advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies. For these reasons, we may have competition for our AOC product platform and product candidates. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that before any product candidate can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of the patent. For this and other risks related to our proprietary technology, inventions, improvements, platforms and product candidates, please see the section entitled “Risk Factors—Risks Related to Our Intellectual Property.”

 

We intend to file applications for trademark registrations in connection with our product candidates in various jurisdictions, including the United States. We have filed for trademark protection of the Avidity Biosciences mark with the United States Patent and Trademark Office and foreign patent and trademark organizations.

 

We also rely on trade secret protection for our confidential and proprietary information. Although we take steps to protect our confidential and proprietary information as trade secrets, including through contractual means with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements under the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the individual’s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In many cases our confidentiality and other agreements with consultants, outside scientific collaborators, sponsored researchers and other advisors require them to assign or grant us licenses to inventions they invent as a result of the work or services they render under such agreements or grant us an option to negotiate a license to use such inventions. Despite these efforts, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, and we may not be able to obtain adequate remedies for such breaches.

We also seek to preserve the integrity and confidentiality of our proprietary technology and processes by maintaining physical security of our premises and physical and electronic security of our information technology systems. Although we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any

17

 

breach. To the extent that our employees, contractors, consultants, collaborators and advisors use intellectual property owned by others in their work for us, disputes may arise as to the rights in relation to the resulting know-how or inventions. For more information, please see the section entitled “Risk Factors—Risks Related to Our Intellectual Property.”

Research Collaboration and License Agreement with Lilly

In April 2019, we entered into the Lilly Agreement with Lilly for the discovery, development and commercialization of antibody-oligonucleotide conjugate products, or Products, in immunology and other select indications on a worldwide basis. Under the Lilly Agreement, the parties will collaborate on preclinical research and discovery activities for Products and Lilly will be responsible for funding the cost of preclinical research and discovery activities of both parties for all Products. Lilly will lead the clinical development, regulatory approval and commercialization of all Products, at Lilly’s sole cost.

Under the Lilly Agreement, we granted Lilly an exclusive, worldwide, royalty-bearing license under our technology to research, develop, manufacture, and sell Products directed to up to six mRNA targets. Lilly has the right to sublicense its rights under the Lilly Agreement subject to certain conditions. Lilly granted us a non-exclusive license under certain Lilly technology solely to conduct research under the Lilly Agreement. We retain the right to use our technology to perform our obligations under the Lilly Agreement and for all purposes not granted to Lilly. We agreed that we will not, ourselves or with a third party, research, develop, manufacture or commercialize or otherwise exploit any compound or product directed against targets subject to the collaboration.

Lilly paid us an upfront license fee of $20.0 million, and we are eligible to receive up to $60.0 million in development milestone payments, up to $140.0 million in regulatory milestone payments and up to $205.0 million in commercialization milestone payments per target. In addition, Lilly is obligated to pay us a tiered royalty ranging from the mid-single to low-double digits on worldwide annual net sales of licensed Products, subject to specified and capped reductions for the market entry of biosimilar products, loss of patent coverage of licensed Products and for payments owed to third parties for additional rights necessary to commercialize licensed Products in the territory. Lilly’s royalty obligations and the Lilly Agreement will expire on a licensed Product-by-licensed Product and country-by-country basis on the later of ten years from the date of the first commercial sale or when there is no longer a valid patent claim covering such licensed Product in such country.

The Lilly Agreement may be terminated either by us or Lilly in the event of an uncured material breach by the other party. Lilly may terminate the Lilly Agreement on a target-by-target basis or in its entirety without cause, subject to certain limitations, including that Lilly may not terminate the Lilly Agreement on a target-by-target basis within the first three years of the effective date of the Lilly Agreement if doing so would reduce the number of Products subject to the collaboration to fewer than a certain number. In the event either party commences a legal action challenging the validity or enforceability of any licensed patents, the other party will have the right to terminate the Lilly Agreement with respect to the challenged patents.

The Lilly Agreement includes various representations, warranties, covenants, dispute resolution mechanisms, indemnities and other provisions customary for transactions of this nature.

Concurrently with the Lilly Agreement, we issued a convertible promissory note to Lilly, or the Lilly Note, and received cash proceeds of $15.0 million. The Lilly Note accrued simple interest of 8.0% per annum and converted into shares of our Series C convertible preferred stock in November 2019.

Research Collaboration with Myokardia, a wholly-owned subsidiary of Bristol Myers Squibb

In December 2020, we entered into a research collaboration with MyoKardia, a wholly-owned subsidiary of Bristol Myers Squibb, to demonstrate the potential utility of AOCs in cardiac tissue by leveraging MyoKardia’s genetic cardiomyopathy platform including, among other aspects, its novel target discovery engine and proprietary cardiac disease models.

18

 

Government Regulation

Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and import of products such as those we are developing. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates.

We believe our AOC product candidates may be subject to regulation in the United States as drug-biologic combination products. Combination products are comprised of components, such as drug components and biologic components, that would normally be subject to different regulatory frameworks by the FDA and frequently regulated by different centers at the FDA. Under the Federal Food, Drug and Cosmetic Act, or FDCA, the FDA is charged with assigning a center with primary jurisdiction, or a lead center, for review of a combination product. The determination of which center will be the lead center is based on the “primary mode of action” of the combination product. Thus, if the primary mode of action of a drug-biologic combination product is attributable to the biologic component, the FDA’s Center for Biologics Evaluation and Research would have primary jurisdiction for the combination product. The FDA has also established the Office of Combination Products to address issues surrounding combination products and provide more certainty to the regulatory review process. That office serves as a focal point for combination product issues for agency reviewers and industry. It is also responsible for developing guidance and regulations to clarify the regulation of combination products, and for assignment of the FDA center that has primary jurisdiction for review of combination products where the jurisdiction is unclear or in dispute. A combination product with a primary mode of action attributable to the biologic component generally would be reviewed and approved pursuant to the biological product licensure processes set forth in the Public Health Service Act, or PHSA, and FDCA. In reviewing the marketing application for such a product, however, FDA reviewers would consult with their counterparts in the FDA’s Center for Drug Evaluation and Research to ensure that the drug component of the combination product met applicable requirements regarding safety and effectiveness. We believe our AOCs will be subject to the primary review of the Center for Biologics Evaluation and Research, and will require approval of Biologics License Application, or BLA, for the combination drug-biologic.

U.S. Biologics Regulation

 

In the United States, biological products are subject to regulation under the FDCA, PHSA, and other federal, state, and local statutes and regulations. The process required by the FDA before a biological product may be marketed in the United States generally involves the following:

 

●

completion of preclinical laboratory tests, animal studies and formulation studies in accordance with GLP regulations and other applicable regulations;

 

●

submission to the FDA of an IND, which must become effective before human clinical trials may begin;

 

●

approval by an independent institutional review board, or IRB, or ethics committee at each clinical site before each trial may be initiated;

 

●

performance of adequate and well-controlled human clinical trials in accordance with Good Clinical Practice, or GCP, requirements to establish the safety, purity and potency of the proposed biologic for its intended use;

 

●

submission to the FDA of a BLA  after completion of all pivotal trials;

 

●

satisfactory completion of an FDA advisory committee review, if applicable;

 

●

a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;

 

●

satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the biological product is produced to assess compliance with cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the product’s identity, strength, quality and purity, and of selected clinical investigation sites to assess compliance with GCP; and

19

 

 

●

FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for use in the United States.

Once a pharmaceutical candidate is identified for development, it enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies, in an effort to support subsequent clinical testing. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. Prior to beginning the first clinical trial with a product candidate in the United States, the trial sponsor must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product candidate, chemistry, manufacturing, and controls information, and any available human data or literature to support the use of the product candidate. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns about ongoing or proposed clinical trials or non-compliance with specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.

Clinical trials involve the administration of the investigational product to human subjects under the supervision of one or more qualified investigators, generally physicians not employed by or under the trial sponsor’s control, in accordance with GCP regulations, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials must be conducted under protocols detailing, among other things, the objectives of the trial, dosing procedures, subject selection and exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND as well as any subsequent protocol amendments, and timely safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events. An independent IRB at each institution participating in the clinical trial must review and approve each protocol before a clinical trial commences at that institution and must also approve the information regarding the trial and the consent form that must be provided to each trial subject or his or her legal representative, monitor the study until completed and otherwise comply with IRB regulations. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.

 

Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:

 

●

Phase 1:  The product candidate is initially introduced into healthy human volunteers or patients with the target disease or condition. These studies are designed to test for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early indication of its effectiveness.

 

●

Phase 2:  The product candidate is administered to a limited patient population with a specified disease or condition to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and appropriate dosage. Multiple Phase 2 trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 trials.

20

 

 

●

Phase 3:  The product candidate is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy, and to further test for safety in an expanded patient population, generally at geographically dispersed clinical study sites. These clinical trials are intended to establish the overall risk-benefit ratio of the product candidate and provide, if appropriate, an adequate basis for product approval and labeling.

Post-approval trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of a BLA.

 

While the IND is active and before approval, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.

During the development of a new biologic, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before a BLA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered, for the FDA to provide advice, and for the sponsor and the FDA to reach alignment on the next phase of development. Sponsors typically use the meetings at the end of the Phase 2 trial to discuss Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the biological product candidate.

Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and biological characteristics of the product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.

 

There are also requirements governing the reporting of ongoing clinical trials and completed trial results to public registries. Sponsors of certain clinical trials of FDA-regulated products are required to register and disclose specified clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved.

BLA Review and Approval Process

Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, preclinical and other non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an BLA requesting approval to market the product for one or more indications. The submission of a BLA is subject to the payment of substantial user fees, unless a waiver or exemption applies.

Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the FDA accepts it for filing. The FDA may refuse to file any BLA that it

21

 

deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. Once a BLA has been accepted for filing, the FDA’s goal is to review standard applications within ten months after the filing date, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process may also be extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product’s continued safety, purity and potency.

The FDA may also convene an advisory committee to provide clinical insight on application review questions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.

Before approving a BLA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an BLA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.

After the FDA evaluates a BLA, it will issue an approval letter or a Complete Response Letter, or CRL. An approval letter authorizes commercial marketing of the biologic with prescribing information for specific indications. A CRL indicates that the review cycle of the application is complete and the application will not be approved in its present form. A CRL will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the CRL without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the CRL, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. Even if such  information are submitted, the FDA may decide that the BLA does not satisfy the criteria for approval. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.

If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. In addition, the FDA may require a sponsor to conduct Phase 4 testing, which involves clinical trials designed to further assess a biological product’s safety and effectiveness after BLA approval, and may require testing and surveillance programs to monitor the safety of approved products which have been commercialized. The FDA may also place other conditions on approval including the requirement for a risk evaluation and mitigation strategy, or REMS, to assure the safe use of the product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve the BLA without an approved REMS, if required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Marketing approval may be withdrawn for non-compliance with regulatory requirements or if problems occur following initial marketing.

In addition, the Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original BLAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric

22

 

subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.

Expedited Development and Review Programs

A sponsor may seek approval of its product candidate under programs designed to expedite FDA’s review and approval of biological products that meet certain criteria. The FDA has a fast track designation program that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. For example, product candidates are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once a BLA is submitted, the product candidate may be eligible for priority review. A fast track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.

A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product candidate can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.

Any product submitted to the FDA for approval, including a product candidate with a fast track designation or breakthrough therapy designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A product is eligible for priority review if it is designed to treat a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA will attempt to direct additional resources to the evaluation of an application for the product candidate designated for priority review in an effort to facilitate the review. For original BLAs, priority review designation means the FDA’s goal is to take action on the marketing application within six months of the 60-day filing date (as compared to ten months under standard review).

Additionally, product candidates studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA will generally the sponsor of a drug receiving accelerated approval to perform adequate and well-controlled post-marketing clinical trials to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. FDA may withdraw approval of a drug or indication approved

23

 

under accelerated approval on an expedited basis if, for example, the sponsor fails to conduct the required confirmatory trial or if such confirmatory trial fails to verify the predicted clinical benefit of the product.

Fast track designation, priority review and breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.

Post-Approval Requirements

Any products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fees for any marketed products. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks, or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:

 

●

restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;

 

●

fines, warning letters, or untitled letters;

 

●

clinical holds on clinical studies;

 

●

refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;

 

●

product seizure or detention, or refusal to permit the import or export of products;

 

●

consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;

 

●

mandated modification of promotional materials and labeling and the issuance of corrective information;

 

●

the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or

 

●

injunctions or the imposition of civil or criminal penalties.

In addition, the FDA closely regulates the marketing, labeling, advertising and promotion of drug products. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product’s labeling and that differ from those tested by the

24

 

manufacturer and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer’s communications on the subject of off-label use of their products.

Orphan Drug Designation and Exclusivity

Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States or, if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making a drug product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting a BLA. After the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.

If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or inability to manufacture the product in sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application user fee.

A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or, as noted above, if a second applicant demonstrates that its product is clinically superior to the approved product with orphan exclusivity or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.

Biosimilars and reference product exclusivity

The Affordable Care Act, signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product.

Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA.

25

 

Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant’s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed “interchangeable” by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.

A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued “Written Request” for such a study.

U.S. Healthcare Fraud and Abuse Laws and Compliance Requirements

In addition to FDA regulation of pharmaceutical products, U.S. federal and state healthcare laws and regulations restrict business practices in the pharmaceutical industry. These laws may impact, among other things, our current and future business operations, including our clinical research activities, and constrain the business or financial arrangements and relationships with healthcare providers and other parties. These laws include anti-kickback and false claims laws, civil monetary penalties laws, and physician and other healthcare provider payment transparency laws. In addition to the federal laws summarized below, we may also be subject to similar state and local laws and regulations that may apply to business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, or by patients themselves.

The federal Anti-Kickback Statute prohibits, among other things, individuals or entities from knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in kind to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation.

The federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws prohibit, among other things, any individual or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act.

The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate it in order to have committed a violation.

26

 

The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare & Medicaid Services, or CMS, information related to payments or other transfers of value made during the previous year to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other health care providers including, among others, physician assistants and nurse practitioners, and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held during the previous year by physicians as defined under statute and their immediate family members.

Similar state and local laws and regulations may also restrict business practices in the pharmaceutical industry, such as state anti-kickback and false claims laws, which may apply to business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, or by patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information or which require tracking gifts and other remuneration and items of value provided to physicians, other healthcare providers and entities; and state and local laws that require the registration of pharmaceutical sales representatives.

Violation of any of such laws or any other governmental regulations that apply may result in significant criminal, civil and administrative penalties including damages, fines, imprisonment, disgorgement, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, disgorgement, exclusion from participation in government healthcare programs and the curtailment or restructuring of our operations.

U.S. Coverage and Reimbursement

Significant uncertainty exists as to the coverage and reimbursement status of any product candidate for which we may seek regulatory approval. Sales in the United States will depend, in part, on the availability of sufficient coverage and adequate reimbursement from third-party payors, which include government health programs such as Medicare, Medicaid, TRICARE and the Veterans Administration, as well as managed care organizations and private health insurers. Prices at which we or our customers seek reimbursement for our product candidates can be subject to challenge, reduction or denial by third-party payors. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs.

The process for determining whether a third-party payor will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the payor will pay for the product. In the United States, there is no uniform policy among payors for coverage or reimbursement. Decisions regarding whether to cover any of a product, the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies, but also have their own methods and approval processes. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that can require manufacturers to provide scientific and clinical support for the use of a product to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.

 

Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Third-party

27

 

payors may not consider our product candidates to be medically necessary or cost-effective compared to other available therapies, or the rebate percentages required to secure favorable coverage may not yield an adequate margin over cost or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development. Additionally, decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product.

U.S. Healthcare Reform

In the United States, there has been, and continues to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect the profitable sale of product candidates.

Among policy makers and payors in the United States, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly affected the pharmaceutical industry. The ACA increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%; required collection of rebates for drugs paid by Medicaid managed care organizations; required manufacturers to participate in a coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer’s outpatient drugs to be covered under Medicare Part D; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain “branded prescription drugs” to specified federal government programs, implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expanded eligibility criteria for Medicaid programs; creates a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.

Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA.  Prior to the Supreme Court's decision, President Biden issued an executive order to initiate a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, from February 15, 2021 through August 15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures of the Biden administration or other efforts, if any, to challenge, repeal or replace the ACA will impact the law.

In addition, other legislative changes have been proposed and adopted since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.

28

 

Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. The likelihood of success for these and other proposals to control drug costs is uncertain, particularly in light of the new Biden administration. Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine which drugs and suppliers will be included in their healthcare programs Furthermore, there has been increased interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices.

Foreign Regulation

In order to market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we can commence clinical trials or marketing of the product in foreign countries and jurisdictions. Although many of the issues discussed above with respect to the United States apply similarly in the context of the European Union, or EU, the approval process varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.

To market a medicinal product in the European Economic Area, or EEA (which is comprised of the 28 Member States of the EU plus Norway, Iceland and Liechtenstein), we must obtain a Marketing Authorization, or MA. There are two types of marketing authorizations:

 

●

the Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use of the EMA and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, advanced therapy products, and medicinal products containing a new active substance indicated for the treatment certain diseases, such as AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU; and

 

●

National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member State through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure.

Under the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.

29

 

Data and marketing exclusivity

In the EEA, new products authorized for marketing, or reference products, qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial authorization of the reference product in the EU. The 10-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those 10 years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.

Pediatric investigation plan

In the EEA, marketing authorization applications for new medicinal products not authorized have to include the results of studies conducted in the pediatric population, in compliance with a pediatric investigation plan, or PIP, agreed with the EMA’s Pediatric Committee, or PDCO. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which marketing authorization is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data is not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the marketing authorization is obtained in all Member States of the EU and study results are included in the product information, even when negative, the product is eligible for six months’ supplementary protection certificate extension.

Clinical trials

Clinical trials of medicinal products in the European Union must be conducted in accordance with European Union and national regulations and the International Conference on Harmonization, or ICH, guidelines on GCPs. Additional GCP guidelines from the European Commission, focusing in particular on traceability, apply to clinical trials of advanced therapy medicinal products. If the sponsor of the clinical trial is not established within the European Union, it must appoint an entity within the European Union to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU countries, the sponsor is liable to provide ‘no fault’ compensation to any study subject injured in the clinical trial.

Prior to commencing a clinical trial, the sponsor must obtain a clinical trial authorization from the competent authority, and a positive opinion from an independent ethics committee. The application for a clinical trial authorization must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. Currently, clinical trial authorization applications must be submitted to the competent authority in each EU Member State in which the trial will be conducted. Under the new Regulation on Clinical Trials, which is currently expected to take effect in 2019, there will be a centralized application procedure where one national authority takes the lead in reviewing the application and the other national authorities have only a limited involvement. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be notified to or approved by the relevant competent authorities and ethics committees. Medicines used in clinical trials must be manufactured in accordance with cGMP. Other national and European Union-wide regulatory requirements also apply.

Data Privacy and Security Laws

We are subject to laws and regulations governing data privacy and the protection of health-related and other personal information. In the United States, numerous federal and state laws and regulations,

30

 

including data breach notification laws, health information privacy and security laws, including HIPAA, and federal and state consumer protection laws and regulations (e.g., Section 5 of the FTC Act), that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. In addition, certain state and non-U.S. laws, such as the California Consumer Privacy Act, or the CCPA, the California Privacy Rights Act, or the CPRA, and the General Data Protection Regulation, or the GDPR, govern the privacy and security of personal information, including health-related information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation.  Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.

Human Capital

As of February 7, 2022, we had 125 full-time employees, 48 of whom have a Ph.D. or M.D. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.

Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, and incentivizing our management team and our clinical, scientific and other employees and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and motivate personnel through the granting of stock-based and cash-based compensation awards, in order to align our interests and the interests of our stockholders with those of our employees and consultants.

Corporate Information  

We were originally founded as a Delaware limited liability company on November 13, 2012, under the name Avidity NanoMedicines LLC. On June 4, 2016, we changed our name to Avidity Biosciences LLC, and on April 1, 2019, we converted into a Delaware corporation under the name Avidity Biosciences, Inc. Our principal executive offices are located at 10578 Science Center Drive, Suite 125, San Diego, California 92121, and our telephone number is (858) 401-7900.

Available Information

Our internet address is www.aviditybiosciences.com. Our investor relations website is located at https://aviditybiosciences.investorroom.com/home. We make available free of charge on our investor relations website under “SEC Filings” our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, our directors’ and officers’ Section 16 reports and any amendments to those reports as soon as reasonably practicable after filing or furnishing such materials to the U.S. Securities and Exchange Commission, or SEC. They are also available for free on the SEC’s website at www.sec.gov.

We use our investor relations website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor such website, in addition to following our press releases, SEC filings and public conference calls and webcasts. Information relating to our corporate governance is also included on our investor relations website. The information in or accessible through the SEC and our website are not incorporated into, and are not considered part of, this filing.

31

 

ITEM 1A.    Risk Factors

You should carefully consider the following risk factors, together with the other information contained in this annual report on Form 10-K, including our financial statements and the related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before making a decision to purchase or sell shares of our common stock. We cannot assure you that any of the events discussed in the risk factors below will not occur. These risks could have a material and adverse impact on our business, results of operations, financial condition and growth prospects. If that were to happen, the trading price of our common stock could decline. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations or financial condition.

Summary of Risk Factors

The principal risks and uncertainties affecting our business include the following:

 

•

We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.

 

•

We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations.

 

•

We are early in our development efforts and only have one product candidate in clinical development.  All of our other development programs are in the preclinical or discovery stage. If we are unable to successfully develop, obtain regulatory approval and ultimately commercialize product candidates, or experience significant delays in doing so, our business will be materially harmed.

 

•

Interim, topline and preliminary data from our preclinical studies and clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.

 

•

Our approach to the discovery and development of product candidates based on our AOC platform is unproven, and we do not know whether we will be able to develop any products of commercial value, or if competing technological approaches will limit the commercial value of our product candidates or render our AOC platform obsolete.

 

•

Preclinical and clinical development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results. Our product candidates may not have favorable results in clinical trials, if any, or receive regulatory approval on a timely basis, if at all.

 

•

The COVID-19 pandemic could adversely impact our business, including our preclinical studies, clinical trials and financial condition.

 

•

Any difficulties or delays in the commencement or completion, or termination or suspension, of our ongoing and planned clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.

 

•

We rely on third parties to conduct our preclinical studies and clinical trials, and these parties may not perform satisfactorily.

32

 

 

•

We face significant competition, and if our competitors develop technologies or product candidates more rapidly than we do or their technologies are more effective, our business and our ability to develop and successfully commercialize products may be adversely affected.

 

•

Our success depends on our ability to protect our intellectual property and our proprietary technologies.

Risks Related to Our Limited Operating History, Financial Position and Capital Requirements

We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.

Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are a preclinical-stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. Our lead product candidate, AOC 1001, is in clinical development while all of our other development programs are in preclinical development or in the drug discovery stage. We commenced operations in 2012, and to date, we have focused primarily on organizing and staffing our company, business planning, raising capital, developing our proprietary AOC technology platform, identifying product candidates, establishing our intellectual property portfolio and conducting research and preclinical studies. Our approach to the discovery and development of product candidates based on our AOC platform is unproven, and we do not know whether we will be able to develop any product candidates that succeed in clinical development or products of commercial value. As an organization, we have not yet completed any clinical trials, obtained regulatory approvals, manufactured a commercial-scale product, or arranged for a third party to do so on our behalf, or conducted sales and marketing activities necessary for successful product commercialization. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing biopharmaceutical products.

We have incurred significant operating losses since our inception. We do not have any products approved for sale and have not generated any product revenue since our inception. If our product candidates are not successfully developed and approved, we may never generate any significant revenue. Our net losses were $118.0 million, $44.4 million and $24.7 million for the years ended December 31, 2021, 2020 and 2019, respectively. As of December 31, 2021, we had an accumulated deficit of $184.5 million. Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. All of our product candidates will require substantial additional development time and resources before we would be able to apply for or receive regulatory approvals and begin generating revenue from product sales. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase substantially as we continue our development of, seek regulatory approval for and potentially commercialize any of our product candidates.

To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, identifying lead product candidates, discovering additional product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling any products for which we may obtain regulatory approval. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. In addition, we have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry. Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable may have an adverse effect on the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product candidates or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.

33

 

We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations.

The development of biopharmaceutical product candidates is capital-intensive. We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct our ongoing and planned preclinical studies of our development programs, initiate clinical trials for our product candidates and seek regulatory approval for our current product candidates and any future product candidates we may develop. If we obtain regulatory approval for any of our product candidates, we also expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Because the outcome of any preclinical study or clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates. Furthermore, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.

We believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operations for at least the next 12 months. In particular, we expect that these funds will allow us to  complete our Phase 1/2 MARINA trial for AOC 1001 in myotonic dystrophy type 1, or DM1, and advance AOC 1044 for Duchenne muscular dystrophy, or DMD, and AOC 1020 for facioscapulohumeral muscular dystrophy, or FSHD, into clinical development as well as to further advance our AOC platform in and beyond our muscle franchise. We have based these estimates on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other capital sources, including potentially additional collaborations, licenses and other similar arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. For example, in July 2021 we entered into a sales agreement, or the Sales Agreement, with Cowen and Company, LLC, or the Sales Agent, under which we may, from time to time, sell shares of common stock having an aggregate offering price of up to $150.0 million through the Sales Agent.  However, there can be no assurance that the Sales Agent will be successful in consummating future sales based on prevailing market conditions or in the quantities or at the prices that we deem appropriate. In addition, the Sales Agreement may be terminated by us or the Sales Agent at any time upon specified notice to the other party, or by the Sales Agent at any time in certain circumstances, including the occurrence of a material adverse change. Attempting to secure additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop our product candidates.

Our future capital requirements will depend on many factors, including, but not limited to:

 

•

the type, number, scope, progress, expansions, results, costs and timing of, discovery, preclinical studies and clinical trials of our product candidates which we are pursuing or may choose to pursue in the future;

 

•

the costs and timing of manufacturing for our product candidates and commercial manufacturing if any product candidate is approved;

 

•

the costs, timing and outcome of regulatory review of our product candidates;

 

•

the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements;

 

•

the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;

34

 

 

•

our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal controls over financial reporting;

 

•

the costs associated with hiring additional personnel and consultants as our preclinical and clinical activities increase;

 

•

the timing and amount of the milestone or other payments made to us under our Research Collaboration and License Agreement, or the Lilly Agreement, with Eli Lilly and Company, or Lilly, or any future collaboration agreements;

 

•

the costs and timing of establishing or securing sales and marketing capabilities if any product candidate is approved;

 

•

our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products;

 

•

the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; and

 

•

costs associated with any products or technologies that we may in-license or acquire.

Identifying potential product candidates and conducting preclinical studies and clinical trials is a time consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and commercialize our product candidates. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.

Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.

Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through equity offerings, debt financings, or other capital sources, including potential additional collaborations, licenses and other similar arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Any future debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making capital expenditures, declaring dividends or encumbering our assets to secure future indebtedness. Such restrictions could adversely impact our ability to conduct our operations and execute our business plan.

If we raise additional funds through future collaborations, licenses and other similar arrangements, we may have to relinquish valuable rights to our future revenue streams, research programs, product candidates or AOC platform, or grant licenses on terms that may not be favorable to us and/or that may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed or on terms acceptable to us, we would be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

35

 

Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates

We are early in our development efforts and only have one product candidate in clinical development.  All of our other development programs are in the preclinical or discovery stage. If we are unable to successfully develop, obtain regulatory approval and ultimately commercialize product candidates, or experience significant delays in doing so, our business will be materially harmed.

We are in the early stages of our development efforts and only AOC 1001 is in clinical development. All of our other development programs, including AOC 1044 and AOC 1020, are in the preclinical or drug discovery stage. We have invested substantially all of our efforts in developing our AOC platform, identifying potential product candidates and conducting preclinical studies. We will need to progress AOC 1044 and AOC 1020 through IND-enabling studies and receive authorization from the U.S. Food and Drug Administration, or the FDA, or the equivalent regulatory authority in other countries, to proceed under an IND, or its equivalent, prior to initiating their clinical development. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates. The success of our product candidates will depend on several factors, including the following:

 

•

successful completion of preclinical studies with favorable results, including those compliant with good laboratory practices, or GLP, toxicology studies, biodistribution studies and minimum effective dose studies in animals;

 

•

acceptance of INDs by the FDA, or similar regulatory submissions by comparable foreign regulatory authorities for the conduct of clinical trials of our product candidates and our proposed design of future clinical trials;

 

•

successful enrollment in clinical trials and completion of clinical trials with favorable results;

 

•

demonstrating safety, purity, potency and efficacy of our product candidates to the satisfaction of applicable regulatory authorities;

 

•

receipt of marketing approvals from applicable regulatory authorities, including biologics license applications, or BLAs, from the FDA and maintaining such approvals;

 

•

making arrangements with our third-party manufacturers for, or establishing, commercial manufacturing capabilities;

 

•

establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in collaboration with others;

 

•

establishing and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates;

 

•

maintaining an acceptable safety profile of our products following approval; and

 

•

maintaining and growing an organization of people who can develop and commercialize our products and technology.

If we are unable to develop, obtain regulatory approval for, or, if approved, successfully commercialize our product candidates, we may not be able to generate sufficient revenue to continue our business.

Interim, topline and preliminary data from our preclinical studies and clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.

From time to time, we may publicly disclose preliminary or topline data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate

36

 

all data. As a result, the preliminary or topline results that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the data we previously published. As a result, topline and preliminary data should be viewed with caution until the final data are available.

From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. Adverse differences between preliminary, topline or interim data and final data could significantly harm our business prospects.

Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and the value of our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, product candidate or our business. If the topline data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.

Our approach to the discovery and development of product candidates based on our AOC platform is unproven, and we do not know whether we will be able to develop any products of commercial value, or if competing technological approaches will limit the commercial value of our product candidates or render our AOC platform obsolete.

The success of our business depends primarily upon our ability to identify, develop and commercialize products based on our proprietary AOC platform, which leverages a novel and unproven approach. While we have had favorable preclinical study results based on our technology platform, we have not yet succeeded and may not succeed in demonstrating safety, purity or potency for any product candidates in clinical trials or in obtaining marketing approval thereafter. We initiated our Phase 1/2 MARINA clinical trial of AOC 1001 in adults with DM1 in October 2021, but have not yet completed any clinical trials for any product candidate. Our research methodology and novel approach to oligonucleotide based therapy may be unsuccessful in identifying additional product candidates, and any product candidates based on our technology platform may be shown to have harmful side effects or may have other characteristics that may necessitate additional clinical testing, or make the product candidates unmarketable or unlikely to receive marketing approval. We may also be unsuccessful in developing and demonstrating utility of our AOCs in cell types beyond the muscle, including under our Lilly Agreement for immunology and other select indications and under our research collaboration with MyoKardia for cardiac tissue. Further, because all of our product candidates and development programs are based on our AOC platform, adverse developments with respect to one of our programs may have a significant adverse impact on the actual or perceived likelihood of success and value of our other programs.

In addition, the biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies. Our future success will depend in part on our ability to maintain a competitive position with our AOC approach. If we fail to stay at the forefront of technological change in utilizing our AOC platform to create and develop product candidates, we may be unable to compete effectively. Our competitors may render our AOC approach obsolete, or limit the commercial value of our product candidates, by advances in existing technological approaches or the development of new or different approaches (including, for example, using different mAbs or transporter protein combinations with oligonucleotides than us), potentially eliminating the advantages in our drug discovery process that we believe we derive from our research approach and proprietary technologies. By contrast, adverse

37

 

developments with respect to other companies that attempt to use a similar approach to our approach may adversely impact the actual or perceived value of our AOC platform and potential of our product candidates.

If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations.

Preclinical and clinical development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results. Our product candidates may not have favorable results in clinical trials, if any, or receive regulatory approval on a timely basis, if at all.

Preclinical and clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain. We cannot guarantee that any preclinical studies or clinical trials will be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process. For example, we may not be able to meet expected timeframes for data readouts, such as our planned preliminary assessment of safety, tolerability and key biomarkers from the MARINA study, Despite promising preclinical or clinical results, any product candidate can unexpectedly fail at any stage of preclinical or clinical development. The historical failure rate for product candidates in our industry is high.

The results from preclinical studies or clinical trials of a product candidate may not predict the results of later clinical trials of the product candidate, and interim, topline, or preliminary results of a clinical trial are not necessarily indicative of final results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed through preclinical studies and initial clinical trials. In particular, while we have conducted certain preclinical studies of AOC 1001 and other potential product candidates targeting rare muscle disorders, we do not know whether AOC 1001 or the other potential product candidates will perform in ongoing or future clinical trials as they have performed in these prior studies. The positive results we have observed for our product candidates in preclinical animal models may not be predictive of our ongoing and future clinical trials in humans. Furthermore, for some indications that we are pursuing, there are no animal models of the human disease and therefore the animal models may not be predictive for human disease outcomes. It is not uncommon to observe results in clinical trials that are unexpected based on preclinical studies and early clinical trials, and many product candidates fail in clinical trials despite very promising early results. We have advanced AOC 1044 and AOC 1020 into IND-enabling studies. If unexpected observations or toxicities are observed in these studies, or in IND-enabling studies for any of our other development programs, this will delay clinical trials for such development programs. Moreover, preclinical and clinical data may be susceptible to varying interpretations and analyses. A number of companies in the biopharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies. For the foregoing reasons, we cannot be certain that our ongoing and planned preclinical studies and planned clinical trials will be successful. Any safety concerns observed in any of our preclinical studies or clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition and results of operations.

Any difficulties or delays in the commencement or completion, or termination or suspension, of our current or planned clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.

  Before we can initiate clinical trials for our preclinical product candidates, we must submit the results of preclinical studies to the FDA or comparable foreign regulatory authorities along with other information, including information about product candidate chemistry, manufacturing and controls and our proposed clinical trial protocol, as part of an IND or similar regulatory filing required for authorization to proceed with clinical development. We will need to complete IND-enabling studies and submit INDs for AOC 1044 and AOC 1020 and other development programs prior to initiating clinical development. The FDA or comparable

38

 

foreign regulatory authorities may require us to conduct additional preclinical studies for any product candidate before it allows us to initiate clinical trials under any IND or similar regulatory filing, which may lead to delays and increase the costs of our preclinical development programs. Any such delays in the commencement or completion of our ongoing or planned clinical trials for AOC 1001 or any other product candidate could significantly affect our product development costs.

We do not know whether our planned trials will begin on time or if our ongoing or future clinical trials will be completed on schedule, if at all. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to:

 

•

obtaining regulatory authorizations to commence a trial or reaching a consensus with regulatory authorities on trial design;

 

•

the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical studies;

 

•

any failure or delay in reaching an agreement with contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;

 

•

obtaining approval from one or more institutional review boards, or IRBs;

 

•

IRBs refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial;

 

•

changes to clinical trial protocol;

 

•

clinical sites deviating from trial protocol or dropping out of a trial;

 

•

manufacturing sufficient quantities of product candidate for use in clinical trials;

 

•

subjects failing to enroll or remain in our trials at the rate we expect, or failing to return for post-treatment follow-up, including subjects failing to remain in our trials due to movement restrictions, heath reasons or otherwise resulting from the novel strain of coronavirus, COVID-19;

 

•

subjects choosing an alternative treatment for the indications for which we are developing our product candidates, or participating in competing clinical trials;

 

•

lack of adequate funding to continue the clinical trial;

 

•

subjects experiencing severe or unexpected drug-related adverse effects;

 

•

occurrence of serious adverse events in trials of the same class of agents conducted by other companies;

 

•

selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data;

 

•

a facility manufacturing our product candidates or any of their components being ordered by the FDA or comparable foreign regulatory authorities to temporarily or permanently shut down due to violations of current good manufacturing practice, or cGMP, regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process;

 

•

any changes to our manufacturing process that may be necessary or desired;

 

•

third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices, or GCP, or other regulatory requirements;

 

•

third-party contractors not performing data collection or analysis in a timely or accurate manner; or

39

 

 

•

third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications.

In addition, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned clinical trials. We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA or comparable foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial.

Further, conducting clinical trials in foreign countries, as we may do for our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks, including war, relevant to such foreign countries.

Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.

If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. Moreover, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues.

In addition, many of the factors that cause, or lead to, the termination or suspension of, or a delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. We may make formulation or manufacturing changes to our product candidates, in which case we may need to conduct additional preclinical studies to bridge our modified product candidates to earlier versions. Any delays to our clinical trials that occur as a result could shorten any period during which we may have the exclusive right to commercialize our product candidates and our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects significantly.

40

 

We may find it difficult to enroll patients in our clinical trials. If we encounter difficulties enrolling subjects in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.

We may not be able to initiate or continue clinical trials for our product candidates if we are unable to identify and enroll a sufficient number of eligible patients to participate in these trials as may be required by the FDA or similar regulatory authorities outside the United States. Subject enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility and exclusion criteria for the trial, the design of the clinical trial, the risk that enrolled patients will not complete a clinical trial, our ability to recruit clinical trial investigators with the appropriate competencies and experience, competing clinical trials and clinicians’ and patients’ perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating as well as any product candidates under development. We will be required to identify and enroll a sufficient number of subjects for each of our clinical trials. Potential subjects for any planned clinical trials may not be adequately diagnosed or identified with the diseases which we are targeting or may not meet the entry criteria for such trials. We are initially developing product candidates targeting genetically defined, rare muscle disorders with limited patient pools from which to draw for clinical trials. Genetically defined diseases generally, including those for which our current product candidates are targeted, have low incidence and prevalence. We also may encounter difficulties in identifying and enrolling subjects with a stage of disease appropriate for our planned clinical trials and monitoring such subjects adequately during and after treatment. We may not be able to initiate or continue clinical trials if we are unable to locate a sufficient number of eligible subjects to participate in the clinical trials required by the FDA or comparable foreign regulatory authorities. In addition, the process of finding and diagnosing subjects may prove costly.

The timing of our clinical trials depends, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required follow-up periods. The eligibility criteria of our clinical trials, once established, will further limit the pool of available trial participants. If patients are unwilling to participate in our trials for any reason, including the existence of concurrent clinical trials for similar patient populations or the availability of approved therapies, or we otherwise have difficulty enrolling a sufficient number of patients, the timeline for recruiting subjects, conducting studies and obtaining regulatory approval of our product candidates may be delayed. Our inability to enroll a sufficient number of subjects for any of our future clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. In addition, we expect to rely on CROs and clinical trial sites to ensure proper and timely conduct of our future clinical trials and, while we intend to enter into agreements governing their services, we will have limited influence over their actual performance.

We cannot assure you that our assumptions used in determining expected clinical trial timelines are correct or that we will not experience delays in enrollment, which would result in the delay of completion of such trials beyond our expected timelines.

Use of our product candidates could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon a product candidate, limit the commercial profile of an approved label or result in other significant negative consequences that could severely harm our business, prospects, operating results and financial condition.

As is the case with biopharmaceuticals generally, it is likely that there may be side effects and adverse events associated with our product candidates’ use. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Although other oligonucleotide therapeutics have received regulatory approval, our AOCs, which combine oligonucleotides with a mAb, are a novel approach to oligonucleotide therapies, which may present enhanced risk and uncertainty for our product candidates compared to more well-established classes of therapies, or oligonucleotide or mAb-based therapies on their own. Moreover, there have been only a limited number of clinical trials involving the use of oligonucleotide therapeutics and none involving the proprietary technology

41

 

used in our AOC platform. It is impossible to predict when or if any product candidates we may develop will prove safe in humans. Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.

Moreover, if our product candidates are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we may elect to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for the product candidate if approved. We may also be required to modify our study plans based on findings after we commence our clinical trials. Many compounds that initially showed promise in early-stage testing have later been found to cause side effects that prevented further development of the compound. In addition, regulatory authorities may draw different conclusions or require additional testing to confirm these determinations.

It is possible that as we test our product candidates in larger, longer and more extensive clinical trials, or as the use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, may be reported by subjects. If such side effects become known later in development or upon approval, if any, such findings may harm our business, financial condition and prospects significantly.

Patients treated with our products, if approved, may experience previously unreported adverse reactions, and it is possible that the FDA or other regulatory authorities may ask for additional safety data as a condition of, or in connection with, our efforts to obtain approval of our product candidates. If safety problems occur or are identified after our products, if any, reach the market, we may make the decision or be required by regulatory authorities to amend the labeling of our products, recall our products or even withdraw approval for our products.

In addition, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such product, a number of potentially significant negative consequences could result, including:

 

•

regulatory authorities may withdraw, suspend or limit approvals of such product, or seek an injunction against its manufacture or distribution;

 

•

we may be required to recall a product or change the way such product is administered to patients;

 

•

regulatory authorities may require additional warnings on the label, such as a “black box” warning or a contraindication;

 

•

we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for distribution to patients;

 

•

we may be required to change the way a product is distributed, conduct additional clinical trials or change the labeling of a product or be required to conduct additional post-marketing studies or surveillance;

 

•

we could be sued and held liable for harm caused to patients;

 

•

sales of the product may decrease significantly, or the product could become less competitive; and

 

•

our reputation may suffer.

42

 

 

Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects.

As an organization, we have never completed any clinical trials or submitted a BLA for regulatory approval and may be unable to do so for any of our product candidates.

We are early in our development efforts for our product candidates and we will need to successfully complete Phase 1 clinical trials, and later-stage and pivotal clinical trials in order to obtain FDA or comparable foreign regulatory approval to market AOC 1001 or any other product candidates, as well as complete IND-enabling studies for our preclinical product candidates. Carrying out clinical trials and the submission of a successful BLA is a complicated process. As an organization, we commenced our first clinical trial, our Phase 1/2 MARINA trial for AOC 1001, in October 2021. We have not previously conducted any clinical trials, have limited experience as a company in preparing, submitting and prosecuting regulatory filings and have not previously submitted a BLA or other comparable foreign regulatory submission for any product candidate. As interactions with the FDA may not be comprehensive, we cannot be certain how many clinical trials of AOC 1001 or any other product candidates will be required or how such trials should be designed. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to regulatory submission and approval of any of our product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in, our planned clinical trials, could prevent us from or delay us in submitting BLAs for and commercializing our product candidates.

Our product candidates are subject to extensive regulation and compliance, which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.

The clinical development, manufacturing, labeling, packaging, storage, record-keeping, advertising, promotion, import, export, marketing, distribution and adverse event reporting, including the submission of safety and other information, of our product candidates are subject to extensive regulation by the FDA in the United States and by comparable foreign regulatory authorities in foreign markets. In the United States, we are not permitted to market our product candidates until we receive regulatory approval from the FDA. The process of obtaining regulatory approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and patient population. Approval policies or regulations may change, and the FDA has substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, regulatory approval is never guaranteed. Neither we nor any current or future collaborator is permitted to market any of our product candidates in the United States until we receive approval from the FDA.

Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe, pure, or effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities, as the case may be, may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval, or may object to elements of our clinical development program.

The FDA or comparable foreign regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including:

 

•

such authorities may disagree with the design or implementation of our or our collaborators’ current or future clinical trials;

43

 

 

•

negative or ambiguous results from our clinical trials or results may not meet the level of statistical significance required by the FDA or comparable foreign regulatory agencies for approval;

 

•

serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates;

 

•

such authorities may not accept clinical data from trials which are conducted at clinical facilities or in countries where the standard of care is potentially different from that of the United States;

 

•

we or any of our current or future collaborators may be unable to demonstrate that a product candidate is safe and effective, and that product candidate’s clinical and other benefits outweigh its safety risks;

 

•

such authorities may disagree with our interpretation of data from preclinical studies or clinical trials;

 

•

such authorities may not agree that the data collected from clinical trials of our product candidates are acceptable or sufficient to support the submission of a BLA or other submission or to obtain regulatory approval in the United States or elsewhere, and such authorities may impose requirements for additional preclinical studies or clinical trials;

 

•

such authorities may disagree regarding the formulation, labeling and/or the specifications of our product candidates;

 

•

approval may be granted only for indications that are significantly more limited than what we apply for and/or with other significant restrictions on distribution and use;

 

•

such authorities may find deficiencies in the manufacturing processes, approval policies or facilities of our third-party manufacturers with which we or any of our current or future collaborators contract for clinical and commercial supplies;

 

•

regulations of such authorities may significantly change in a manner rendering our or any of our potential future collaborators’ clinical data insufficient for approval; or

 

•

such authorities may not accept a submission due to, among other reasons, the content or formatting of the submission.

With respect to foreign markets, approval procedures vary among countries and, in addition to the foregoing risks, may involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, events raising questions about the safety of certain marketed biopharmaceuticals may result in increased cautiousness by the FDA and comparable foreign regulatory authorities in reviewing new drugs and biologics based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals could prevent us or any of our potential future collaborators from commercializing our product candidates.

We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.

Because we have limited financial and managerial resources, we focus on specific product candidates and specific indications. As a result, we may forgo or delay pursuit of opportunities with other product candidates that could have had greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaborations, licenses and other similar arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.

44

 

We may not be able to obtain or maintain orphan drug designations for any of our product candidates, and we may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.

Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs or biologics for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a drug or biologic as an orphan product if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population of greater than 200,000 individuals in the United States, but for which there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the European Union, the European Medicines Agency’s, or EMA’s, Committee for Orphan Medicinal Products grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union. We have received orphan drug designation in the United States and the European Union for AOC 1001 for the treatment of DM1, and we may seek orphan drug designation for certain of our other product candidates. There can be no assurance that we will be able to maintain such designation or that the FDA or the EMA’s Committee for Orphan Medicinal Products will grant orphan designation for any additional indication for which we apply.

In the United States, orphan designation entitles a party to financial incentives such as opportunities for grant funding toward clinical trial costs, tax advantages and user-fee waivers. In addition, if a product candidate that has orphan designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a BLA, to market the same product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity. The applicable exclusivity period is ten years in Europe, but such exclusivity period can be reduced to six years if a product no longer meets the criteria for orphan designation or if the product is sufficiently profitable that market exclusivity is no longer justified.

Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA or comparable foreign regulatory authority can subsequently approve the same drug for the same condition if such regulatory authority concludes that the later drug is clinically superior because it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity may also be lost if the FDA later determines that the initial request for designation was materially defective. In addition, orphan drug exclusivity does not prevent the FDA from approving competing drugs containing different active ingredients for the same or similar indication. In addition, if a subsequent drug is approved for marketing for the same or a similar indication as any of our product candidates that receive marketing approval, we may face increased competition and lose market share regardless of orphan drug exclusivity. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.

Receipt of breakthrough therapy designation or fast track designation by the FDA for one or more of our product candidates may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.

We may seek breakthrough therapy or fast track designation for some of our product candidates. If a product candidate is intended for the treatment of a serious or life-threatening condition and clinical or preclinical data demonstrate the potential to address unmet medical needs for this condition, the sponsor may apply for fast track designation. In October 2021, the FDA granted fast track designation to AOC 1001 for the treatment of DM1.  The sponsor of a fast track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once a BLA is submitted, the product candidate may be eligible for priority review if the relevant criteria are met. A fast track product

45

 

candidate may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.  

Breakthrough therapy designation may be granted to a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs or biologics that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. The designation also includes the same benefits as fast track designation, including eligibility for rolling review of a BLA.

Whether to grant breakthrough therapy or fast track designation is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for these designations, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of either of these designations for a product candidate, including the fast track designation granted to AOC 1001 for the treatment of DM1, may not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA review procedures and does not assure ultimate approval by the FDA. In addition, the FDA may later decide that the product candidate no longer meets the conditions for qualification of any granted designations.

We may conduct certain of our clinical trials for our product candidates outside of the United States. However, the FDA and other foreign equivalents may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business.

We may conduct one or more of our clinical trials for our product candidates outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA. Where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will not approve the application on the basis of foreign data alone unless those data are applicable to the U.S. population and U.S. medical practice; the studies were performed by clinical investigators of recognized competence; and the data are considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. For studies that are conducted only at sites outside of the United States and not subject to an IND, the FDA requires the clinical trial to have been conducted in accordance with GCPs, and the FDA must be able to validate the data from the clinical trial through an on-site inspection if it deems such inspection necessary. For such studies not subject to an IND, the FDA generally does not provide advance comment on the clinical protocols for the studies, and therefore there is an additional potential risk that the FDA could determine that the study design or protocol for a non-U.S. clinical trial was inadequate, which could require us to conduct additional clinical trials. There can be no assurance the FDA will accept data from clinical trials conducted outside of the United States. If the FDA does not accept data from our clinical trials of our product candidates, it would likely result in the need for additional clinical trials, which would be costly and time consuming and delay or permanently halt our development of our product candidates.

Conducting clinical trials outside the United States also exposes us to additional risks, including risks associated with:

 

•

additional foreign regulatory requirements;

 

•

foreign exchange fluctuations;

 

•

compliance with foreign manufacturing, customs, shipment and storage requirements;

 

•

cultural differences in medical practice and clinical research; and

46

 

 

 

•

diminished protection of intellectual property in some countries.

Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.

The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, the FDA’s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA’s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs and biologics or modifications to approved drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.

Separately, in response to the COVID-19 pandemic, in March 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, in July 2020, the FDA resumed certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA utilized this risk-based assessment system to assist in determining when and where it was safest to conduct prioritized domestic inspections. Additionally, on April 15, 2021, the FDA issued a guidance document in which the FDA described its plans to conduct voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites, among other facilities. According to the guidance, the FDA may request such remote interactive evaluations where the FDA determines that  remote evaluation would be appropriate based on mission needs and travel limitations. In May 2021, the FDA outlined a detailed plan to move toward a more consistent state of inspectional operations, and in July 2021, the FDA resumed standard inspectional operations of domestic facilities and was continuing to maintain this level of operation as of September 2021. More recently, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates as it adapts to the evolving COVID-19 pandemic. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.

Risks Related to Our Reliance on Third Parties

We rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, our development programs and our ability to seek or obtain regulatory approval for or commercialize our product candidates may be delayed.

We are dependent on third parties to conduct our preclinical studies and clinical trials. Specifically, we have used and relied on, and intend to use and rely on, medical institutions, clinical investigators, CROs and consultants to conduct our preclinical studies and clinical trials in accordance with our clinical protocols and regulatory requirements. These CROs, investigators and other third parties play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. While we have and will have agreements governing the activities of our third-party contractors, we have limited influence over their actual performance. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on our CROs and other third parties does not relieve us of our regulatory responsibilities. We

47

 

and our CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs or trial sites fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. In addition, our clinical trials must be conducted with products produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.

There is no guarantee that any of our CROs, investigators or other third parties will devote adequate time and resources to such trials or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be extended, delayed or terminated. In addition, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other development activities that could harm our competitive position. In addition, principal investigators for our clinical trials are expected to serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection by the FDA of any BLA we submit. Any such delay or rejection could prevent us from commercializing our product candidates.

If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties on commercially reasonable terms or at all. Switching or adding additional CROs, investigators and other third parties involves additional cost and requires our management’s time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, investigators and other third parties, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.

We rely on third parties for the manufacture of our product candidates for preclinical and clinical development. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.

We do not own or operate manufacturing facilities and have no plans to develop our own clinical or commercial-scale manufacturing capabilities. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates and related raw materials for preclinical and clinical development, as well as for commercial manufacture if any of our product candidates receive marketing approval. The facilities used by third-party manufacturers to manufacture our product candidates must be approved by the FDA and any comparable foreign regulatory authority pursuant to inspections that will be conducted after we submit a BLA to the FDA or any comparable filing to a foreign regulatory authority. We do not control the manufacturing process of, and are completely dependent on, third-party manufacturers for compliance with cGMP requirements for manufacture of products. If these third-party manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or any comparable foreign regulatory authority, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. Our AOCs, including AOC 1001, consist of a proprietary mAb conjugated with the oligonucleotide therapy. All of our mAbs are manufactured by starting with cells which are stored in a cell bank. We have multiple working cell banks and one master cell bank for our mAbs manufactured in accordance with cGMP and believe we would have adequate backup should any cell bank be lost in a catastrophic event. However, it is possible that we could lose multiple cell banks and have our manufacturing impacted by the need to replace the cell banks. In addition, we have no control

48

 

over the ability of third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or any comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products.

Our or a third party’s failure to execute on our manufacturing requirements on commercially reasonable terms and in compliance with cGMP could adversely affect our business in a number of ways, including:

 

•

an inability to initiate clinical trials of our product candidates under development;

 

•

delay in submitting regulatory applications, or receiving marketing approvals, for our product candidates;

 

•

subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities;

 

•

requirements to cease development or to recall batches of our product candidates; and

 

•

in the event of approval to market and commercialize our product candidates, an inability to meet commercial demands for our product candidates or any other future product candidates.

In addition, we may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:

 

•

failure of third-party manufacturers to comply with regulatory requirements and maintain quality assurance;

 

•

breach of the manufacturing agreement by the third party;

 

•

failure to manufacture our product according to our specifications;

 

•

failure to manufacture our product according to our schedule or at all;

 

•

misappropriation of our proprietary information, including our trade secrets and know-how; and

 

•

termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.

Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.

Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval, and any related remedial measures may be costly or time consuming to implement. We do not currently have arrangements in place for redundant supply or a second source for all required raw materials used in the manufacture of our product candidates. If our existing or future third-party manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace them on a timely basis or at all.

Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.

49

 

Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.

Because we currently rely on third parties to manufacture our product candidates and to perform quality testing, we must, at times, share our proprietary technology and confidential information, including trade secrets, with them. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements, and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are intentionally or inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets and despite our efforts to protect our trade secrets, a competitor’s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business, financial condition, results of operations and prospects.

We are dependent on the Lilly Agreement for the discovery, development and commercialization of AOCs directed against certain targets in immunology and other select indications. Under certain circumstances, Lilly may unilaterally terminate the agreement for convenience, which could materially and adversely affect our business.

In April 2019, we entered into the Lilly Agreement for the discovery, development and commercialization of AOCs directed against certain targets in immunology and other select indications, or the Lilly AOCs. Under the Lilly Agreement, Lilly will be solely responsible for funding the cost of preclinical research and discovery activities, clinical development, regulatory approval and commercialization for the Lilly AOCs. Lilly primarily controls the research and development activities, pursuant to the terms of the Lilly Agreement, and our lack of control over such activities could result in delays or other difficulties in the development and commercialization of the Lilly AOCs. Any dispute with Lilly may result in the delay or termination of the research, development or commercialization of the Lilly AOCs, and may result in costly litigation that diverts our management’s attention and resources away from our day-to-day activities and which may adversely affect our business, financial condition, results of operation and prospects.

In addition, Lilly can terminate the Lilly Agreement (including for convenience), and in the event Lilly terminates the Lilly Agreement, we would be prevented from receiving any research and development funding, milestone payments, royalty payments and other benefits under the agreement.

In addition, any decision by Lilly to terminate the Lilly Agreement may negatively impact public perception of our AOC product candidates, which could adversely affect the market price of our common stock. We cannot provide any assurance with respect to the success of the collaboration with Lilly. Any of the foregoing events could have a materially adverse effect on our business, financial condition, results of operations and prospects.

We may seek to enter into additional collaborations, licenses and other similar arrangements and may not be successful in doing so, and even if we are, we may relinquish valuable rights and may not realize the benefits of such relationships.

We may seek to enter into collaborations, joint ventures, licenses and other similar arrangements for the development or commercialization of our product candidates, due to capital costs required to develop or commercialize the product candidate or manufacturing constraints. For example, we have a research collaboration with MyoKardia to evaluate the potential of AOCs in cardia tissue. Such collaboration may not yield additional development or product candidates for our pipeline. We may not be successful in our efforts to establish or maintain such collaborations for our product candidates because our research and development pipeline may be insufficient, our product candidates may be deemed to be at too early of a stage of development for collaborative effort or third parties may not view our product candidates as having

50

 

the requisite potential to demonstrate safety and efficacy or significant commercial opportunity. In addition, we face significant competition in seeking appropriate strategic partners, and the negotiation process can be time-consuming and complex. We may have to relinquish valuable rights to our future revenue streams, research programs, product candidates or AOC platform, or grant licenses on terms that may not be favorable to us, as part of any such arrangement, and such arrangements may restrict us from entering into additional agreements with other potential collaborators. We cannot be certain that, following a collaboration, license or strategic transaction, we will achieve an economic benefit that justifies such transaction.

Even if we are successful in our efforts to establish such collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain or current or any future collaborations if, for example, the development or approval of a product candidate is delayed, the safety of a product candidate is questioned or the sales of an approved product candidate are unsatisfactory.

In addition, collaborations may be terminable by our strategic partners, and we may not be able to adequately protect our rights under these agreements. Furthermore, strategic partners may negotiate for certain rights to control decisions regarding the development and commercialization of our product candidates, if approved, and may not conduct those activities in the same manner as we do. Any termination of collaborations we enter into in the future, or any delay in entering into collaborations related to our product candidates, could delay the development and commercialization of our product candidates and reduce their competitiveness if they reach the market, which could have a material adverse effect on our business, financial condition and results of operations.

Risks Related to Commercialization of Our Product Candidates

Even if we receive regulatory approval for any product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions on marketing or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.

Following potential approval of any our product candidates, the FDA may impose significant restrictions on a product’s indicated uses or marketing or impose ongoing requirements for potentially costly and time-consuming post-approval studies, post-market surveillance or clinical trials to monitor the safety and efficacy of the product. The FDA may also require a REMS as a condition of approval of our product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our products will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCP requirements for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our products, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:

 

•

restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls;

 

•

restrictions on product distribution or use, or requirements to conduct post-marketing studies or clinical trials;

 

•

fines, restitutions, disgorgement of profits or revenues, warning letters, untitled letters or holds on clinical trials;

 

•

refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals;

51

 

 

•

product seizure or detention, or refusal to permit the import or export of our products; and

 

•

injunctions or the imposition of civil or criminal penalties.

The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.

In addition, if any of our product candidates are approved, our product labeling, advertising and promotion will be subject to regulatory requirements and continuing regulatory review. The FDA strictly regulates the promotional claims that may be made about drug products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product’s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless, in their independent medical judgment, prescribe it to their patients in a manner that is inconsistent with the approved label. The FDA does not regulate the behavior of physicians in their choice of treatments but the FDA does restrict manufacturer’s communications on the subject of off-label use of their products. If we are found to have promoted such off-label uses, we may become subject to significant liability. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.

The FDA’s and other regulatory authorities’ policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. In addition, the FDA’s and other regulatory authorities’ policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We also cannot predict the likelihood, nature or extent of government If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.

Our product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.

The Affordable Care Act, or the ACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a “biosimilar” product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor’s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of their product.

We believe that any of our product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of

52

 

our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.

The commercial success of our product candidates will depend upon the degree of market acceptance of such product candidates by physicians, patients, healthcare payors and others in the medical community.

Our product candidates may not be commercially successful. Even if any of our product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors or the medical community. The commercial success of any of our current or future product candidates will depend significantly on the broad adoption and use of the resulting product by physicians and patients for approved indications. The degree of market acceptance of our products will depend on a number of factors, including:

 

•

demonstration of clinical efficacy and safety compared to other more-established products;

 

•

the indications for which our product candidates are approved;

 

•

the limitation of our targeted patient population and other limitations or warnings contained in any FDA-approved labeling;

 

•

acceptance of a new drug for the relevant indication by healthcare providers and their patients;

 

•

the pricing and cost-effectiveness of our products, as well as the cost of treatment with our products in relation to alternative treatments and therapies;

 

•

our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government healthcare programs, including Medicare and Medicaid, private health insurers and other third-party payors;

 

•

the willingness of patients to pay all, or a portion of, out-of-pocket costs associated with our products in the absence of sufficient third-party coverage and adequate reimbursement;

 

•

any restrictions on the use of our products, and the prevalence and severity of any adverse effects;

 

•

potential product liability claims;

 

•

the timing of market introduction of our products as well as competitive drugs;

 

•

the effectiveness of our or any of our current or potential future collaborators’ sales and marketing strategies; and

 

•

unfavorable publicity relating to the product.

If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors or patients, we may not generate sufficient revenue from that product and may not become or remain profitable. Our efforts to educate the medical community and third-party payors regarding the benefits of our products may require significant resources and may never be successful.

The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found or alleged to have improperly promoted off-label uses, we may become subject to significant liability.

The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, as our product candidates would be, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product’s approved labeling. If we are found to have promoted such off-label uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label

53

 

promotion. The FDA has also required companies to enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.

The successful commercialization of our product candidates, if approved, will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our products could limit our ability to market those products and decrease our ability to generate revenue.

The availability of coverage and the adequacy of reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as our product candidates, if approved. Our ability to achieve coverage and acceptable levels of reimbursement for our products by third-party payors will have an effect on our ability to successfully commercialize those products. Moreover, we are initially developing product candidates targeting rare muscle disorders with small patient populations. In order for products that are designed to treat smaller patient populations to be commercially viable, the reimbursement for such products must be higher, on a relative basis, to account for the lack of volume. Accordingly, we will need to implement a coverage and reimbursement strategy for any approved product candidate with a smaller patient population that accounts for the smaller potential market size. Even if we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization.

We cannot be sure that coverage and reimbursement in the United States, the European Union or elsewhere will be available for any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.

Third-party payors increasingly are challenging prices charged for biopharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor may consider our products as substitutable and only offer to reimburse patients for the less expensive product. Even if we are successful in demonstrating improved efficacy or improved convenience of administration with our products, pricing of existing drugs may limit the amount we will be able to charge for our products. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our products and may not be able to obtain a satisfactory financial return on products that we may develop.

There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs will be covered. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our products.

Obtaining and maintaining reimbursement status is time consuming, costly and uncertain. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs. However, no uniform

54

 

policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely.

Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe and other countries has and will continue to put pressure on the pricing and usage of our products. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our products. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.

Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our products. We expect to experience pricing pressures in connection with the sale of any of our products due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.

We face significant competition, and if our competitors develop technologies or product candidates more rapidly than we do or their technologies are more effective, our business and our ability to develop and successfully commercialize products may be adversely affected.

The biotechnology and biopharmaceutical industries are characterized by rapid advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products, product candidates and processes competitive with our product candidates. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may attempt to develop product candidates. In particular, there is intense competition amongst RNA targeted therapies. Our competitors include larger and better funded pharmaceutical, biopharmaceutical, biotechnological and therapeutics companies. Moreover, we may also compete with universities and other research institutions who may be active in the indications we are targeting and could be in direct competition with us. We also compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites, enrolling subjects for clinical trials and in identifying and in-licensing new product candidates. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.

We expect to face competition from existing products and products in development for each of our product candidates. With respect to AOC 1001, there are currently no approved therapies to treat the underlying cause of DM1. Products currently in development to treat DM1 include: tideglusib, a GSK3-ß inhibitor in late-stage clinical development by AMO Pharma for the congenital phenotype of DM1; AT466, which is an AAV-antisense candidate in preclinical development by Astellas Gene Therapies; an antibody linked oligonucleotide in preclinical development by Dyne Therapeutics Inc.; gene editing treatments in preclinical development by Vertex Pharmaceuticals, Inc.; an RNA-targeting gene therapy in preclinical

55

 

development by Locana, Inc.; and small molecules interacting with RNA in preclinical development by Expansion Therapeutics. There are a growing number of companies pursuing different paths to treat DM1 and we expect that the space will continue to evolve as additional candidates advance.

There are currently no therapies to treat the underlying cause of facioscapulohumeral muscular dystrophy, or FSHD. Products currently in development to treat FSHD include: creatine monohydrate, a supplement that enhances muscle performance, which is being evaluated in a Phase 2 clinical trial by Murdoch Children’s Research Institute; losmapimod, a p38 MAPK inhibitor that may modulate DUX4 expression, which is being evaluated in a Phase 2 clinical trial by Fulcrum Therapeutics Inc. an antibody linked oligonucleotide in preclinical development by Dyne Therapeutics Inc.; and a ligand conjugated oligonucleotide in preclinical development by Arrowhead Therapeutics.

The only approved therapies for Pompe disease are Lumizyme (known as Myozyme outside of the United States) and Nexviazyme, ERTs delivered by bi-weekly intravenous infusion, and marketed by Sanofi Genzyme. We are aware of multiple ERT therapies in clinical development, including AT-GAA, which uses a pharmacological chaperone, with a BLA under FDA review submitted by Amicus Therapeutics, Inc. In addition, several companies are developing gene therapies, including Actus Therapeutics, Inc. (ACTUS101), Asklepios BioPharmaceutical, Inc. (AAV2/8-LSPhGAA), Astellas Gene Therapeutics (AT845) and Spark Therapeutics, Inc. (SPK-3006).

Currently people with DMD are treated with corticosteroids to manage the inflammatory component of the disease. Deflazacort is an FDA approved corticosteroid marketed by PTC Therapeutics, Inc. In addition, there are three FDA approved exon skipping drugs marketed by Sarepta Therapeutics, Inc.: Eteplirsen, an unconjugated PMO approved for people with DMD amenable to skipping Exon 51; golodirsen for the treatment of people with DMD amenable to skipping Exon 53; and casimersen for the treatment of DMD in patients with a confirmed mutation amenable to exon 45 skipping. There is an FDA-approved exon skipping drug marketed by Nippon Shinyaku Co., Inc.: viltolarsen, an unconjugated PMO approved for people with DMD amenable to skipping Exon 53. Companies focused on developing treatments for DMD that target dystrophin mechanisms, as does our DMD program, include Sarepta Therapeutics with SRP-5051, a PPMO currently being evaluated in a Phase 2 clinical trial for patients amenable to Exon 51 skipping , and PTC Therapeutics with ataluren, a small molecule targeting nonsense mutations in a Phase 3 clinical trial. In addition, several companies are developing gene therapies, including Milo Biotechnology (AAV1-FS344), Pfizer (PF-06939926), Sarepta Therapeutics (SRP-9001 and Galgt2 gene therapy program), and Solid Biosciences Inc. (SGT-001). Dyne Therapeutics Inc. has submitted an IND to the FDA to initiate a clinical trial of DYNE-251, a PMO conjugated to an antibody  for treatment of patients with DMD amendable to skipping exon 51. We are also aware of several companies targeting non-dystrophin mechanisms for the treatment of DMD.

Current treatments for muscle atrophy are primarily focused on nutritional intake and physical exercise. Other products in developments for muscle atrophy in cachexia include: adlumiz and AEZS-130, which are ghrelin agonists in a Phase 3 clinical trial by Helsinn Healthcare SA and a Phase 2 trial by Aeterna Zentaris Inc., respectively; GSK2881078, an androgen receptor modulator in Phase 2 clinical in development by GlaxoSmithKline plc; NGM120, a GSF15 inhibitor by NGM Biopharmaceuticals Inc.; and PF-06946860 in Phase 1 clinical development by Pfizer Inc.

We will also compete more generally with other companies developing alternative scientific and technological approaches, including other companies working to develop conjugates with oligonucleotides for extra-hepatic delivery, including Alnylam Pharmaceuticals, Aro Biotherapeutics, Arrowhead Therapeutics, Dyne Therapeutics, Ionis Pharmaceuticals, Sarepta Therapeutics, DTx Pharma, Inc., PepGen, Inc., PeptiDream Inc. and Bicycle Therapeutics, as well as gene therapy and CRISPR approaches.

Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered and the extent to which patients

56

 

accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive or marketed and sold more effectively than any products we may develop. Competitive products or technological approaches may make any products we develop, or our AOC platform, obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected.

If the market opportunities for our products are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.

The precise incidence and prevalence for all the conditions we aim to address with our product candidates are unknown. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new trials may change the estimated incidence or prevalence of these diseases. The total addressable market across all of our product candidates will ultimately depend upon, among other things, the diagnosis criteria included in the final label for each of our product candidates approved for sale for these indications, the availability of alternative treatments and the safety, convenience, cost and efficacy of our product candidates relative to such alternative treatments, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients in the United States and other major markets and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. Further, even if we obtain significant market share for our product candidates, because some of our potential target populations are very small, we may never achieve profitability despite obtaining such significant market share.

We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.

We have no internal sales, marketing or distribution capabilities, nor have we commercialized a product. If any of our product candidates ultimately receives regulatory approval, we must build a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in major markets, which will be expensive and time consuming, or collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We have no prior experience as a company in the marketing, sale and distribution of biopharmaceutical products and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we are not successful in commercializing our products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.

57

 

Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.

Our future growth may depend, in part, on our ability to develop and commercialize our product candidates in foreign markets. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive such regulatory approvals for any of our product candidates. To obtain separate regulatory approval in many other countries we must comply with numerous and varying regulatory requirements regarding safety and efficacy and governing, among other things, clinical trials, commercial sales, pricing and distribution of our product candidates. If we obtain regulatory approval of our product candidates and ultimately commercialize our products in foreign markets, we would be subject to additional risks and uncertainties, including:

 

•

different regulatory requirements for approval of drugs in foreign countries;

 

•

reduced protection for intellectual property rights;

 

•

the existence of additional third-party patent rights of potential relevance to our business;

 

•

unexpected changes in tariffs, trade barriers and regulatory requirements;

 

•

economic weakness, including inflation, or political instability in particular foreign economies and markets;

 

•

compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;

 

•

foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;

 

•

foreign reimbursement, pricing and insurance regimes;

 

•

workforce uncertainty in countries where labor unrest is common;

 

•

production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and

 

•

business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires.

Risks Related to Our Business Operations and Industry

Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.

Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:

 

•

the timing and cost of, and level of investment in, research, development, regulatory approval and commercialization activities relating to our product candidates, which may change from time to time;

 

•

coverage and reimbursement policies with respect to our product candidates, if approved, and potential future drugs that compete with our products;

 

•

the cost of manufacturing our product candidates, which may vary depending on the quantity of production and the terms of our agreements with third-party manufacturers;

 

•

the timing and amount of the milestone or other payments we may receive under the Lilly Agreement;

58

 

 

•

expenditures that we may incur to acquire, develop or commercialize additional product candidates and technologies;

 

•

the level of demand for any approved products, which may vary significantly;

 

•

future accounting pronouncements or changes in our accounting policies; and

 

•

the timing and success or failure of preclinical studies or clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners.

The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.

This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide.

We are dependent on the services of our management and other clinical and scientific personnel, and if we are not able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer.

Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. We are highly dependent upon our senior management,  as well as our senior scientists and other members of our management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, initiation or completion of our preclinical studies and clinical trials or the commercialization of our product candidates. Although we have executed employment agreements or offer letters with each member of our senior management team, these agreements are terminable at will with or without notice and, therefore, we may not be able to retain their services as expected. We do not currently maintain “key person” life insurance on the lives of our executives or any of our employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals.

We will need to expand and effectively manage our managerial, operational, financial and other resources in order to successfully pursue our clinical development and commercialization efforts. We may not be successful in maintaining our unique company culture and continuing to attract or retain qualified management and scientific and clinical personnel in the future due to the intense competition for qualified personnel among biopharmaceutical, biotechnology and other businesses, particularly in the San Diego area. Our industry has experienced a high rate of turnover of management personnel in recent years. If we are not able to attract, integrate, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.

We may encounter difficulties in managing our growth and expanding our operations successfully.

We had 118 full-time employees as of December 31, 2021. As we continue development and pursue the potential commercialization of our product candidates, as well as function as a public company, we will need to expand our financial, development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with various strategic partners, suppliers and other third parties.

59

 

Our future financial performance and our ability to develop and commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively.

We are subject to various federal, state and foreign healthcare laws and regulations, which could increase compliance costs, and our failure to comply with these laws and regulations could harm our results of operations and financial condition.

Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors and customers expose us to broadly applicable foreign, federal and state fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute any products for which we obtain marketing approval. Such laws include:

 

•

the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe or certain rebates), directly or indirectly, overtly or covertly, in cash or in kind, in return for, either the referral of an individual or the purchase, lease, or order, or arranging for or recommending the purchase, lease, or order of any good, facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation;

 

•

the federal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making or causing to be made a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;

 

•

the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;

 

•

the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare & Medicaid Services, or CMS, information related to payments and other “transfers of value” made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other healthcare professionals (including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiology assistants and certified nurse midwives) and teaching hospitals, as well as ownership and investment interests held by such healthcare professionals and their immediate family members;

 

•

analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers;

 

•

some state laws require biotechnology companies to comply with the biotechnology industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the

60

 

 

federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and

 

•

some state laws that require biotechnology companies to report information on the pricing of certain drug products; and some state and local laws require the registration or pharmaceutical sales representatives.

Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve ongoing substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare program.

Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and commercialize our product candidates and may affect the prices we may set.

In the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system, including cost-containment measures that may reduce or limit coverage and reimbursement for newly approved drugs and affect our ability to profitably sell any product candidates for which we obtain marketing approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare.

For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, was enacted in the United States. Among the provisions of the Affordable Care Act of importance to our potential product candidates, the Affordable Care Act: established an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents; extended manufacturers’ Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; expands eligibility criteria for Medicaid programs; expands the entities eligible for discounts under the Public Health program; increases the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; creates a new Medicare Part D coverage gap discount program; establishes a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research; and establishes a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending.

Since its enactment, there have been executive, judicial and Congressional challenges to certain aspects of the ACA, and on June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court’s decision, President Biden had issued an executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to

61

 

healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how the healthcare reform measures of the Biden administration, or other efforts to challenge the ACA, if any, will impact the ACA or our business.

In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, resulted in reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional Congressional action is taken. In addition, on January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.

Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. It is unclear whether the new Biden administration will continue to seek new legislative and/or administrative measures to control drug costs. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors.

At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates, if approved, or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects.

We expect that the ACA, these new laws and other healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates, if approved.

If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products.

We face an inherent risk of product liability as a result of the clinical trials of our product candidates and will face an even greater risk if we commercialize our product candidates. For example, we may be sued if our product candidates allegedly cause injury or are found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability and a breach of warranties. Claims may be brought against us by clinical trial participants, patients or others using, administering or selling products that may be approved in the future. Claims could also be asserted under state consumer protection acts.

62

 

If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or cease the commercialization of our products. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:

 

•

decreased demand for our products;

 

•

injury to our reputation and significant negative media attention;

 

•

withdrawal of clinical trial participants;

 

•

costs to defend the related litigation;

 

•

a diversion of our management’s time and our resources;

 

•

substantial monetary awards to trial participants or patients;

 

•

product recalls, withdrawals or labeling, marketing or promotional restrictions;

 

•

significant negative financial impact;

 

•

the inability to commercialize our product candidates; and

 

•

a decline in our stock price.

We currently hold approximately $10 million in product liability insurance coverage in the aggregate. We may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of our product candidates. Although we will maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies will also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.

Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities.

We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include property, general liability, employment benefits liability, business automobile, workers’ compensation, malicious invasion of our electronic systems, directors’ and officers’, employment practices and fiduciary liability insurance, and plan to obtain product liability insurance coverage prior to commencing clinical trials. We do not know, however, if we will be able to maintain insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our financial position and results of operations.

We and any of our current and potential future collaborators will be required to report to regulatory authorities if any of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business.

If we or any of our current and potential future collaborators are successful in commercializing our products, the FDA and foreign regulatory authorities would require that we and such collaborators report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We and any of our current or potential future collaborators or CROs may fail to report adverse events within the prescribed timeframe. If we or any of our current or potential future collaborators or CROs fail to comply with such reporting obligations, the FDA

63

 

or a foreign regulatory authority could take action, including criminal prosecution, the imposition of civil monetary penalties, seizure of our products or delay in approval or clearance of future products.

The COVID-19 pandemic and other epidemic diseases could adversely impact our business, including our preclinical studies, planned clinical trials and financial condition.

The COVID-19 worldwide pandemic has presented substantial public health and economic challenges and is affecting our employees, clinical trial subjects, physicians and other healthcare providers, communities and business operations, as well as the U.S. and global economies and financial markets. International and U.S. governmental authorities in impacted regions have taken, and are continuing to take, actions in an effort to slow the spread of COVID-19 and variants of the virus.  In December 2021, we began to transition to a hybrid model with our employees generally working both remotely and onsite, and we anticipate we will continue to use this model going forward. The continuing COVID-19 pandemic and any future epidemic diseases may cause disruptions that could severely impact our business, preclinical studies, planned clinical trials and financial condition, including:

 

•

delays or difficulties in enrolling patients in our preclinical studies or clinical trials;

 

•

delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and staff;

 

•

interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems;

 

•

interruptions in preclinical studies due to restricted or limited operations at our laboratory facility or those of our outsourced service providers;

 

•

limitations on employee resources that would otherwise be focused on the conduct of our preclinical studies or clinical trials due to sickness of employees or their families or the desire of employees to avoid contact with large groups of people, or other staffing shortages as a result of remote working requirements or otherwise;

 

•

delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials and interruption in global shipping that may affect the transport of clinical trial materials;

 

•

diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;  

 

•

interruption of key clinical trial activities, such as clinical trial site monitoring and source data verification, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical study endpoints;

 

•

interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines;

 

•

delays in receiving authorization from local regulatory authorities to initiate our planned clinical trials;

 

•

changes in local regulations as part of a response to COVID-19 which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue such clinical trials altogether;

 

•

delays in necessary interactions with local regulators, ethics committees, and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees;

 

•

refusal of the FDA to accept data from clinical trials in affected geographies outside the United States;

64

 

 

•

interruption or delays to our pipeline of AOC development programs; and

 

•

patent office interruption or delays in our ability to timely secure patent coverage for our product candidates.

The COVID-19 pandemic continues to rapidly evolve. The extent to which the COVID-19 may impact our business, including our preclinical studies, planned clinical trials, and financial condition will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the continued geographic spread of variants, the duration of the pandemic, the timing and effectiveness of vaccine distribution, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.

To the extent the COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this section. In addition, if in the future there is an outbreak of another highly infectious or contagious disease or other health concern, we may be subject to similar risks as posed by COVID-19.

Our business could be affected by litigation, government investigations and enforcement actions.

We currently operate in a number of jurisdictions in a highly regulated industry and we could be subject to litigation, government investigation and enforcement actions on a variety of matters in the United States or foreign jurisdictions, including, without limitation, intellectual property, regulatory, product liability, environmental, whistleblower, false claims, privacy, anti-kickback, anti-bribery, securities, commercial, employment and other claims and legal proceedings which may arise from conducting our business. Any determination that our operations or activities are not in compliance with existing laws or regulations could result in the imposition of fines, civil and criminal penalties, equitable remedies, including disgorgement, injunctive relief and/or other sanctions against us, and remediation of any such findings could have an adverse effect on our business operations.

Legal proceedings, government investigations and enforcement actions can be expensive and time consuming. An adverse outcome resulting from any such proceeding, investigations or enforcement actions could result in significant damages awards, fines, penalties, exclusion from the federal healthcare programs, healthcare debarment, injunctive relief, product recalls, reputational damage and modifications of our business practices, which could have a material adverse effect on our business and results of operations.

Our employees and independent contractors, including principal investigators, CROs, consultants and vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.

We are exposed to the risk that our employees and independent contractors, including principal investigators, CROs, consultants and vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate: (i) the laws and regulations of the FDA and other similar regulatory requirements, including those laws that require the reporting of true, complete and accurate information to such authorities, (ii) manufacturing standards, including cGMP requirements, (iii) federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad or (iv) laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none

65

 

occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management.

From time to time, we may consider strategic transactions, such as acquisitions of companies, asset purchases and out-licensing or in-licensing of intellectual property, products or technologies. Additional potential transactions that we may consider in the future include a variety of business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Any future transactions could increase our near and long-term expenditures, result in potentially dilutive issuances of our equity securities, including our common stock, or the incurrence of debt, contingent liabilities, amortization expenses or acquired in-process research and development expenses, any of which could affect our financial condition, liquidity and results of operations. Future acquisitions may also require us to obtain additional financing, which may not be available on favorable terms or at all.

These transactions may never be successful and may require significant time and attention of our management. In addition, the integration of any business that we may acquire in the future may disrupt our existing business and may be a complex, risky and costly endeavor for which we may never realize the full benefits of the acquisition. Accordingly, although there can be no assurance that we will undertake or successfully complete any additional transactions of the nature described above, any additional transactions that we do complete could have a material adverse effect on our business, results of operations, financial condition and prospects.

Our ability to use net operating loss carryforwards and other tax attributes may be limited.

We have incurred substantial losses during our history, do not expect to become profitable in the near future and may never achieve profitability. To the extent that we continue to incur losses for tax purposes, or NOLs, such NOLs will carry forward to offset future taxable income, if any, until such unused losses expire (if subject to expiration). At December 31, 2021, we had federal and state NOLs of approximately $147.9 million and $147.7 million, respectively.

Under the Tax Act, as modified by the CARES Act, federal NOLs generated in periods after December 31, 2017, may be carried forward indefinitely but may only be used to offset 80% of our taxable income in years beginning after December 31, 2020. Under the CARES Act, NOLs arising in tax years beginning after December 31, 2017 and before January 1, 2021 may be carried back to each of the five tax years preceding the tax year of such loss. Because we had no taxable income in our tax year ended December 31, 2019, which was our first corporate tax year, we do not anticipate that such provision of the CARES Act will be relevant to us. It is uncertain if and to what extent various states will conform to the Tax Act or the CARES Act.

In addition, our NOLs and other tax attributes are subject to review and possible adjustment by the IRS, and state tax authorities. Under Section 382 of the Code, our federal NOLs may become subject to an annual limitation in the event of certain cumulative changes in the ownership of our company. An “ownership change” pursuant to Section 382 of the Code generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a company’s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. Our ability to

66

 

utilize our NOLs and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including potential changes in connection with our initial public offering, or IPO, that was completed in June 2020 or future offerings. Similar rules may apply under state tax laws. We have not yet determined the amount of the cumulative change in our ownership resulting from our IPO or other transactions, or any resulting limitations on our ability to utilize our NOLs and other tax attributes. If we earn taxable income, such limitations could result in increased future income tax liability to us and our future cash flows could be adversely affected. We have recorded a full valuation allowance related to our NOLs and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits of those assets.

Risks Related to Our Intellectual Property

If we are unable to obtain and maintain patent protection for our therapeutic programs and other proprietary technologies we develop, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our therapeutic programs and other proprietary technologies we may develop may be adversely affected.

Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our therapeutic programs and other proprietary technologies we may develop. We seek to protect our proprietary position, in part, by filing patent applications in the United States and abroad relating to our therapeutic programs and other proprietary technologies we may develop. If we are unable to obtain or maintain patent protection with respect to our therapeutic programs and other proprietary technologies we may develop, our business, financial condition, results of operations and prospects could be materially harmed.

Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions, obtain, maintain and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our protection. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection against competitors or other third parties.

The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner, including delays as a result of the COVID-19 pandemic impacting our or our licensor’s operations. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art.

Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in any of our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions. The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our patent applications may not result in patents being issued which protect our therapeutic programs and

67

 

other proprietary technologies we may develop or which effectively prevent others from commercializing competitive technologies and products.

Moreover, the claim coverage in a patent application can be significantly reduced before the patent is granted. Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Any patents issuing from our patent applications may be challenged, narrowed, circumvented or invalidated by third parties. Consequently, we do not know whether our therapeutic programs and other proprietary technology will be protectable or remain protected by valid and enforceable patents. Even if a patent is granted, our competitors or other third parties may be able to circumvent the patent by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and prospects. In addition, given the amount of time required for the development, testing and regulatory review of our therapeutic programs and eventual product candidates, patents protecting the product candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.

The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability and our patents may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third-party pre-issuance submission of prior art to the United States Patent and Trademark Office, or the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant and inter partes review, or other similar proceedings challenging our patent rights. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize our therapeutic programs and other proprietary technologies we may develop and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us.

We may not be able to protect our intellectual property and proprietary rights throughout the world.

Filing, prosecuting and defending patents on our therapeutic programs and other proprietary technologies we may develop in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. In addition, some jurisdictions, such as Europe, Japan and China, may have a higher standard for patentability than in the United States, including, for example, the requirement of claims having literal support in the original patent filing and the limitation on using supporting data that is not in the original patent filing. Under those heightened patentability requirements, we may not be able to obtain sufficient patent protection in certain jurisdictions even though the same or similar patent protection can be secured in U.S. and other jurisdictions.

68

 

Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop.

Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.

Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned or licensed patents and applications. In certain circumstances, we rely on our licensing partners to pay these fees due to U.S. and non-U.S. patent agencies. The USPTO and various non-U.S. government agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.

Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.

Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent.

After March 2013, under the Leahy-Smith America Invents Act, or the America Invents Act, enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to either (i) file any patent application related to our therapeutic programs and other proprietary technologies we may develop or (ii) invent any of the inventions claimed in our patent applications.

69

 

The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of patents issuing from those patent applications, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.

In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.

Issued patents covering our therapeutic programs and other proprietary technologies we may develop could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad.

If we initiated legal proceedings against a third party to enforce a patent covering our therapeutic programs and other proprietary technologies we may develop, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may raise claims challenging the validity or enforceability of a patent before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, inter partes review, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation of, cancellation of or amendment to our patents in such a way that they no longer cover our therapeutic programs and other proprietary technologies we may develop. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we or our licensing partners and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our therapeutic programs and other proprietary technologies we may develop. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations and prospects.

If we do not obtain patent term extension for our product candidate, our business may be materially harmed.

Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidate we may develop, one or more of patents issuing from our U.S. patent applications may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984, or the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term

70

 

extension, or PTE, of up to five years as compensation for patent term lost during the FDA regulatory review process. A PTE cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. Similar patent term restoration provisions to compensate for commercialization delay caused by regulatory review are also available in certain foreign jurisdictions, such as in Europe under Supplemental Protection Certificate, or SPC.

We may be subject to claims challenging the inventorship of our patents and other intellectual property.

We may be subject to claims that former employees, collaborators or other third parties have an interest in our patent rights, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our therapeutic programs and other proprietary technologies we may develop. Litigation may be necessary to defend against these and other claims challenging inventorship or our patent rights, trade secrets or other intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our therapeutic programs and other proprietary technologies we may develop. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.

If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.

In addition to seeking patent protection for our therapeutic programs and other proprietary technologies we may develop, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology, and other proprietary information and to maintain our competitive position. With respect to our AOC platform and development programs, we consider trade secrets and know-how to be one of our important sources of intellectual property, including our extensive knowledge of the modulation of RNA processes using oligonucleotides and siRNA, oligonucleotide drug delivery techniques and antibody conjugation. Trade secrets and know-how can be difficult to protect. In particular, the trade secrets and know-how in connection with our AOC platform, development programs and other proprietary technology we may develop may over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology and the movement of personnel with scientific positions in academic and industry.

We seek to protect these trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed.

71

 

We may be subject to claims that third parties have an ownership interest in our trade secrets. For example, we may have disputes arise from conflicting obligations of our employees, consultants or others who are involved in developing our product candidate. Litigation may be necessary to defend against these and other claims challenging ownership of our trade secrets. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable trade secret rights, such as exclusive ownership of, or right to use, trade secrets that are important to our therapeutic programs and other proprietary technologies we may develop. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our management and other employees.

We may not be successful in obtaining necessary rights to any product candidate we may develop through acquisitions and in-licenses.

We currently solely own intellectual property rights covering our therapeutic programs. Other pharmaceutical companies and academic institutions may also have filed or are planning to file patent applications potentially relevant to our business. In order to avoid infringing these third-party patents, we may find it necessary or prudent to obtain licenses to such patents from such third-party intellectual property holders. However, we may be unable to secure such licenses or otherwise acquire or in-license any compositions, methods of use, processes or other intellectual property rights from third parties that we identify as necessary for our therapeutic programs and other proprietary technologies we may develop.

The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations and prospects.

We may be subject to claims that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.

Some of our employees, consultants and advisors are currently or were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual’s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our management.

In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations and prospects.

72

 

Third-party claims of intellectual property infringement, misappropriation or other violations against us or our collaborators may prevent or delay the development and commercialization of our therapeutic programs and other proprietary technologies we may develop.

Our commercial success depends in part on our ability to avoid infringing, misappropriating and otherwise violating the patents and other intellectual property rights of third parties. There is a substantial amount of complex litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. As discussed above, recently, due to changes in U.S. law referred to as patent reform, new procedures including inter partes review and post-grant review have also been implemented. As stated above, this reform adds uncertainty to the possibility of challenge to our patents in the future.

Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are commercializing or plan to commercialize our therapeutic programs and in which we are developing other proprietary technologies. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our therapeutic programs and commercializing activities may give rise to claims of infringement of the patent rights of others. We cannot assure you that our therapeutic programs and other proprietary technologies we may develop will not infringe existing or future patents owned by third parties. We may not be aware of patents that have already been issued and that a third party, for example, a competitor in the fields in which we are developing our therapeutic programs, might assert as infringed by us. It is also possible that patents owned by third parties of which we are aware, but which we do not believe we infringe or that we believe we have valid defenses to any claims of patent infringement, could be found to be infringed by us. It is not unusual that corresponding patents issued in different countries have different scopes of coverage, such that in one country a third-party patent does not pose a material risk, but in another country, the corresponding third-party patent may pose a material risk to our planned products. As such, we monitor third-party patents in the relevant pharmaceutical markets. In addition, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that we may infringe.

In the event that any third party claims that we infringe their patents or that we are otherwise employing their proprietary technology without authorization and initiates litigation against us, even if we believe such claims are without merit, a court of competent jurisdiction could hold that such patents are valid, enforceable and infringed by us. In this case, the holders of such patents may be able to block our ability to commercialize the infringing products or technologies unless we obtain a license under the applicable patents, or until such patents expire or are finally determined to be held invalid or unenforceable. Such a license may not be available on commercially reasonable terms or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize the infringing products or technologies or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business.

Defense of infringement claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business, and may impact our reputation. In the event of a successful claim of infringement against us, we may be enjoined from further developing or commercializing the infringing products or technologies. In addition, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, obtain one or more licenses from third parties, pay royalties and/or redesign our infringing products or technologies, which may be impossible or require substantial time and monetary expenditure. In that event, we would be unable to further develop and commercialize our product candidate or technologies, which could harm our business significantly. Further, we cannot predict whether any required license would be available at all or whether it would be available on commercially reasonable terms. In the event that we could not obtain a license, we may be unable to further develop our product candidate and commercialize

73

 

our product, if approved, which could harm our business significantly. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms.

Engaging in litigation defending against third parties alleging infringement of patent and other intellectual property rights is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition or results of operations.

We may in the future pursue invalidity proceedings with respect to third-party patents. The outcome following legal assertions of invalidity is unpredictable. Even if resolved in our favor, these legal proceedings may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such proceedings adequately. Some of these third parties may be able to sustain the costs of such proceedings more effectively than we can because of their greater financial resources. If we do not prevail in the patent proceedings the third parties may assert a claim of patent infringement directed at our product candidates.

We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming and unsuccessful.

Third parties, such as a competitor, may infringe our patent rights. In an infringement proceeding, a court may decide that a patent owned by us is invalid or unenforceable or may refuse to stop the other party from using the invention at issue on the grounds that the patent does not cover the technology in question. In addition, our patent rights may become involved in inventorship, priority or validity disputes. To counter or defend against such claims can be expensive and time consuming. An adverse result in any litigation proceeding could put our patent rights at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.

Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.

74

 

If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, which may not survive such proceedings. Moreover, any name we have proposed to use with our product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA or an equivalent administrative body in a foreign jurisdiction objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark.

We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, domain name or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and prospects.

Intellectual property rights do not necessarily address all potential threats.

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:

 

•

others may be able to make products that are similar to our product candidate or utilize similar technology but that are not covered by the claims of the patents that we license or may own;

 

•

we might not have been the first to make the inventions covered by our current or future patent applications;

 

•

we might not have been the first to file patent applications covering our inventions;

 

•

others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;

 

•

it is possible that our current or future patent applications will not lead to issued patents;

 

•

any patent issuing from our current or future patent applications may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties;

 

•

our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;

75

 

 

•

we may not develop additional proprietary technologies that are patentable;

 

•

the patents of others may harm our business; and

 

•

we may choose not to file for patent protection in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent application covering such intellectual property.

We partially depend on intellectual property licensed from third parties, and our licensors may not always act in our best interest. If we fail to comply with our obligations under our intellectual property licenses, if the licenses are terminated or if disputes regarding these licenses arise, we could lose significant rights that are important to our business.

We are dependent, in part, on patents, know-how and proprietary technology licensed from others. Our licenses to such patents, know-how and proprietary technology may not provide exclusive rights in all relevant fields of use and in all territories in which we may wish to develop or commercialize our products in the future. The agreements under which we license patents, know-how and proprietary technology from others are complex, and certain provisions in such agreements may be susceptible to multiple interpretations.

For example, we are a party to an exclusive option agreement to obtain an exclusive worldwide license with the University of Alberta, pursuant to which we have the option to in-license key patent applications for our Exon 51 skipping AOC for DMD and future product candidates. If we decide to exercise this option, this agreement imposes various diligence, milestone payment, royalty, insurance and other obligations on us and any future license agreements we enter into may do the same. If we fail to comply with obligations under any license agreements, our licensors may have the right to terminate our license, in which event we would not be able to develop or market technology or product candidates covered by the intellectual property licensed under these agreements. In addition, we may need to obtain additional licenses from our existing licensors and others to advance our research or allow commercialization of product candidates we may develop. It is possible that we may be unable to obtain any additional licenses at a reasonable cost or on reasonable terms, if at all. In either event, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology or product candidates.

If we or our licensors fail to adequately protect our licensed intellectual property, our ability to commercialize product candidates could suffer. We do not have complete control over the maintenance, prosecution and litigation of our in-licensed patents and patent applications and may have limited control over future intellectual property that may be in-licensed. For example, we cannot be certain that activities such as the maintenance and prosecution by our licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. It is possible that our licensors’ infringement proceedings or defense activities may be less vigorous than had we conducted them ourselves or may not be conducted in accordance with our best interests.

In addition, the resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant patents, know-how and proprietary technology, or increase what we believe to be our financial or other obligations under the relevant agreement. Disputes that may arise between us and our licensors regarding intellectual property subject to a license agreement could include disputes regarding:

 

•

the scope of rights granted under the license agreement and other interpretation-related issues;

 

•

whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;

76

 

 

•

our right to sublicense patent and other rights to third parties under collaborative development relationships;

 

•

our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates and what activities satisfy those diligence obligations; and

 

•

the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us.

If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected technology or product candidates. As a result, any termination of or disputes over our intellectual property licenses could result in the loss of our ability to develop and commercialize our AOC platform, or AOC products, or we could lose other significant rights, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects.

For example, our agreements with certain of our third-party research partners provide that improvements developed in the course of our relationship may be owned solely by either us or our third-party research partner, or jointly between us and the third party. If we determine that rights to such improvements owned solely by a research partner or other third party with whom we collaborate are necessary to commercialize our product candidates or maintain our competitive advantage, we may need to obtain a license from such third party in order to use the improvements and continue developing, manufacturing or marketing our product candidates. We may not be able to obtain such a license on an exclusive basis, on commercially reasonable terms, or at all, which could prevent us from commercializing our product candidates or allow our competitors or others the chance to access technology that is important to our business. We also may need the cooperation of any co-owners of our intellectual property in order to enforce such intellectual property against third parties, and such cooperation may not be provided to us.

We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.

The growth of our business may depend in part on our ability to acquire, in-license or use third-party proprietary rights. For example, our product candidates may require specific formulations to work effectively and efficiently, we may develop product candidates containing our compounds and pre-existing pharmaceutical compounds, or we may be required by the FDA or comparable foreign regulatory authorities to provide a companion diagnostic test or tests with our product candidates, any of which could require us to obtain rights to use intellectual property held by third parties. In addition, with respect to any patents we may co-own with third parties, we may require licenses to such co-owners’ interest to such patents. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary or important to our business operations. In addition, we may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. Were that to happen, we may need to cease use of the compositions or methods covered by those third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on those intellectual property rights, which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be non-exclusive, which means that our competitors may also receive access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology.

Additionally, we sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution’s rights in technology resulting from the collaboration. Even if we hold such an option, we may be unable to negotiate a license from the institution within the specified timeframe or under terms that are acceptable to us. If we are unable

77

 

to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program.

The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies that may be more established or have greater resources than we do may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. There can be no assurance that we will be able to successfully complete these types of negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to develop or market. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of certain programs and our business financial condition, results of operations and prospects could suffer.

We, our collaborators and our service providers may be subject to a variety of privacy and data security laws and contractual obligations, which could increase compliance costs and our failure to comply with them could subject us to potentially significant fines or penalties and otherwise harm our business.

We maintain a large quantity of sensitive information, including confidential business and patient health information in connection with our preclinical studies, and are subject to laws and regulations governing the privacy and security of such information. The global data protection landscape is rapidly evolving, and we may be affected by or subject to new, amended or existing laws and regulations in the future, including as our operations continue to expand or if we operate in foreign jurisdictions. These laws and regulations may be subject to differing interpretations, which adds to the complexity of processing personal information. Guidance on implementation and compliance practices are often updated or otherwise revised.

In the United States, there are numerous federal and state privacy and data security laws and regulations governing the collection, use, disclosure and protection of personal information, including federal and state health information privacy laws, security breach notification laws and consumer protection laws. Each of these laws is subject to varying interpretations and constantly evolving. By way of example, the regulations promulgated under HIPAA and the Health Information Technology for Economic and Clinical Health Act impose privacy and security requirements and breach reporting obligations with respect to individually identifiable health information upon “covered entities” (health plans, health care clearinghouses and certain health care providers), and their respective business associates, individuals or entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. The HIPAA breach notification rule mandates the reporting of certain breaches of health information to the U.S. Department of Health and Human Services, or HHS, affected individuals and if the breach is large enough, the media. Entities that are found to be in violation of HIPAA as the result of a breach of unsecured protected health information, a complaint about privacy practices or an audit by HHS, may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance. Even when HIPAA does not apply, according to the FTC failing to take appropriate steps to keep consumers’ personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company’s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards.

In addition, certain state laws govern the privacy and security of health-related and other personal information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance

78

 

efforts. By way of example, the CCPA, which went into effect on January 1, 2020, gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. Some observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the United States, which could increase our potential liability and adversely affect our business. Further, the CPRA recently passed in California. The CPRA will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.

In Europe, the GDPR took effect in May 2018. The GDPR governs the collection, use, disclosure, transfer or other processing of personal data of individuals within the EEA. Among other things, the GDPR imposes requirements regarding the security of personal data and notification of data processing obligations to the competent national data processing authorities, changes the lawful bases on which personal data can be processed, expands the definition of personal data and requires changes to informed consent practices, as well as detailed notices for clinical trial subjects and investigators. In addition, the GDPR increases the scrutiny of transfers of personal data from clinical trial sites located in the EEA to the United States and other jurisdictions that the European Commission does not recognize as having “adequate” data protection laws, and imposes substantial fines for breaches and violations (up to the greater of €20 million or 4% of our consolidated annual worldwide gross revenue). For example, in 2016, the EU and United States agreed to a transfer framework for data transferred from the EU to the United States, called the Privacy Shield, but the Privacy Shield was invalidated in July 2020 by the Court of Justice of the European Union. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR. Further, from January 1, 2021, companies have to comply with the GDPR and also the United Kingdom GDPR (UK GDPR), which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of €20 million (£17.5 million) or 4% of global turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, and it is unclear how United Kingdom data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the United Kingdom will be regulated in the long term. On June 28, 2021, the EU Commission published its adequacy decision to designate the United Kingdom as adequate. This adequacy decision is expected to last until June 27, 2025, although the Commission will begin an assessment in late 2024 to decide whether to extend the adequacy decision for a further period up to a maximum of another four years. If the Commission don’t extend the decision, then the UK’s adequacy decision will expire on June 27, 2025. These changes may lead to additional costs and increase our overall risk exposure. Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely affect our business, financial condition and results of operations.

Our use of open source software could impose limitations on our ability to commercialize our product candidates.

Our use of open source software could impose limitations on our ability to commercialize our product candidates. As a result, as we seek to use our platform in connection with commercially available products, we may be required to license that software under different license terms, which may not be possible on commercially reasonable terms, if at all. If we are unable to license software components on terms that

79

 

permit its use for commercial purposes, we may be required to replace those software components, which could result in delays, additional cost and additional regulatory approvals.

Use and distribution of open source software may entail greater risks than use of third-party commercial software, as open source licensors generally do not provide warranties or other contractual protections regarding infringement claims or the quality of the software code. Some open source licenses contain requirements that we make available source code for modifications or derivative works we create based upon the type of open source software we use. If we combine our proprietary software with open source software in a certain manner, we could, under certain of the open source licenses, be required to release the source code of our proprietary software to the public. This could allow our competitors to create similar products with lower development effort and time, and ultimately could result in a loss of product sales for us. Although we monitor our use of open source software, the terms of many open source licenses have not been interpreted by U.S. courts, and there is a risk that those licenses could be construed in a manner that could impose unanticipated conditions or restrictions on our ability to commercialize our product candidates. We could be required to seek licenses from third parties in order to continue offering our product candidates, to re-engineer our product candidates or to discontinue the sale of our product candidates in the event re-engineering cannot be accomplished on a timely basis, any of which could materially and adversely affect our business, financial condition, results of operations and prospects.

Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and prospects.

Risks Related to Our Common Stock

The trading price of the shares of our common stock has been, and is likely to continue to be, highly volatile, and purchasers of our common stock could incur substantial losses.

Our stock price has been, and is likely to continue to be, volatile. The stock market in general and the market for stock of biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above the price at which they paid. The market price for our common stock may be influenced by those factors discussed in this “Risk Factors” section and many others, including:

 

•

results of our preclinical studies and clinical trials, and the results of trials of our competitors or those of other companies in our market sector;

 

•

our ability to enroll subjects in our future clinical trials;

 

•

regulatory approval of our product candidates, or limitations to specific label indications or patient populations for its use, or changes or delays in the regulatory review process;

 

•

regulatory developments in the United States and foreign countries;

 

•

changes in the structure of healthcare payment systems;

 

•

the success or failure of our efforts to develop, acquire or license additional product candidates;

 

•

innovations, clinical trial results, product approvals and other developments regarding our competitors;

 

•

announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;

 

•

manufacturing, supply or distribution delays or shortages;

 

•

any changes to our relationship with any manufacturers, suppliers, collaborators or other strategic partners;

 

•

achievement of expected product sales and profitability;

80

 

 

 

•

variations in our financial results or those of companies that are perceived to be similar to us;

 

•

market conditions in the biopharmaceutical sector and issuance of securities analysts’ reports or recommendations;

 

•

trading volume of our common stock;

 

•

an inability to obtain additional funding;

 

•

sales of our stock by insiders and stockholders;

 

•

general economic, industry and market conditions, other events or factors, many of which are beyond our control;

 

•

additions or departures of key personnel; and

 

•

intellectual property, product liability or other litigation against us.

In addition, in the past, stockholders have initiated class action lawsuits against biopharmaceutical companies following periods of volatility in the market prices of these companies’ stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert our management’s attention and resources, which could have a material adverse effect on our business, financial condition and results of operations.

An active, liquid and orderly market for our common stock may not be maintained.

We can provide no assurance that we will be able to maintain an active trading market for our common stock. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other businesses or technologies using our shares as consideration, which, in turn, could materially adversely affect our business.

Our executive officers, directors and principal stockholders, if they choose to act together, will continue to have the ability to significantly influence all matters submitted to stockholders for approval.

At December 31, 2021, our executive officers, directors and greater than 5% stockholders, in the aggregate, own approximately 55% of our outstanding common stock. As a result, such persons, acting together, have the ability to significantly influence all matters submitted to our board of directors or stockholders for approval, including the appointment of our management, the election and removal of directors and approval of any significant transaction, as well as our management and business affairs. This concentration of ownership may have the effect of delaying, deferring or preventing a change in control, impeding a merger, consolidation, takeover or other business combination involving us, or discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other stockholders.

We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation, if any, in the price of our common stock.

We have never declared or paid any cash dividend on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, the terms of any future debt agreements may preclude us from paying dividends. Any return to stockholders will therefore be limited to the appreciation of their stock. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which stockholders have purchased their shares.

81

 

Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.

Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur could significantly reduce the market price of our common stock and impair our ability to raise adequate capital through the sale of additional equity securities.

The holders of 6,159,929 shares of our outstanding common stock, or approximately 13% of our total outstanding common stock based on shares outstanding as of December 31, 2021, will be entitled to rights with respect to the registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders, or the registration of such shares, could have a material adverse effect on the trading price of our common stock.

Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.

Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could significantly reduce the value of our shares to a potential acquiror or delay or prevent changes in control or changes in our management without the consent of our board of directors. The provisions in our charter documents include the following:

 

•

a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;

 

•

no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;

 

•

the exclusive right of our board of directors, unless the board of directors grants such right to the stockholders, to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;

 

•

the required approval of at least 66-2/3% of the shares entitled to vote to remove a director for cause, and the prohibition on removal of directors without cause;

 

•

the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;

 

•

the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval;

 

•

the required approval of at least 66-2/3% of the shares entitled to vote to adopt, amend or repeal our amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors;

 

•

a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;

 

•

an exclusive forum provision providing that the Court of Chancery of the State of Delaware will be the exclusive forum for certain actions and proceedings;

 

•

the requirement that a special meeting of stockholders may be called only by the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and

 

•

advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders’ meeting,

82

 

 

which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror’s own slate of directors or otherwise attempting to obtain control of us.

We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law. Under Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction.

Our amended and restated certificate of incorporation provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

Our amended and restated certificate of incorporation provide that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided, that, this provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, our amended and restated certificate of incorporation also provides that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. These choice of forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. By agreeing to this provision, however, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies’ certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.

 

General Risk Factors

We and any of our third-party manufacturers or suppliers may use potent chemical agents and hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly.

We and any of our third-party manufacturers or suppliers and current or potential future collaborators will use biological materials, potent chemical agents and may use hazardous materials, including chemicals and biological agents and compounds that could be dangerous to human health and safety of the environment. Our operations and the operations of our third-party manufacturers and suppliers also produce hazardous waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product development efforts. In addition, we cannot eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. In the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.

83

 

Although we maintain workers’ compensation insurance for certain costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for toxic tort claims that may be asserted against us in connection with our storage or disposal of biologic, hazardous or radioactive materials.

In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations, which have tended to become more stringent over time. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions or liabilities, which could materially adversely affect our business, financial condition, results of operations and prospects.

Our internal computer systems, or those of any of our CROs, manufacturers, other contractors or consultants or current or potential future collaborators, may fail or suffer security breaches, which could result in a material disruption of our product development programs.

The United States federal and various state and foreign governments have adopted or proposed requirements regarding the collection, distribution, use, security, and storage of personally identifiable information and other data relating to individuals, and federal and state consumer protection laws are being applied to enforce regulations related to the collection, use, and dissemination of such data. In the ordinary course of business, we collect, store, transmit and otherwise process large amounts of data including, without limitation, proprietary business information and personal information. Despite the implementation of security measures, our internal technology systems (including infrastructure) and those of our current and any future CROs and other contractors, consultants and collaborators are vulnerable to damage from computer viruses, cybersecurity threats (such as denial-of-service attacks, cyber-attacks or cyber-intrusions over the Internet, hacking, phishing and other social engineering attacks), unauthorized access or use, natural disasters, terrorism, war and telecommunication and electrical failures. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. As a result of the COVID-19 pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. If such an event were to occur and cause interruptions in our operations or result in the unauthorized disclosure of or access to personally identifiable information or individually identifiable health information (violating certain privacy laws such as GDPR), it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other similar disruptions. Some of the federal, state and foreign government requirements include obligations of companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships.

Any security breach or other incident, whether real or perceived, could impact our reputation, cause us to incur significant costs, including legal expenses, harm customer confidence, hurt our expansion into new markets, cause us to incur remediation costs, or cause us to lose existing customers. For example, the loss of clinical trial data from clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. We also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any real or perceived disruption or security breach affects our systems (or those of our third-party collaborators, service providers, contractors or consultants) or were to result in a loss of or accidental, unlawful or unauthorized access to, use of, release of, or other processing of personally identifiable information, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, the further

84

 

development and commercialization of our product candidates could be delayed, and we could be subject to significant fines, penalties or liabilities for any noncompliance to certain privacy and security laws. For further discussion on the potential liability related to the violation of these laws, see “Risk Factors—We, our collaborators and our service providers may be subject to a variety of privacy and data security laws and contractual obligations, which could increase compliance costs and our failure to comply with them could subject us to potentially significant fines or penalties and otherwise harm our business.”

Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.

Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured.

We rely on third-party manufacturers to produce our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers were affected by a man-made or natural disaster or other business interruption. In addition, our corporate headquarters is located in San Diego, California near major earthquake faults and fire zones, and the ultimate impact on us of being located near major earthquake faults and fire zones and being consolidated in a certain geographical area is unknown. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.

We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We could face criminal liability and other serious consequences for violations, which could harm our business.

We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Controls and anti-corruption and anti-money laundering laws and regulations, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. § 201, the U.S. Travel Act, the USA PATRIOT Act and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, CROs, contractors and other collaborators and partners from authorizing, promising, offering, providing, soliciting or receiving, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials outside of the United States, to sell our products abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, CROs, contractors and other collaborators and partners, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.

Furthermore, U.S. export control laws and economic sanctions prohibit the provision of certain products and services to countries, governments, and persons targeted by U.S. sanctions. U.S. sanctions that have been or may be imposed as a result of military conflicts in other countries may impact our ability to continue activities at future clinical trial sites within regions covered by such sanctions.  If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges.  These export and import controls and economic sanctions could also adversely affect our supply chain.

85

 

Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.

The global credit and financial markets have from time to time experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, including the conflict between Russia and Ukraine, terrorism or other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts, including the one in Ukraine, may also adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget.

Changes in tax laws may impact our future financial position and results of operations.

New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, or interpreted, changed, modified or applied adversely to us, any of which could adversely affect our business operations and financial performance. For example, the United States government may enact significant changes to the taxation of business entities including, among others, a permanent increase in the corporate income tax rate, an increase in the tax rate applicable to the global intangible low-taxed income and elimination of certain exemptions, and the imposition of minimum taxes or surtaxes on certain types of income. No specific United States tax legislation has been proposed at this time and the likelihood of these changes being enacted or implemented is unclear. We are currently unable to predict whether such changes will occur and, if so, the ultimate impact on our business. To the extent that such changes have a negative impact on us, our customers or our suppliers, including as a result of related uncertainty, these changes may materially and adversely impact our business, financial condition, results of operations and cash flows.

We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives.

As a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. We are subject to the reporting requirements of the Exchange Act, which require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, Sarbanes-Oxley, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of Sarbanes-Oxley, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and regulations in these areas, such as mandatory “say on pay” voting requirements that will apply to us moving forward as we no longer qualify as an emerging growth company. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.

86

 

The rules and regulations applicable to public companies have increased and may continue to increase our legal and financial compliance costs and have made some activities more time consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will decrease our net income or increase our net loss and may require us to reduce costs in other areas of our business. For example, in recent periods obtaining director and officer liability insurance has become more expensive, and we may be required to  continue to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.

If securities or industry analysts do not publish research or reports or publish unfavorable research or reports about our business, our stock price and trading volume could decline.

The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us, our business, our market or our competitors. If these analysts cease coverage of our company, the trading price for our stock would be negatively impacted. If one or more of the analysts who covers us downgrades our stock, our stock price would likely decline. If one or more of these analysts ceases to cover us or fails to regularly publish reports on us, interest in our stock could decrease, which could cause our stock price or trading volume to decline.

If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.

Pursuant to Section 404 of Sarbanes-Oxley, our management will be required to report upon the effectiveness of our internal control over financial reporting beginning with the annual report for our fiscal year ending December 31, 2021. As we have lost our status as an “emerging growth company” due to our becoming a large accelerated filer, our independent registered public accounting firm will also be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for our management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we are in the process of upgrading our information technology systems; implementing additional financial and management controls, reporting systems and procedures; and hiring additional accounting and finance staff. In January 2022, we implemented a new enterprise resource planning/accounting system. The implementation of such a new system may be disruptive to our business. Any disruptions relating to our systems or any problems with the implementation, particularly any disruptions impacting our operations or our ability to accurately report our financial performance on a timely basis following the implementation could materially and adversely affect our business and operations.  If we or, if required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.

87

 

We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begin its Section 404 reviews, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.

We could be subject to securities class action litigation.

In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us, because biotechnology and biopharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of our management’s attention and resources, which could harm our business.

ITEM 1B.    Unresolved Staff Comments

None.

ITEM 2.    Properties

We currently lease approximately 47,737 square feet of office and laboratory space in San Diego, California, under a lease that expires in 2026, with the option to extend the term of the lease for an additional five years. We believe that our facilities are adequate to meet our current needs and that suitable additional alternative spaces will be available in the future on commercially reasonable terms, if required.

88

 

ITEM 3.    Legal Proceedings

We are not currently subject to any material legal proceedings. From time to time, we may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.

ITEM 4.    Mine Safety Disclosures

Not applicable.

89

 

PART II

ITEM 5.    Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market Information

Our common stock is listed on the Nasdaq Global Market under the symbol “RNA.”

Holders of Common Stock

As of February 7, 2022, there were approximately 40 holders of record of our common stock. This number was derived from our shareholder records and does not include beneficial owners of our common stock whose shares are held in the name of various dealers, clearing agencies, banks, brokers and other fiduciaries.

Dividend Policy

We have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation of our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors after considering our financial condition, results of operations, capital requirements, business prospects and other factors the board of directors deems relevant, and subject to the restrictions contained in any future financing instruments.

Securities Authorized for Issuance Under Equity Compensation Plans

See Item 12 of Part III of this annual report on Form 10-K for information about our equity compensation plans which is incorporated by reference herein.

Performance Graph

The following stock performance graph illustrates a comparison from June 12, 2020 (the date our common stock commenced trading on the Nasdaq Global Market) through December 31, 2021, of the total cumulative stockholder return on our common stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Index. The graph assumes an initial investment of $100 on June 12, 2020 at the opening trading price of $18.00 per share, and that all dividends were reinvested, although dividends have not been declared on our common stock. The comparisons in the graph are required by the SEC and are not intended to forecast or be indicative of possible future performance of our common stock.

 

90

 

 

 

Unregistered Sales of Equity Securities

During the year ended December 31, 2021, we did not issue or sell any unregistered securities.

Use of Proceeds

On June 11, 2020, the SEC declared effective our registration statement on Form S-1 (File No. 333-238612), as amended, filed in connection with our IPO. Our IPO closed on June 16, 2020, and we issued and sold 16,560,000 shares of our common stock at a price to the public of $18.00 per share, which included the exercise in full of the underwriters’ option to purchase additional shares. We received gross proceeds from our IPO of $298.1 million, before deducting underwriting discounts, commissions and offering costs of $24.0 million. The managing underwriters of the offering were Cowen and Company, LLC, SVB Leerink LLC, Credit Suisse Securities (USA) LLC and Wells Fargo Securities, LLC. No offering costs were paid or are payable, directly or indirectly, to our directors or officers, to persons owning 10% or more of any class of our equity securities or to any of our affiliates.

As of December 31, 2021, we have used approximately $45.3 million of the proceeds from our IPO for general corporate purposes, including the advancement of our development programs. There has been no material change in our planned use of such proceeds from that described in the prospectus for our IPO dated June 11, 2020.

Issuer Repurchases of Equity Securities

None.

91

 

ITEM 6.    [Reserved]

 

92

 

 

ITEM 7.    Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes thereto included elsewhere in this annual report. This discussion and analysis contains forward-looking statements based upon our current beliefs, plans and expectations that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under “Risk Factors” or in other parts of this annual report.

Overview

We are a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Our proprietary AOC platform is designed to combine the specificity of monoclonal antibodies, or mAbs, with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. We are initially focused on muscle diseases to demonstrate the capabilities of our AOCs, and we expect to have three muscle programs in clinical development by the end of 2022. Our lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, or DM1, a rare monogenic muscle disease. In October 2021, we dosed the first patient in our Phase 1/2 MARINA clinical trial, a trial designed to evaluate the safety and tolerability of single and multiple ascending doses of AOC 1001 administered intravenously in adults with DM1. In the fourth quarter of 2022, we plan to conduct a preliminary assessment of safety, tolerability and key biomarkers in approximately half of the trial participants. The U.S. Food and Drug Administration, or FDA, and European Medicines Agency, or EMA, have granted Orphan Designation for AOC 1001. The FDA has also granted Fast Track Designation to AOC 1001 for the treatment of DM1.  

Our advancing and expanding pipeline also includes AOC 1044, the lead of three programs for the treatment of Duchenne Muscular Dystrophy, or DMD, and AOC 1020, designed to treat facioscapulohumeral muscular dystrophy, or FSHD. We anticipate that both AOC 1044 and AOC 1020 will enter the clinic by the end of 2022 following additional preparatory preclinical studies and regulatory clearance. In addition to our muscle franchise, we are also broadening the development of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships that are focused on immune cells, cardiac tissue and other cell types.

Since our inception in 2012, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, developing our proprietary AOC platform, identifying potential product candidates, establishing our intellectual property portfolio, conducting research, preclinical and clinical studies, and providing other general and administrative support for these operations. We have not generated any revenue from product sales. In June 2020, we completed our initial public offering, or IPO, of 16,560,000 shares of our common stock at a price to the public of $18.00 per share, including the exercise in full by the underwriters of their option to purchase 2,160,000 additional shares of our common stock. Including the option exercise, our aggregate net proceeds from the offering were $274.1 million, net of underwriting discounts, commissions and offering costs. In August 2021, we completed a public offering of 9,200,000 shares of our common stock at a public offering price of $18.00 per share, for aggregate net proceeds of $155.1 million, after deducting underwriting discounts, commissions and offering costs. In July 2021, we entered into a sales agreement, or the Sales Agreement, with Cowen and Company, LLC, or the Sales Agent, under which we may, from time to time, sell shares of common stock having an aggregate offering price of up to $150.0 million through the Sales Agent. To date, we have sold 780,549 shares of our common stock pursuant to the Sales Agreement and received net proceeds of $19.6 million, after deducting offering-related transaction costs and commissions. Since our inception through December 31, 2021, other sources of capital raised to fund our operations were comprised of aggregate gross proceeds of $131.6 million from the sale and issuance of convertible preferred stock/units and convertible notes, $35.2 million from funding under collaboration and research services agreements, and $7.0 million from loans from Silicon Valley Bank, or SVB, under a Loan and Security Agreement, as amended, or the LSA. As of December 31, 2021, we had cash, cash equivalents and marketable securities of $405.5 million.

93

 

We have incurred operating losses in each year since inception. Our net losses were $118.0 million, $44.4 million and $24.7 million for the years ended December 31, 2021, 2020 and 2019, respectively. As of December 31, 2021, we had an accumulated deficit of $184.5 million. We expect our expenses and operating losses will increase substantially as we conduct our ongoing and planned preclinical studies and clinical trials, continue our research and development activities, utilize third parties to manufacture our product candidates and related raw materials, hire additional personnel, protect our intellectual property and incur additional costs associated with being a public company. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our preclinical studies and clinical trials and our expenditures on other research and development activities, as well as the generation of any collaboration and services revenue.

Based upon our current operating plans, we believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our operations for at least 12 months from the date of the filing of this Form 10-K. While we may generate revenue under our current and/or future collaboration agreements, we do not expect to generate any revenues from product sales until we successfully complete development and obtain regulatory approval for one or more of our product candidates, which we expect will take a number of years and may never occur. If we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Accordingly, until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed, on favorable terms or at all. Our failure to raise capital or enter into such other arrangements when needed would have a negative impact on our financial condition and could force us to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

COVID-19

The COVID-19 outbreak in the United States has caused significant business disruption. The extent of the impact of COVID-19 on our operational and financial performance will depend on certain developments, including the continued spread of COVID-19 and the measures taken by the governmental authorities, and its impact on our preclinical studies and clinical trials, employees and vendors, all of which are uncertain and cannot be predicted, particularly as we advance our product candidates into and through clinical development. In December 2021, we began to transition to a hybrid model with our employees generally working both remotely and onsite, and we anticipate we will continue to use this model going forward. To date, we have not experienced material disruptions in our business operations. However, a prolonged outbreak could have a material adverse impact on our financial results and business operations, including the timing of and our ability to complete certain clinical trials and other efforts required to advance the development of our product candidates and raise additional capital.

Agreement and Plan of Conversion

In April 2019, we entered into an Agreement and Plan of Conversion, pursuant to which we converted from Avidity Biosciences LLC, a Delaware limited liability company, or Avidity LLC, into Avidity Biosciences, Inc., a Delaware corporation. All of the membership interests of Avidity LLC were converted into securities of Avidity Biosciences, Inc., as follows: (i) each outstanding common unit of Avidity LLC converted into one share of Avidity Biosciences, Inc.’s common stock; (ii) each outstanding Series A convertible preferred unit of Avidity LLC converted into one share of Avidity Biosciences, Inc.’s Series A convertible preferred stock; and (iii) each outstanding Series B convertible preferred unit of Avidity LLC converted into one share of Avidity Biosciences, Inc.’s Series B convertible preferred stock. Outstanding convertible notes, warrants and stock awards under Avidity LLC’s employee benefit and incentive compensation plans continued on the same terms and conditions and became binding upon Avidity Biosciences, Inc.

94

 

Research Collaboration and License Agreement with Eli Lilly and Company

In April 2019, we entered into a Research Collaboration and License Agreement, or the Lilly Agreement, with Eli Lilly and Company, or Lilly, for the discovery, development and commercialization of AOC products in immunology and other select indications on a worldwide basis. Under the Lilly Agreement, we and Lilly will collaborate on preclinical research and discovery activities for such products, with Lilly being responsible for funding the cost of such activities by both parties. Lilly will also lead the clinical development, regulatory approval and commercialization of all such products, at its sole cost. We granted Lilly an exclusive, worldwide, royalty-bearing license, with the right to sublicense, under our technology to research, develop, manufacture, and sell products containing AOCs that are directed to up to six mRNA targets. We retain the right to use our technology to perform our obligations under the agreement and for all purposes not granted to Lilly. Lilly paid us an upfront license fee of $20.0 million in 2019, and we are eligible to receive up to $60.0 million in development milestone payments, up to $140.0 million in regulatory milestone payments and up to $205.0 million in commercialization milestone payments per target. We are eligible to receive a tiered royalty ranging from the mid-single to low-double digits from Lilly on worldwide annual net sales of licensed products, subject to specified and capped reductions for the market entry of biosimilar products, loss of patent coverage of licensed products and for payments owed to third parties for additional rights necessary to commercialize licensed products in the territory.

Concurrently with the Lilly Agreement, we issued a convertible promissory note to Lilly, or the Lilly Note, and received cash proceeds of $15.0 million in 2019. The Lilly Note accrued simple interest of 8.0% per annum and, if not converted, would have matured in October 2020. In connection with the sale of our Series C convertible preferred stock in November 2019, all outstanding principal and interest accrued under the Lilly Note converted into 4,576,342 shares of our Series C convertible preferred stock, at a conversion price equal to 80% of the per share cash price paid by the investors in the Series C convertible preferred stock financing. In connection with our IPO in June 2020, the Series C convertible preferred stock related to the Lilly Note converted into 2,169,396 shares of our common stock.

Components of Results of Operations

Revenue

Our revenue to date has been derived from payments received under the Lilly Agreement and other license and research agreements. For the foreseeable future, we may generate revenue from reimbursements of services under the Lilly Agreement, as well as a combination of upfront payments and milestone payments under our current and/or future collaboration agreements. We do not expect to generate any revenue from the sale of products unless and until such time that our product candidates have advanced through clinical development and regulatory approval, if ever. We expect that any revenue we generate, if at all, will fluctuate from quarter-to-quarter as a result of the timing and amount of payments relating to such services and milestones and the extent to which any of our products are approved and successfully commercialized. If we fail to complete preclinical and clinical development of product candidates or obtain regulatory approval for them, our ability to generate future revenues and our results of operations and financial position would be adversely affected.

Operating Expenses

Research and Development

Research and development expenses consist of external and internal costs associated with our research and development activities, including our discovery and research efforts, and the preclinical and clinical development of our product candidates. Our research and development expenses include:

 

•

external costs, including expenses incurred under arrangements with third parties, such as contract research organizations, contract manufacturers, consultants and our scientific advisors; and

 

•

internal costs, including;

95

 

 

 

•

employee-related expenses, including salaries, benefits and stock-based compensation;

 

•

the costs of laboratory supplies and acquiring, developing and manufacturing preclinical study materials; and

 

•

facilities, information technology and depreciation, which include direct and allocated expenses for rent and maintenance of facilities and depreciation of leasehold improvements and equipment.

Research and development costs, including costs reimbursed under the Lilly Agreement, are expensed as incurred, with reimbursements of such amounts being recognized as revenue. We account for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received.

At any one time, we are working on multiple programs. Our internal resources, employees and infrastructure are not directly tied to any one research or drug discovery program and are typically deployed across multiple programs. As such, we do not track internal costs on a specific program basis. The following table summarizes our external costs and internal costs for the periods presented (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

External costs

 

$

58,983

 

 

$

22,919

 

 

$

6,634

 

Internal costs:

 

 

 

 

 

 

 

 

 

 

 

 

Employee-related expenses

 

 

31,751

 

 

 

9,679

 

 

 

5,011

 

Facilities, lab supplies and other costs

 

 

10,448

 

 

 

5,004

 

 

 

2,894

 

Total internal costs

 

 

42,199

 

 

 

14,683

 

 

 

7,905

 

Total research and development expenses

 

$

101,182

 

 

$

37,602

 

 

$

14,539

 

 

We expect our research and development expenses to increase for the foreseeable future as we continue to conduct our ongoing research and development activities, advance our preclinical research programs toward clinical development, including conducting IND-enabling studies, and conduct clinical trials. The process of conducting preclinical studies and clinical trials necessary to obtain regulatory approval is costly and time consuming. We may never succeed in achieving marketing approval for any of our product candidates.

The timelines and costs associated with research and development activities are uncertain, can vary significantly for each product candidate and development program, and are difficult to predict. We anticipate we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis in response to preclinical and clinical results, regulatory developments, ongoing assessments as to each program’s commercial potential, and our ability to maintain or enter into new collaborations, to the extent we determine the resources or expertise of a collaborator would be beneficial for a given program. We will need to raise substantial additional capital in the future. In addition, we cannot forecast which development programs may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.

Our development costs may vary significantly based on factors such as:

 

•

the number and scope of clinical, preclinical and IND-enabling studies;

 

•

per patient trial costs;

 

•

the number of trials required for approval;

 

•

the number of sites included in the trials;

 

•

the countries in which the trials are conducted;

96

 

 

 

•

the length of time required to enroll eligible patients;

 

•

the number of patients that participate in the trials;

 

•

the number of doses that patients receive;

 

•

the drop-out or discontinuation rates of patients;

 

•

potential additional safety monitoring requested by regulatory agencies;

 

•

the duration of patient participation in the trials and follow-up;

 

•

the cost and timing of manufacturing our product candidates;

 

•

the phase of development of our product candidates; and

 

•

the efficacy and safety profile of our product candidates.

General and Administrative

General and administrative expenses consist primarily of employee-related expenses, including salaries, benefits and stock-based compensation, for employees in our executive, finance, accounting, legal, business development and support functions. Other general and administrative expenses include allocated facility, information technology and depreciation related costs not otherwise included in research and development expenses and professional fees for auditing, tax, intellectual property and legal services. Costs related to filing and pursuing patent applications are recognized as general and administrative expenses as incurred since recoverability of such expenditures is uncertain.

We expect our general and administrative expenses will increase for the foreseeable future to support our increased research and development activities and costs of operating as a public company. These costs will likely include increased expenses related to audit, legal, regulatory and tax services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums and investor relations costs associated with operating as a public company.

Other Income (Expense)

Interest Income

Interest income consists primarily of interest earned on our cash, cash equivalents and marketable securities.

Interest Expense

Interest expense consists of cash and noncash interest expense associated with our previously outstanding financing arrangements, which included borrowings under the LSA and convertible notes with certain of our investors.

Change in Fair Value of Preferred Warrant Liability

Prior to our IPO, we classified our outstanding warrant to purchase shares of our Series A convertible preferred stock as a liability on our balance sheets at its estimated fair value since the underlying convertible preferred stock was classified as temporary equity. At the end of each reporting period, changes in the estimated fair value during the period were recorded as a component of other income (expense). In connection with our IPO, this warrant was adjusted to become a warrant to purchase shares of our common stock and met the criteria to be classified within stockholders’ equity; therefore, the warrant was no longer subject to liability accounting. Accordingly, the fair value of the warrant liability was reclassified to stockholders’ equity.

97

 

Results of Operations

Comparison of the Years Ended December 31, 2021 and 2020

The following table summarizes our results of operations for the years ended December 31, 2021 and 2020 (in thousands):

 

 

 

Year Ended December 31,

 

 

Increase

 

 

 

2021

 

 

2020

 

 

(decrease)

 

Revenue

 

$

9,326

 

 

$

6,787

 

 

$

2,539

 

Research and development expenses

 

 

101,182

 

 

 

37,602

 

 

 

63,580

 

General and administrative expenses

 

 

26,195

 

 

 

13,462

 

 

 

12,733

 

Other income (expense)

 

 

42

 

 

 

(78

)

 

 

120

 

 

Revenue

Revenue was $9.3 million for the year ended December 31, 2021, compared to $6.8 million for the year ended December 31, 2020. Revenue during both periods was primarily derived from the Lilly Agreement. The increase was primarily due to higher reimbursable collaboration-related research and development expenses resulting in the recognition of higher corresponding revenue under the Lilly Agreement.

Research and Development Expenses

Research and development expenses were $101.2 million for the year ended December 31, 2021, compared to $37.6 million for the year ended December 31, 2020. The increase was primarily driven by higher external and internal research and development costs related to the advancement of AOC 1001, AOC 1044 and AOC 1020, as well as costs related to the expansion of our overall research capabilities. In 2021, external research and development costs were $59.0 million, compared to $22.9 million in 2020. The increase was primarily due to higher manufacturing, clinical, preclinical and research activities. Research and development related internal costs were $42.2 million in 2021, compared to $14.7 million in 2020. The increase was primarily due to higher employee salaries and benefits of $14.7 million, noncash stock compensation of $7.3 million, lab supplies of $3.0 million and facilities of $1.7 million.

General and Administrative Expenses

General and administrative expenses were $26.2 million for the year ended December 31, 2021, compared to $13.5 million for the year ended December 31, 2020. The increase was primarily due to higher costs related to supporting our expanded operations and being a public company, including higher noncash stock-based compensation of $5.4 million, salaries and benefits of $4.1 million, professional fees of $1.6 million, insurance costs of $0.9 million and facilities costs of $0.6 million.

Comparison of the Years Ended December 31, 2020 and 2019

The following table summarizes our results of operations for the years ended December 31, 2020 and 2019 (in thousands):

 

 

 

Year Ended December 31,

 

 

Increase

 

 

 

2020

 

 

2019

 

 

(decrease)

 

Revenue

 

$

6,787

 

 

$

2,319

 

 

$

4,468

 

Research and development expenses

 

 

37,602

 

 

 

14,539

 

 

 

23,063

 

General and administrative expenses

 

 

13,462

 

 

 

5,112

 

 

 

8,350

 

Other income (expense)

 

 

(78

)

 

 

(7,402

)

 

 

7,324

 

98

 

 

 

Revenue

Revenue was $6.8 million for the year ended December 31, 2020, compared to $2.3 million for the year ended December 31, 2019. Revenue during both periods was derived from the Lilly Agreement, which was entered into in April 2019. The increase was due to higher reimbursable collaboration-related research and development expenses resulting in the recognition of higher corresponding revenue under the Lilly Agreement.

Research and Development Expenses

Research and development expenses were $37.6 million for the year ended December 31, 2020, compared to $14.5 million for the year ended December 31, 2019. The increase was primarily driven by higher external and internal research and development costs related to the advancement of AOC 1001 and our other programs, as well as costs related to the expansion of our overall research capabilities. In 2020, external research and development costs were $22.9 million, compared to $6.6 million in 2019. The increase was primarily due to higher research and preclinical activities, including manufacturing activities. Research and development related internal costs were $14.7 million in 2020, compared to $7.9 million in 2019. The increase was primarily due to higher employee salaries and benefits of $2.9 million, noncash stock compensation of $1.8 million, lab supplies of $1.1 million and facilities of $0.5 million.

General and Administrative Expenses

General and administrative expenses were $13.5 million for the year ended December 31, 2020, compared to $5.1 million for the year ended December 31, 2019. The increase was primarily due to higher costs related to being a public company, including higher salaries and benefits of $2.1 million, noncash stock-based compensation of $2.1 million, professional fees of $1.8 million and insurance costs of $1.0 million, as well as higher patent filing fees of $0.8 million.

Other Income (Expense)

Other expense was $0.1 million for the year ended December 31, 2020, compared to $7.4 million for the year ended December 31, 2019. The change was primarily related to reduced interest expense as a result of the November 2019 conversion of all outstanding convertible notes into convertible preferred stock, which was subsequently converted into common stock in connection with our IPO.

Liquidity and Capital Resources

Sources of Liquidity

In June 2020, we completed our IPO of 16,560,000 shares of our common stock at a price to the public of $18.00 per share, including the exercise in full by the underwriters of their option to purchase 2,160,000 additional shares of our common stock. Including the option exercise, our aggregate net proceeds from the offering were $274.1 million, net of underwriting discounts, commissions and offering costs. In August 2021, we completed a public offering of 9,200,000 shares of our common stock at a public offering price of $18.00 per share, for aggregate net proceeds of $155.1 million, after deducting underwriting discounts, commissions and offering costs. In July 2021, we entered into the Sales Agreement with the Sales Agent, under which we may, from time to time, sell shares of common stock having an aggregate offering price of up to $150.0 million through the Sales Agent. To date, we have sold 780,549 shares of our common stock pursuant to the Sales Agreement and received net proceeds of $19.6 million, after deducting offering-related transaction costs and commissions. Since our inception through December 31, 2021, other sources of capital raised to fund our operations were comprised of aggregate gross proceeds of $131.6 million from the sale and issuance of convertible preferred stock/units and convertible notes, $35.2 million from funding under collaboration and research services agreements, and $7.0 million from loans from SVB under the LSA. As of December 31, 2021, we had cash, cash equivalents and marketable securities of $405.5 million.

99

 

Convertible Promissory Notes

In July 2018 and February 2019, we issued convertible promissory notes to certain of our existing investors, or the 2018 Notes and 2019 Notes, respectively, and received proceeds of $3.0 million and $4.5 million, respectively. The 2018 Notes and 2019 Notes accrued simple interest at a rate of 8% and 10% per annum, respectively, and had a maturity date in December 2020, subject to earlier conversion.

In addition, in April 2019, as described above, in connection with the Lilly Agreement, we issued the Lilly Note and received cash proceeds of $15.0 million.

In November 2019, in connection with our Series C financing transaction, all outstanding amounts of principal and accrued interest from the 2018 Notes, 2019 Notes and Lilly Note, which totaled $23.8 million, were converted into an aggregate of 6,893,036 shares of our Series C convertible preferred stock, which subsequently converted into shares of our common stock in connection with our IPO.

SVB Loan and Security Agreement

In June 2017, we entered into an amendment to the LSA with SVB, or the First LSA Amendment, which provided up to $7.0 million in available borrowings in two tranches. In 2017, we drew the first tranche of $5.0 million, of which $4.6 million was used to repay our existing debt obligations to SVB. In August 2018, we drew the second tranche of $2.0 million. Interest accrued on the unpaid principal balance at an adjustable annual rate of the prime rate per the Wall Street Journal plus 0.20%. In addition to our monthly payments of principal and interest, our repayment obligations included a final payment of 6.5% of the original principal advanced, which was due upon final maturity of the loan in June 2021. On June 30, 2020, we voluntarily prepaid the outstanding principal balance of $2.8 million and final payments and accrued interest of $0.5 million under the LSA, and the LSA was terminated.

In connection with execution of the LSA, we issued SVB a warrant to purchase 16,474 shares of our Series A convertible preferred stock at an exercise price of $2.2615 per share, exercisable at any time following issuance with a term of ten years. In connection with the completion of our IPO in June 2020, the preferred stock warrant was adjusted to become a warrant exercisable for 7,809 shares of common stock at an exercise price of $4.77 per share. In connection with the First LSA Amendment in June 2017, we issued SVB an additional warrant to purchase 9,442 shares of common stock at an exercise price of $0.53 per share, exercisable at any time following issuance with a term of seven years. On June 17, 2020, the warrants were cashless exercised for an aggregate of 15,833 shares of common stock.

Future Capital Requirements

As of December 31, 2021, we had cash, cash equivalents and marketable securities of $405.5 million. Based upon our current operating plans, we believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our operations for at least 12 months from the date of the filing of this Form 10-K. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect. Additionally, the process of conducting preclinical studies and testing product candidates in clinical trials is costly, and the timing of progress and expenses in these studies and trials is uncertain.

Our future capital requirements are difficult to forecast and will depend on many factors, including but not limited to:

 

•

the type, number, scope, progress, expansions, results, costs and timing of discovery, preclinical studies and clinical trials of our product candidates that we are pursuing or may choose to pursue in the future;

 

•

the costs and timing of manufacturing for our product candidates and commercial manufacturing if any product candidate is approved;

100

 

 

•

the costs, timing and outcome of regulatory review of our product candidates;

 

•

the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements;

 

•

the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;

 

•

our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal controls over financial reporting;

 

•

the costs associated with hiring additional personnel and consultants as our preclinical and clinical activities increase;

 

•

the timing and amount of the milestone or other payments made to us under the Lilly Agreement or any future collaboration agreements;

 

•

the costs and timing of establishing or securing sales and marketing capabilities if any product candidate is approved;

 

•

our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products; and

 

•

costs associated with any products or technologies that we may in-license or acquire.

While we may generate revenue under our current and/or future collaboration agreements, we do not expect to generate any revenues from product sales until we successfully complete development and obtain regulatory approval for one or more of our product candidates, which we expect will take a number of years and may never occur. If we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Accordingly, until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including current and potential future collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed, on favorable terms or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Our failure to raise capital or enter into such other arrangements when needed would have a negative impact on our financial condition and could force us to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Cash Flows

The following table summarizes our cash flows for the periods presented (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Net cash provided by (used in):

 

 

 

 

 

 

 

 

 

 

 

 

Operating activities

 

$

(94,813

)

 

$

(37,117

)

 

$

2,490

 

Investing activities

 

 

(82,517

)

 

 

(7,785

)

 

 

(235

)

Financing activities

 

 

176,316

 

 

 

272,037

 

 

 

89,233

 

Net (decrease) increase in cash, cash

   equivalents and restricted cash

 

$

(1,014

)

 

$

227,135

 

 

$

91,488

 

Operating Activities

Net cash used in operating activities was $94.8 million for the year ended December 31, 2021, which consisted primarily of cash used to fund our operations related to the development of AOC 1001, AOC 1044 and AOC 1020. Net cash used in operating activities was $37.1 million for the year ended December 31, 2020, which consisted primarily of cash used to fund our operations related to the development of AOC

101

 

1001 and our other programs. Net cash provided by operating activities was $2.5 million for the year ended December 31, 2019, which consisted primarily of the $20.0 million upfront fee related to the Lilly Agreement, partially offset by cash used to fund our operations related to the development of AOC 1001 and our other programs.

Investing Activities

Net cash used in investing activities was $82.5 million for the year ended December 31, 2021, which consisted primarily of cash used to purchase marketable securities and property and equipment, partially offset by proceeds from maturities of marketable securities. Net cash used in investing activities was $7.8 million for the year ended December 31, 2020, which consisted primarily of cash used to purchase marketable securities and property and equipment. Net cash used in investing activities was $0.2 million for the year ended December 31, 2019, which consisted primarily of cash used to purchase property and equipment.

Financing Activities

Net cash provided by financing activities was $176.3 million for the year ended December 31, 2021, which consisted primarily of net proceeds from the issuance of common stock in our August 2021 public offering and sales of our common stock made pursuant to the Sales Agreement, as well as proceeds from the exercise of stock options and issuance of common stock under the ESPP. Net cash provided by financing activities was $272.0 million for the year ended December 31, 2020, which consisted primarily of net proceeds from our IPO and net proceeds from the issuance of Series C convertible preferred stock, partially offset by payments related to the LSA. Net cash provided by financing activities was $89.2 million for the year ended December 31, 2019, which consisted primarily of net proceeds from the issuance of Series C convertible preferred stock and the issuance of convertible notes, partially offset by payments related to the LSA.

Contractual Obligations and Commitments

We have operating lease obligations related to our lease for office and laboratory space in San Diego, California. In June 2020, and as amended in December 2020, we entered into a non-cancellable operating lease for approximately 47,737 square feet of office and laboratory space, or the Lease, which commenced in November 2021. The Lease has a five-year initial term with a renewal option for an additional five years. Under the terms of the Lease, the initial monthly base rent of approximately $251,000 will increase to approximately $282,000 during the last year of the Lease's initial term, and the first year includes five months of rent abatement. The total remaining base rent commitment for the initial term under the Lease is $14.5 million.

We enter into contracts in the normal course of business for contract research services, contract manufacturing services, clinical trials, professional services, and other services and products for operating purposes. These contracts may include certain provisions that could require payments for early termination. The amount of the termination payments vary depending on the timing of the termination and the specific terms of the contract. Therefore, these contracts are considered cancellable contracts.

Critical Accounting Polices and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses. On an ongoing basis, we evaluate these estimates and judgments. We base our estimates on historical experience and on various assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and

102

 

liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates.

While our significant accounting policies are described in more detail in Note 2 to our financial statements included elsewhere in this annual report, we believe that the following accounting policies are the most critical to understanding and evaluating our historical and future performance.

Revenue Recognition

To date, all of our revenue has been derived from our collaboration and research agreements entered into with Lilly and various other parties. The terms of these arrangements include payments to us for the following: non-refundable, upfront license fees; development, regulatory and commercial milestone payments; payments for research and development services provided by us or for manufacturing supply services we may provide through our contract manufacturers; and royalties on net sales of licensed products.

Effective January 1, 2019, we began recognizing revenue in accordance with the provisions of Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers. The adoption of ASC 606 using the modified retrospective approach did not have a material impact on our financial position, results of operations or cash flows as we did not have any revenue-generating arrangements in effect at January 1, 2019. In accordance with ASC 606, we perform the following five steps in determining the appropriate amount of revenue to be recognized as we fulfill our obligations under each of these agreements: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including any constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as, we satisfy each performance obligation.

If an agreement includes a license to our intellectual property and that license is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.

With respect to our assessment of the Lilly Agreement, we identified multiple promises to deliver goods and services, which include at inception of the agreement: (i) a license to technology and patents, information and know-how; and (ii) collaboration, including research services, technical and regulatory support provided by us. We have identified one performance obligation for all the deliverables under the Lilly Agreement since the delivered elements are either not capable of being distinct or are not distinct within the context of the contract. Accordingly, we will recognize revenue for the fixed or determinable collaboration in an amount proportional to the collaboration expenses incurred and the total estimated collaboration expenses over the five-year period over which we expect to deliver our performance obligations. We periodically review and update the estimated collaboration expenses, when appropriate, which adjusts the percentage of revenue that is recognized for the period. While such changes to our estimates have no impact on our reported cash flows, the amount of revenue recorded in the period could be materially impacted.

For all periods presented, amounts received prior to satisfying the above revenue recognition criteria were recorded as deferred revenue until all applicable revenue recognition criteria were met. Deferred revenue represented the portion of payments received that have not been earned.

103

 

Stock-Based Compensation

Stock-based compensation expense for employee and non-employee stock option grants is recorded at the estimated fair value of the award as of the grant date and is recognized as expense on a straight-line basis over the requisite service period (usually the vesting period) of the stock-based award, and forfeitures are recognized as incurred. Stock-based compensation expense for employee stock purchases under the Employee Stock Purchase Plan, or the ESPP, is recorded at the estimated fair value of the purchase as of the plan enrollment date and is recognized as expense on a straight-line basis over the applicable six-month ESPP offering period.

We estimate the fair value of our stock-based awards using the Black-Scholes model. The Black-Scholes model requires the use of subjective assumptions, including the fair value of the underlying common stock on the date of grant, risk-free interest rate, expected volatility, expected term and expected dividend yield. Changes in the assumptions can materially affect the fair value and ultimately how much stock-based compensation expense is recognized. These inputs are subjective and generally require judgment to develop.

Fair Value of our Common Stock. Prior to our IPO in June 2020, the fair value of the common stock underlying our equity awards was determined on each grant date by our board of directors, taking into account input from management and independent third-party valuation analyses. Following the completion of our IPO, the fair value of our common stock is based on the closing price as reported on the date of grant on the Nasdaq Global Market.

Risk-Free Interest Rate. We base the risk-free interest rate assumption for equity awards on the rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued.

Expected Volatility. Due to the limited trading history of our common stock, the expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology industry. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available.

Expected Term. Due to our limited option exercise history not providing a reasonable basis for estimating expected term, we have estimated the expected life of our stock options using the simplified method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The expected life assumption for employee stock purchases under the ESPP is six months to conform with the six-month ESPP offering period.

Expected Dividend Yield. Our expected dividend yield assumption is zero as we have never paid dividends and have no present intention to do so in the future.

Accrued Research and Development Costs

As part of the process of preparing our financial statements, we are required to make estimates of our accrued research and development expenses resulting from our obligations under contracts with CROs, manufacturers, vendors and consultants. The financial terms of these contracts vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. We reflect research and development expenses in our financial statements by matching those expenses with the period in which services and efforts are expended. In accruing for these activities, we obtain information from various sources and estimate the level of effort or expense allocated to each period.

Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in our reporting amounts that are too high or too low in any particular

104

 

period. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.

Recent Accounting Pronouncements

See Note 2 to our financial statements included elsewhere in this annual report.

ITEM 7A.    Quantitative and Qualitative Disclosures about Market Risk

Interest Rate Risk

Our cash, cash equivalents and marketable securities consist of cash held in readily available checking and money market accounts, as well as debt securities. We are exposed to market risk related to fluctuations in interest rates and market prices. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of United States interest rates. However, due to the short- and intermediate-term nature of the instruments in our portfolio, we believe an immediate hypothetical 10% change in interest rates would not have had a material effect on our results of operations during the periods presented.

Effects of Inflation

Inflation generally affects us by increasing our cost of labor and research and development contract costs. We do not believe inflation has had a material effect on our results of operations during the periods presented.

Foreign Currency Exchange Risk

We are exposed to market risk related to changes in foreign currency exchange rates. We contract with vendors that are located outside the United States, and certain invoices are denominated in foreign currencies. We are subject to fluctuations in foreign currency exchange rates in connection with these arrangements. To date, we have not experienced any material effects from foreign currency fluctuations. We believe an immediate hypothetical 10% change in foreign currency exchange rates would not have had a material effect on our results of operations during the periods presented.

ITEM 8.    Financial Statements and Supplementary Data

The financial statements required pursuant to this item are incorporated by reference herein from the applicable information included in Item 15 of this annual report and are presented beginning on page F-1.

ITEM 9.    Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None.

ITEM 9A.    Controls and Procedures

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of

105

 

possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of the end of the period covered by this annual report. Based on such evaluation, our principal executive officer and principal financial officer have concluded that as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Management’s Annual Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2021 based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in its 2013 Internal Control — Integrated Framework. Based on this assessment, our management has concluded that our internal control over financial reporting was effective as of December 31, 2021.

Attestation Report of the Registered Public Accounting Firm

BDO USA, LLP has audited the effectiveness of the company’s internal control over financial reporting as of December 31, 2021, as stated in its report dated March 1, 2022, which is included below.

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting during the quarter ended December 31, 2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.


106

 

 

Report of Independent Registered Public Accounting Firm

Stockholders and Board of Directors

Avidity Biosciences, Inc.

San Diego, California

Opinion on Internal Control Over Financial Reporting

We have audited Avidity Biosciences, Inc.’s (the “Company’s”) internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (the “COSO criteria”). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the balance sheets of the Company as of December 31, 2021 and 2020, the related statements of operations and comprehensive loss, convertible preferred stock/units and stockholders’/members’ equity (deficit), and cash flows for each of the three years in the period ended December 31, 2021, and the related notes and our report dated March 1, 2022 expressed an unqualified opinion thereon.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Item 9A, Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit of internal control over financial reporting in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

107

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ BDO USA, LLP

San Diego, California

March 1, 2022


108

 

 

ITEM 9B.    Other Information

None.

ITEM 9C.    Disclosure Regarding Foreign Jurisdictions that Prevent Inspections  

Not applicable.

 

109

 

 

PART III

ITEM 10.    Directors, Executive Officers and Corporate Governance

The information required by this item will be contained in our definitive proxy statement to be filed with the SEC in connection with our 2022 Annual Meeting of Stockholders, or the Definitive Proxy Statement, which is expected to be filed not later than 120 days after the end of our fiscal year ended December 31, 2021, under the headings “Election of Directors,” “Corporate Governance,” “Executive Officers,” and, if applicable, “Delinquent Section 16(a) Reports,” and is incorporated herein by reference.

Code of Business Conduct and Ethics

We have adopted a Code of Business Conduct and Ethics that applies to our officers, directors and employees, which is available on our website at www.aviditybiosciences.com. The Code of Business Conduct and Ethics contains general guidelines for conducting the business of our company consistent with the highest standards of business ethics and is intended to qualify as a “code of ethics” within the meaning of Section 406 of the Sarbanes-Oxley Act of 2002 and Item 406 of Regulation S-K. In addition, we intend to promptly disclose (1) the nature of any amendment to our Code of Business Conduct and Ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions and (2) the nature of any waiver, including an implicit waiver, from a provision of our code of ethics that is granted to one of these specified officers, the name of such person who is granted the waiver and the date of the waiver on our website in the future.

ITEM 11.    Executive Compensation

The information required by this item will be contained in our Definitive Proxy Statement under the heading “Executive Compensation and Other Information” and is incorporated herein by reference.

ITEM 12.    Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The information required by this item will be contained in our Definitive Proxy Statement under the heading “Security Ownership of Certain Beneficial Owners and Management” and is incorporated herein by reference.

The information required by Item 201(d) of Regulation S-K will be contained in our Definitive Proxy Statement under the heading “Executive Compensation” and is incorporated herein by reference.

ITEM 13.    Certain Relationships and Related Transactions, and Director Independence

The information required by this item will be contained in our Definitive Proxy Statement under the headings “Certain Relationships and Related Person Transactions,” “Board Independence” and “Committees of the Board of Directors” and is incorporated herein by reference.

ITEM 14.    Principal Accounting Fees and Services

The information required by this item will be contained in our Definitive Proxy Statement under the heading “Independent Registered Public Accountants’ Fees” and is incorporated herein by reference.

110

 

PART IV

ITEM 15.    Exhibits, Financial Statement Schedules

1.

Financial Statements.

The financial statements of Avidity Biosciences, Inc., together with the report thereon of BDO USA, LLP, an independent registered public accounting firm, are included in this annual report on Form 10-K beginning on page F-1.

2.

Financial Statement Schedules.

All schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.

3.

Exhibits.

A list of exhibits is set forth on the Exhibit Index immediately preceding the signature page of this annual report on Form 10-K and is incorporated herein by reference.

ITEM 16.    Form 10-K Summary

None.

 

 

111

 

 

Avidity Biosciences, Inc.

Index to Financial Statements

 

 

 

Report of Independent Registered Public Accounting Firm

Stockholders and Board of Directors

Avidity Biosciences, Inc.

San Diego, California

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Avidity Biosciences, Inc. (the “Company”) as of December 31, 2021 and 2020, the related statements of operations and comprehensive loss, convertible preferred stock/units and stockholders’/members’ equity (deficit), and cash flows for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the Company's internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) and our report dated March 1, 2022 expressed an unqualified opinion thereon.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.

 

As described in Note 5 to the financial statements, the Company primarily derives its revenue from a research collaboration and license agreement (the “Lilly Agreement”) with Eli Lilly and Company (“Lilly”). The Company recognizes revenue from the collaboration in an amount proportional to the collaboration expenses incurred during the period to the total estimated collaboration expenses over the five-year period

f-2

that it expects to deliver its performance obligations. In connection with the Lilly Agreement, the Company recognized revenue of approximately $9.1 million for the year ended December 31, 2021.

 

We identified the determination of total estimated collaboration expenses as a critical audit matter due to the application of significant management judgment to estimate the total collaboration expenses. Specifically, the amount of total expenses includes a mix of budgeted expenses approved by Lilly for the upcoming year and estimated remaining expenses over the remaining term of the collaboration. The assumptions used to estimate the remaining expenses are subjective. Auditing these estimates involved especially subjective auditor judgment due to the nature of the audit evidence available to address these estimates.

 

The primary procedures we performed to address this critical audit matter included:

 

 

•

Evaluating management’s ability to make reliable estimates by comparing the costs incurred for activities completed to date to the costs forecasted for those activities.

 

•

Evaluating management’s ability to achieve the estimates for future periods by i) comparing the estimated costs for future periods to the actual costs incurred to date, ii) performing inquiries with the Company’s operations teams and examining the meeting minutes of meetings with Lilly to corroborate the assumptions used in developing the estimated costs for future periods, and iii) comparing the activities budgeted for future periods to the collaboration plan specified in the Lilly Agreement.

 

•

Examining the communication records between the Company and Lilly as well as the Company’s board minutes and press releases.

/s/ BDO USA, LLP

We have served as the Company’s auditor since 2016.

San Diego, California

March 1, 2022

 

f-3

 

Avidity Biosciences, Inc.

Balance Sheets

(in thousands, except par value)

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

320,448

 

 

$

321,462

 

Marketable securities

 

 

85,095

 

 

 

6,679

 

Prepaid and other assets

 

 

5,598

 

 

 

3,537

 

Total current assets

 

 

411,141

 

 

 

331,678

 

Property and equipment, net

 

 

4,805

 

 

 

1,468

 

Restricted cash

 

 

251

 

 

 

251

 

Right-of-use asset

 

 

10,784

 

 

 

454

 

Other assets

 

 

599

 

 

 

47

 

Total assets

 

$

427,580

 

 

$

333,898

 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable and accrued liabilities

 

$

14,085

 

 

$

7,745

 

Accrued compensation

 

 

8,940

 

 

 

3,152

 

Lease liabilities, current portion

 

 

1,769

 

 

 

—

 

Deferred revenue, current portion

 

 

4,864

 

 

 

3,690

 

Total current liabilities

 

 

29,658

 

 

 

14,587

 

Lease liabilities, net of current portion

 

 

9,960

 

 

 

938

 

Deferred revenue, net of current portion

 

 

6,532

 

 

 

12,150

 

Total liabilities

 

 

46,150

 

 

 

27,675

 

Commitments and contingencies (Note 9)

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Preferred stock, $0.0001 par value; authorized shares – 40,000;

   issued and outstanding shares – none

 

 

—

 

 

 

—

 

Common stock, $0.0001 par value; authorized shares – 400,000;

   issued and outstanding shares – 47,754 and 37,569 at

   December 31, 2021 and 2020, respectively

 

 

5

 

 

 

4

 

Additional paid-in capital

 

 

566,161

 

 

 

372,764

 

Accumulated other comprehensive loss

 

 

(187

)

 

 

(5

)

Accumulated deficit

 

 

(184,549

)

 

 

(66,540

)

Total stockholders’ equity

 

 

381,430

 

 

 

306,223

 

Total liabilities and stockholders’ equity

 

$

427,580

 

 

$

333,898

 

 

See accompanying notes.

f-4

Avidity Biosciences, Inc.

Statements of Operations and Comprehensive Loss

(in thousands, except per share/unit data)

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Collaboration revenue

 

$

9,326

 

 

$

6,787

 

 

$

2,319

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

101,182

 

 

 

37,602

 

 

 

14,539

 

General and administrative

 

 

26,195

 

 

 

13,462

 

 

 

5,112

 

Total operating expenses

 

 

127,377

 

 

 

51,064

 

 

 

19,651

 

Loss from operations

 

 

(118,051

)

 

 

(44,277

)

 

 

(17,332

)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

104

 

 

 

206

 

 

 

—

 

Interest expense

 

 

—

 

 

 

(209

)

 

 

(7,387

)

Change in fair value of preferred warrant liability

 

 

—

 

 

 

(75

)

 

 

(15

)

Other expense

 

 

(62

)

 

 

—

 

 

 

—

 

Total other income (expense)

 

 

42

 

 

 

(78

)

 

 

(7,402

)

Net loss

 

 

(118,009

)

 

 

(44,355

)

 

 

(24,734

)

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

 

 

 

 

Net unrealized losses on marketable securities

 

 

(182

)

 

 

(5

)

 

 

—

 

Comprehensive loss

 

$

(118,191

)

 

$

(44,360

)

 

$

(24,734

)

Net loss per share/unit, basic and diluted

 

$

(2.85

)

 

$

(2.05

)

 

$

(9.12

)

Weighted-average shares/units outstanding,

   basic and diluted

 

 

41,428

 

 

 

21,663

 

 

 

2,713

 

 

See accompanying notes.

 

 

 

f-5

 

Avidity Biosciences, Inc.

Statements of Convertible Preferred Stock/Units and Stockholders’/Members’ Equity (Deficit)

(in thousands)

 

 

 

Preferred Units

 

 

Convertible

Preferred

Stock

 

 

 

Common Units

 

 

Common Stock

 

 

Additional

Paid-in

 

 

Accumulated

Other

Comprehensive

 

 

Accumulated

 

 

Predecessor's

 

 

Total

Stockholders’/

Members'

Equity

 

 

 

Units

 

 

Amount

 

 

Shares

 

 

Amount

 

 

 

Units

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Loss

 

 

Deficit

 

 

Deficit

 

 

(Deficit)

 

Balance at December 31, 2018

 

 

12,459

 

 

$

32,693

 

 

 

—

 

 

$

—

 

 

 

 

2,842

 

 

$

426

 

 

 

—

 

 

$

—

 

 

$

—

 

 

$

—

 

 

$

—

 

 

$

(41,555

)

 

$

(41,129

)

Distribution to members

 

 

—

 

 

 

(106

)

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Issuance of common units upon

   exercise of unit options

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

78

 

 

 

38

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

38

 

Stock-based compensation

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

17

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

17

 

Net loss to date of conversion

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(2,549

)

 

 

(2,549

)

Conversion from LLC to C

   corporation

 

 

(12,459

)

 

 

(32,587

)

 

 

12,459

 

 

 

32,587

 

 

 

 

(2,920

)

 

 

(481

)

 

 

2,920

 

 

 

—

 

 

 

(43,623

)

 

 

—

 

 

 

—

 

 

 

44,104

 

 

 

—

 

Issuance of Series C convertible

   preferred stock, net of issuance

   costs of $4,100

 

 

—

 

 

 

—

 

 

 

17,915

 

 

 

72,623

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Issuance of Series C convertible

   preferred stock upon conversion

   of convertible notes

 

 

—

 

 

 

—

 

 

 

6,893

 

 

 

29,510

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Issuance of common stock upon

   exercise of stock options, net

   of repurchases

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

69

 

 

 

—

 

 

 

26

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

26

 

Vesting of early exercise options

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

36

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

36

 

Stock-based compensation

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

389

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

389

 

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(22,185

)

 

 

—

 

 

 

(22,185

)

Balance at December 31, 2019

 

 

—

 

 

$

—

 

 

 

37,267

 

 

$

134,720

 

 

 

 

—

 

 

$

—

 

 

 

2,989

 

 

$

—

 

 

$

(43,172

)

 

$

—

 

 

$

(22,185

)

 

$

—

 

 

$

(65,357

)

Issuance of Series C convertible

   preferred stock, net of issuance

   costs of $100

 

 

—

 

 

 

—

 

 

 

538

 

 

 

2,200

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Issuance of common stock in

   initial public offering, net of

   issuance costs of $24,026

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

16,560

 

 

 

2

 

 

 

274,052

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

274,054

 

Conversion of convertible preferred

   stock into common stock upon

   completion of initial public offering

 

 

—

 

 

 

—

 

 

 

(37,805

)

 

 

(136,920

)

 

 

 

—

 

 

 

—

 

 

 

17,921

 

 

 

2

 

 

 

136,918

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

136,920

 

Reclassification of warrant liability to

   equity due to adjustment from

   preferred stock warrant to common

   stock warrant upon completion of

   initial public offering

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

120

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

120

 

Cashless exercise of common stock

   warrants

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

16

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Issuance of common stock upon

   exercise of stock options, net

   of repurchases

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

54

 

 

 

—

 

 

 

22

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

22

 

Issuance of common stock

   under employee stock

   purchase plan

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

29

 

 

 

—

 

 

 

444

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

444

 

Vesting of early exercise options

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

70

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

70

 

Stock-based compensation

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

4,310

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

4,310

 

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(44,355

)

 

 

—

 

 

 

(44,355

)

Other comprehensive loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(5

)

 

 

—

 

 

 

—

 

 

 

(5

)

Balance at December 31, 2020

 

 

—

 

 

$

—

 

 

 

—

 

 

$

—

 

 

 

 

—

 

 

$

—

 

 

 

37,569

 

 

$

4

 

 

$

372,764

 

 

$

(5

)

 

$

(66,540

)

 

$

—

 

 

$

306,223

 

Issuance of common stock in

   public offerings, net of issuance

   costs of $11,262

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

9,980

 

 

 

1

 

 

 

174,676

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

174,677

 

Issuance of common stock upon

   exercise of stock options

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

172

 

 

 

—

 

 

 

930

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

930

 

Issuance of common stock

   under employee stock

   purchase plan

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

33

 

 

 

—

 

 

 

709

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

709

 

Vesting of early exercise options

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

26

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

26

 

Stock-based compensation

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

17,056

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

17,056

 

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(118,009

)

 

 

—

 

 

 

(118,009

)

Other comprehensive loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(182

)

 

 

—

 

 

 

—

 

 

 

(182

)

Balance at December 31, 2021

 

 

—

 

 

$

—

 

 

 

—

 

 

$

—

 

 

 

 

—

 

 

$

—

 

 

 

47,754

 

 

$

5

 

 

$

566,161

 

 

$

(187

)

 

$

(184,549

)

 

$

—

 

 

$

381,430

 

 

See accompanying notes.

 

f-6

 

Avidity Biosciences, Inc.

Statements of Cash Flows

(in thousands)

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Cash flows from operating activities

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(118,009

)

 

$

(44,355

)

 

$

(24,734

)

Adjustments to reconcile net loss to net cash (used in) provided by

   operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation

 

 

639

 

 

 

373

 

 

 

348

 

Stock-based compensation expense

 

 

17,056

 

 

 

4,310

 

 

 

406

 

Amortization of premiums and discounts on marketable securities, net

 

 

179

 

 

 

9

 

 

 

—

 

Amortization of discounts and loan issuance costs

 

 

—

 

 

 

29

 

 

 

71

 

Gain on disposal of property and equipment

 

 

(16

)

 

 

—

 

 

 

—

 

Noncash interest expense

 

 

—

 

 

 

110

 

 

 

7,027

 

Change in fair value of preferred warrant liability

 

 

—

 

 

 

75

 

 

 

15

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Prepaid and other assets

 

 

(2,510

)

 

 

(2,444

)

 

 

(949

)

Accounts payable and accrued liabilities

 

 

6,043

 

 

 

5,749

 

 

 

436

 

Accrued compensation

 

 

5,788

 

 

 

1,838

 

 

 

1,010

 

Operating lease right-of-use assets and liabilities, net

 

 

461

 

 

 

289

 

 

 

(80

)

Deferred revenue

 

 

(4,444

)

 

 

(3,100

)

 

 

18,940

 

Net cash (used in) provided by operating activities

 

 

(94,813

)

 

 

(37,117

)

 

 

2,490

 

Cash flows from investing activities

 

 

 

 

 

 

 

 

 

 

 

 

Purchases of marketable securities

 

 

(85,357

)

 

 

(6,693

)

 

 

—

 

Maturities of marketable securities

 

 

6,580

 

 

 

—

 

 

 

—

 

Purchases of property and equipment

 

 

(3,740

)

 

 

(1,092

)

 

 

(235

)

Net cash used in investing activities

 

 

(82,517

)

 

 

(7,785

)

 

 

(235

)

Cash flows from financing activities

 

 

 

 

 

 

 

 

 

 

 

 

Proceeds from issuance of common stock in public offerings, gross

 

 

185,939

 

 

 

298,080

 

 

 

—

 

Payment of issuance costs related to public offerings

 

 

(11,262

)

 

 

(24,026

)

 

 

—

 

Proceeds from exercise of stock/unit options, net of repurchases

 

 

930

 

 

 

22

 

 

 

65

 

Proceeds from issuance of common stock under employee stock

   purchase plan

 

 

709

 

 

 

444

 

 

 

—

 

Payments on long-term debt

 

 

—

 

 

 

(4,683

)

 

 

(2,800

)

Distributions to members

 

 

—

 

 

 

—

 

 

 

(106

)

Proceeds from issuance of Series C convertible preferred stock,

   net of issuance costs

 

 

—

 

 

 

2,200

 

 

 

72,623

 

Proceeds from issuance of convertible notes, net of issuance costs

 

 

—

 

 

 

—

 

 

 

19,451

 

Net cash provided by financing activities

 

 

176,316

 

 

 

272,037

 

 

 

89,233

 

Net (decrease) increase in cash, cash equivalents and restricted cash

 

 

(1,014

)

 

 

227,135

 

 

 

91,488

 

Cash, cash equivalents and restricted cash at beginning of period

 

 

321,713

 

 

 

94,578

 

 

 

3,090

 

Cash, cash equivalents and restricted cash at end of period

 

$

320,699

 

 

$

321,713

 

 

$

94,578

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

 

 

 

 

 

 

 

Cash paid for interest

 

$

—

 

 

$

571

 

 

$

322

 

Supplemental schedule of noncash investing and financing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Right-of-use assets obtained in exchange for operating lease liabilities

 

$

12,074

 

 

$

936

 

 

$

807

 

Costs incurred, but not paid, in connection with purchases of property

   and equipment included in accounts payable and accrued liabilities

 

$

220

 

 

$

118

 

 

$

43

 

Conversion of convertible preferred stock into common stock upon

   completion of initial public offering

 

$

—

 

 

$

136,920

 

 

$

—

 

Issuance of Series C convertible preferred stock upon conversion

   of outstanding convertible notes

 

$

—

 

 

$

—

 

 

$

29,510

 

Reclassification of warrant liability to equity due to adjustment from

   preferred stock warrant to common stock warrant upon completion

   of initial public offering

 

$

—

 

 

$

120

 

 

$

—

 

 

See accompanying notes.

 

 

f-7

 

Avidity Biosciences, Inc.

Notes to Financial Statements

1.

Description of Business and Basis of Presentation

Description of Business

Avidity Biosciences, Inc. (the Company or Avidity) is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs). The Company’s proprietary AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics.

Formation and Conversion

The Company was formed under the laws of the State of Delaware in November 2012 as a Delaware limited liability company. In April 2019, pursuant to an Agreement and Plan of Conversion, Avidity Biosciences LLC (Avidity LLC) was converted into Avidity Biosciences, Inc., a Delaware corporation. The entire membership interests of Avidity LLC were converted into securities of Avidity Biosciences, Inc. as follows: (i) each outstanding common unit of Avidity LLC was converted into one share of Avidity Biosciences, Inc.’s common stock; (ii) each outstanding Series A convertible preferred unit of Avidity LLC converted into one share of Avidity Biosciences, Inc.’s Series A convertible preferred stock; and (iii) each outstanding Series B convertible preferred unit of Avidity LLC converted into one share of Avidity Biosciences, Inc.’s Series B convertible preferred stock. All the property, rights, privileges, powers and franchises of Avidity LLC vested in Avidity Biosciences, Inc., and all debts, liabilities and duties of Avidity LLC became debts, liabilities and duties of Avidity Biosciences, Inc. Outstanding convertible notes, warrants and stock awards under Avidity LLC’s employee benefit and incentive compensation plans continued on the same terms and conditions and became binding upon Avidity Biosciences, Inc.

Initial Public Offering

On June 16, 2020, the Company completed its initial public offering (IPO) in which it sold 16,560,000 shares of common stock at an offering price of $18.00 per share. Proceeds from the IPO, net of underwriting discounts, commissions and offering costs, were $274.1 million.

In addition, each of the following occurred in connection with the completion of the IPO:

 

•

the conversion of all outstanding shares of convertible preferred stock into 17,921,069 shares of the Company’s common stock;

 

•

the adjustment of an outstanding warrant to purchase convertible preferred stock into a warrant to purchase 7,809 shares of the Company’s common stock; and

 

•

the amendment and restatement of the Company’s certificate of incorporation, authorizing 400,000,000 shares of common stock and 40,000,000 shares of undesignated preferred stock.

Reverse Stock Split

On June 4, 2020, the Company effected a one-for-2.1095 reverse stock split of its common stock (the Reverse Stock Split). The par value and the authorized shares of the common stock were not adjusted as a result of the Reverse Stock Split. All issued and outstanding common stock and the conversion ratio of the convertible preferred stock have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented.

Liquidity

On August 6, 2021, the Company completed a public offering of 9,200,000 shares of its common stock at a public offering price of $18.00 per share. The net proceeds from the offering were $155.1 million,

F-8

after deducting underwriting discounts, commissions and offering costs. On July 2, 2021, the Company entered into a sales agreement (the Sales Agreement) with Cowen and Company, LLC (the Sales Agent), under which the Company may, from time to time, sell shares of its common stock having an aggregate offering price of up to $150.0 million through the Sales Agent. During the year ended December 31, 2021, the Company sold 780,549 shares of its common stock pursuant to the Sales Agreement and received net proceeds of $19.6 million, after deducting offering-related transaction costs and commissions. See Note 10 (Stockholders Equity (Deficit)) for more information on the Company’s public offerings.

As of December 31, 2021, the Company has devoted substantially all of its resources to organizing and staffing the company, business planning, raising capital, developing its proprietary AOC platform, identifying potential product candidates, establishing its intellectual property portfolio, conducting research, preclinical and clinical studies, and providing other general and administrative support for these operations. In addition, the Company has a limited operating history, has incurred operating losses since inception and expects that it will continue to incur net losses into the foreseeable future as it continues the development of its product candidates and development programs. As of December 31, 2021, the Company had an accumulated deficit of $184.5 million and cash, cash equivalents and marketable securities of $405.5 million.

The Company believes that existing cash, cash equivalents and marketable securities will be sufficient to fund the Company’s operations for at least 12 months from the date of the filing of this Form 10-K. The Company plans to finance its future cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. If the Company is not able to secure adequate additional funding, it may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or delay or reduce the scope of its planned development programs. Any of these actions could materially harm the Company’s business, results of operations and future prospects.

Basis of Presentation

The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC). The financial statements reflect all adjustments which, in the opinion of management, are necessary for a fair statement of the results for the periods presented. All such adjustments are of a normal and recurring nature. The operating results presented in these financial statements are not necessarily indicative of the results that may be expected for any future periods.

2.

Summary of Significant Accounting Policies

Use of Estimates

The Company’s financial statements are prepared in accordance with GAAP, which requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to revenue recognition, stock-based compensation, and accrued research and development costs. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents include cash in readily available checking and money market accounts. Restricted cash represents cash held as collateral for the letter of credit required under the Company’s facility lease and is reported as a long-term asset in the accompanying balance sheets.

F-9

Marketable Securities

The Company’s marketable securities consist of corporate debt securities. The Company classifies its marketable securities as available-for-sale and records such assets at estimated fair value in the balance sheets, with unrealized gains and losses, if any, reported as a component of other comprehensive income (loss) within the statements of operations and comprehensive loss and as a separate component of stockholders’ equity. The Company classifies marketable securities with remaining maturities greater than one year as current assets because such marketable securities are available to fund the Company’s current operations. Realized gains and losses are calculated on the specific identification method and recorded as interest income. There were no realized gains and losses for the years ended December 31, 2021, 2020 and 2019.

At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. When the Company determines that a decline in the fair value below its cost basis is other-than-temporary, the Company recognizes an impairment loss in the period in which the other-than-temporary decline occurred. There have been no other-than-temporary impairments recognized for the years ended December 31, 2021, 2020 and 2019.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments, credit quality, diversification, liquidity and maturities of investments, which are designed to maintain safety and liquidity.

Fair Value of Financial Instruments

Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:

 

•

Level 1—Quoted prices in active markets for identical assets or liabilities.

 

•

Level 2—Observable inputs, such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.

 

•

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

None of the Company’s non-financial assets are recorded at fair value on a non-recurring basis. The carrying amounts reflected in the Company’s balance sheets for prepaid and other assets and accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The carrying value of the Company’s previously outstanding debt approximated fair value due to the interest being reflective of then-current market rates for debt with similar terms and conditions. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. No transfers between levels have occurred during the periods presented.

F-10

See Note 3 (Fair Value Measurements) for information on assets and liabilities measured at fair value.

Property and Equipment

Property and equipment, including leasehold improvements, are stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recorded using the straight-line method over the estimated useful lives of the related assets, which ranges from three to five years. Leasehold improvements are amortized on a straight-line basis over the shorter of the estimated useful lives of the assets or the remaining lease term. Repairs and maintenance charges that do not increase the useful life of the assets are charged to operating expenses as incurred.

Impairment of Long-Lived Assets

Long-lived assets consist of property and equipment. An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. The Company has not recognized any impairment losses in any of the periods presented in these financial statements.

Segment Information

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by management in making decisions regarding resource allocation and assessing performance. The Company manages its operations as a single operating segment in the United States for the purposes of assessing performance and making operating decisions.

Revenue Recognition

To date, all the Company’s revenue has been derived from collaboration and research agreements. The terms of these arrangements include the following types of payments to the Company: non-refundable, upfront license fees; development, regulatory and commercial milestone payments; payments for research and development services provided by the Company or for manufacturing supply services the Company provides through its contract manufacturers; and royalties on net sales of licensed products.

Effective January 1, 2019, the Company adopted Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, using the modified retrospective approach. This new standard requires a company to recognize revenues when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. An adjustment to retained earnings was not required upon adoption as the Company had no revenue generating agreements in effect on the date of adoption.

In accordance with Topic 606, the Company performs the following steps in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of these agreements: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as, the Company satisfies each performance obligation.

The Company receives payments from its collaborators based on billing schedules established in each contract. Upfront and other payments may require deferral of revenue recognition to a future period until the Company performs its obligations under its research and collaboration arrangements. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional.

F-11

See Note 5 (Collaboration, License and Research Agreements) for further information.

Research and Development Costs

Research and development costs are expensed as incurred and include salaries, benefits and stock-based compensation associated with research and development personnel, third-party research and development expenses, license fees, laboratory supplies, facilities, overhead costs, and consultants. Nonrefundable advance payments for goods and services that will be used in future research and development activities are capitalized and recorded as expense in the period that the Company receives the goods or when services are performed.

Upfront and milestone payments to acquire contractual rights to licensed technology are recorded when incurred if there is uncertainty in the Company receiving future economic benefit from the acquired contractual rights.

Patent Costs

Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.

Income Taxes

The Company accounts for income taxes in accordance with Accounting Standards Codification (ASC) 740, Income Taxes, which provides for deferred taxes using the asset and liability method. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.

The Company is subject to taxation in the United States and various state jurisdictions. As of December 31, 2021, the Company’s tax years since conversion to a corporation in 2019 are subject to examination by taxing authorities.

Stock-Based Compensation

Stock-based compensation expense for employee and non-employee stock option grants is recorded at the estimated fair value of the award as of the grant date and is recognized as expense on a straight-line basis over the requisite service period (usually the vesting period) of the stock-based award, and forfeitures are recognized as incurred. Stock-based compensation expense for employee stock purchases under the Company’s Employee Stock Purchase Plan (the ESPP) is recorded at the estimated fair value of the purchase as of the plan enrollment date and is recognized as expense on a straight-line basis over the applicable six-month ESPP offering period. The estimation of fair value for stock-based compensation requires management to make estimates and judgments about, among other things, the estimated life of options and volatility of the Company’s common stock. The judgments directly affect the amount of compensation expense that will be recognized.

F-12

Comprehensive Loss

Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on marketable securities. Comprehensive gains (losses) have been reflected in the statements of operations and comprehensive loss for all periods presented.

Net Loss Per Share/Unit

Basic net loss per share/unit is computed by dividing the net loss by the weighted-average number of common shares/units outstanding for the period, adjusted for the weighted-average number of common shares/units outstanding that are subject to repurchase or forfeiture. The Company has excluded 33,600, 123,285 and 217,524 weighted-average shares/units subject to repurchase or forfeiture from the weighted-average number of common shares/units outstanding for the years ended December 31, 2021, 2020 and 2019, respectively. Diluted net loss per share/unit is computed by dividing the net loss by the weighted-average number of common shares/units and dilutive common stock/unit equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For all periods presented, there is no difference in the number of shares/units used to calculate basic and diluted shares/units outstanding as inclusion of the potentially dilutive securities would be anti-dilutive.

Potentially dilutive securities not included in the calculation of diluted net loss per share/unit, because to do so would be anti-dilutive, are as follows (in common stock/unit equivalent shares; in thousands):

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Convertible preferred stock

 

 

—

 

 

 

—

 

 

 

17,666

 

Warrant to purchase convertible preferred stock

 

 

—

 

 

 

—

 

 

 

8

 

Warrant to purchase common stock

 

 

—

 

 

 

—

 

 

 

9

 

Common stock options issued and outstanding

 

 

5,778

 

 

 

3,788

 

 

 

1,667

 

Common stock subject to repurchase or

   forfeiture

 

 

15

 

 

 

69

 

 

 

195

 

ESPP shares pending issuance

 

 

3

 

 

 

1

 

 

 

—

 

Total

 

 

5,796

 

 

 

3,858

 

 

 

19,545

 

 

Recently Adopted Accounting Pronouncements

In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing certain separation models required under existing guidance. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and amends the diluted earnings-per-share (EPS) calculation guidance in certain areas to improve the consistency of EPS calculations. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020. The Company early adopted the new standard, effective January 1, 2021, on a modified retrospective basis. The adoption of ASU 2020-06 had no impact on the Company's financial statements and related disclosures.

Recently Issued Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. The Company

F-13

believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

3.

Fair Value Measurements

The Company determines the fair value of its cash equivalents and marketable securities based on one or more valuations from its investment accounting and reporting service provider. The investment service provider values the securities using a hierarchical security pricing model that relies primarily on valuations provided by an industry-recognized valuation service. Such valuations may be based on trade prices in active markets for identical assets (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets, yield curves, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, and broker and dealer quotes, as well as other relevant economic measures.

The following tables summarize the Company’s cash equivalents and marketable securities measured at fair value (in thousands):

 

 

 

 

 

 

 

Fair Value Measurements Using

 

As of December 31, 2021

 

Total

 

 

Quoted Prices in

Active Markets

for Identical

Assets (Level 1)

 

 

Significant

Other

Observable

Inputs (Level 2)

 

 

Significant

Unobservable

Inputs

(Level 3)

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

$

65,372

 

 

$

65,372

 

 

$

—

 

 

$

—

 

Negotiable certificates of deposit

 

 

3,873

 

 

 

—

 

 

 

3,873

 

 

 

—

 

Corporate debt securities

 

 

15,850

 

 

 

—

 

 

 

15,850

 

 

 

—

 

Total

 

$

85,095

 

 

$

65,372

 

 

$

19,723

 

 

$

—

 

 

 

 

 

 

 

 

Fair Value Measurements Using

 

As of December 31, 2020

 

Total

 

 

Quoted Prices in

Active Markets

for Identical

Assets (Level 1)

 

 

Significant

Other

Observable

Inputs (Level 2)

 

 

Significant

Unobservable

Inputs

(Level 3)

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Negotiable certificates of deposit

 

$

720

 

 

$

—

 

 

$

720

 

 

$

—

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

 

6,679

 

 

 

—

 

 

 

6,679

 

 

 

—

 

Total

 

$

7,399

 

 

$

—

 

 

$

7,399

 

 

$

—

 

Prior to completion of the IPO in June 2020, the Company had an outstanding warrant to purchase shares of its Series A convertible preferred stock. Since the underlying Series A convertible preferred stock was classified outside of permanent equity, the preferred stock warrant was classified as other long-term liabilities in the accompanying balance sheet. The preferred stock warrant liability was recorded at fair value utilizing the Black-Scholes model using significant unobservable inputs adjusted for the preferred stock warrant’s expected life and the fair value of the underlying convertible preferred stock. The Company adjusted the carrying value of the preferred stock warrant to its estimated fair value at each reporting date, with any related increase or decrease in the fair value recorded as an increase or decrease to other income (expense) in the statements of operations and comprehensive loss. In connection with the IPO, the preferred stock warrant was adjusted to become a warrant to purchase shares of the Company’s common stock and met the criteria to be classified within stockholders’ equity. Accordingly, the fair value of the warrant liability was reclassified to stockholders’ equity.

The following table provides a reconciliation of the preferred stock warrant liability measured at fair value using Level 3 unobservable inputs (in thousands):

F-14

 

Balance at December 31, 2018

 

$

30

 

Change in fair value

 

 

15

 

Balance at December 31, 2019

 

 

45

 

Change in fair value

 

 

75

 

Reclassification of warrant liability

   to stockholders’ equity

 

 

(120

)

Balance at December 31, 2020

 

$

—

 

 

4.

Marketable Securities

The Company’s marketable securities, which consist of highly liquid marketable debt securities, are classified as available-for-sale and are stated at fair value. The following tables summarize the Company’s marketable securities (in thousands):

 

As of December 31, 2021

 

Maturity

(in years)

 

Amortized

Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Estimated

Fair Value

 

U.S. Treasury securities

 

1 or less

 

$

2,492

 

 

$

—

 

 

$

(1

)

 

$

2,491

 

Negotiable certificates of deposit

 

1 or less

 

 

1,190

 

 

 

—

 

 

 

(1

)

 

 

1,189

 

U.S. Treasury securities

 

1 - 2

 

 

63,034

 

 

 

—

 

 

 

(153

)

 

 

62,881

 

Negotiable certificates of deposit

 

1 - 2

 

 

2,687

 

 

 

—

 

 

 

(3

)

 

 

2,684

 

Corporate debt securities

 

1 - 2

 

 

15,879

 

 

 

—

 

 

 

(29

)

 

 

15,850

 

Total

 

 

 

$

85,282

 

 

$

—

 

 

$

(187

)

 

$

85,095

 

 

As of December 31, 2020

 

Maturity

(in years)

 

Amortized

Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Estimated

Fair Value

 

Corporate debt securities

 

1 or less

 

$

3,612

 

 

$

—

 

 

$

(2

)

 

$

3,610

 

Corporate debt securities

 

1 - 2

 

 

3,072

 

 

 

—

 

 

 

(3

)

 

 

3,069

 

Total

 

 

 

$

6,684

 

 

$

—

 

 

$

(5

)

 

$

6,679

 

 

5.

Collaboration, License and Research Agreements

Research Collaboration and License Agreement with Eli Lilly and Company

In April 2019, the Company entered into a Research Collaboration and License Agreement (the Lilly Agreement) with Eli Lilly and Company (Lilly) for the discovery, development and commercialization of AOC products directed against certain targets in immunology and other select indications on a worldwide basis. Under the Lilly Agreement, the Company granted Lilly an exclusive, worldwide, royalty-bearing license, with the right to sublicense (subject to certain conditions), under the Company’s technology to research, develop, manufacture and sell products containing AOCs that are directed to up to six mRNA targets. The Company retains the right to use its technology to perform its obligations under the Lilly Agreement and for all purposes not granted to Lilly. The Company agreed that it will not, itself or with a third party, research, develop, manufacture or commercialize or otherwise exploit any compound or product directed against targets subject to the Lilly Agreement.

In consideration of the rights granted to Lilly under the Lilly Agreement, the Company received a one-time upfront fee of $20.0 million and is eligible to receive up to $60.0 million in development milestone payments, up to $140.0 million in regulatory milestone payments and up to $205.0 million in commercialization milestone payments per target. In addition, Lilly is obligated to reimburse the Company for research expenses, as defined in and incurred under the Lilly Agreement. Lilly is obligated to pay the Company a tiered royalty ranging from the mid-single to low-double digits on worldwide annual net sales of licensed products, subject to specified and capped reductions for the market entry of biosimilar products, loss of patent coverage of licensed products and for payments owed to third parties for additional rights necessary to commercialize licensed products in the territory. Lilly’s royalty obligations and the Lilly

F-15

Agreement will expire on a licensed product-by-licensed product and country-by-country basis on the later of ten years from the date of the first commercial sale or when there is no longer a valid patent claim covering such licensed product in such country.

The Company has identified multiple promises to deliver goods and services, which include at inception of the agreement: (i) a license to technology and patents, information and know-how; and (ii) collaboration, including research services, technical and regulatory support provided by the Company. At inception and through December 31, 2021, the Company has identified one performance obligation for all the deliverables under the Lilly Agreement since the delivered elements are either not capable of being distinct or are not distinct within the context of the contract. Accordingly, the Company will recognize revenue for the fixed or determinable collaboration in an amount proportional to the collaboration expenses incurred and the total estimated collaboration expenses over the five-year period over which it expects to deliver its performance obligations. The Company periodically reviews and updates the estimated collaboration expenses, when appropriate, which adjusts the percentage of revenue that is recognized for the period. In connection with the Lilly Agreement, the Company recognized revenue of $9.1 million, $6.8 million and $2.3 million for the years ended December 31, 2021, 2020 and 2019, respectively, and had deferred revenue of $11.1 million and $15.8 million as of December 31, 2021 and 2020, respectively. Collaboration receivables related to the Lilly Agreement were $0.9 million and $1.2 million as of December 31, 2021 and 2020, respectively, which are included in prepaid and other assets on the balance sheets.

A reconciliation of the closing balance of deferred revenue related to the Lilly Agreement is as follows (in thousands):

 

Balance at December 31, 2019

 

$

18,940

 

Revenue recognized

 

 

(3,100

)

Balance at December 31, 2020

 

 

15,840

 

Revenue recognized

 

 

(4,732

)

Balance at December 31, 2021

 

$

11,108

 

 

Concurrently with the execution of the Lilly Agreement, the Company issued a convertible promissory note to Lilly (the Lilly Note). In connection with the Series C financing in November 2019, all outstanding principal and interest accrued under the Lilly Note converted into 4,576,342 shares of Series C convertible preferred stock. See Note 8 (Convertible Notes) for further discussion.

Research Agreement with MyoKardia, Inc.

In December 2020, the Company entered into a research collaboration (the MyoKardia Agreement) with MyoKardia, Inc. (MyoKardia), a wholly-owned subsidiary of Bristol Myers Squibb, to demonstrate the potential utility of AOCs in cardiac tissue by leveraging MyoKardia’s genetic cardiomyopathy platform including, among other aspects, its novel target discovery engine and proprietary cardiac disease models. In connection with the MyoKardia Agreement, the Company recognized revenue of $0.2 million and $0 for the years ended December 31, 2021 and 2020, respectively.

F-16

6.

Property and Equipment

Property and equipment consist of the following (in thousands):

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Laboratory equipment

 

$

4,775

 

 

$

2,928

 

Computers and software

 

 

116

 

 

 

58

 

Office furniture and equipment

 

 

1,398

 

 

 

44

 

Leasehold improvements

 

 

249

 

 

 

417

 

Property and equipment, gross

 

 

6,538

 

 

 

3,447

 

Less accumulated depreciation

 

 

(1,733

)

 

 

(1,979

)

Total property and equipment, net

 

$

4,805

 

 

$

1,468

 

 

Depreciation expense related to property and equipment was $0.6 million, $0.4 million and $0.3 million for the years ended December 31, 2021, 2020 and 2019, respectively.

7.

Debt

Term Loan

In June 2017, the Company entered into an amendment (the LSA Amendment) to the Amended and Restated Loan and Security Agreement (as amended, the LSA) with Silicon Valley Bank (SVB). Pursuant to the LSA Amendment, SVB agreed to make loans of up to $7.0 million, comprising (i) a $5.0 million term loan, funded at the closing date (the Term C Loan), and (ii) subject to the achievement of a specified milestone relating to the Company’s research, an additional term loan totaling up to $2.0 million (the Term D Loan), of which $4.1 million was used to repay the Company’s existing loan with SVB, in addition to the final payments totaling $0.4 million.

The Term C Loan was scheduled to mature on June 1, 2021 and bore interest at an adjustable annual rate of the prime rate per the Wall Street Journal plus one-fifth of one percent (0.20%). The LSA Amendment provided an extension of the interest only period through June 1, 2019, upon the Term D Loan advance. Beginning July 1, 2019, the Company was required to repay the principal amount in 36 equal monthly installments, in addition to the monthly interest payment. In addition, a final payment of 6.5% of the funded amount, or $0.3 million, was due on the maturity date. The final payment fee was accrued as interest expense over the term of the loan and recorded in long-term debt, net of current portion.

In August 2018, the Company entered into a second amendment to the LSA (the LSA Second Amendment). Pursuant to the LSA Second Amendment, SVB provided the Term D Loan of $2.0 million, upon the Company’s receipt of $3.0 million in convertible note financing. In addition, a final payment of 6.5% of the funded amount, or $0.1 million, was due on the maturity date. The Company accounted for the financing prospectively as a debt modification.  

On June 30, 2020, the Company voluntarily prepaid the aggregate outstanding principal balance of $2.8 million and final payments and accrued interest of $0.5 million related to the Term C and Term D Loans, and the LSA was terminated.

In conjunction with the Term A and Term B Loans, the Company issued a warrant to SVB to purchase up to 16,474 shares of Series A convertible preferred stock at an exercise price of $2.2615 per share, exercisable at any time following the issuance, with a term of ten years. In connection with the completion of the IPO in June 2020, the preferred stock warrant was adjusted to become a warrant exercisable for 7,809 shares of common stock at an exercise price of $4.77 per share. In conjunction with the Term C Loan entered into in June 2017, the Company issued a warrant to SVB to purchase up to 9,442 shares of common stock at an exercise price of $0.53 per share, exercisable at any time following the issuance, with a term of seven years. The Company estimated the fair value of the warrants granted using the Black-Scholes model and recorded the fair value as debt discounts, which were being amortized to interest expense using the

F-17

effective interest method over the term of the loans. On June 17, 2020, the warrants were cashless exercised for an aggregate of 15,833 shares of common stock.

8.

Convertible Notes

In 2018 and 2019, the Company issued convertible promissory notes in the aggregate principal amount of $3.0 million and $4.5 million, respectively (the 2018 Notes and 2019 Notes, respectively). The 2018 Notes and the 2019 Notes accrued interest at 8% and 10% per annum, respectively, and automatically converted into preferred equity in the next qualified financing of at least $10 million at 85% and 80%, respectively, of the per share price paid by the investors in such financing.

Concurrently with the execution of the Lilly Agreement in April 2019, the Company issued the Lilly Note and received cash proceeds of $15.0 million. The Lilly Note accrued simple interest of 8.0% per annum and, if not converted, would have matured in October 2020. All unpaid principal and interest were due at maturity.

The 2018 Notes, 2019 Notes and the Lilly Note (collectively, the Notes) represented share settled debt that were accounted for at amortized cost by accreting the Notes to their redemption value over the life of the debt using the effective interest method.  In connection with the Series C financing in November 2019, all outstanding principal and interest accrued under the Notes converted into 6,893,036 shares of Series C convertible preferred stock. The Company recorded interest expense of $6.9 million for the year ended December 31, 2019 for the stated interest rate and the discount at which the Notes converted.

9.

Commitments and Contingencies

Lease Agreements

The Company adopted ASC 842, Leases, as of January 1, 2019. In accordance with ASC 842, the Company determines if an arrangement is a finance lease, operating lease or short-term lease at inception, or as applicable, and accounts for the arrangement under the relevant accounting literature. During the periods presented, the Company was party to various non-cancellable office and laboratory space operating leases and short-term leases. Currently, the Company is only party to a non-cancellable office and laboratory space operating lease. Under the relevant guidance, the Company recognizes operating lease right-of-use (ROU) assets and liabilities based on the present value of the future minimum lease payments over the lease term at the commencement date, using the Company’s assumed incremental borrowing rate of 5.5%, and amortizes the ROU assets and liabilities over the lease term. Lease expense for operating leases is recognized on a straight-line basis over the lease term. The Company’s short-term leases are not subject to recognition of an ROU asset or liability or straight-line lease expense requirements.

In March 2014, the Company entered into a non-cancellable operating lease for office and laboratory space with a lease term through November 2017. In July 2017, the Company entered into an amendment to this lease to extend the lease term through December 2021.

On June 1, 2020, the Company entered into a second amendment to its existing operating lease (as amended, the 2014 Lease) and entered into a new non-cancellable temporary operating lease in connection with a newly executed non-cancellable operating lease for its new headquarters location, with a projected commencement date of July 1, 2021.

On December 18, 2020, the Company entered into an amendment to the non-cancellable operating lease for its new headquarters location (as amended, the New Lease), which increased the square footage by adding adjacent space and extended the projected commencement date to November 1, 2021. Additionally, the non-cancellable temporary operating lease was amended (as amended, the Temporary Lease) to accommodate the projected commencement date of the New Lease. The lease term under both the 2014 Lease and the Temporary Lease ends 15 days after the commencement date of the New Lease in November 2021. The remaining monthly rental payments under the 2014 Lease and the rent under the Temporary Lease were abated beginning on June 1, 2020, given the execution of the New Lease. The New

F-18

Lease has a five-year term upon commencement in November 2021 and a renewal option for an additional five years. Under the terms of the New Lease, the initial monthly base rent of approximately $251,000 will increase to approximately $282,000 during the last year of the New Lease's initial term, and the first year includes five months of rent abatement. The total lease payments under the initial term of the New Lease of $14.7 million were allocated amongst the 2014 Lease, Temporary Lease and New Lease based on the relative standalone price of the separate lease components. Furthermore, pursuant to the terms of the New Lease, the Company is required to maintain a letter of credit totaling $251,000 throughout the lease term.

In June 2020, in accordance with the lease terms applicable at that time, the Company adjusted the ROU asset and liability of the 2014 Lease to conform to the modification terms and recorded an ROU asset and liability for the Temporary Lease upon occupancy. In December 2020, in connection with the lease amendments described above, the Company adjusted the ROU asset and liability of the 2014 Lease and Temporary Lease to conform to the modification terms. In November 2021, the Company recognized an ROU asset and liability related to the New Lease in connection with obtaining control of the asset upon occupancy of the new space.

As of December 31, 2021, the Company’s ROU assets and liabilities related to the New Lease are as follows (in thousands):

 

ROU assets

 

$

10,784

 

 

 

 

 

 

Lease liabilities, current portion

 

$

1,769

 

Lease liabilities, net of current portion

 

 

9,960

 

Total lease liabilities

 

$

11,729

 

 

As of December 31, 2021, maturities of the lease liabilities due under the New Lease are as follows (in thousands):

 

Year ending December 31,

 

 

 

 

2022

 

$

1,769

 

2023

 

 

3,113

 

2024

 

 

3,207

 

2025

 

 

3,303

 

2026

 

 

3,111

 

Total lease payments

 

 

14,503

 

Less imputed interest

 

 

(2,774

)

Total operating lease liabilities

 

 

11,729

 

Less lease liabilities, current portion

 

 

(1,769

)

Lease liabilities, net of current portion

 

$

9,960

 

 

Supplemental cash flow information related to cash paid for amounts included in the measurement of operating lease liabilities was as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Cash paid included in operating cash flows

 

$

234

 

 

$

163

 

 

$

382

 

 

F-19

 

Rent expense was as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Operating leases

 

$

946

 

 

$

453

 

 

$

302

 

Short-term leases

 

 

216

 

 

 

36

 

 

 

6

 

Total rent expense

 

$

1,162

 

 

$

489

 

 

$

308

 

 

As of December 31, 2021, the weighted-average remaining term of the Company’s operating lease was 4.9 years.

 

Litigation

Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. There are no matters currently outstanding for which any liabilities have been accrued.

Contractual Obligations

The Company enters into contracts in the normal course of business for contract research services, contract manufacturing services, professional services, and other services and products for operating purposes. These contracts may include certain provisions that could require payments for early termination. The amount of the termination payments vary depending on the timing of the termination and the specific terms of the contract.

10.

Stockholders’ Equity (Deficit)

Amended and Restated Certificate of Incorporation

On June 16, 2020, the Company’s certificate of incorporation was amended and restated to authorize 400,000,000 shares of common stock and 40,000,000 shares of undesignated preferred stock, each with a par value of $0.0001 per share.

Common Stock

On June 16, 2020, the Company completed its IPO in which it sold 16,560,000 shares of common stock at an offering price of $18.00 per share. Proceeds from the IPO, net of underwriting discounts, commissions and offering costs, were $274.1 million.

On July 2, 2021, the Company entered into the Sales Agreement with the Sales Agent, under which the Company may, from time to time, sell shares of its common stock having an aggregate offering price of up to $150.0 million through the Sales Agent. Sales of the Company’s common stock made pursuant to the Sales Agreement are made under the Company’s shelf registration statement on Form S-3, which became automatically effective upon filing on July 2, 2021 (the Shelf Registration Statement). In addition, the Sales Agreement may be terminated by the Company or the Sales Agent at any time upon ten days’ notice to the other party, or by the Sales Agent, with respect to itself, at any time in certain circumstances, including the occurrence of a material adverse change. During the year ended December 31, 2021, the Company sold 780,549 shares of its common stock pursuant to the Sales Agreement and received net proceeds of $19.6 million, after deducting offering-related transaction costs and commissions.

On August 6, 2021, the Company completed a public offering of 9,200,000 shares of its common stock at a public offering price of $18.00 per share. The net proceeds from the offering were $155.1 million, after deducting underwriting discounts, commissions and offering costs. The shares sold in the offering were registered pursuant to the Company’s Shelf Registration Statement.

F-20

Conversion

On April 1, 2019, Avidity Biosciences LLC (Avidity LLC), a Delaware limited liability company, was converted into Avidity Biosciences, Inc., a Delaware corporation. The entire membership interests of Avidity LLC were converted into securities of Avidity Biosciences, Inc. as follows: (i) each outstanding common unit of Avidity LLC was converted into one share of Avidity Biosciences, Inc.’s common stock; (ii) each outstanding Series A convertible preferred unit of Avidity LLC converted into one share of Avidity Biosciences, Inc.’s Series A convertible preferred stock; and (iii) each outstanding Series B convertible preferred unit of Avidity LLC converted into one share of Avidity Biosciences, Inc.’s Series B convertible preferred stock. All the property, rights, privileges, powers and franchises of Avidity LLC vested in Avidity Biosciences, Inc., and all debts, liabilities and duties of Avidity LLC became debts, liabilities and duties of Avidity Biosciences, Inc. All references to the former members’ equity accounts in Avidity LLC have been adjusted to reflect the equivalent number of Avidity Biosciences, Inc.’s shares of common stock. Upon completion of the conversion, the Company reclassified an accumulated deficit of $44.1 million from predecessor deficit to additional paid-in capital.

Convertible Preferred Stock

In November 2019, the Company issued 17,915,525 shares of Series C convertible preferred stock, for cash, at a price of $4.2812 per share, for net proceeds of $72.6 million, net of issuance costs of $4.1 million. In addition, all outstanding principal and accrued interest under the Notes were automatically converted into 6,893,036 shares of Series C convertible preferred stock, at a stated discount pursuant to the original terms of the notes at issuance. In January 2020, the Company issued an additional 537,232 shares of Series C convertible preferred stock, for cash, at a price of $4.2812 per share, for net proceeds of $2.2 million, net of issuance costs of $100,000.

In connection with the completion of the IPO in June 2020, all of the outstanding shares of convertible preferred stock were converted into 17,921,069 shares of the Company’s common stock. Prior to conversion, the Company’s convertible preferred stock was classified as temporary equity in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities whose redemption is based upon certain change in control events outside of the Company’s control.

 

Equity Incentive Plans

In January 2013, the Company adopted the 2013 Equity Incentive Plan (the 2013 Plan). The 2013 Plan provided for the issuance of incentive units to employees and nonemployees of the Company and non‑statutory unit options, restricted unit awards, unit appreciation rights, and unit bonuses to directors, employees and consultants of the Company. Under the 2013 Plan, 2,127,013 units were initially reserved for issuance. Upon the conversion of the Company to a C corporation, the 2013 Plan continued on the same terms and conditions. In 2019, the number of shares reserved under the 2013 Plan was increased to 4,771,615 shares.

In June 2020, the Company’s board of directors adopted, and the Company’s stockholders approved, the 2020 Incentive Award Plan (the 2020 Plan), which became effective in connection with the IPO. Pursuant to the 2020 Plan, the Company ceased granting awards under the 2013 Plan. Under the 2020 Plan, the Company may grant stock options, restricted stock, dividend equivalents, restricted stock units, stock appreciation rights, and other stock or cash-based awards to individuals who are then employees, officers, non-employee directors or consultants of the Company. A total of 3,900,000 shares of common stock were initially reserved for issuance under the 2020 Plan. In addition, the number of shares of common stock available for issuance under the 2020 Plan will be increased annually on the first day of each fiscal year during the term of the 2020 Plan, beginning with the 2021 fiscal year, by an amount equal to the lesser

F-21

of (a) 5% of the shares of common stock outstanding on the final day of the immediately preceding calendar year or (b) such smaller number of shares as determined by the Company’s board of directors. At December 31, 2021, 2,574,824 shares remain available for issuance under the 2020 Plan.

Stock Options

Options granted from the 2013 Plan and 2020 Plan are exercisable at various dates and will expire no more than ten years from their date of grant. Options generally vest over a four-year period. Prior to the IPO, the exercise price of options was determined by the Company’s board of directors. Following the IPO, the Company grants options with an exercise price equal to the fair market value of the Company’s stock on the date of the option grant.

Stock option activity for employee and nonemployee awards and related information is as follows (in thousands, except per share and contractual term data):

 

 

 

Number of

Options

 

 

Weighted-

Average

Exercise

Price Per

Share

 

 

Weighted-

Average

Remaining

Contractual

Term

(in years)

 

 

Aggregate

Intrinsic

Value

 

Outstanding at December 31, 2020

 

 

3,788

 

 

$

9.06

 

 

 

 

 

 

 

 

 

Granted

 

 

2,671

 

 

 

23.23

 

 

 

 

 

 

 

 

 

Exercised

 

 

(172

)

 

 

5.42

 

 

 

 

 

 

 

 

 

Forfeited/expired

 

 

(509

)

 

 

22.99

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2021

 

 

5,778

 

 

$

14.49

 

 

 

8.5

 

 

$

58,950

 

Vested and expected to vest at

    December 31, 2021

 

 

5,778

 

 

$

14.49

 

 

 

8.5

 

 

$

58,950

 

Exercisable at December 31, 2021

 

 

1,885

 

 

$

8.91

 

 

 

7.8

 

 

$

29,226

 

 

The aggregate intrinsic values presented in the table above were calculated as the difference between the closing price of the Company’s common stock at December 31, 2021 and the exercise price of stock options that had strike prices below the closing price. The total intrinsic value of options exercised during the years ended December 31, 2021, 2020 and 2019 were $3.4 million, $0.5 million and $7,000, respectively. The total intrinsic values of options exercised were calculated as the difference between the fair value of the Company’s common stock/units at the time of the option exercise and the exercise price of that stock/unit option.

The weighted-average grant date fair value of options granted during the years ended December 31, 2021, 2020 and 2019 were $16.78, $11.63 and $3.46 per share/unit, respectively.

As of December 31, 2021 and 2020, 15,288 and 69,359, respectively, of the stock options exercised were unvested and subject to repurchase.

Employee Stock Purchase Plan

In June 2020, the Company adopted the ESPP, which permits participants to contribute up to 15% of their eligible compensation during defined rolling six-month periods to purchase the Company’s common stock. The purchase price of the shares will be 85% of the lower of the fair market value of the Company’s common stock on the first day of trading of the offering period or on the applicable purchase date. The Company issued 33,147 and 28,979 shares of common stock under the ESPP during the years ended December 31, 2021 and 2020, respectively. The Company had an outstanding liability of $53,000 at December 31, 2021, which is included in accounts payable and accrued liabilities on the balance sheet, for employee contributions to the ESPP for shares pending issuance at the end of the offering period. As of December 31, 2021, 638,563 shares of common stock were available for issuance under the ESPP.

F-22

Stock-Based Compensation Expense

The assumptions used in the Black-Scholes model to determine the fair value of stock/unit option grants and shares purchasable under the ESPP were as follows:

 

 

 

Year Ended December 31,

Stock/Unit Option Grants

 

2021

 

2020

 

2019

Risk-free interest rate

 

0.5% - 1.3%

 

0.3% - 1.5%

 

1.4% - 2.7%

Expected volatility

 

86% - 88%

 

88% - 92%

 

84% - 88%

Expected term (in years)

 

5.5 - 6.1

 

5.4 - 6.1

 

2.0 - 6.1

Expected dividend yield

 

—%

 

—%

 

—%

 

 

 

Year Ended December 31,

ESPP

 

2021

 

 

2020

 

2019

Risk-free interest rate

 

0.1%

 

 

0.1% - 0.2%

 

N/A

Expected volatility

 

69% - 75%

 

 

75% - 96%

 

N/A

Expected term (in years)

 

0.5

 

 

0.5

 

N/A

Expected dividend yield

 

—%

 

 

—%

 

N/A

 

Risk-Free Interest Rate. The Company bases the risk-free interest rate assumption for equity awards on the rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued.

Expected Volatility. Due to the limited trading history of the Company’s common stock, the expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology industry. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.

Expected Term. Due to its limited option exercise history not providing a reasonable basis for estimating expected term, the Company has estimated the expected life of its stock options using the simplified method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The expected life assumption for employee stock purchases under the ESPP is six months to conform with the six-month ESPP offering period.

Expected Dividend Yield. The Company’s expected dividend yield assumption is zero as it has never paid dividends and has no present intention to do so in the future.

The allocation of stock-based compensation expense was as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Research and development expense

 

$

9,228

 

 

$

1,895

 

 

$

84

 

General and administrative expense

 

 

7,828

 

 

 

2,415

 

 

 

322

 

Total stock-based compensation expense

 

$

17,056

 

 

$

4,310

 

 

$

406

 

 

As of December 31, 2021, the unrecognized compensation cost related to outstanding time-based options was $46.9 million, which is expected to be recognized over a weighted-average period of 2.6 years. As of December 31, 2021, the unrecognized compensation cost related to stock purchase rights under the ESPP was $0.2 million, which is expected to be recognized over a weighted-average period of 0.5 years.

F-23

Common Stock Reserved for Future Issuance

Common stock reserved for future issuance consisted of the following (in thousands):

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Common stock options issued and outstanding

 

 

5,778

 

 

 

3,788

 

Equity awards available for future issuance

   under equity plans

 

 

2,575

 

 

 

2,852

 

Common stock authorized under the ESPP

 

 

639

 

 

 

296

 

Total

 

 

8,992

 

 

 

6,936

 

 

11.

Income Taxes

The Company operated as a nontaxable partnership until its conversion on March 31, 2019. The Company had deferred tax assets in existence on March 31, 2019 when the Company became a taxable entity. Deferred tax assets were not recognized due to the uncertainty that such assets will be realized. The Company retained the valuation allowance on the deferred tax assets at December 31, 2019.

No provision for income taxes was recorded for the years ended December 31, 2021, 2020 and 2019.

A reconciliation of income taxes to the amount computed by applying the statutory federal income tax rate to the net loss is summarized as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Income tax expense (benefit) at statutory rates

 

$

(24,784

)

 

$

(9,315

)

 

$

(5,194

)

State income tax, net of federal benefit

 

 

(7,868

)

 

 

(3,004

)

 

 

(1,057

)

Permanent items

 

 

210

 

 

 

1

 

 

 

14

 

Book income for pre-conversion period

 

 

—

 

 

 

—

 

 

 

527

 

Interest on convertible notes

 

 

—

 

 

 

—

 

 

 

445

 

Realized gain on conversion of convertible notes

 

 

—

 

 

 

—

 

 

 

958

 

Reserve for uncertain tax positions

 

 

1,170

 

 

 

398

 

 

 

140

 

Research and development tax credits

 

 

(4,792

)

 

 

(1,639

)

 

 

(584

)

Deferred taxes recognized upon conversion

 

 

—

 

 

 

—

 

 

 

(3,076

)

Valuation allowance

 

 

35,326

 

 

 

13,488

 

 

 

7,827

 

Other

 

 

738

 

 

 

71

 

 

 

—

 

Income tax expense (benefit)

 

$

—

 

 

$

—

 

 

$

—

 

F-24

 

 

Significant components of the Company’s deferred tax assets as of December 31, 2021 and 2020 are shown below (in thousands):

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Deferred tax assets:

 

 

 

 

 

 

 

 

Net operating loss carryforwards

 

$

41,443

 

 

$

11,277

 

Research and development tax credits

 

 

5,586

 

 

 

1,855

 

Deferred revenue

 

 

3,117

 

 

 

4,443

 

Accrued expenses

 

 

477

 

 

 

153

 

Intangibles and fixed assets

 

 

2,137

 

 

 

2,483

 

Lease liability

 

 

3,291

 

 

 

263

 

Stock-based compensation

 

 

3,668

 

 

 

969

 

Total deferred tax assets

 

 

59,719

 

 

 

21,443

 

Less valuation allowance

 

 

(56,693

)

 

 

(21,316

)

Net deferred tax assets

 

 

3,026

 

 

 

127

 

Deferred tax liabilities:

 

 

 

 

 

 

 

 

Right-of-use asset

 

 

(3,026

)

 

 

(127

)

Total deferred tax liabilities

 

 

(3,026

)

 

 

(127

)

Net deferred tax assets

 

$

—

 

 

$

—

 

 

The Company has established a full valuation allowance against its net deferred tax assets due to the uncertainty that such assets will be realized. The Company periodically evaluates the recoverability of the deferred tax assets. At such time as it is determined that it is more likely than not that the deferred tax assets will be realizable, the valuation allowance will be released. The change in the valuation allowance was an increase of $35.4 million and $13.5 million for the years ended December 31, 2021 and 2020, respectively.

At December 31, 2021, the Company had federal and state net operating loss (NOL) carryforwards of $147.9 million and $147.7 million, respectively. On March 27, 2020, the CARES Act was signed into law in response to the economic challenges facing U.S. businesses. Under the CARES Act, the Internal Revenue Code of 1986, as amended (IRC) was amended to allow for federal NOLs to be carried back for five years to offset previous years’ income or carried forward indefinitely to offset 100% of taxable income for the tax year 2020 and 80% of taxable income for tax years 2021 and thereafter. The state NOLs begin to expire in 2039 unless previously utilized.

At December 31, 2021, the Company had federal and state research and development tax credits of $4.7 million and $2.6 million, respectively. The federal research and development tax credits begin to expire in 2039 unless previously utilized, and the state credits carry forward indefinitely. At December 31, 2021, the Company had federal orphan drug tax credits of $0.7 million, which begin to expire in 2041.

Pursuant to IRC Section 382 and Section 383, the Company’s ability to use NOL and R&D tax credit carryforwards (tax attribute carryforwards) to offset future taxable income is limited if the Company experiences a cumulative change in ownership of more than 50% within a three-year testing period. The Company has not completed an ownership change analysis pursuant to IRC Section 382. If ownership changes within the meaning of IRC Section 382 have occurred, the amount of remaining tax attribute carryforwards available to offset future taxable income and income taxes in future years may be significantly restricted or eliminated. Further, the Company’s deferred tax assets, along with the corresponding valuation allowance, associated with such tax attributes could be significantly reduced upon an ownership change within the meaning of IRC Section 382. Due to the existence of the valuation allowance, changes in the Company’s deferred tax assets from any such limitation will not impact the Company’s effective tax rate.

F-25

The following table summarizes the activity related to the Company’s gross unrecognized tax benefits for the years ended December 31, 2021 and 2020 (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Gross unrecognized tax benefits at the

   beginning of the year

 

$

671

 

 

$

156

 

Increases related to current year positions

 

 

1,283

 

 

 

446

 

Increases related to prior year positions

 

 

42

 

 

 

62

 

Other true up

 

 

—

 

 

 

7

 

Gross unrecognized tax benefits at the

   end of the year

 

$

1,996

 

 

$

671

 

The unrecognized tax benefit amounts are reflected in the determination of the Company’s deferred tax assets. If recognized, none of these amounts would affect the Company’s effective tax rate, since it would be offset by a corresponding adjustment to the deferred tax asset valuation allowance. The Company does not foresee material changes to its liability for uncertain tax benefits within the next twelve months.

The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties as of December 31, 2021 or 2020.

As of December 31, 2021, the Company’s tax years since conversion to a corporation in 2019 are subject to examination by U.S. federal and various state taxing authorities.

F-26

12.

COVID-19

The COVID-19 outbreak in the United States has caused significant business disruption. The extent of the impact of COVID-19 on the Company’s operational and financial performance will depend on certain developments, including the continued spread of COVID-19 and the measures taken by the governmental authorities, and its impact on the Company’s preclinical studies and clinical trials, employees and vendors, all of which are uncertain and cannot be predicted, particularly as the Company advances its product candidates into and through clinical development. In December 2021, the Company began to transition to a hybrid model with its employees generally working both remotely and onsite, and the Company anticipates it will continue to use this model going forward. To date, the Company has not experienced material disruptions in its business operations. However, a prolonged outbreak could have a material adverse impact on the financial results and business operations of the Company, including the timing and ability of the Company to complete certain clinical trials and other efforts required to advance the development of its product candidates and raise additional capital.

13.

Subsequent Events

From January 1, 2022 through March 1, 2022, the Company sold 1,100,000 shares of its common stock pursuant to the Sales Agreement and received net proceeds of $16.9 million, after deducting offering-related transaction costs and commissions.

 

 

F-27

 

EXHIBIT INDEX

 

Exhibit

 

 

 

Incorporated by Reference

 

Filed

Number

 

Exhibit Description

 

Form

 

 

Date

 

 

Number

 

Herewith

 

 

 

 

 

 

 

 

 

 

 

 

 

  3.1

  

Amended and Restated Certificate of Incorporation.

  

8-K

 

 

6/16/2020

 

 

3.1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  3.2

  

Amended and Restated Bylaws.

  

8-K

 

 

6/16/2020

 

 

3.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  4.1

  

Form of Common Stock Certificate.

  

S-1

 

 

5/22/2020

 

 

4.1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  4.2

  

Amended and Restated Registration Rights Agreement, dated November 8, 2019, by and among the Registrant and certain of its stockholders.

  

S-1

 

 

5/22/2020

 

 

4.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  4.3

 

Description of Registered Securities

 

10-K

 

 

3/15/2021

 

 

4.3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10.1#

 

Avidity Biosciences, Inc. 2013 Amended and Restated Equity Incentive Plan, including form of stock option grant notice and stock option agreement thereunder.

 

S-1

 

 

5/22/2020

 

 

10.1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10.2#

 

Avidity Biosciences, Inc. 2020 Incentive Award Plan, including form of stock option grant notice and stock option agreement thereunder.

 

S-1/A

 

 

6/8/2020

 

 

10.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10.3#

 

Avidity Biosciences, Inc. 2020 Employee Stock Purchase Plan.

 

S-1/A

 

 

6/8/2020

 

 

10.3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10.4#

 

Non-Employee Director Compensation Program.

 

10-K

 

 

3/15/2021

 

 

10.4

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10.5#

 

Employment Letter Agreement, dated May 15, 2020, by and between Sarah Boyce and the Registrant.

 

S-1

 

 

5/22/2020

 

 

10.5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10.6#

 

Employment Letter Agreement, dated May 15, 2020, by and between Joseph Baroldi and the Registrant.

 

S-1

 

 

5/22/2020

 

 

10.6

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10.7#

 

Employment Letter Agreement, dated May 15, 2020, by and between Arthur A. Levin, Ph.D. and the Registrant.

 

S-1

 

 

5/22/2020

 

 

10.7

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10.8#

  

Employment Letter Agreement, dated May 14, 2020, by and between Michael F. MacLean and the Registrant.

  

S-1

 

 

5/22/2020

 

 

10.8

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10.9#

  

Employment Agreement, dated July 6, 2020, by and between Jae B. Kim, M.D. and the Registrant.

 

10-Q

 

 

11/10/2020

 

 

10.1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10.10#

  

Employment Agreement, dated December 8, 2020, by and between W. Michael Flanagan, Ph.D. and the Registrant.

  

10-K

 

 

3/15/2021

 

 

10.10

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10.11#

  

General Release of Claims, dated August 30, 2021, by and between Avidity Biosciences, Inc. and Jae B. Kim, M.D.

  

10-Q

 

 

11/9/2021

 

 

10.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10.12#

  

Consulting Agreement, dated January 22, 2022, by and between Joseph Baroldi and the Registrant

  

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

112

10.13#

  

Form of Indemnification Agreement for Directors and Officers.

  

S-1

 

 

5/22/2020

 

 

10.11

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10.14†

  

Research Collaboration and License Agreement, dated April 17, 2019, by and between Eli Lilly and Company and the Registrant.

  

S-1

 

 

5/22/2020

 

 

10.12

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10.15

  

Lease Agreement, dated March 31, 2014, as amended, by and between ARE-10933 North Torrey Pines, LLC and the Registrant.

  

S-1/A

 

 

6/8/2020

 

 

10.14

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10.16

 

Amended and Restated Lease Agreement, dated December 18, 2020, by and between ARE-SD Region No. 44, LLC and the Registrant.

 

10-K

 

 

3/15/2021

 

 

10.14

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10.17

  

Sales Agreement, dated July 2, 2021, between Avidity Biosciences, Inc. and Cowen and Company, LLC

  

8-K

 

 

7/2/2021

 

 

1.1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

23.1

 

Consent of BDO USA, LLP, independent registered public accounting firm.

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

31.1

  

Certification of Chief Executive Officer of Avidity Biosciences, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.

  

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

31.2

  

Certification of Chief Financial Officer of Avidity Biosciences, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.

  

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

32.1*

  

Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

  

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

32.2*

  

Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

  

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

101.INS

 

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.

  

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document

  

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

  

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

  

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

101.LAB

 

Inline XBRL Taxonomy Extension Label Linkbase Document

  

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

  

 

 

 

 

 

 

 

 

X

113

 

 

 

 

 

 

 

 

 

 

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

  

 

 

 

 

 

 

 

 

X

 

#

Indicates management contract or compensatory plan.

  †

Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.

*

These certifications are being furnished solely to accompany this annual report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

114

 

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this annual report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

AVIDITY BIOSCIENCES, INC.

 

 

 

/s/ Sarah Boyce

 

Sarah Boyce

 

President and Chief Executive Officer

 

Date: March 1, 2022

Pursuant to the requirements of the Securities Exchange Act of 1934, this annual report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Signature

  

Title

 

Date

 

 

 

/s/ Sarah Boyce

Sarah Boyce

  

President, Chief Executive Officer and

Director (Principal Executive Officer)

 

March 1, 2022

 

 

 

/s/ Michael F. MacLean

Michael F. MacLean

  

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

March 1, 2022

 

 

 

/s/ Troy Wilson

Troy Wilson, Ph.D., J.D.

  

Chairman of the Board of Directors

 

March 1, 2022

 

 

 

/s/ Carsten Boess

Carsten Boess

  

Director

 

March 1, 2022

 

 

 

/s/ Noreen Henig

 

Director

 

March 1, 2022

 

Noreen Henig, M.D.

 

 

 

/s/ Edward Kaye

Edward Kaye, M.D.

  

Director

 

March 1, 2022

 

 

 

/s/ Jean Kim

Jean Kim

 

Director

 

March 1, 2022

 

 

 

 

 

/s/ Eric Mosbrooker

Eric Mosbrooker

  

Director

 

March 1, 2022

 

 

 

 

 

/s/ Tamar Thompson

Tamar Thompson

  

Director

 

March 1, 2022

 

115

 EX-10.12 2 rna-ex1012_82.htm EX-10.12 rna-ex1012_82.htm

 

Exhibit 10.12

 

CONSULTING AGREEMENT

(Non-HCP)

 

This Consulting Agreement (the “Agreement”) is entered into and effective 22 January 2022 (the “Effective Date”) by and between Joseph Baroldi (“Consultant”) and Avidity Biosciences, Inc. (“Avidity”), a Delaware corporation, with offices located at 10578 Science Center Drive, Suite 125, San Diego, California 92121, USA.  Consultant and Avidity shall be referred to individually as a “Party” and together as the “Parties.”

 

This Agreement sets forth the general terms whereby Consultant will provide to Avidity the consulting services described in Exhibit A attached hereto and incorporated by reference (the “Consulting Services”).  To the extent any terms set forth in Exhibit A conflict with the terms set forth in this Agreement, the terms of this Agreement will control unless it is otherwise specifically set forth in Exhibit A that certain terms of Exhibit A will control.

 

1.

Description of Consulting Services.  Consultant is hereby retained by Avidity to perform the Consulting Services.  In the performance of the Consulting Services, Consultant shall:

 

 

A.

Perform all of the Consulting Services personally without resort to any delegate or assignee without the prior written permission of Avidity;

 

 

B.

Perform the Consulting Services in conformity with generally accepted professional standards; and

 

 

C.

Comply with all applicable laws and regulations.

 

2.

Compensation and Payment.

 

 

A.

In consideration for Consultant’s performance of the Consulting Services, Avidity shall pay Consultant the fees and other compensation specified in, or calculated in accordance with, Exhibit A.  

 

 

B.

Consultant shall submit invoices to Avidity in accordance with the schedule specified in Exhibit A.  Invoices shall include a detailed description of the Consulting Services performed by Consultant during the period covered by the invoice, as well as a reference to the Purchase Order Number.  If the Consultant is being compensated based on an hourly rate, Consultant’s invoices shall indicate the amount of time spent on the Consulting Services and any partial hour shall be rounded to the nearest quarter hour.  All invoices must be sent to Avidity as specified in Exhibit A.  

 

 

C.

Consultant acknowledges and agrees that Avidity shall only be responsible for paying transaction-based taxes, such as sales taxes, if such taxes are applicable or imposed by a relevant taxing authority on payments made to Consultant pursuant to this Agreement.  Consultant further acknowledges and agrees that Consultant is solely responsible for the payment of all other foreign or domestic taxes, such as income tax, gross receipts tax, and foreign withholding tax, imposed on account of payment of fees made to the Consultant pursuant to this Agreement.  Consultant expressly agrees to treat any compensation or fees earned under this Agreement as self-employment income for federal and state income taxes, unemployment insurance taxes, disability insurance taxes or any other taxes when such amounts become due and payable.

 

 

 

 

D.

Avidity shall make payment to Consultant within thirty (30) days upon Avidity’s receipt from Consultant of invoices satisfying the requirements in Section 2(C) of this Agreement, or as otherwise agreed to in writing by the Parties.  

 

3.

Reimbursement for Expenses.  

 

 

A.

Avidity shall reimburse Consultant for the pre-approved, documented and reasonable travel and other direct out-of-pocket expenses incurred by Consultant during the performance of the Consulting Services under this Agreement.

 

 

B.

Avidity shall reimburse Consultant for authorized out-of-pocket expenses within thirty (30) days of receipt of Consultant’s invoice plus all required receipts or invoices and in accordance with Company’s expense reimbursement policies and procedures.  

 

4.

Avidity’s Representative.  Avidity hereby designates the person identified in Exhibit A to serve as the Avidity representative (“Avidity Representative”) in all interactions with Consultant.  Avidity may change the Avidity Representative at any time upon written notice to Consultant.

 

5.

Confidentiality; Restrictions on Publications.

 

 

A.

In the course of performing the Consulting Services, Consultant may be given, or have access to, confidential and proprietary information of Avidity or its business partners, including, but not limited to, information relating to pricing, marketing strategies and tactics, clinical research and development, and/or the approval, administration, use or experience of any or all of Avidity’s business partners’ products (whether approved or in development), all of which information is considered confidential by Avidity and of irreplaceable value (collectively, “Confidential Information”).  

 

 

B.

Consultant hereby agrees to use such Confidential Information, whether prepared by Consultant or otherwise coming into Consultant’s possession, solely to render the Consulting Services pursuant to this Agreement.  Consultant further agrees that all files, documents, records and similar items relating to any Confidential Information, whether prepared by Consultant or otherwise coming into Consultant’s possession, shall remain the Confidential Information of Avidity.  During the term of this Agreement and for a period of ten (10) years from the date of the Agreement’s termination or expiration, Consultant shall not use or disclose to any third party any Confidential Information without Avidity’ prior written consent.

 

 

C.

Consultant shall immediately inform Avidity by telephone and in writing if Consultant receives a request, order, subpoena, or summons directing Consultant to disclose any communication received from, or given to, Avidity in connection with Consultant’s work pursuant to this Agreement.  Likewise, Consultant shall inform Avidity if Consultant receives a request, order, subpoena, or summons directing Consultant to produce any document or other material prepared by Consultant, given to Avidity by Consultant, or given to Consultant by Avidity in connection with Consultant’s work pursuant to this Agreement.  Consultant shall not divulge to anyone (other than Avidity) any such communications, nor produce to anyone (other than Avidity) any such documents or materials, except at the express and specific direction of Avidity, or in compliance with an order of a court of competent jurisdiction after Avidity has raised all legal objections available in good faith in opposition to such an order, request, subpoena, or summons.

 

 

 

 

 

D.

At any time, upon request by Avidity, or immediately on the expiration or earlier termination of this Agreement, whichever event occurs first, Consultant shall return to Avidity all originals and copies of Confidential Information, including, but not limited to, any files, notes, memoranda, documents, records, analyses, any and all excerpts or other similar items, whether in written, electronic or other format.  

 

 

E.

Consultant shall not publish, nor submit for publication, any document describing, resulting from, or otherwise related to the performance of the Consulting Services without obtaining Avidity’s prior written consent.  

 

 

F.

Consultant shall keep confidential the existence of this Agreement and the terms of this Agreement.  Consultant agrees not to identify Avidity in any of Consultant’s marketing materials, lists of clients or for any other purpose whatsoever without Avidity’s prior written consent.

 

 

G.

Consultant’s obligations under this Section 5 shall not apply to any Confidential Information that (i) is or becomes known to the general public under circumstances involving no breach by Consultant or others of the terms of this Section 5, (ii) is approved for release by written authorization of an officer of Avidity, (iii) at the time of disclosure is, or thereafter becomes, available to the Consultant from a third-party source on a non-confidential basis, provided that such third party is not and was not prohibited from disclosing such Confidential Information to Consultant by any legal, fiduciary or contractual obligation, (iv) was known by or in the possession of the Consultant, as established by documentary evidence, prior to being disclosed by or on behalf of Avidity in connection with the Services, or (v) was or is independently developed by Consultant, as established by documentary evidence, without reference to or use of, in whole or in part, any Confidential Information. If the Consultant is required by law or regulation to disclose any Confidential Information, the Consultant shall: (x) notify Avidity as promptly as practicable in writing of such requirement so that Avidity may seek a protective order or other appropriate remedy, (y) furnish only that portion of the Confidential Information which the Consultant is legally required to disclose, in accordance with advice of counsel, and (z) exercise all reasonable efforts to obtain reliable assurances that confidential treatment will be accorded to such Confidential Information. The Consultant shall, at the sole expense of Avidity, cooperate with Avidity in its efforts to obtain a protective order or reliable assurance that only the designated portion of the Confidential Information shall be disclosed.

 

 

H.

Consultant shall not disclose to Avidity any information which is confidential or proprietary to a third party without first obtaining the written consent of both such third party and Avidity.

 

 

I.

Notwithstanding the foregoing, obligations of confidentiality and non-use with respect to any Confidential Information identified as a trade secret by Avidity shall remain in place for so long as the applicable Confidential Information retains its status as a trade secret under applicable law.

 

6.

Intellectual Property.  All inventions, discoveries, trademarks, copyrights, information, data, concepts, reports, innovations or other intellectual property that may arise from Consultant’s performance of the Consulting Services or through use of any Confidential Information (collectively, “Intellectual Property”) shall be promptly disclosed in writing to Avidity, and title thereto shall immediately vest in Avidity or such designated member of Avidity.  Consultant agrees to assign and hereby assigns to Avidity all Consultant’s right, title and interest in and to all

 

 

Intellectual Property.  Consultant agrees that all information and written materials prepared in the performance of the Consulting Services to be “works for hire” and copyright therein shall immediately vest in Avidity.  During the term of this Agreement and thereafter, Consultant agrees to cooperate fully with, and assist Avidity in filing, prosecuting patent, trademark and/or copyright applications and otherwise protecting Avidity’s rights to the Intellectual Property described in this Section.  In this regard, Consultant agrees to execute any assignments and other documents as Avidity deems necessary to protect its rights to any such Intellectual Property.  

 

7.

Independent Contractor.  Avidity and Consultant agree that Consultant’s status under this Agreement shall be that of an independent contractor and that Consultant is not an agent or employee of Avidity.  Consultant acknowledges and agrees that Consultant is not entitled to any medical benefits, paid time off, tax withholding or other benefits routinely provided to employees.  

 

8.

Limitation on Authority.  In no event shall Consultant have any authority, or hold himself or herself out as having authority, to enter into, bind or obligate Avidity to any agreement, purchase or obligation of any kind without Avidity’s prior written authorization.

 

9.

Representations, Warranties and Covenants.

 

 

A.

Consultant represents, warrants and covenants that Consultant (i) has disclosed to Avidity any potential conflict of interest in connection with the provision of Consulting Services hereunder; (ii) is not under any existing obligation that is inconsistent with this Agreement or would restrict or conflict with the performance of Consultant’s obligations hereunder; (iii) shall promptly disclose to Avidity any such conflict that may arise during the term of this Agreement; and (iv) shall not take any action or fail to take any action with respect to any existing agreement (whether written, oral or otherwise) or any agreement (whether written, oral or otherwise) entered into during the Term that would create a conflict or otherwise impede the ability to fully perform the Consulting Services or any other obligations of Consultant under this Agreement.  In the event that any conflict of interest arises, Avidity, as it deems necessary, shall have the right to terminate this Agreement and/or require Consultant to refrain from performing any portion of the Consulting Services related to the conflict of interest.  Nothing in this Section shall be construed so as to relieve Consultant of any of his or her obligations under this Agreement.

 

 

B.

Consultant covenants that Consultant will perform the Services consistent with the professional skill and care ordinarily provided by professionals practicing in the same or similar locality under the same or similar circumstances.

 

 

C.

Consultant represents and warrants to Avidity that the terms of this Agreement do not violate the terms of any other contractual or legal obligations Consultant may have or any policies of any institution with which Consultant is associated or employed.  Consultant represents and warrants that Consultant is not affiliated with the U.S. Department of Veterans Affairs, the National Institutes of Health or any other federal, state, or local government institution, or, if Consultant is so affiliated, Consultant has provided a signed acknowledgement form of an authorized official from said institution before executing this Agreement.


 

 

 

 

10.

Term and Termination.

 

 

A.

The term of this Agreement shall take effect on the Effective Date and shall continue for six (6) months from the Effective Date when it will automatically expire.

 

 

B.

Either Party may terminate this Agreement immediately upon written notice to the other Party if said other Party commits a material breach of any term hereof which is not cured to the satisfaction of the non-breaching Party within fifteen (15) days of written notice of said breach.

 

 

C.

Either Party may terminate this Agreement at any time upon fifteen (15) days’ prior written notice to the other Party.  During such notice period, Consultant shall continue to perform the Consulting Services unless otherwise requested by Avidity.

 

11.

Debarment; Exclusion.  Consultant represents and warrants that neither Consultant, Consultant’s group practice (if applicable), nor any person or entity authorized to assist Consultant in the performance of the Consulting Services has ever been and is not currently debarred, suspended, or excluded from, proposed for debarment, suspension, or exclusion from, or otherwise ineligible for the award of contracts by any federal agency or participation in any federal health care program.  Consultant’s representation and warranty hereunder includes, but is not limited to, debarment under Section 306(a) or (b) of the federal Food, Drug, and Cosmetic Act, exclusion from participation in any federal health care program (as defined in 42 U.S.C. § 1320a–7b(f)) under 42 U.S.C. § 1320a-7(a) or (b), or exclusion by any federal government agency from receiving federal contracts or federally approved subcontracts under the Federal Acquisition Regulations (FAR) or supplements thereto.  

 

12.

Injunctive Relief.  Without limiting Avidity’s remedies in any way, Consultant agrees that Avidity shall be entitled to injunctive relief to prevent any actual or threatened breach or continuing breaches by Consultant of this Agreement since such actual or threatened breach may cause irreparable harm to Avidity that may not reasonably or adequately be compensated by damages in an action of law.  

 

13.

Liability and Indemnification.  Avidity shall not be liable for any loss, injury or damage incurred by Consultant or by a third party as a result of Consultant’s performance of the Consulting Services, including any loss, injury or damage resulting from the negligent or willful act or omission by Consultant.  Consultant shall indemnify and hold Avidity harmless from any liability, loss, cost and expense (including attorneys’ fees and costs) incurred by Avidity as a result of Consultant’s negligent acts or omissions or breach of this Agreement.

 

14.

Rights Under Agreement.  Neither the expiration nor the earlier termination of this Agreement shall affect in any way the rights and obligations of either Party which have accrued prior to such event or in connection therewith.  The obligations and rights contained in Sections 5 (“Confidentiality; Restrictions on Publications”), 6 (“Intellectual Property”), 9 (“Representations, Warranties and Covenants”), 12 (“Injunctive Relief”), 13 (“Liability and Indemnification”), 15 (“Compliance with Law), 16 (“Publicity”), and 25 (“Governing Law”) of this Agreement shall survive the expiry or earlier termination of this Agreement.

 

 

15.

Compliance with Law.  

 

 

A.

Each Party shall comply with applicable national laws, regulations and industry codes that require such Party (i) to submit this Agreement to national Transparency Registries or public entities, or (ii) to fulfil other transparency or reporting obligations, as applicable. Avidity may disclose the existence of this Agreement and any payments or donations made (including in cash or in kind, reimbursement of expenses, sponsorships or other transfers of value) under this Agreement to the extent necessary to comply with any financial disclosures or transparency obligations applicable to Avidity under any applicable laws, regulations or codes of conduct.  By signing this Agreement, Consultant consents to Avidity:

 

 

(i)

Collecting, processing and storing Consultant’s information, including his or her contact details, and the payments and transfers of value made to the Consultant under this Agreement.

 

(ii)

Making public disclosures of such information in accordance with the applicable laws, regulations or codes of conduct. Such disclosures may be made using any media (paper or electronic), web-site or platform, including an industry association’s electronic platform. The information to be published will clearly identify the Consultant and the types of transfers of value he or she received from Avidity.

 

(iii)

Disclosing such information to pharmaceutical industry associations and/or competent authorities for compliance with applicable laws, regulations or codes of conduct.

 

B.

Consultant represents and warrants that Consultant will comply with all applicable laws with respect to the Consulting Services performed under this Agreement, as amended from time to time, including, without limitation, all applicable laws on anti-corruption, and the United States Foreign Corrupt Practices Act.

 

16.

Publicity.  Consultant hereby acknowledges and agrees that Avidity shall have the right to use Consultant’s name and likeness in any publicity materials prepared by it and in presentations to current or prospective clients, investors and others.

 

17.

Notice and Notification.  

 

 

A.

Consultant shall immediately notify Avidity in writing if any of the representations and warranties made by Consultant under this Agreement become untrue or if Consultant becomes aware of any fact or circumstance which is reasonably expected to make any such representation or warranty become untrue.

 

 

B.

All notices, requests, consents, claims, demands, waivers and other communications hereunder shall be in writing and shall be deemed to have been given (i) when delivered by hand (with written confirmation of receipt); (ii) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested); (iii) on the date sent by facsimile or email (with confirmation of transmission) if sent during normal business hours of the recipient, and on the next business day if sent after normal business hours of the recipient; or (iv) on the fifth (5th) day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid to the following address:

 

 

If to Avidity:

 

Avidity Biosciences, Inc.

 

 

 

 

10578 Science Center Drive, Suite 125

 

 

San Diego, California 92121, USA.  

 

 

Attn:

CEO

 

 

Telephone:

858-401-7900

 

 

Facsimile:

858-401-7901

 

With a copy to:

 

Avidity Biosciences, Inc.

 

 

10578 Science Center Drive, Suite 125

 

 

San Diego, California 92121, USA.  

 

 

Attn:

General Counsel

 

 

Facsimile:

858-401-7901

 

 

 

 

If to Consultant:

 

Joseph Baroldi

 

18.

Assignment.  Neither Party may assign all or any part of this Agreement without the prior written consent of the other Party; provided, however, that Avidity may assign this Agreement to a corporate affiliate or to a successor to all or substantially all of its business without obtaining prior written consent from Consultant.

 

19.

Non-Solicitation

 

 

A.

During the Term of this Agreement and for a period of twelve (12) months thereafter, Consultant shall not, directly or indirectly, in any manner solicit or induce for employment any person who is then in the employment of Avidity. A general advertisement or notice of a job listing or opening or other similar general publication of a job search or availability to fill employment positions, including on the internet, shall not be construed as a solicitation or inducement for the purposes of this Section, and the hiring of any such employees or independent contractor who freely respond thereto shall not be a breach of this Section.

 

 

B.

If Consultant breaches the above Section, Consultant shall, on demand, pay to Avidity a sum equal to three (3) month’s basic salary or the fee that would have been payable by Avidity to that employee, worker or independent contractor for a three (3) month period plus the recruitment costs incurred by Avidity replacing such person.

 

20.

Entire Agreement.  This Agreement, including Exhibit A and any exhibits attached hereto, sets forth the entire agreement and understanding of the Parties with respect to the subject matter described herein and supersedes all prior written or oral agreements relating to said subject matter.  In the event of any inconsistency between the provisions of this Agreement and Exhibit A, the provisions of this Agreement shall govern.  No waiver of any term, provision or condition of this Agreement, whether by conduct or otherwise in any one or more instances shall be deemed to be or construed as further or continuing waiver of any such term, provision or condition, or of any other term, provision or condition.  The invalidity or unenforceability of any term or provision of the Parties with respect to the subject matter of this Agreement shall not affect the validity or enforceability of any other term or provision of this Agreement.  This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument.

 

21.

Amendments.  This Agreement may not be amended except in writing signed by duly authorized representatives of both Parties.  

 

 

 

 

22.

Severability. If any one or more of the provisions of this Agreement shall, for any reason, be held invalid, illegal or unenforceable in any respect, it shall not affect any other term or provision of this Agreement.  If any provision in this Agreement shall be held to be excessively broad, it shall be construed by limiting it so as to be enforceable to the extent compatible with applicable law.

 

23.

Captions.  Captions of sections have been added only for convenience and shall not be deemed to be a part of this Agreement.

 

24.

Successors and Assigns. This Agreement shall be binding upon, and inure to the benefit of, both Parties and their respective successors and assigns, including any corporation with which, or into which, Avidity may be merged or which may succeed to its assets or business; provided, however, that the obligations of Consultant are personal and shall not be assigned by Consultant.

 

25.

Governing Law.  This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York, USA without giving effect to any choice or conflict of law provision or rule. Any legal suit, action or proceeding arising out of or related to this Agreement or the Services provided hereunder shall be instituted in the federal courts of the United States or the courts of the State of New York.

 

IN WITNESS WHEREOF, each Party has executed this Agreement by a duly authorized individual effective as of the Effective Date as evidenced by execution of an authorized representative of each Party in the spaces below.

 

Consultant

 

Avidity Biosciences, Inc.

 

 

 

 

 

 

/s/ Joseph Baroldi

 

By:

/s/ Sarah Boyce

Signature

 

 

 

Signature

 

 

 

 

 

Name:

Joseph Baroldi

 

Name:

Sarah Boyce

 

 

 

 

 

 

 

 

Title:

CEO

 

 

 

 

 

Date:

6 January 2022

 

Date:

6 January 2022

 


 

 

 

Exhibit A

 

1.  

Description of Consulting Services:  Consultant shall provide the following Consulting Services to Avidity:  A) Assist and advise Avidity personnel regarding business development activities that predate the Effective Date; B) Assist and advise Avidity personnel with any follow-up business development activities that result from Consultant’s participation in meetings at the 2022 JP Morgan Conference; and C) other business development matters that may arise from time to time during the term of this Agreement..

 

2.  

Compensation:  In consideration for the Consulting Services performed by Consultant under this Agreement, Avidity shall compensate Consultant as follows:  $350.00 per hour in an amount not to exceed $3,500.00 per month without Avidity’s prior written permission.  In addition, Consultant’s unvested stock option grants that are in effect as of the Effective Date will continue to vest according to the existing vesting schedule of any such option grants, for the term of this Agreement or shorter term resulting from the early termination provisions of Section 10 of this Agreement.

 

3.

Deliverables:Not Applicable

 

4.  

Avidity Representative:  Sarah Boyce, CEO

 

5.

Invoices:  Consultant will reference the applicable Avidity Purchase Order Number on each invoice.  All of Consultant’s invoices should be sent to:

 

Via email: Leslie Ann Kerins

 

 EX-23.1 3 rna-ex231_8.htm EX-23.1 rna-ex231_8.htm

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

 

Avidity Biosciences, Inc.

San Diego, California

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-257691) and Form S-8 (No. 333-239148) of Avidity Biosciences, Inc., of our reports dated March 1, 2022, relating to the financial statements, and the effectiveness of the Company’s internal control over financial reporting, which appear in this annual report on Form 10-K.

/s/ BDO USA, LLP

 

San Diego, California

March 1, 2022

 

 EX-31.1 4 rna-ex311_9.htm EX-31.1 rna-ex311_9.htm

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Sarah Boyce, certify that:

1. I have reviewed this annual report on Form 10-K of Avidity Biosciences, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 1, 2022

 

/s/ Sarah Boyce

 

 

Sarah Boyce

 

 

President, Chief Executive Officer and Director

 

 

(Principal Executive Officer)

 

 EX-31.2 5 rna-ex312_6.htm EX-31.2 rna-ex312_6.htm

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael F. MacLean, certify that:

1. I have reviewed this annual report on Form 10-K of Avidity Biosciences, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 1, 2022

 

/s/ Michael F. MacLean 

 

 

Michael F. MacLean

 

 

Chief Financial Officer

 

 

(Principal Financial Officer)

 

 EX-32.1 6 rna-ex321_10.htm EX-32.1 rna-ex321_10.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the annual report of Avidity Biosciences, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Sarah Boyce, President, Chief Executive Officer and Director of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 1, 2022

 

/s/ Sarah Boyce 

 

 

Sarah Boyce

 

 

President, Chief Executive Officer and Director

(Principal Executive Officer)

 

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

 EX-32.2 7 rna-ex322_7.htm EX-32.2 rna-ex322_7.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the annual report of Avidity Biosciences, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael F. MacLean, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 1, 2022

 

/s/ Michael F. MacLean 

 

 

Michael F. MacLean

 

 

Chief Financial Officer

(Principal Financial Officer)

 

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

 GRAPHIC 8 gsua0c5v34oe000002.jpg GRAPHIC begin 644 gsua0c5v34oe000002.jpg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�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gsua0c5v34oe000003.jpg GRAPHIC begin 644 gsua0c5v34oe000003.jpg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end GRAPHIC 10 gsua0c5v34oe000001.jpg GRAPHIC begin 644 gsua0c5v34oe000001.jpg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end EX-101.SCH 11 rna-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Statements of Operations and Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Statements of Convertible Preferred Stock/Units and Stockholders'/Members' Equity (Deficit) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Statements of Convertible Preferred Stock/Units and Stockholders'/Members' Equity (Deficit) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100060 - Statement - Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Description of Business and Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Marketable Securities link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Collaboration, License and Research Agreements link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Property and Equipment link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Debt link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Convertible Notes link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Stockholders' Equity (Deficit) link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - COVID-19 link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Summary of Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Marketable Securities (Tables) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Collaboration, License and Research Agreements (Tables) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Property and Equipment (Tables) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Commitments and Contingencies (Tables) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Stockholders' Equity (Deficit) (Tables) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Income Taxes (Tables) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share/Unit (Details) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Fair Value Measurements - Summary of Cash Equivalents and Marketable Securities Measured at Fair Value (Details) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Fair Value Measurements - Schedule of Reconciliation of Preferred Stock Warrant Liability Measured at Fair Value Using Level 3 Unobservable Inputs (Details) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Collaboration, License and Research Agreements - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Collaboration, License and Research Agreements - Reconciliation of Deferred Revenue Related to Lilly Agreement (Details) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Property,and Equipment - Schedule of Property and Equipment (Details) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Property and Equipment - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Debt - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Convertible Notes - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Commitments and Contingencies - Schedule of ROU Assets and Liabilities Related to 2014 Lease and Temporary Lease (Details) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Lease Liabilities due under 2014 Lease and Temporary Lease (Details) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Lease Liabilities due under 2014 Lease and Temporary Lease (Details)2 link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Commitments and Contingencies - Supplemental Cash Flow Information Related to Cash Paid for Amounts Included in Measurement of Operating Lease Liabilities (Details) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Commitments and Contingencies - Schedule of Rent Expense (Details) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Stockholders' Equity (Deficit) - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Stockholders' Equity (Deficit) - Summary of Stock Option Activity (Details) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Stockholders' Equity (Deficit) - Schedule of Assumptions used in Black-Scholes Model to Determine Fair Value of Stock/Unit Option Grants and Shares Purchasable under ESPP (Details) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Stockholders' Equity (Deficit) - Schedule of Allocated Stock-based Compensation Expense (Details) link:calculationLink link:presentationLink link:definitionLink 100510 - Disclosure - Stockholders' Equity (Deficit) - Schedule of Common Stock Reserved for Future Issuance (Details) link:calculationLink link:presentationLink link:definitionLink 100520 - Disclosure - Income Taxes - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100530 - Disclosure - Income Taxes - Reconciliation of Income Taxes Computed by Applying Statutory Federal Income Tax Rate (Details) link:calculationLink link:presentationLink link:definitionLink 100540 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details) link:calculationLink link:presentationLink link:definitionLink 100550 - Disclosure - Income Taxes - Summarizes of Activity Related to Gross Unrecognized Tax Benefits (Details) link:calculationLink link:presentationLink link:definitionLink 100560 - Disclosure - Subsequent Events - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 12 rna-20211231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 13 rna-20211231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 14 rna-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Current Fiscal Year End Date Current Fiscal Year End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Document Annual Report Document Annual Report Document Transition Report Document Transition Report Entity Well-known Seasoned Issuer Entity Well Known Seasoned Issuer Entity Voluntary Filers Entity Voluntary Filers Entity Public Float Entity Public Float ICFR Auditor Attestation Flag Icfr Auditor Attestation Flag Auditor Name Auditor Name Auditor Location Auditor Location Auditor Firm ID Auditor Firm Id Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Marketable securities Marketable Securities Current Prepaid and other assets Prepaid Expense And Other Assets Total current assets Assets Current Property and equipment, net Property Plant And Equipment Net Restricted cash Restricted Cash Noncurrent Right-of-use asset Operating Lease Right Of Use Asset Other assets Other Assets Noncurrent Total assets Assets Liabilities and Stockholders' Equity Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable and accrued liabilities Accounts Payable And Accrued Liabilities Current Accrued compensation Deferred Compensation Liability Current Lease liabilities, current portion Operating Lease Liability Current Deferred revenue, current portion Contract With Customer Liability Current Total current liabilities Liabilities Current Lease liabilities, net of current portion Operating Lease Liability Noncurrent Deferred revenue, net of current portion Contract With Customer Liability Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 9) Commitments And Contingencies Stockholders’ equity: Stockholders Equity [Abstract] Preferred stock, $0.0001 par value; authorized shares – 40,000; issued and outstanding shares – none Preferred Stock Value Common stock, $0.0001 par value; authorized shares – 400,000; issued and outstanding shares – 47,754 and 37,569 at December 31, 2021 and 2020, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Accumulated other comprehensive loss Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders’ equity Stockholders Equity Total liabilities and stockholders’ equity Liabilities And Stockholders Equity Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred stock, shares issued Preferred Stock Shares Issued Preferred stock, shares outstanding Preferred Stock Shares Outstanding Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Income Statement [Abstract] Collaboration revenue Revenue From Contract With Customer Excluding Assessed Tax Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Revenue From Contract With Customer Product And Service Extensible List Operating expenses: Operating Expenses [Abstract] Research and development Research And Development Expense General and administrative General And Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income Loss Other income (expense): Nonoperating Income Expense [Abstract] Interest income Investment Income Nonoperating Interest expense Interest Expense Change in fair value of preferred warrant liability Fair Value Adjustment Of Warrants Other expense Other Nonoperating Income Expense Total other income (expense) Nonoperating Income Expense Net loss Net Income Loss Other comprehensive income (loss): Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract] Net unrealized losses on marketable securities Marketable Securities Unrealized Gain Loss Comprehensive loss Comprehensive Income Net Of Tax Net loss per share/unit, basic and diluted Earnings Per Share Basic And Diluted Weighted-average shares/units outstanding, basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Partners capital units issued during period value unit options exercised. Partners capital units issued during period shares unit options exercised. Net income (loss) to date of conversion. Temporary equity stock issued during period shares conversion of units. Temporary equity stock issued during period value conversion of units. Temporary equity stock issued during period shares new issues. Temporary equity stock issued during period value upon conversion of convertible notes. Temporary equity stock issued during period shares upon conversion of convertible notes. Stock issued during period value stock options exercised net of repurchases. Stock issued during period shares stock options exercised net of repurchases. Net income loss excluding conversion. Reclassification of warrant liability to equity due to adjustment from preferred stock warrant to common stock warrant upon completion of initial public offering. Cashless exercise value of common stock warrants. Cashless exercise shares of common stock warrants. Preferred units, value. Statement Of Stockholders Equity [Abstract] Statement [Table] Statement [Table] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid In Capital [Member] Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Income [Member] Accumulated Deficit Retained Earnings [Member] Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Convertible Preferred Stock Convertible Preferred Stock [Member] Partner Capital Components Partner Capital Components [Axis] Partner Capital Components Partner Capital Components [Domain] Preferred units. Preferred Units Preferred Units [Member] Common units. Common Units Common Units [Member] Predecessor's deficit. Predecessor's Deficit Predecessors Deficit [Member] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] Public Offering I P O [Member] Statement [Line Items] Statement [Line Items] Balance Balance, Shares Shares Outstanding Preferred Units, balance, Units Preferred Units Outstanding Preferred Units, balance Preferred Units Value Temporary equity, balance, Shares Temporary Equity Shares Outstanding Temporary equity, balance Temporary Equity Carrying Amount Attributable To Parent Members' equity, balance, Units Capital Units Outstanding Members' equity, balance Capital Units Balance Members Equity Distribution to members Partners Capital Account Distributions Issuance of common units upon exercise of unit options Partners Capital Units Issued During Period Value Unit Options Exercised Issuance of common units upon exercise of unit options, Units Partners Capital Units Issued During Period Shares Unit Options Exercised Net loss to date of conversion Net Income Loss To Date Of Conversion Conversion from LLC to C corporation Stock Issued During Period Value Conversion Of Units Conversion from LLC to C corporation, Temporary equity, Shares Temporary Equity Stock Issued During Period Shares Conversion Of Units Conversion from LLC to C corporation, Temporary equity Temporary Equity Stock Issued During Period Value Conversion Of Units Conversion from LLC to C corporation, Shares Stock Issued During Period Shares Conversion Of Units Issuance of Series C convertible preferred stock, net of issuance costs Temporary Equity Stock Issued During Period Value New Issues Issuance of Series C convertible preferred stock, net of issuance costs, Shares Temporary Equity Stock Issued During Period Shares New Issues Issuance of Series C convertible preferred stock upon conversion of convertible notes Temporary Equity Stock Issued During Period Value Upon Conversion Of Convertible Notes Issuance of Series C convertible preferred stock upon conversion of convertible notes, Shares Temporary Equity Stock Issued During Period Shares Upon Conversion Of Convertible Notes Issuance of stock, net of issuance costs, Value Stock Issued During Period Value New Issues Issuance of stock, net of issuance costs, Shares Stock Issued During Period Shares New Issues Issuance of common stock upon exercise of stock options Stock Issued During Period Value Stock Options Exercised Issuance of common stock upon exercise of stock options, Shares Stock Issued During Period Shares Stock Options Exercised Conversion of convertible preferred stock into common stock upon completion of initial public offering Stock Issued During Period Value Conversion Of Convertible Securities Conversion of convertible preferred stock into common stock upon completion of initial public offering, Shares Stock Issued During Period Shares Conversion Of Convertible Securities Reclassification of warrant liability to equity due to adjustment from preferred stock warrant to common stock warrant upon completion of initial public offering Reclassification Of Warrant Liability To Equity Due To Adjustment From Preferred Stock Warrant To Common Stock Warrant Upon Completion Of Initial Public Offering Cashless exercise of common stock warrants Cashless Exercise Value Of Common Stock Warrants Cashless exercise of common stock warrants, Shares Cashless Exercise Shares Of Common Stock Warrants Issuance of common stock upon exercise of stock options, net of repurchases Stock Issued During Period Value Stock Options Exercised Net Of Repurchases Issuance of common stock upon exercise of stock options, net of repurchases, Shares Stock Issued During Period Shares Stock Options Exercised Net Of Repurchases Issuance of common stock under employee stock purchase plan Stock Issued During Period Value Employee Stock Purchase Plan Issuance of common stock under employee stock purchase plan, Shares Stock Issued During Period Shares Employee Stock Purchase Plans Vesting of early exercise options Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options Stock-based compensation Stock Issued During Period Value Share Based Compensation Stock-based compensation Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Net loss Net loss Net Income Loss Excluding Conversion Other comprehensive loss Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax Balance Preferred Units, balance, Units Preferred Units, balance Temporary equity, balance, Shares Temporary equity, balance Members' equity, balance, Units Members' equity, balance Balance, Shares Balance Stock-based compensation, Shares Stock Issued During Period Shares Share Based Compensation Stock issuance costs. Stock issuance costs Stock Issuance Costs Noncash interest expense. Increase (decrease) in operating lease right-of-use assets and liabilities, net. Proceeds from issuance of common stock in public offering, gross. Distributions to members. Issuance of convertible preferred stock upon conversion of convertible notes. Statement Of Cash Flows [Abstract] Cash flows from operating activities Net Cash Provided By Used In Operating Activities [Abstract] Net loss Profit Loss Adjustments to reconcile net loss to net cash (used in) provided by operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation Depreciation Stock-based compensation expense Share Based Compensation Amortization of premiums and discounts on marketable securities, net Accretion Amortization Of Discounts And Premiums Investments Amortization of discounts and loan issuance costs Amortization Of Financing Costs And Discounts Gain on disposal of property and equipment Gain Loss On Sale Of Property Plant Equipment Noncash interest expense Noncash Interest Expense Change in fair value of preferred warrant liability Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Prepaid and other assets Increase Decrease In Prepaid Deferred Expense And Other Assets Accounts payable and accrued liabilities Increase Decrease In Accounts Payable And Accrued Liabilities Accrued compensation Increase Decrease In Employee Related Liabilities Operating lease right-of-use assets and liabilities, net Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net Deferred revenue Increase Decrease In Deferred Revenue Net cash (used in) provided by operating activities Net Cash Provided By Used In Operating Activities Cash flows from investing activities Net Cash Provided By Used In Investing Activities [Abstract] Purchases of marketable securities Payments To Acquire Marketable Securities Maturities of marketable securities Proceeds From Sale And Maturity Of Marketable Securities Purchases of property and equipment Payments To Acquire Property Plant And Equipment Net cash used in investing activities Net Cash Provided By Used In Investing Activities Cash flows from financing activities Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from issuance of common stock in public offerings, gross Proceeds From Issuance Of Common Stock In Public Offering Gross Payment of issuance costs related to public offerings Payments Of Stock Issuance Costs Proceeds from exercise of stock/unit options, net of repurchases Proceeds From Stock Options Exercised Proceeds from issuance of common stock under employee stock purchase plan Proceeds From Stock Plans Payments on long-term debt Repayments Of Long Term Debt Distributions to members Distributions To Members Proceeds from issuance of Series C convertible preferred stock, net of issuance costs Proceeds From Issuance Of Convertible Preferred Stock Proceeds from issuance of convertible notes, net of issuance costs Proceeds From Convertible Debt Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Net (decrease) increase in cash, cash equivalents and restricted cash Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Cash, cash equivalents and restricted cash at beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations Cash, cash equivalents and restricted cash at end of period Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid Net Supplemental schedule of noncash investing and financing activities: Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Right-of-use assets obtained in exchange for operating lease liabilities Right Of Use Asset Obtained In Exchange For Operating Lease Liability Costs incurred, but not paid, in connection with purchases of property and equipment included in accounts payable and accrued liabilities Capital Expenditures Incurred But Not Yet Paid Conversion of convertible preferred stock into common stock upon completion of initial public offering Conversion Of Stock Amount Issued1 Issuance of Series C convertible preferred stock upon conversion of outstanding convertible notes Issuance Of Convertible Preferred Stock Upon Conversion Of Convertible Notes Accounting Policies [Abstract] Description of Business and Basis of Presentation Business Description And Basis Of Presentation [Text Block] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Investments Debt And Equity Securities [Abstract] Marketable Securities Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block] Collaboration, license and research agreements. Collaboration License And Research Agreements [Abstract] Collaboration, License and Research Agreements Collaborative Arrangement Disclosure [Text Block] Property Plant And Equipment [Abstract] Property and Equipment Property Plant And Equipment Disclosure [Text Block] Debt Disclosure [Abstract] Debt Debt Disclosure [Text Block] Convertible notes disclosure. Convertible Notes Convertible Notes Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Equity [Abstract] Stockholders' Equity (Deficit) Shareholders Equity And Share Based Payments [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Extraordinary And Unusual Items [Abstract] COVID-19 Unusual Or Infrequent Items Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Basis of Presentation Basis Of Accounting Policy Policy [Text Block] Use of Estimates Use Of Estimates Cash, Cash Equivalents and Restricted Cash Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy Marketable Securities Marketable Securities Policy Concentration of Credit Risk Concentration Risk Credit Risk Fair Value of Financial Instruments Fair Value Of Financial Instruments Policy Property and Equipment Property Plant And Equipment Policy [Text Block] Impairment of Long-Lived Assets Impairment Or Disposal Of Long Lived Assets Policy [Text Block] Segment Information Segment Reporting Policy Policy [Text Block] Revenue Recognition Revenue From Contract With Customer Policy [Text Block] Research and Development Costs Research And Development Expense Policy Patent Costs Legal Costs Policy [Text Block] Income Taxes Income Tax Policy [Text Block] Stock-Based Compensation Share Based Compensation Option And Incentive Plans Policy Comprehensive Loss Comprehensive Income Policy Policy [Text Block] Net Loss Per Share/Unit Earnings Per Share Policy [Text Block] Recently Adopted and Issued Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share/Unit Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Summary of Cash Equivalents and Marketable Securities Measured at Fair Value Fair Value Assets Measured On Recurring Basis [Text Block] Schedule of Reconciliation of Preferred Stock Warrant Liability Measured at Fair Value Using Level 3 Unobservable Inputs Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block] Summary of Marketable Securities Schedule Of Available For Sale Securities Reconciliation Table [Text Block] Summary of Reconciliation of Deferred Revenue Related to Lilly Agreement Contract With Customer Asset And Liability Table [Text Block] Schedule of Property and Equipment Property Plant And Equipment [Text Block] Lessee, lease assets and liabilities. Schedule of ROU Assets and Liabilities Related to 2014 Lease and Temporary Lease Lessee Lease Assets And Liabilities Table [Text Block] Schedule of Maturities of Lease Liabilities due under 2014 Lease and Temporary Lease Lessee Operating Lease Liability Maturity Table [Text Block] Lessee, cash flow information. Supplemental Cash Flow Information Related to Cash Paid for Amounts Included in Measurement of Operating Lease Liabilities Lessee Cash Flow Information Table [Text Block] Schedule of lease rent expense. Schedule of Rent Expense Schedule Of Lease Rent Expense Table [Text Block] Summary of Stock Option Activity Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Schedule of share based payment award stock options and employee stock purchase plan valuation assumptions. Schedule of Assumptions used in Black-Scholes Model to Determine Fair Value of Stock/Unit Option Grants and Shares Purchasable under ESPP Schedule Of Share Based Payment Award Stock Options And Employee Stock Purchase Plan Valuation Assumptions Table [Text Block] Schedule of Allocated Stock-based Compensation Expense Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Schedule of common stock reserved for future issuance. Schedule of Common Stock Reserved for Future Issuance Schedule Of Common Stock Reserved For Future Issuance Table [Text Block] Reconciliation of Income Taxes Computed by Applying Statutory Federal Income Tax Rate Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block] Components of Deferred Tax Assets Schedule Of Deferred Tax Assets And Liabilities Table [Text Block] Summarizes of Activity Related to Gross Unrecognized Tax Benefits Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block] Common unit converted into common stock. Preferred unit converted into convertible preferred stock. Description of business and basis of presentation. Description of business and basis of presentation. Description Of Business And Basis Of Presentation [Table] Description Of Business And Basis Of Presentation [Table] Series A convertible preferred stock. Series A Convertible Preferred Stock Series A Convertible Preferred Stock [Member] Series B convertible preferred stock. Series B Convertible Preferred Stock Series B Convertible Preferred Stock [Member] Initial Public Offering Undesignated preferred stock. Undesignated Preferred Stock Undesignated Preferred Stock [Member] Follow-on public offering. Follow-on Public Offering Follow On Public Offering [Member] Description Of Business And Basis Of Presentation [Line Items] Description Of Business And Basis Of Presentation [Line Items] Common unit converted into common stock Common Unit Converted Into Common Stock Preferred unit converted into convertible preferred stock Preferred Unit Converted Into Convertible Preferred Stock Sale of stock number of shares issued in transaction Sale Of Stock Number Of Shares Issued In Transaction Sale of stock, price per share Sale Of Stock Price Per Share Proceeds from the IPO, net of underwriting discounts, commissions and offering costs Proceeds From Issuance Initial Public Offering Outstanding shares of convertible preferred stock converted into common stock Warrant to purchase of common stock Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Reverse stock split, description Stockholders Equity Reverse Stock Split Stockholders' equity note, stock split, conversion ratio Stockholders Equity Note Stock Split Conversion Ratio1 Proceeds from issuance of follow on public offering. Sale of common stock maximum aggregate offering price. Proceeds from the follow-on public offering, net of underwriting discounts, commissions and offering costs Proceeds From Issuance Of Follow On Public Offering Sale of common stock maximum aggregate offering price Sale Of Common Stock Maximum Aggregate Offering Price Net proceeds from Issuance of common stock after deducting offering-related transaction costs and commissions Proceeds From Issuance Of Common Stock Accumulated deficit Cash, cash equivalents and marketable securities Cash Cash Equivalents And Short Term Investments Summary of significant accounting policies line items. Summary of significant accounting policies table. Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Minimum Minimum [Member] Maximum Maximum [Member] Accounting Standards Update Adjustments For New Accounting Pronouncements [Axis] Accounting Standards Update Type Of Adoption [Member] Accounting Standards Update 2020-06 Accounting Standards Update202006 [Member] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Realized gains and losses on marketable securities Debt Securities Available For Sale Realized Gain Loss Other-than-temporary impairments on marketable securities Other Than Temporary Impairment Loss Debt Securities Available For Sale Transfers of assets measured on recurring basis out of Level 1 into Level 2 Fair Value Assets Level1 To Level2 Transfers Amount Transfers of assets measured on recurring basis out of Level 2 into Level 1 Fair Value Assets Level2 To Level1 Transfers Amount Transfers of liabilities measured on recurring basis out of Level 1 into Level 2 Fair Value Liabilities Level1 To Level2 Transfers Amount Transfers of liabilities measured on recurring basis out of Level 2 into Level 1 Fair Value Liabilities Level2 To Level1 Transfers Amount Transfers of financial instrument classified as liability into level 3 Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 Transfers of financial instrument classified as liability out of level 3 Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 Transfers of financial instrument classified as asset into level 3 Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 Transfers of financial instrument classified as asset out of level 3 Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 Estimated useful lives of assets Property Plant And Equipment Useful Life Number of operating segment Number Of Operating Segments Change in Accounting Principle, Accounting Standards Update, Adopted [true false] Change In Accounting Principle Accounting Standards Update Adopted Change in Accounting Principle, Accounting Standards Update, Adoption Date Change In Accounting Principle Accounting Standards Update Adoption Date Weighted-average shares/units subject to repurchase or forfeiture Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Securities Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities Name [Domain] Warrant Warrant [Member] Common Stock Options Issued and Outstanding Employee Stock Option [Member] Common stock subject to repurchase or forfeiture. Common Stock Subject to Repurchase or Forfeiture Common Stock Subject To Repurchase Or Forfeiture [Member] ESPP shares pending issuance. ESPP Shares Pending Issuance Employee Stock Purchase Plan Shares Pending Issuance [Member] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Total Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] Change In Accounting Principle Accounting Standards Update Immaterial Effect Change in Accounting Principle, Accounting Standards Update, Early Adoption [true false] Change In Accounting Principle Accounting Standards Update Early Adoption Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Measurement Frequency Fair Value By Measurement Frequency [Axis] Measurement Frequency Fair Value Measurement Frequency [Domain] Recurring Fair Value Measurements Recurring [Member] Fair Value Hierarchy and NAV Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value Inputs Level1 [Member] Significant Other Observable Inputs (Level 2) Fair Value Inputs Level2 [Member] Significant Unobservable Inputs (Level 3) Fair Value Inputs Level3 [Member] Asset Class Fair Value By Asset Class [Axis] Asset Class Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] U.S. Treasury securities U S Treasury Securities [Member] Negotiable certificates of deposit Certificates Of Deposit [Member] Corporate debt securities Corporate Debt Securities [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Marketable securities Available For Sale Securities Debt Securities Total Assets Fair Value Disclosure Cash equivalents Cash And Cash Equivalents Fair Value Disclosure Fair value measurement with unobservable inputs reconciliation recurring basis liability reclassification of preferred stock warrant liability to stockholders equity. Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Table] Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Table] Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Beginning Balance Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value Change in fair value Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease Reclassification of warrant liability to stockholders? equity Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reclassification Of Preferred Stock Warrant Liability To Stockholders Equity Ending Balance Debt Securities Available For Sale [Table] Debt Securities Available For Sale [Table] Investment Type Investment Type [Axis] Investments Investment Type Categorization [Member] U . S treasury securities one year or less maturity. U.S. Treasury Securities with 1 Year or Less Maturity U S Treasury Securities One Year Or Less Maturity [Member] Corporate debt securities with one to two years maturity. Corporate Debt Securities with 1 to 2 Years Maturity Corporate Debt Securities With One To Two Years Maturity [Member] Negotiable certificates of deposit one year or less maturity. Negotiable Certificates of Deposit with 1 Year or Less Maturity Negotiable Certificates Of Deposit One Year Or Less Maturity [Member] U.S. treasury securities with one to two years maturity. U.S. Treasury Securities with 1 to 2 Years Maturity U S Treasury Securities With One To Two Years Maturity [Member] Negotiable certificates of deposit with one to two years maturity. Negotiable Certificates of Deposit with 1 to 2 Years Maturity Negotiable Certificates Of Deposit With One To Two Years Maturity [Member] Corporate debt securities with one year or less maturity. Corporate Debt Securities with 1 Year or Less Maturity Corporate Debt Securities One Year Or Less Maturity [Member] Schedule Of Available For Sale Securities [Line Items] Schedule Of Available For Sale Securities [Line Items] Amortized Cost Available For Sale Debt Securities Amortized Cost Basis Unrealized Gains Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Unrealized Losses Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Rights to antibody oligonucleotide conjugates for messengers RNA targets. Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] Research collaboration and license agreement with Eli Lilly and company Research Collaboration and License Agreement with Eli Lilly Research Collaboration And License Agreement With Eli Lilly And Company [Member] Balance Sheet Location Balance Sheet Location [Axis] Balance Sheet Location Balance Sheet Location [Domain] Prepaid and Other Assets Prepaid Expenses And Other Current Assets [Member] Debt Instrument Debt Instrument [Axis] Debt Instrument, Name Debt Instrument Name [Domain] Lilly convertible promissory notes. Lilly Note Lilly Convertible Promissory Notes [Member] Series C convertible preferred stock. Series C Convertible Preferred Stock Series C Convertible Preferred Stock [Member] Research collaboration with MyoKardia, Inc. Research Collaboration with MyoKardia, Inc. Research Collaboration With Myo Kardia Inc [Member] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Rights to antibody oligonucleotide conjugates for messengers RNA targets. Rights To Antibody Oligonucleotide Conjugates For Messengers R N A Targets Upfront fees received. Development milestone payment eligible to receive per target. Regulatory milestone payment eligible to receive per target. Commercialization milestone payment eligible to receive per target. License agreement expiry period. Upfront fees received Upfront Fees Received Development milestone payment eligible to receive per target Development Milestone Payment Eligible To Receive Per Target Regulatory milestone payment eligible to receive per target Regulatory Milestone Payment Eligible To Receive Per Target Commercialization milestone payment eligible to receive Commercialization Milestone Payment Eligible To Receive Per Target License agreement expiry period License Agreement Expiry Period Number of performance obligation. Period for expects performance obligation. Collaboration receivables current. Number of performance obligation Number Of Performance Obligation Period for expects performance obligation Period For Expects Performance Obligation Revenue recognized Deferred revenue Contract With Customer Liability Collaboration receivables Collaboration Receivables Current Balance Revenue recognized Contract With Customer Liability Revenue Recognized Balance Conversion of convertible note payable to preferred stock Debt Conversion Converted Instrument Shares Issued1 Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Long-Lived Tangible Asset Property Plant And Equipment By Type [Axis] Long-Lived Tangible Asset Property Plant And Equipment Type [Domain] Laboratory equipment. Laboratory Equipment Laboratory Equipment [Member] Computers and Software Computer Equipment [Member] Office furniture and equipment. Office Furniture and Equipment Office Furniture And Equipment [Member] Leasehold Improvements Leasehold Improvements [Member] Property Plant And Equipment [Line Items] Property Plant And Equipment [Line Items] Property and equipment, gross Property Plant And Equipment Gross Less accumulated depreciation Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Total property and equipment, net Depreciation expenses related to property and equipment Debt instrument final payments. Debt Instrument [Table] Debt Instrument [Table] Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] Silicon valley bank. SVB Silicon Valley Bank [Member] Loan and security agreement amendment. LSA Amendment Loan And Security Agreement Amendment [Member] Term C loan. Term C Loan Term C Loan [Member] Term D loan. Term D Loan Term D Loan [Member] Loan and security agreement second amendment. LSA Second Amendment Loan And Security Agreement Second Amendment [Member] Long-term Debt, Type Longterm Debt Type [Axis] Long-term Debt, Type Longterm Debt Type [Domain] Convertible Notes Convertible Notes Payable [Member] Amended and restated loan and security agreement. LSA Amended And Restated Loan And Security Agreement [Member] Term C and D loans. Term C And D Loans Term C And D Loans [Member] Term A and term B loans. Term A And Term B Loans Term A And Term B Loans [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Loan facility maximum borrowing capacity Line Of Credit Facility Maximum Borrowing Capacity Face amount of loans Debt Instrument Face Amount Repayment of existing loan Debt instrument final payments Debt Instrument Final Payments Debt instrument frequency of periodic payment principal. Number of monthly installments of principal. Debt instrument frequency of periodic payment interest Debt instrument final payment percentage. Maturity date Debt Instrument Maturity Date Basis spread on variable rate Debt Instrument Basis Spread On Variable Rate1 Frequency of periodic payment principal Debt Instrument Frequency Of Periodic Payment Principal Number of equal monthly installments of principal Number Of Monthly Installments Of Principal Frequency of periodic payment interest Debt Instrument Frequency Of Periodic Payment Interest Debt instrument final payment percentage Debt Instrument Final Payment Percentage Proceeds from issuance of long-term debt Proceeds From Issuance Of Long Term Debt Proceeds from notes Payment of final payment and accrued interest. Loans prepaid amount Extinguishment Of Debt Amount Payment of final payment and accrued interest Payment Of Final Payment And Accrued Interest Class of warrant number of securities called by each warrant to purchase convertible preferred stock. Class of warrant or right term. Class of warrant exercisable for common stock. Class of warrant exercisable common stock warrant exercise price. Class of warrant number of securities called by each warrant to purchase common stock. Cashless exercise of warrants. Warrant to purchase convertible preferred stock Class Of Warrant Number Of Securities Called By Each Warrant To Purchase Convertible Preferred Stock Exercise price of warrant Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 Warrant term Class Of Warrant Or Right Term Warrant exercisable Class Of Warrant Exercisable For Common Stock Exercise price of warrant Class Of Warrant Exercisable Common Stock Warrant Exercise Price Warrant to purchase common stock Class Of Warrant Number Of Securities Called By Each Warrant To Purchase Common Stock Cashless exercise of warrants Cashless Exercise Of Warrants Debt instrument accrued interest rate. Convertible promissory notes conversion percentage on per share price paid by investors. Debt instrument minimum qualified financing of convertible promissory notes converted into preferred equity. Two thousand and eighteen convertible promissory notes. 2018 Notes Two Thousand And Eighteen Convertible Promissory Notes [Member] Two thousand nineteen convertible promissory notes. 2019 Notes Two Thousand And Nineteen Convertible Promissory Notes [Member] Convertible promissory notes accrued interest rate Debt Instrument Accrued Interest Rate Convertible promissory notes conversion percentage on per share price paid by investors Convertible Promissory Notes Conversion Percentage On Per Share Price Paid By Investors Qualified financing of convertible promissory notes converted into preferred equity Debt Instrument Minimum Qualified Financing Of Convertible Promissory Notes Converted Into Preferred Equity Debt instrument maturity month and year. Proceeds from issuance of convertible notes Maturity date Debt Instrument Maturity Month And Year Conversion of convertible notes payable to preferred stock Interest expense Commitments and Contingencies. Commitments and contingencies Commitments And Contingencies [Table] Commitments And Contingencies [Table] Lease Contractual Term Lease Contractual Term [Axis] Lease Contractual Term Lease Contractual Term [Domain] Lease term through November 2017. Lease Term through November 2017 Lease Term Through November Two Thousand And Seventeen [Member] Lease term through December 2021. Lease Term through December 2021 Lease Term Through December Two Thousand And Twenty One [Member] Office and laboratory space. Office and Laboratory Space Office And Laboratory Space [Member] New lease. New Lease New Lease [Member] Temporary lease. Temporary Lease Temporary Lease [Member] Commitments and Contingencies [Line Items] Commitments And Contingencies [Line Items] Operating lease, description Lessee Operating Lease Description Incremental borrowing rate Operating Lease Weighted Average Discount Rate Percent Lessee, operating lease, term of contract, description. Operating lease, term of contract, description Lessee Operating Lease Term Of Contract Description Lessee operating lease expiration period description. Lessee operating lease expiration period after commencement of new lease. Lessee operating lease, lease payment under new lease. Lessee operating lease, initial monthly base rent. Lessee operating lease, monthly base rent for last year lease. Operating lease, lease payment under new lease Lessee Operating Lease Lease Payment Under New Lease Operating lease, expiration period, description Lessee Operating Lease Expiration Period Description Operating lease expiration period Lessee Operating Lease Expiration Period After Commencement Of New Lease Operating lease, term of contract Lessee Operating Lease Term Of Contract Operating lease, renewal term Lessee Operating Lease Renewal Term Lessee, operating lease, existence of option to extend [true false] Lessee Operating Lease Existence Of Option To Extend Operating lease, initial monthly base rent Lessee Operating Lease Initial Monthly Base Rent Operating lease, monthly base rent for last year lease Lessee Operating Lease Monthly Base Rent For Last Year Lease Letter of credit throughout the lease term Letters Of Credit Outstanding Amount Total lease liabilities Operating Lease Liability 2022 Lessee Operating Lease Liability Payments Due Next Twelve Months 2023 Lessee Operating Lease Liability Payments Due Year Two 2024 Lessee Operating Lease Liability Payments Due Year Three 2025 Lessee Operating Lease Liability Payments Due Year Four 2026 Lessee Operating Lease Liability Payments Due Year Five Total lease payments Lessee Operating Lease Liability Payments Due Less imputed interest Lessee Operating Lease Liability Undiscounted Excess Amount Less lease liabilities, current portion Cash paid included in operating cash flows Operating Lease Payments Short-term lease rent expense. Lease rent expense. Operating leases Operating Lease Expense Short-term leases Short Term Lease Rent Expense Total rent expense Lease Rent Expense Weighted-average remaining term of operating leases Operating Lease Weighted Average Remaining Lease Term1 Loss contingencies accrued Loss Contingency Accrual At Carrying Value Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] 2013 equity incentive plan. 2013 Equity Incentive Plan Two Thousand Thirteen Equity Incentive Plan [Member] 2020 incentive award plan. 2020 Incentive Award Plan Two Thousand Twenty Incentive Award Plan [Member] Employee stock purchase plan. Employee Stock Purchase Plan Employee Stock Purchase Plan [Member] Accounts Payable and Accrued Liabilities Accounts Payable And Accrued Liabilities [Member] Award Type Award Type [Axis] Award Type Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Time based options. Time-based Options Time Based Options [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Common stock shares authorized Preferred stock undesignated shares authorized Common stock par value per share Preferred stock par value per share Proceeds from the IPO, net of underwriting discounts, commissions and offering costs Termination notice period for sales agreement. Termination notice period for sales agreement Termination Notice Period For Sales Agreement Retained earnings accumulated deficit reclassified to additional paid in capital. Reclassified accumulated deficit from predecessor deficit to additional paid in capital Retained Earnings Accumulated Deficit Reclassified To Additional Paid In Capital Preferred stock, shares issued Temporary Equity Shares Issued Stock issued price per share Shares Issued Price Per Share Issuance costs Units initially reserved for issuance. Increased to number of shares reserved under plan. Units initially reserved for issuance Units Initially Reserved For Issuance Increased to number of shares reserved under plan Increased To Number Of Shares Reserved Under Plan Percentage of shares of common stock outstanding on final day of immediately preceding calendar year. Number of remaining shares available for future issuance. Shares of common stock reserved for future issuance Common Stock Capital Shares Reserved For Future Issuance Percentage of shares of common stock outstanding on final day of immediately preceding calendar year Percentage Of Shares Of Common Stock Outstanding On Final Day Of Immediately Preceding Calendar Year Number of remaining shares available for issuance Number Of Remaining Shares Available For Future Issuance Expiration period Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period Award vesting period Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 Number of Options Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward Outstanding at December 31, 2020 Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Exercised Forfeited/expired Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Outstanding at December 31, 2021 Vested and expected to vest at December 31, 2021 Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number Exercisable at December 31, 2021 Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Weighted-Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward Outstanding at December 31, 2020 Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Granted Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Exercised Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Forfeited/expired Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price Outstanding at December 31, 2021 Vested and expected to vest at December 31, 2021 Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price Exercisable at December 31, 2021 Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract] Outstanding, Weighted- Average Remaining Contractual Term (in years) Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Vested and expected to vest, Weighted - Average Remaining Contractual Term (in years) Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 Exercisable, Weighted- Average Remaining Contractual Term (in years) Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 Outstanding, Aggregate Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Vested and expected to vest, Aggregate Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value Exercisable, Aggregate Intrinsic Value Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 Total intrinsic value of options exercised Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value Weighted-average grant date fair value of options granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value Share based compensation arrangement by share based payment award number of unvested shares early exercised. Stock options exercised were unvested Share Based Compensation Arrangement By Share Based Payment Award Number Of Unvested Shares Early Exercised Share-based compensation arrangement by share-based payment award, number of shares available for issuance. Participant maximum contribution as percentage of eligible compensation Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate Percentage of purchase price of shares of lower of fair market value Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent Shares of common stock available for issuance Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Issuance Shares issued under ESPP Outstanding liability Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent Risk-free interest rate, Minimum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum Risk-free interest rate, Maximum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum Expected volatility Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Expected term (in years) Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 Expected dividend yield Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Risk-free interest rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Share Based Compensation Allocation And Classification In Financial Statements [Abstract] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Research and Development Expense Research And Development Expense [Member] General and Administrative Expense General And Administrative Expense [Member] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Total stock-based compensation expense Allocated Share Based Compensation Expense Unrecognized compensation cost Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Weighted-average period of unrecognized compensation cost Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] Equity awards available for future issuance under equity plans. Equity Awards Available for Future Issuance under Equity Plans Equity Awards Available For Future Issuance Under Equity Plans [Member] Common stock authorized under ESPP. Common Stock Authorized under the ESPP Common Stock Authorized Under E S P P [Member] Common stock option issued and outstanding. Common Stock Options Issued and Outstanding Common Stock Option Issued And Outstanding [Member] Class Of Stock [Line Items] Class Of Stock [Line Items] Common stock reserved for future issuance Income taxes disclosure. Income taxes disclosure. Income Taxes Disclosure [Table] Income Taxes Disclosure [Table] Income Tax Authority Income Tax Authority [Axis] Income Tax Authority Income Tax Authority [Domain] Federal Domestic Country [Member] State State And Local Jurisdiction [Member] Tax Credit Carryforward Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name Tax Credit Carryforward Name [Domain] Orphan drug tax credits. Orphan Drug Tax Credits Orphan Drug Tax Credits [Member] Income Taxes Disclosure [Line Items] Income Taxes Disclosure [Line Items] Provision for income taxes Income Tax Expense Benefit Income tax reconciliation permanent items. Income tax reconciliation book income (loss) for pre-conversion period. Income tax reconciliation interest on convertible notes. Income tax reconciliation realized gain on conversion of convertible notes. Income tax reconciliation reserve for uncertain tax positions. Income tax reconciliation deferred tax recognized upon conversion. Income tax expense (benefit) at statutory rates Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate State income tax, net of federal benefit Income Tax Reconciliation State And Local Income Taxes Permanent items Income Tax Reconciliation Permanent Items Book income for pre-conversion period Income Tax Reconciliation Book Income Loss For Pre Conversion Period Interest on convertible notes Income Tax Reconciliation Interest On Convertible Notes Realized gain on conversion of convertible notes Income Tax Reconciliation Realized Gain On Conversion Of Convertible Notes Reserve for uncertain tax positions Income Tax Reconciliation Reserve For Uncertain Tax Positions Research and development tax credits Income Tax Reconciliation Tax Credits Research Deferred taxes recognized upon conversion Income Tax Reconciliation Deferred Tax Recognized Upon Conversion Valuation allowance Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance Other Income Tax Reconciliation Other Adjustments Income tax expense (benefit) Deferred tax assets, intangibles and fixed assets. Deferred tax assets lease liability. Deferred tax liabilities right-of-use asset. Deferred Income Taxes [Abstract] Deferred tax assets: Components Of Deferred Tax Assets [Abstract] Net operating loss carryforwards Deferred Tax Assets Operating Loss Carryforwards Research and development tax credits Deferred Tax Assets Tax Credit Carryforwards Research Deferred revenue Deferred Tax Assets Deferred Income Accrued expenses Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities Intangibles and fixed assets Deferred Tax Assets Intangibles And Fixed Assets Lease liability Deferred Tax Assets Lease Liability Stock-based compensation Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost Total deferred tax assets Deferred Tax Assets Gross Less valuation allowance Deferred Tax Assets Valuation Allowance Net deferred tax assets Deferred Tax Assets Net Deferred tax liabilities: Components Of Deferred Tax Liabilities [Abstract] Right-of-use asset Deferred Tax Liabilities Right Of Use Asset Total deferred tax liabilities Deferred Income Tax Liabilities Net deferred tax assets Deferred Tax Assets Liabilities Net Increase in the valuation allowance Valuation Allowance Deferred Tax Asset Change In Amount Net operating loss carry forward available for offsetting against future taxable income percentage. Net operating loss carryforwards expiration beginning year. Net operating loss carry forward available for offsetting against taxable income percentage. Net operating loss (NOL) carryforwards Operating Loss Carryforwards Net operating loss available to offset against current taxable income percentage Net Operating Loss Carry Forward Available For Offsetting Against Taxable Income Percentage Net operating loss available to offset against future taxable income percentage Net Operating Loss Carry Forward Available For Offsetting Against Future Taxable Income Percentage Net operating loss carryforwards, expiration beginning year Net Operating Loss Carryforwards Expiration Beginning Year Tax credit carryforwards expiration beginning year. Federal and state tax credit carryforwards Deferred Tax Assets Tax Credit Carryforwards Tax credit expiration beginning year Tax Credit Carryforwards Expiration Beginning Year Unrecognized tax benefits other true up adjustment. Gross unrecognized tax benefits at the beginning of the year Unrecognized Tax Benefits Increases related to current year positions Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions Increases related to prior year positions Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions Other true up Unrecognized Tax Benefits Other True Up Adjustment Gross unrecognized tax benefits at the end of the year Accruals for interest or penalties Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued Interest or penalties Unrecognized Tax Benefits Income Tax Penalties And Interest Expense Subsequent Event [Table] Subsequent Event [Table] Subsequent Event Type Subsequent Event Type [Axis] Subsequent Event Type Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Sales agreement. Sales Agreement Sales Agreement [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] EX-101.PRE 15 rna-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 16 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Feb. 07, 2022
Jun. 30, 2021
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2021    
Document Fiscal Year Focus 2021    
Document Fiscal Period Focus FY    
Current Fiscal Year End Date --12-31    
Entity Registrant Name AVIDITY BIOSCIENCES, INC.    
Entity Central Index Key 0001599901    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Filer Category Large Accelerated Filer    
Entity Common Stock, Shares Outstanding   47,754,677  
Entity File Number 001-39321    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 46-1336960    
Entity Address, Address Line One 10578 Science Center Drive    
Entity Address, Address Line Two Suite 125    
Entity Address, City or Town San Diego    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 92121    
City Area Code 858    
Local Phone Number 401-7900    
Title of 12(b) Security Common Stock, par value $0.0001 per share    
Trading Symbol RNA    
Security Exchange Name NASDAQ    
Document Annual Report true    
Document Transition Report false    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Public Float     $ 798.1
ICFR Auditor Attestation Flag true    
Auditor Name BDO USA, LLP    
Auditor Location San Diego, California    
Auditor Firm ID 243    

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�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

 XML 17 R2.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 320,448 $ 321,462
Marketable securities 85,095 6,679
Prepaid and other assets 5,598 3,537
Total current assets 411,141 331,678
Property and equipment, net 4,805 1,468
Restricted cash 251 251
Right-of-use asset 10,784 454
Other assets 599 47
Total assets 427,580 333,898
Current liabilities:    
Accounts payable and accrued liabilities 14,085 7,745
Accrued compensation 8,940 3,152
Lease liabilities, current portion 1,769 0
Deferred revenue, current portion 4,864 3,690
Total current liabilities 29,658 14,587
Lease liabilities, net of current portion 9,960 938
Deferred revenue, net of current portion 6,532 12,150
Total liabilities 46,150 27,675
Commitments and contingencies (Note 9) 0 0
Stockholders’ equity:    
Preferred stock, $0.0001 par value; authorized shares – 40,000; issued and outstanding shares – none 0 0
Common stock, $0.0001 par value; authorized shares – 400,000; issued and outstanding shares – 47,754 and 37,569 at December 31, 2021 and 2020, respectively 5 4
Additional paid-in capital 566,161 372,764
Accumulated other comprehensive loss (187) (5)
Accumulated deficit (184,549) (66,540)
Total stockholders’ equity 381,430 306,223
Total liabilities and stockholders’ equity $ 427,580 $ 333,898
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2021
Dec. 31, 2020
Statement Of Financial Position [Abstract]    
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 40,000,000 40,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 400,000,000 400,000,000
Common stock, shares issued 47,754,000 37,569,000
Common stock, shares outstanding 47,754,000 37,569,000
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.22.0.1
Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Statement [Abstract]      
Collaboration revenue $ 9,326 $ 6,787 $ 2,319
Revenue from Contract with Customer, Product and Service [Extensible Enumeration] us-gaap:LicenseAndServiceMember us-gaap:LicenseAndServiceMember us-gaap:LicenseAndServiceMember
Operating expenses:      
Research and development $ 101,182 $ 37,602 $ 14,539
General and administrative 26,195 13,462 5,112
Total operating expenses 127,377 51,064 19,651
Loss from operations (118,051) (44,277) (17,332)
Other income (expense):      
Interest income 104 206 0
Interest expense 0 (209) (7,387)
Change in fair value of preferred warrant liability 0 (75) (15)
Other expense (62) 0 0
Total other income (expense) 42 (78) (7,402)
Net loss (118,009) (44,355) (24,734)
Other comprehensive income (loss):      
Net unrealized losses on marketable securities (182) (5) 0
Comprehensive loss $ (118,191) $ (44,360) $ (24,734)
Net loss per share/unit, basic and diluted $ (2.85) $ (2.05) $ (9.12)
Weighted-average shares/units outstanding, basic and diluted 41,428 21,663 2,713
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
Statements of Convertible Preferred Stock/Units and Stockholders'/Members' Equity (Deficit) - USD ($)
shares in Thousands, $ in Thousands
Total
Public Offering
Preferred Units
Common Units
Predecessor's Deficit
Convertible Preferred Stock
Common Stock
Common Stock
Public Offering
Additional Paid-in Capital
Additional Paid-in Capital
Public Offering
Accumulated Other Comprehensive Loss
Accumulated Deficit
Preferred Units, balance, Units at Dec. 31, 2018     12,459                  
Preferred Units, balance at Dec. 31, 2018     $ 32,693                  
Members' equity, balance, Units at Dec. 31, 2018       2,842                
Members' equity, balance at Dec. 31, 2018       $ 426                
Balance at Dec. 31, 2018 $ (41,129)       $ (41,555)              
Distribution to members     $ (106)                  
Issuance of common units upon exercise of unit options 38     $ 38                
Issuance of common units upon exercise of unit options, Units       78                
Net loss to date of conversion (2,549)       (2,549)              
Conversion from LLC to C corporation       $ (481) $ 44,104       $ (43,623)      
Conversion from LLC to C corporation, Temporary equity, Shares     (12,459)     12,459            
Conversion from LLC to C corporation, Temporary equity     $ (32,587)     $ 32,587            
Conversion from LLC to C corporation, Shares       (2,920)     2,920          
Issuance of Series C convertible preferred stock, net of issuance costs           $ 72,623            
Issuance of Series C convertible preferred stock, net of issuance costs, Shares           17,915            
Issuance of Series C convertible preferred stock upon conversion of convertible notes           $ 29,510            
Issuance of Series C convertible preferred stock upon conversion of convertible notes, Shares           6,893            
Reclassification of warrant liability to equity due to adjustment from preferred stock warrant to common stock warrant upon completion of initial public offering 0                      
Issuance of common stock upon exercise of stock options, net of repurchases 26               26      
Issuance of common stock upon exercise of stock options, net of repurchases, Shares             69          
Vesting of early exercise options 36               36      
Stock-based compensation 17     $ 17                
Stock-based compensation 389               389      
Net loss (24,734)                      
Net loss (22,185)                     $ (22,185)
Temporary equity, balance, Shares at Dec. 31, 2019           37,267            
Temporary equity, balance at Dec. 31, 2019           $ 134,720            
Balance, Shares at Dec. 31, 2019             2,989          
Balance at Dec. 31, 2019 (65,357)               (43,172)     (22,185)
Issuance of Series C convertible preferred stock, net of issuance costs           $ 2,200            
Issuance of Series C convertible preferred stock, net of issuance costs, Shares           538            
Issuance of stock, net of issuance costs, Value   $ 274,054           $ 2   $ 274,052    
Issuance of stock, net of issuance costs, Shares               16,560        
Conversion of convertible preferred stock into common stock upon completion of initial public offering 136,920         $ (136,920) $ 2   136,918      
Conversion of convertible preferred stock into common stock upon completion of initial public offering, Shares           (37,805) 17,921          
Reclassification of warrant liability to equity due to adjustment from preferred stock warrant to common stock warrant upon completion of initial public offering 120               120      
Cashless exercise of common stock warrants, Shares             16          
Issuance of common stock upon exercise of stock options, net of repurchases 22               22      
Issuance of common stock upon exercise of stock options, net of repurchases, Shares             54          
Issuance of common stock under employee stock purchase plan 444               444      
Issuance of common stock under employee stock purchase plan, Shares             29          
Vesting of early exercise options 70               70      
Stock-based compensation 4,310               4,310      
Net loss (44,355)                     (44,355)
Other comprehensive loss (5)                   $ (5)  
Balance, Shares at Dec. 31, 2020             37,569          
Balance at Dec. 31, 2020 306,223           $ 4   372,764   (5) (66,540)
Issuance of stock, net of issuance costs, Value   $ 174,677           $ 1   $ 174,676    
Issuance of stock, net of issuance costs, Shares               9,980        
Issuance of common stock upon exercise of stock options $ 930               930      
Issuance of common stock upon exercise of stock options, Shares 172           172          
Reclassification of warrant liability to equity due to adjustment from preferred stock warrant to common stock warrant upon completion of initial public offering $ 0                      
Issuance of common stock under employee stock purchase plan 709               709      
Issuance of common stock under employee stock purchase plan, Shares             33          
Vesting of early exercise options 26               26      
Stock-based compensation 17,056               17,056      
Net loss (118,009)                     (118,009)
Other comprehensive loss (182)                   (182)  
Balance, Shares at Dec. 31, 2021             47,754          
Balance at Dec. 31, 2021 $ 381,430           $ 5   $ 566,161   $ (187) $ (184,549)
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
Statements of Convertible Preferred Stock/Units and Stockholders'/Members' Equity (Deficit) (Parenthetical) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Convertible Preferred Stock      
Stock issuance costs   $ 100 $ 4,100
Public Offering | Common Stock      
Stock issuance costs $ 11,262 $ 24,026  
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities      
Net loss $ (118,009) $ (44,355) $ (24,734)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:      
Depreciation 639 373 348
Stock-based compensation expense 17,056 4,310 406
Amortization of premiums and discounts on marketable securities, net 179 9 0
Amortization of discounts and loan issuance costs 0 29 71
Gain on disposal of property and equipment (16) 0 0
Noncash interest expense 0 110 7,027
Change in fair value of preferred warrant liability 0 75 15
Changes in operating assets and liabilities:      
Prepaid and other assets (2,510) (2,444) (949)
Accounts payable and accrued liabilities 6,043 5,749 436
Accrued compensation 5,788 1,838 1,010
Operating lease right-of-use assets and liabilities, net 461 289 (80)
Deferred revenue (4,444) (3,100) 18,940
Net cash (used in) provided by operating activities (94,813) (37,117) 2,490
Cash flows from investing activities      
Purchases of marketable securities (85,357) (6,693) 0
Maturities of marketable securities 6,580 0 0
Purchases of property and equipment (3,740) (1,092) (235)
Net cash used in investing activities (82,517) (7,785) (235)
Cash flows from financing activities      
Proceeds from issuance of common stock in public offerings, gross 185,939 298,080 0
Payment of issuance costs related to public offerings (11,262) (24,026) 0
Proceeds from exercise of stock/unit options, net of repurchases 930 22 65
Proceeds from issuance of common stock under employee stock purchase plan 709 444 0
Payments on long-term debt 0 (4,683) (2,800)
Distributions to members 0 0 (106)
Proceeds from issuance of Series C convertible preferred stock, net of issuance costs 0 2,200 72,623
Proceeds from issuance of convertible notes, net of issuance costs 0 0 19,451
Net cash provided by financing activities 176,316 272,037 89,233
Net (decrease) increase in cash, cash equivalents and restricted cash (1,014) 227,135 91,488
Cash, cash equivalents and restricted cash at beginning of period 321,713 94,578 3,090
Cash, cash equivalents and restricted cash at end of period 320,699 321,713 94,578
Supplemental disclosure of cash flow information:      
Cash paid for interest 0 571 322
Supplemental schedule of noncash investing and financing activities:      
Right-of-use assets obtained in exchange for operating lease liabilities 12,074 936 807
Costs incurred, but not paid, in connection with purchases of property and equipment included in accounts payable and accrued liabilities 220 118 43
Conversion of convertible preferred stock into common stock upon completion of initial public offering 0 136,920 0
Issuance of Series C convertible preferred stock upon conversion of outstanding convertible notes 0 0 29,510
Reclassification of warrant liability to equity due to adjustment from preferred stock warrant to common stock warrant upon completion of initial public offering $ 0 $ 120 $ 0
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
Description of Business and Basis of Presentation
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Description of Business and Basis of Presentation

1.

Description of Business and Basis of Presentation

Description of Business

Avidity Biosciences, Inc. (the Company or Avidity) is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs). The Company’s proprietary AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics.

Formation and Conversion

The Company was formed under the laws of the State of Delaware in November 2012 as a Delaware limited liability company. In April 2019, pursuant to an Agreement and Plan of Conversion, Avidity Biosciences LLC (Avidity LLC) was converted into Avidity Biosciences, Inc., a Delaware corporation. The entire membership interests of Avidity LLC were converted into securities of Avidity Biosciences, Inc. as follows: (i) each outstanding common unit of Avidity LLC was converted into one share of Avidity Biosciences, Inc.’s common stock; (ii) each outstanding Series A convertible preferred unit of Avidity LLC converted into one share of Avidity Biosciences, Inc.’s Series A convertible preferred stock; and (iii) each outstanding Series B convertible preferred unit of Avidity LLC converted into one share of Avidity Biosciences, Inc.’s Series B convertible preferred stock. All the property, rights, privileges, powers and franchises of Avidity LLC vested in Avidity Biosciences, Inc., and all debts, liabilities and duties of Avidity LLC became debts, liabilities and duties of Avidity Biosciences, Inc. Outstanding convertible notes, warrants and stock awards under Avidity LLC’s employee benefit and incentive compensation plans continued on the same terms and conditions and became binding upon Avidity Biosciences, Inc.

Initial Public Offering

On June 16, 2020, the Company completed its initial public offering (IPO) in which it sold 16,560,000 shares of common stock at an offering price of $18.00 per share. Proceeds from the IPO, net of underwriting discounts, commissions and offering costs, were $274.1 million.

In addition, each of the following occurred in connection with the completion of the IPO:

 

•

the conversion of all outstanding shares of convertible preferred stock into 17,921,069 shares of the Company’s common stock;

 

•

the adjustment of an outstanding warrant to purchase convertible preferred stock into a warrant to purchase 7,809 shares of the Company’s common stock; and

 

•

the amendment and restatement of the Company’s certificate of incorporation, authorizing 400,000,000 shares of common stock and 40,000,000 shares of undesignated preferred stock.

Reverse Stock Split

On June 4, 2020, the Company effected a one-for-2.1095 reverse stock split of its common stock (the Reverse Stock Split). The par value and the authorized shares of the common stock were not adjusted as a result of the Reverse Stock Split. All issued and outstanding common stock and the conversion ratio of the convertible preferred stock have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented.

Liquidity

On August 6, 2021, the Company completed a public offering of 9,200,000 shares of its common stock at a public offering price of $18.00 per share. The net proceeds from the offering were $155.1 million,

after deducting underwriting discounts, commissions and offering costs. On July 2, 2021, the Company entered into a sales agreement (the Sales Agreement) with Cowen and Company, LLC (the Sales Agent), under which the Company may, from time to time, sell shares of its common stock having an aggregate offering price of up to $150.0 million through the Sales Agent. During the year ended December 31, 2021, the Company sold 780,549 shares of its common stock pursuant to the Sales Agreement and received net proceeds of $19.6 million, after deducting offering-related transaction costs and commissions. See Note 10 (Stockholders Equity (Deficit)) for more information on the Company’s public offerings.

As of December 31, 2021, the Company has devoted substantially all of its resources to organizing and staffing the company, business planning, raising capital, developing its proprietary AOC platform, identifying potential product candidates, establishing its intellectual property portfolio, conducting research, preclinical and clinical studies, and providing other general and administrative support for these operations. In addition, the Company has a limited operating history, has incurred operating losses since inception and expects that it will continue to incur net losses into the foreseeable future as it continues the development of its product candidates and development programs. As of December 31, 2021, the Company had an accumulated deficit of $184.5 million and cash, cash equivalents and marketable securities of $405.5 million.

The Company believes that existing cash, cash equivalents and marketable securities will be sufficient to fund the Company’s operations for at least 12 months from the date of the filing of this Form 10-K. The Company plans to finance its future cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. If the Company is not able to secure adequate additional funding, it may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or delay or reduce the scope of its planned development programs. Any of these actions could materially harm the Company’s business, results of operations and future prospects.

Basis of Presentation

The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC). The financial statements reflect all adjustments which, in the opinion of management, are necessary for a fair statement of the results for the periods presented. All such adjustments are of a normal and recurring nature. The operating results presented in these financial statements are not necessarily indicative of the results that may be expected for any future periods.
XML 24 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

2.

Summary of Significant Accounting Policies

Use of Estimates

The Company’s financial statements are prepared in accordance with GAAP, which requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to revenue recognition, stock-based compensation, and accrued research and development costs. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents include cash in readily available checking and money market accounts. Restricted cash represents cash held as collateral for the letter of credit required under the Company’s facility lease and is reported as a long-term asset in the accompanying balance sheets.

Marketable Securities

The Company’s marketable securities consist of corporate debt securities. The Company classifies its marketable securities as available-for-sale and records such assets at estimated fair value in the balance sheets, with unrealized gains and losses, if any, reported as a component of other comprehensive income (loss) within the statements of operations and comprehensive loss and as a separate component of stockholders’ equity. The Company classifies marketable securities with remaining maturities greater than one year as current assets because such marketable securities are available to fund the Company’s current operations. Realized gains and losses are calculated on the specific identification method and recorded as interest income. There were no realized gains and losses for the years ended December 31, 2021, 2020 and 2019.

At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. When the Company determines that a decline in the fair value below its cost basis is other-than-temporary, the Company recognizes an impairment loss in the period in which the other-than-temporary decline occurred. There have been no other-than-temporary impairments recognized for the years ended December 31, 2021, 2020 and 2019.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments, credit quality, diversification, liquidity and maturities of investments, which are designed to maintain safety and liquidity.

Fair Value of Financial Instruments

Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:

 

•

Level 1—Quoted prices in active markets for identical assets or liabilities.

 

•

Level 2—Observable inputs, such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.

 

•

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

None of the Company’s non-financial assets are recorded at fair value on a non-recurring basis. The carrying amounts reflected in the Company’s balance sheets for prepaid and other assets and accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The carrying value of the Company’s previously outstanding debt approximated fair value due to the interest being reflective of then-current market rates for debt with similar terms and conditions. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. No transfers between levels have occurred during the periods presented.

See Note 3 (Fair Value Measurements) for information on assets and liabilities measured at fair value.

Property and Equipment

Property and equipment, including leasehold improvements, are stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recorded using the straight-line method over the estimated useful lives of the related assets, which ranges from three to five years. Leasehold improvements are amortized on a straight-line basis over the shorter of the estimated useful lives of the assets or the remaining lease term. Repairs and maintenance charges that do not increase the useful life of the assets are charged to operating expenses as incurred.

Impairment of Long-Lived Assets

Long-lived assets consist of property and equipment. An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. The Company has not recognized any impairment losses in any of the periods presented in these financial statements.

Segment Information

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by management in making decisions regarding resource allocation and assessing performance. The Company manages its operations as a single operating segment in the United States for the purposes of assessing performance and making operating decisions.

Revenue Recognition

To date, all the Company’s revenue has been derived from collaboration and research agreements. The terms of these arrangements include the following types of payments to the Company: non-refundable, upfront license fees; development, regulatory and commercial milestone payments; payments for research and development services provided by the Company or for manufacturing supply services the Company provides through its contract manufacturers; and royalties on net sales of licensed products.

Effective January 1, 2019, the Company adopted Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, using the modified retrospective approach. This new standard requires a company to recognize revenues when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. An adjustment to retained earnings was not required upon adoption as the Company had no revenue generating agreements in effect on the date of adoption.

In accordance with Topic 606, the Company performs the following steps in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of these agreements: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as, the Company satisfies each performance obligation.

The Company receives payments from its collaborators based on billing schedules established in each contract. Upfront and other payments may require deferral of revenue recognition to a future period until the Company performs its obligations under its research and collaboration arrangements. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional.

See Note 5 (Collaboration, License and Research Agreements) for further information.

Research and Development Costs

Research and development costs are expensed as incurred and include salaries, benefits and stock-based compensation associated with research and development personnel, third-party research and development expenses, license fees, laboratory supplies, facilities, overhead costs, and consultants. Nonrefundable advance payments for goods and services that will be used in future research and development activities are capitalized and recorded as expense in the period that the Company receives the goods or when services are performed.

Upfront and milestone payments to acquire contractual rights to licensed technology are recorded when incurred if there is uncertainty in the Company receiving future economic benefit from the acquired contractual rights.

Patent Costs

Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.

Income Taxes

The Company accounts for income taxes in accordance with Accounting Standards Codification (ASC) 740, Income Taxes, which provides for deferred taxes using the asset and liability method. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.

The Company is subject to taxation in the United States and various state jurisdictions. As of December 31, 2021, the Company’s tax years since conversion to a corporation in 2019 are subject to examination by taxing authorities.

Stock-Based Compensation

Stock-based compensation expense for employee and non-employee stock option grants is recorded at the estimated fair value of the award as of the grant date and is recognized as expense on a straight-line basis over the requisite service period (usually the vesting period) of the stock-based award, and forfeitures are recognized as incurred. Stock-based compensation expense for employee stock purchases under the Company’s Employee Stock Purchase Plan (the ESPP) is recorded at the estimated fair value of the purchase as of the plan enrollment date and is recognized as expense on a straight-line basis over the applicable six-month ESPP offering period. The estimation of fair value for stock-based compensation requires management to make estimates and judgments about, among other things, the estimated life of options and volatility of the Company’s common stock. The judgments directly affect the amount of compensation expense that will be recognized.

Comprehensive Loss

Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on marketable securities. Comprehensive gains (losses) have been reflected in the statements of operations and comprehensive loss for all periods presented.

Net Loss Per Share/Unit

Basic net loss per share/unit is computed by dividing the net loss by the weighted-average number of common shares/units outstanding for the period, adjusted for the weighted-average number of common shares/units outstanding that are subject to repurchase or forfeiture. The Company has excluded 33,600, 123,285 and 217,524 weighted-average shares/units subject to repurchase or forfeiture from the weighted-average number of common shares/units outstanding for the years ended December 31, 2021, 2020 and 2019, respectively. Diluted net loss per share/unit is computed by dividing the net loss by the weighted-average number of common shares/units and dilutive common stock/unit equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For all periods presented, there is no difference in the number of shares/units used to calculate basic and diluted shares/units outstanding as inclusion of the potentially dilutive securities would be anti-dilutive.

Potentially dilutive securities not included in the calculation of diluted net loss per share/unit, because to do so would be anti-dilutive, are as follows (in common stock/unit equivalent shares; in thousands):

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Convertible preferred stock

 

 

—

 

 

 

—

 

 

 

17,666

 

Warrant to purchase convertible preferred stock

 

 

—

 

 

 

—

 

 

 

8

 

Warrant to purchase common stock

 

 

—

 

 

 

—

 

 

 

9

 

Common stock options issued and outstanding

 

 

5,778

 

 

 

3,788

 

 

 

1,667

 

Common stock subject to repurchase or

   forfeiture

 

 

15

 

 

 

69

 

 

 

195

 

ESPP shares pending issuance

 

 

3

 

 

 

1

 

 

 

—

 

Total

 

 

5,796

 

 

 

3,858

 

 

 

19,545

 

 

Recently Adopted Accounting Pronouncements

In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing certain separation models required under existing guidance. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and amends the diluted earnings-per-share (EPS) calculation guidance in certain areas to improve the consistency of EPS calculations. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020. The Company early adopted the new standard, effective January 1, 2021, on a modified retrospective basis. The adoption of ASU 2020-06 had no impact on the Company's financial statements and related disclosures.

Recently Issued Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. The Company

believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.
XML 25 R10.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements
 12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements

3.

Fair Value Measurements

The Company determines the fair value of its cash equivalents and marketable securities based on one or more valuations from its investment accounting and reporting service provider. The investment service provider values the securities using a hierarchical security pricing model that relies primarily on valuations provided by an industry-recognized valuation service. Such valuations may be based on trade prices in active markets for identical assets (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets, yield curves, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, and broker and dealer quotes, as well as other relevant economic measures.

The following tables summarize the Company’s cash equivalents and marketable securities measured at fair value (in thousands):

 

 

 

 

 

 

 

Fair Value Measurements Using

 

As of December 31, 2021

 

Total

 

 

Quoted Prices in

Active Markets

for Identical

Assets (Level 1)

 

 

Significant

Other

Observable

Inputs (Level 2)

 

 

Significant

Unobservable

Inputs

(Level 3)

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

$

65,372

 

 

$

65,372

 

 

$

—

 

 

$

—

 

Negotiable certificates of deposit

 

 

3,873

 

 

 

—

 

 

 

3,873

 

 

 

—

 

Corporate debt securities

 

 

15,850

 

 

 

—

 

 

 

15,850

 

 

 

—

 

Total

 

$

85,095

 

 

$

65,372

 

 

$

19,723

 

 

$

—

 

 

 

 

 

 

 

 

Fair Value Measurements Using

 

As of December 31, 2020

 

Total

 

 

Quoted Prices in

Active Markets

for Identical

Assets (Level 1)

 

 

Significant

Other

Observable

Inputs (Level 2)

 

 

Significant

Unobservable

Inputs

(Level 3)

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Negotiable certificates of deposit

 

$

720

 

 

$

—

 

 

$

720

 

 

$

—

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

 

6,679

 

 

 

—

 

 

 

6,679

 

 

 

—

 

Total

 

$

7,399

 

 

$

—

 

 

$

7,399

 

 

$

—

 

Prior to completion of the IPO in June 2020, the Company had an outstanding warrant to purchase shares of its Series A convertible preferred stock. Since the underlying Series A convertible preferred stock was classified outside of permanent equity, the preferred stock warrant was classified as other long-term liabilities in the accompanying balance sheet. The preferred stock warrant liability was recorded at fair value utilizing the Black-Scholes model using significant unobservable inputs adjusted for the preferred stock warrant’s expected life and the fair value of the underlying convertible preferred stock. The Company adjusted the carrying value of the preferred stock warrant to its estimated fair value at each reporting date, with any related increase or decrease in the fair value recorded as an increase or decrease to other income (expense) in the statements of operations and comprehensive loss. In connection with the IPO, the preferred stock warrant was adjusted to become a warrant to purchase shares of the Company’s common stock and met the criteria to be classified within stockholders’ equity. Accordingly, the fair value of the warrant liability was reclassified to stockholders’ equity.

The following table provides a reconciliation of the preferred stock warrant liability measured at fair value using Level 3 unobservable inputs (in thousands):

 

Balance at December 31, 2018

 

$

30

 

Change in fair value

 

 

15

 

Balance at December 31, 2019

 

 

45

 

Change in fair value

 

 

75

 

Reclassification of warrant liability

   to stockholders’ equity

 

 

(120

)

Balance at December 31, 2020

 

$

—

 

 
XML 26 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
Marketable Securities
 12 Months Ended
Dec. 31, 2021
Investments Debt And Equity Securities [Abstract]  
Marketable Securities

4.

Marketable Securities

The Company’s marketable securities, which consist of highly liquid marketable debt securities, are classified as available-for-sale and are stated at fair value. The following tables summarize the Company’s marketable securities (in thousands):

 

As of December 31, 2021

 

Maturity

(in years)

 

Amortized

Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Estimated

Fair Value

 

U.S. Treasury securities

 

1 or less

 

$

2,492

 

 

$

—

 

 

$

(1

)

 

$

2,491

 

Negotiable certificates of deposit

 

1 or less

 

 

1,190

 

 

 

—

 

 

 

(1

)

 

 

1,189

 

U.S. Treasury securities

 

1 - 2

 

 

63,034

 

 

 

—

 

 

 

(153

)

 

 

62,881

 

Negotiable certificates of deposit

 

1 - 2

 

 

2,687

 

 

 

—

 

 

 

(3

)

 

 

2,684

 

Corporate debt securities

 

1 - 2

 

 

15,879

 

 

 

—

 

 

 

(29

)

 

 

15,850

 

Total

 

 

 

$

85,282

 

 

$

—

 

 

$

(187

)

 

$

85,095

 

 

As of December 31, 2020

 

Maturity

(in years)

 

Amortized

Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Estimated

Fair Value

 

Corporate debt securities

 

1 or less

 

$

3,612

 

 

$

—

 

 

$

(2

)

 

$

3,610

 

Corporate debt securities

 

1 - 2

 

 

3,072

 

 

 

—

 

 

 

(3

)

 

 

3,069

 

Total

 

 

 

$

6,684

 

 

$

—

 

 

$

(5

)

 

$

6,679

 

 
XML 27 R12.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaboration, License and Research Agreements
 12 Months Ended
Dec. 31, 2021
Collaboration License And Research Agreements [Abstract]  
Collaboration, License and Research Agreements

5.

Collaboration, License and Research Agreements

Research Collaboration and License Agreement with Eli Lilly and Company

In April 2019, the Company entered into a Research Collaboration and License Agreement (the Lilly Agreement) with Eli Lilly and Company (Lilly) for the discovery, development and commercialization of AOC products directed against certain targets in immunology and other select indications on a worldwide basis. Under the Lilly Agreement, the Company granted Lilly an exclusive, worldwide, royalty-bearing license, with the right to sublicense (subject to certain conditions), under the Company’s technology to research, develop, manufacture and sell products containing AOCs that are directed to up to six mRNA targets. The Company retains the right to use its technology to perform its obligations under the Lilly Agreement and for all purposes not granted to Lilly. The Company agreed that it will not, itself or with a third party, research, develop, manufacture or commercialize or otherwise exploit any compound or product directed against targets subject to the Lilly Agreement.

In consideration of the rights granted to Lilly under the Lilly Agreement, the Company received a one-time upfront fee of $20.0 million and is eligible to receive up to $60.0 million in development milestone payments, up to $140.0 million in regulatory milestone payments and up to $205.0 million in commercialization milestone payments per target. In addition, Lilly is obligated to reimburse the Company for research expenses, as defined in and incurred under the Lilly Agreement. Lilly is obligated to pay the Company a tiered royalty ranging from the mid-single to low-double digits on worldwide annual net sales of licensed products, subject to specified and capped reductions for the market entry of biosimilar products, loss of patent coverage of licensed products and for payments owed to third parties for additional rights necessary to commercialize licensed products in the territory. Lilly’s royalty obligations and the Lilly

Agreement will expire on a licensed product-by-licensed product and country-by-country basis on the later of ten years from the date of the first commercial sale or when there is no longer a valid patent claim covering such licensed product in such country.

The Company has identified multiple promises to deliver goods and services, which include at inception of the agreement: (i) a license to technology and patents, information and know-how; and (ii) collaboration, including research services, technical and regulatory support provided by the Company. At inception and through December 31, 2021, the Company has identified one performance obligation for all the deliverables under the Lilly Agreement since the delivered elements are either not capable of being distinct or are not distinct within the context of the contract. Accordingly, the Company will recognize revenue for the fixed or determinable collaboration in an amount proportional to the collaboration expenses incurred and the total estimated collaboration expenses over the five-year period over which it expects to deliver its performance obligations. The Company periodically reviews and updates the estimated collaboration expenses, when appropriate, which adjusts the percentage of revenue that is recognized for the period. In connection with the Lilly Agreement, the Company recognized revenue of $9.1 million, $6.8 million and $2.3 million for the years ended December 31, 2021, 2020 and 2019, respectively, and had deferred revenue of $11.1 million and $15.8 million as of December 31, 2021 and 2020, respectively. Collaboration receivables related to the Lilly Agreement were $0.9 million and $1.2 million as of December 31, 2021 and 2020, respectively, which are included in prepaid and other assets on the balance sheets.

A reconciliation of the closing balance of deferred revenue related to the Lilly Agreement is as follows (in thousands):

 

Balance at December 31, 2019

 

$

18,940

 

Revenue recognized

 

 

(3,100

)

Balance at December 31, 2020

 

 

15,840

 

Revenue recognized

 

 

(4,732

)

Balance at December 31, 2021

 

$

11,108

 

 

Concurrently with the execution of the Lilly Agreement, the Company issued a convertible promissory note to Lilly (the Lilly Note). In connection with the Series C financing in November 2019, all outstanding principal and interest accrued under the Lilly Note converted into 4,576,342 shares of Series C convertible preferred stock. See Note 8 (Convertible Notes) for further discussion.

Research Agreement with MyoKardia, Inc.

In December 2020, the Company entered into a research collaboration (the MyoKardia Agreement) with MyoKardia, Inc. (MyoKardia), a wholly-owned subsidiary of Bristol Myers Squibb, to demonstrate the potential utility of AOCs in cardiac tissue by leveraging MyoKardia’s genetic cardiomyopathy platform including, among other aspects, its novel target discovery engine and proprietary cardiac disease models. In connection with the MyoKardia Agreement, the Company recognized revenue of $0.2 million and $0 for the years ended December 31, 2021 and 2020, respectively.
XML 28 R13.htm IDEA: XBRL DOCUMENT v3.22.0.1
Property and Equipment
 12 Months Ended
Dec. 31, 2021
Property Plant And Equipment [Abstract]  
Property and Equipment

6.

Property and Equipment

Property and equipment consist of the following (in thousands):

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Laboratory equipment

 

$

4,775

 

 

$

2,928

 

Computers and software

 

 

116

 

 

 

58

 

Office furniture and equipment

 

 

1,398

 

 

 

44

 

Leasehold improvements

 

 

249

 

 

 

417

 

Property and equipment, gross

 

 

6,538

 

 

 

3,447

 

Less accumulated depreciation

 

 

(1,733

)

 

 

(1,979

)

Total property and equipment, net

 

$

4,805

 

 

$

1,468

 

 

Depreciation expense related to property and equipment was $0.6 million, $0.4 million and $0.3 million for the years ended December 31, 2021, 2020 and 2019, respectively.
XML 29 R14.htm IDEA: XBRL DOCUMENT v3.22.0.1
Debt
 12 Months Ended
Dec. 31, 2021
Debt Disclosure [Abstract]  
Debt

7.

Debt

Term Loan

In June 2017, the Company entered into an amendment (the LSA Amendment) to the Amended and Restated Loan and Security Agreement (as amended, the LSA) with Silicon Valley Bank (SVB). Pursuant to the LSA Amendment, SVB agreed to make loans of up to $7.0 million, comprising (i) a $5.0 million term loan, funded at the closing date (the Term C Loan), and (ii) subject to the achievement of a specified milestone relating to the Company’s research, an additional term loan totaling up to $2.0 million (the Term D Loan), of which $4.1 million was used to repay the Company’s existing loan with SVB, in addition to the final payments totaling $0.4 million.

The Term C Loan was scheduled to mature on June 1, 2021 and bore interest at an adjustable annual rate of the prime rate per the Wall Street Journal plus one-fifth of one percent (0.20%). The LSA Amendment provided an extension of the interest only period through June 1, 2019, upon the Term D Loan advance. Beginning July 1, 2019, the Company was required to repay the principal amount in 36 equal monthly installments, in addition to the monthly interest payment. In addition, a final payment of 6.5% of the funded amount, or $0.3 million, was due on the maturity date. The final payment fee was accrued as interest expense over the term of the loan and recorded in long-term debt, net of current portion.

In August 2018, the Company entered into a second amendment to the LSA (the LSA Second Amendment). Pursuant to the LSA Second Amendment, SVB provided the Term D Loan of $2.0 million, upon the Company’s receipt of $3.0 million in convertible note financing. In addition, a final payment of 6.5% of the funded amount, or $0.1 million, was due on the maturity date. The Company accounted for the financing prospectively as a debt modification.  

On June 30, 2020, the Company voluntarily prepaid the aggregate outstanding principal balance of $2.8 million and final payments and accrued interest of $0.5 million related to the Term C and Term D Loans, and the LSA was terminated.

In conjunction with the Term A and Term B Loans, the Company issued a warrant to SVB to purchase up to 16,474 shares of Series A convertible preferred stock at an exercise price of $2.2615 per share, exercisable at any time following the issuance, with a term of ten years. In connection with the completion of the IPO in June 2020, the preferred stock warrant was adjusted to become a warrant exercisable for 7,809 shares of common stock at an exercise price of $4.77 per share. In conjunction with the Term C Loan entered into in June 2017, the Company issued a warrant to SVB to purchase up to 9,442 shares of common stock at an exercise price of $0.53 per share, exercisable at any time following the issuance, with a term of seven years. The Company estimated the fair value of the warrants granted using the Black-Scholes model and recorded the fair value as debt discounts, which were being amortized to interest expense using the

effective interest method over the term of the loans. On June 17, 2020, the warrants were cashless exercised for an aggregate of 15,833 shares of common stock.
XML 30 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1
Convertible Notes
 12 Months Ended
Dec. 31, 2021
Debt Disclosure [Abstract]  
Convertible Notes

8.

Convertible Notes

In 2018 and 2019, the Company issued convertible promissory notes in the aggregate principal amount of $3.0 million and $4.5 million, respectively (the 2018 Notes and 2019 Notes, respectively). The 2018 Notes and the 2019 Notes accrued interest at 8% and 10% per annum, respectively, and automatically converted into preferred equity in the next qualified financing of at least $10 million at 85% and 80%, respectively, of the per share price paid by the investors in such financing.

Concurrently with the execution of the Lilly Agreement in April 2019, the Company issued the Lilly Note and received cash proceeds of $15.0 million. The Lilly Note accrued simple interest of 8.0% per annum and, if not converted, would have matured in October 2020. All unpaid principal and interest were due at maturity.

The 2018 Notes, 2019 Notes and the Lilly Note (collectively, the Notes) represented share settled debt that were accounted for at amortized cost by accreting the Notes to their redemption value over the life of the debt using the effective interest method.  In connection with the Series C financing in November 2019, all outstanding principal and interest accrued under the Notes converted into 6,893,036 shares of Series C convertible preferred stock. The Company recorded interest expense of $6.9 million for the year ended December 31, 2019 for the stated interest rate and the discount at which the Notes converted.
XML 31 R16.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]  
Commitments and Contingencies

9.

Commitments and Contingencies

Lease Agreements

The Company adopted ASC 842, Leases, as of January 1, 2019. In accordance with ASC 842, the Company determines if an arrangement is a finance lease, operating lease or short-term lease at inception, or as applicable, and accounts for the arrangement under the relevant accounting literature. During the periods presented, the Company was party to various non-cancellable office and laboratory space operating leases and short-term leases. Currently, the Company is only party to a non-cancellable office and laboratory space operating lease. Under the relevant guidance, the Company recognizes operating lease right-of-use (ROU) assets and liabilities based on the present value of the future minimum lease payments over the lease term at the commencement date, using the Company’s assumed incremental borrowing rate of 5.5%, and amortizes the ROU assets and liabilities over the lease term. Lease expense for operating leases is recognized on a straight-line basis over the lease term. The Company’s short-term leases are not subject to recognition of an ROU asset or liability or straight-line lease expense requirements.

In March 2014, the Company entered into a non-cancellable operating lease for office and laboratory space with a lease term through November 2017. In July 2017, the Company entered into an amendment to this lease to extend the lease term through December 2021.

On June 1, 2020, the Company entered into a second amendment to its existing operating lease (as amended, the 2014 Lease) and entered into a new non-cancellable temporary operating lease in connection with a newly executed non-cancellable operating lease for its new headquarters location, with a projected commencement date of July 1, 2021.

On December 18, 2020, the Company entered into an amendment to the non-cancellable operating lease for its new headquarters location (as amended, the New Lease), which increased the square footage by adding adjacent space and extended the projected commencement date to November 1, 2021. Additionally, the non-cancellable temporary operating lease was amended (as amended, the Temporary Lease) to accommodate the projected commencement date of the New Lease. The lease term under both the 2014 Lease and the Temporary Lease ends 15 days after the commencement date of the New Lease in November 2021. The remaining monthly rental payments under the 2014 Lease and the rent under the Temporary Lease were abated beginning on June 1, 2020, given the execution of the New Lease. The New

Lease has a five-year term upon commencement in November 2021 and a renewal option for an additional five years. Under the terms of the New Lease, the initial monthly base rent of approximately $251,000 will increase to approximately $282,000 during the last year of the New Lease's initial term, and the first year includes five months of rent abatement. The total lease payments under the initial term of the New Lease of $14.7 million were allocated amongst the 2014 Lease, Temporary Lease and New Lease based on the relative standalone price of the separate lease components. Furthermore, pursuant to the terms of the New Lease, the Company is required to maintain a letter of credit totaling $251,000 throughout the lease term.

In June 2020, in accordance with the lease terms applicable at that time, the Company adjusted the ROU asset and liability of the 2014 Lease to conform to the modification terms and recorded an ROU asset and liability for the Temporary Lease upon occupancy. In December 2020, in connection with the lease amendments described above, the Company adjusted the ROU asset and liability of the 2014 Lease and Temporary Lease to conform to the modification terms. In November 2021, the Company recognized an ROU asset and liability related to the New Lease in connection with obtaining control of the asset upon occupancy of the new space.

As of December 31, 2021, the Company’s ROU assets and liabilities related to the New Lease are as follows (in thousands):

 

ROU assets

 

$

10,784

 

 

 

 

 

 

Lease liabilities, current portion

 

$

1,769

 

Lease liabilities, net of current portion

 

 

9,960

 

Total lease liabilities

 

$

11,729

 

 

As of December 31, 2021, maturities of the lease liabilities due under the New Lease are as follows (in thousands):

 

Year ending December 31,

 

 

 

 

2022

 

$

1,769

 

2023

 

 

3,113

 

2024

 

 

3,207

 

2025

 

 

3,303

 

2026

 

 

3,111

 

Total lease payments

 

 

14,503

 

Less imputed interest

 

 

(2,774

)

Total operating lease liabilities

 

 

11,729

 

Less lease liabilities, current portion

 

 

(1,769

)

Lease liabilities, net of current portion

 

$

9,960

 

 

Supplemental cash flow information related to cash paid for amounts included in the measurement of operating lease liabilities was as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Cash paid included in operating cash flows

 

$

234

 

 

$

163

 

 

$

382

 

 

 

Rent expense was as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Operating leases

 

$

946

 

 

$

453

 

 

$

302

 

Short-term leases

 

 

216

 

 

 

36

 

 

 

6

 

Total rent expense

 

$

1,162

 

 

$

489

 

 

$

308

 

 

As of December 31, 2021, the weighted-average remaining term of the Company’s operating lease was 4.9 years.

 

Litigation

Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. There are no matters currently outstanding for which any liabilities have been accrued.

Contractual Obligations

The Company enters into contracts in the normal course of business for contract research services, contract manufacturing services, professional services, and other services and products for operating purposes. These contracts may include certain provisions that could require payments for early termination. The amount of the termination payments vary depending on the timing of the termination and the specific terms of the contract.
XML 32 R17.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stockholders' Equity (Deficit)
 12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Stockholders' Equity (Deficit)

10.

Stockholders’ Equity (Deficit)

Amended and Restated Certificate of Incorporation

On June 16, 2020, the Company’s certificate of incorporation was amended and restated to authorize 400,000,000 shares of common stock and 40,000,000 shares of undesignated preferred stock, each with a par value of $0.0001 per share.

Common Stock

On June 16, 2020, the Company completed its IPO in which it sold 16,560,000 shares of common stock at an offering price of $18.00 per share. Proceeds from the IPO, net of underwriting discounts, commissions and offering costs, were $274.1 million.

On July 2, 2021, the Company entered into the Sales Agreement with the Sales Agent, under which the Company may, from time to time, sell shares of its common stock having an aggregate offering price of up to $150.0 million through the Sales Agent. Sales of the Company’s common stock made pursuant to the Sales Agreement are made under the Company’s shelf registration statement on Form S-3, which became automatically effective upon filing on July 2, 2021 (the Shelf Registration Statement). In addition, the Sales Agreement may be terminated by the Company or the Sales Agent at any time upon ten days’ notice to the other party, or by the Sales Agent, with respect to itself, at any time in certain circumstances, including the occurrence of a material adverse change. During the year ended December 31, 2021, the Company sold 780,549 shares of its common stock pursuant to the Sales Agreement and received net proceeds of $19.6 million, after deducting offering-related transaction costs and commissions.

On August 6, 2021, the Company completed a public offering of 9,200,000 shares of its common stock at a public offering price of $18.00 per share. The net proceeds from the offering were $155.1 million, after deducting underwriting discounts, commissions and offering costs. The shares sold in the offering were registered pursuant to the Company’s Shelf Registration Statement.

Conversion

On April 1, 2019, Avidity Biosciences LLC (Avidity LLC), a Delaware limited liability company, was converted into Avidity Biosciences, Inc., a Delaware corporation. The entire membership interests of Avidity LLC were converted into securities of Avidity Biosciences, Inc. as follows: (i) each outstanding common unit of Avidity LLC was converted into one share of Avidity Biosciences, Inc.’s common stock; (ii) each outstanding Series A convertible preferred unit of Avidity LLC converted into one share of Avidity Biosciences, Inc.’s Series A convertible preferred stock; and (iii) each outstanding Series B convertible preferred unit of Avidity LLC converted into one share of Avidity Biosciences, Inc.’s Series B convertible preferred stock. All the property, rights, privileges, powers and franchises of Avidity LLC vested in Avidity Biosciences, Inc., and all debts, liabilities and duties of Avidity LLC became debts, liabilities and duties of Avidity Biosciences, Inc. All references to the former members’ equity accounts in Avidity LLC have been adjusted to reflect the equivalent number of Avidity Biosciences, Inc.’s shares of common stock. Upon completion of the conversion, the Company reclassified an accumulated deficit of $44.1 million from predecessor deficit to additional paid-in capital.

Convertible Preferred Stock

In November 2019, the Company issued 17,915,525 shares of Series C convertible preferred stock, for cash, at a price of $4.2812 per share, for net proceeds of $72.6 million, net of issuance costs of $4.1 million. In addition, all outstanding principal and accrued interest under the Notes were automatically converted into 6,893,036 shares of Series C convertible preferred stock, at a stated discount pursuant to the original terms of the notes at issuance. In January 2020, the Company issued an additional 537,232 shares of Series C convertible preferred stock, for cash, at a price of $4.2812 per share, for net proceeds of $2.2 million, net of issuance costs of $100,000.

In connection with the completion of the IPO in June 2020, all of the outstanding shares of convertible preferred stock were converted into 17,921,069 shares of the Company’s common stock. Prior to conversion, the Company’s convertible preferred stock was classified as temporary equity in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities whose redemption is based upon certain change in control events outside of the Company’s control.

 

Equity Incentive Plans

In January 2013, the Company adopted the 2013 Equity Incentive Plan (the 2013 Plan). The 2013 Plan provided for the issuance of incentive units to employees and nonemployees of the Company and non‑statutory unit options, restricted unit awards, unit appreciation rights, and unit bonuses to directors, employees and consultants of the Company. Under the 2013 Plan, 2,127,013 units were initially reserved for issuance. Upon the conversion of the Company to a C corporation, the 2013 Plan continued on the same terms and conditions. In 2019, the number of shares reserved under the 2013 Plan was increased to 4,771,615 shares.

In June 2020, the Company’s board of directors adopted, and the Company’s stockholders approved, the 2020 Incentive Award Plan (the 2020 Plan), which became effective in connection with the IPO. Pursuant to the 2020 Plan, the Company ceased granting awards under the 2013 Plan. Under the 2020 Plan, the Company may grant stock options, restricted stock, dividend equivalents, restricted stock units, stock appreciation rights, and other stock or cash-based awards to individuals who are then employees, officers, non-employee directors or consultants of the Company. A total of 3,900,000 shares of common stock were initially reserved for issuance under the 2020 Plan. In addition, the number of shares of common stock available for issuance under the 2020 Plan will be increased annually on the first day of each fiscal year during the term of the 2020 Plan, beginning with the 2021 fiscal year, by an amount equal to the lesser

of (a) 5% of the shares of common stock outstanding on the final day of the immediately preceding calendar year or (b) such smaller number of shares as determined by the Company’s board of directors. At December 31, 2021, 2,574,824 shares remain available for issuance under the 2020 Plan.

Stock Options

Options granted from the 2013 Plan and 2020 Plan are exercisable at various dates and will expire no more than ten years from their date of grant. Options generally vest over a four-year period. Prior to the IPO, the exercise price of options was determined by the Company’s board of directors. Following the IPO, the Company grants options with an exercise price equal to the fair market value of the Company’s stock on the date of the option grant.

Stock option activity for employee and nonemployee awards and related information is as follows (in thousands, except per share and contractual term data):

 

 

 

Number of

Options

 

 

Weighted-

Average

Exercise

Price Per

Share

 

 

Weighted-

Average

Remaining

Contractual

Term

(in years)

 

 

Aggregate

Intrinsic

Value

 

Outstanding at December 31, 2020

 

 

3,788

 

 

$

9.06

 

 

 

 

 

 

 

 

 

Granted

 

 

2,671

 

 

 

23.23

 

 

 

 

 

 

 

 

 

Exercised

 

 

(172

)

 

 

5.42

 

 

 

 

 

 

 

 

 

Forfeited/expired

 

 

(509

)

 

 

22.99

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2021

 

 

5,778

 

 

$

14.49

 

 

 

8.5

 

 

$

58,950

 

Vested and expected to vest at

    December 31, 2021

 

 

5,778

 

 

$

14.49

 

 

 

8.5

 

 

$

58,950

 

Exercisable at December 31, 2021

 

 

1,885

 

 

$

8.91

 

 

 

7.8

 

 

$

29,226

 

 

The aggregate intrinsic values presented in the table above were calculated as the difference between the closing price of the Company’s common stock at December 31, 2021 and the exercise price of stock options that had strike prices below the closing price. The total intrinsic value of options exercised during the years ended December 31, 2021, 2020 and 2019 were $3.4 million, $0.5 million and $7,000, respectively. The total intrinsic values of options exercised were calculated as the difference between the fair value of the Company’s common stock/units at the time of the option exercise and the exercise price of that stock/unit option.

The weighted-average grant date fair value of options granted during the years ended December 31, 2021, 2020 and 2019 were $16.78, $11.63 and $3.46 per share/unit, respectively.

As of December 31, 2021 and 2020, 15,288 and 69,359, respectively, of the stock options exercised were unvested and subject to repurchase.

Employee Stock Purchase Plan

In June 2020, the Company adopted the ESPP, which permits participants to contribute up to 15% of their eligible compensation during defined rolling six-month periods to purchase the Company’s common stock. The purchase price of the shares will be 85% of the lower of the fair market value of the Company’s common stock on the first day of trading of the offering period or on the applicable purchase date. The Company issued 33,147 and 28,979 shares of common stock under the ESPP during the years ended December 31, 2021 and 2020, respectively. The Company had an outstanding liability of $53,000 at December 31, 2021, which is included in accounts payable and accrued liabilities on the balance sheet, for employee contributions to the ESPP for shares pending issuance at the end of the offering period. As of December 31, 2021, 638,563 shares of common stock were available for issuance under the ESPP.

Stock-Based Compensation Expense

The assumptions used in the Black-Scholes model to determine the fair value of stock/unit option grants and shares purchasable under the ESPP were as follows:

 

 

 

Year Ended December 31,

Stock/Unit Option Grants

 

2021

 

2020

 

2019

Risk-free interest rate

 

0.5% - 1.3%

 

0.3% - 1.5%

 

1.4% - 2.7%

Expected volatility

 

86% - 88%

 

88% - 92%

 

84% - 88%

Expected term (in years)

 

5.5 - 6.1

 

5.4 - 6.1

 

2.0 - 6.1

Expected dividend yield

 

—%

 

—%

 

—%

 

 

 

Year Ended December 31,

ESPP

 

2021

 

 

2020

 

2019

Risk-free interest rate

 

0.1%

 

 

0.1% - 0.2%

 

N/A

Expected volatility

 

69% - 75%

 

 

75% - 96%

 

N/A

Expected term (in years)

 

0.5

 

 

0.5

 

N/A

Expected dividend yield

 

—%

 

 

—%

 

N/A

 

Risk-Free Interest Rate. The Company bases the risk-free interest rate assumption for equity awards on the rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued.

Expected Volatility. Due to the limited trading history of the Company’s common stock, the expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology industry. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.

Expected Term. Due to its limited option exercise history not providing a reasonable basis for estimating expected term, the Company has estimated the expected life of its stock options using the simplified method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The expected life assumption for employee stock purchases under the ESPP is six months to conform with the six-month ESPP offering period.

Expected Dividend Yield. The Company’s expected dividend yield assumption is zero as it has never paid dividends and has no present intention to do so in the future.

The allocation of stock-based compensation expense was as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Research and development expense

 

$

9,228

 

 

$

1,895

 

 

$

84

 

General and administrative expense

 

 

7,828

 

 

 

2,415

 

 

 

322

 

Total stock-based compensation expense

 

$

17,056

 

 

$

4,310

 

 

$

406

 

 

As of December 31, 2021, the unrecognized compensation cost related to outstanding time-based options was $46.9 million, which is expected to be recognized over a weighted-average period of 2.6 years. As of December 31, 2021, the unrecognized compensation cost related to stock purchase rights under the ESPP was $0.2 million, which is expected to be recognized over a weighted-average period of 0.5 years.

Common Stock Reserved for Future Issuance

Common stock reserved for future issuance consisted of the following (in thousands):

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Common stock options issued and outstanding

 

 

5,778

 

 

 

3,788

 

Equity awards available for future issuance

   under equity plans

 

 

2,575

 

 

 

2,852

 

Common stock authorized under the ESPP

 

 

639

 

 

 

296

 

Total

 

 

8,992

 

 

 

6,936

 

 
XML 33 R18.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Income Taxes

11.

Income Taxes

The Company operated as a nontaxable partnership until its conversion on March 31, 2019. The Company had deferred tax assets in existence on March 31, 2019 when the Company became a taxable entity. Deferred tax assets were not recognized due to the uncertainty that such assets will be realized. The Company retained the valuation allowance on the deferred tax assets at December 31, 2019.

No provision for income taxes was recorded for the years ended December 31, 2021, 2020 and 2019.

A reconciliation of income taxes to the amount computed by applying the statutory federal income tax rate to the net loss is summarized as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Income tax expense (benefit) at statutory rates

 

$

(24,784

)

 

$

(9,315

)

 

$

(5,194

)

State income tax, net of federal benefit

 

 

(7,868

)

 

 

(3,004

)

 

 

(1,057

)

Permanent items

 

 

210

 

 

 

1

 

 

 

14

 

Book income for pre-conversion period

 

 

—

 

 

 

—

 

 

 

527

 

Interest on convertible notes

 

 

—

 

 

 

—

 

 

 

445

 

Realized gain on conversion of convertible notes

 

 

—

 

 

 

—

 

 

 

958

 

Reserve for uncertain tax positions

 

 

1,170

 

 

 

398

 

 

 

140

 

Research and development tax credits

 

 

(4,792

)

 

 

(1,639

)

 

 

(584

)

Deferred taxes recognized upon conversion

 

 

—

 

 

 

—

 

 

 

(3,076

)

Valuation allowance

 

 

35,326

 

 

 

13,488

 

 

 

7,827

 

Other

 

 

738

 

 

 

71

 

 

 

—

 

Income tax expense (benefit)

 

$

—

 

 

$

—

 

 

$

—

 

 

 

Significant components of the Company’s deferred tax assets as of December 31, 2021 and 2020 are shown below (in thousands):

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Deferred tax assets:

 

 

 

 

 

 

 

 

Net operating loss carryforwards

 

$

41,443

 

 

$

11,277

 

Research and development tax credits

 

 

5,586

 

 

 

1,855

 

Deferred revenue

 

 

3,117

 

 

 

4,443

 

Accrued expenses

 

 

477

 

 

 

153

 

Intangibles and fixed assets

 

 

2,137

 

 

 

2,483

 

Lease liability

 

 

3,291

 

 

 

263

 

Stock-based compensation

 

 

3,668

 

 

 

969

 

Total deferred tax assets

 

 

59,719

 

 

 

21,443

 

Less valuation allowance

 

 

(56,693

)

 

 

(21,316

)

Net deferred tax assets

 

 

3,026

 

 

 

127

 

Deferred tax liabilities:

 

 

 

 

 

 

 

 

Right-of-use asset

 

 

(3,026

)

 

 

(127

)

Total deferred tax liabilities

 

 

(3,026

)

 

 

(127

)

Net deferred tax assets

 

$

—

 

 

$

—

 

 

The Company has established a full valuation allowance against its net deferred tax assets due to the uncertainty that such assets will be realized. The Company periodically evaluates the recoverability of the deferred tax assets. At such time as it is determined that it is more likely than not that the deferred tax assets will be realizable, the valuation allowance will be released. The change in the valuation allowance was an increase of $35.4 million and $13.5 million for the years ended December 31, 2021 and 2020, respectively.

At December 31, 2021, the Company had federal and state net operating loss (NOL) carryforwards of $147.9 million and $147.7 million, respectively. On March 27, 2020, the CARES Act was signed into law in response to the economic challenges facing U.S. businesses. Under the CARES Act, the Internal Revenue Code of 1986, as amended (IRC) was amended to allow for federal NOLs to be carried back for five years to offset previous years’ income or carried forward indefinitely to offset 100% of taxable income for the tax year 2020 and 80% of taxable income for tax years 2021 and thereafter. The state NOLs begin to expire in 2039 unless previously utilized.

At December 31, 2021, the Company had federal and state research and development tax credits of $4.7 million and $2.6 million, respectively. The federal research and development tax credits begin to expire in 2039 unless previously utilized, and the state credits carry forward indefinitely. At December 31, 2021, the Company had federal orphan drug tax credits of $0.7 million, which begin to expire in 2041.

Pursuant to IRC Section 382 and Section 383, the Company’s ability to use NOL and R&D tax credit carryforwards (tax attribute carryforwards) to offset future taxable income is limited if the Company experiences a cumulative change in ownership of more than 50% within a three-year testing period. The Company has not completed an ownership change analysis pursuant to IRC Section 382. If ownership changes within the meaning of IRC Section 382 have occurred, the amount of remaining tax attribute carryforwards available to offset future taxable income and income taxes in future years may be significantly restricted or eliminated. Further, the Company’s deferred tax assets, along with the corresponding valuation allowance, associated with such tax attributes could be significantly reduced upon an ownership change within the meaning of IRC Section 382. Due to the existence of the valuation allowance, changes in the Company’s deferred tax assets from any such limitation will not impact the Company’s effective tax rate.

The following table summarizes the activity related to the Company’s gross unrecognized tax benefits for the years ended December 31, 2021 and 2020 (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Gross unrecognized tax benefits at the

   beginning of the year

 

$

671

 

 

$

156

 

Increases related to current year positions

 

 

1,283

 

 

 

446

 

Increases related to prior year positions

 

 

42

 

 

 

62

 

Other true up

 

 

—

 

 

 

7

 

Gross unrecognized tax benefits at the

   end of the year

 

$

1,996

 

 

$

671

 

The unrecognized tax benefit amounts are reflected in the determination of the Company’s deferred tax assets. If recognized, none of these amounts would affect the Company’s effective tax rate, since it would be offset by a corresponding adjustment to the deferred tax asset valuation allowance. The Company does not foresee material changes to its liability for uncertain tax benefits within the next twelve months.

The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties as of December 31, 2021 or 2020.

As of December 31, 2021, the Company’s tax years since conversion to a corporation in 2019 are subject to examination by U.S. federal and various state taxing authorities.
XML 34 R19.htm IDEA: XBRL DOCUMENT v3.22.0.1
COVID-19
 12 Months Ended
Dec. 31, 2021
Extraordinary And Unusual Items [Abstract]  
COVID-19

12.

COVID-19

The COVID-19 outbreak in the United States has caused significant business disruption. The extent of the impact of COVID-19 on the Company’s operational and financial performance will depend on certain developments, including the continued spread of COVID-19 and the measures taken by the governmental authorities, and its impact on the Company’s preclinical studies and clinical trials, employees and vendors, all of which are uncertain and cannot be predicted, particularly as the Company advances its product candidates into and through clinical development. In December 2021, the Company began to transition to a hybrid model with its employees generally working both remotely and onsite, and the Company anticipates it will continue to use this model going forward. To date, the Company has not experienced material disruptions in its business operations. However, a prolonged outbreak could have a material adverse impact on the financial results and business operations of the Company, including the timing and ability of the Company to complete certain clinical trials and other efforts required to advance the development of its product candidates and raise additional capital.
XML 35 R20.htm IDEA: XBRL DOCUMENT v3.22.0.1
Subsequent Events
 12 Months Ended
Dec. 31, 2021
Subsequent Events [Abstract]  
Subsequent Events

13.

Subsequent Events

From January 1, 2022 through March 1, 2022, the Company sold 1,100,000 shares of its common stock pursuant to the Sales Agreement and received net proceeds of $16.9 million, after deducting offering-related transaction costs and commissions.
XML 36 R21.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC). The financial statements reflect all adjustments which, in the opinion of management, are necessary for a fair statement of the results for the periods presented. All such adjustments are of a normal and recurring nature. The operating results presented in these financial statements are not necessarily indicative of the results that may be expected for any future periods.
Use of Estimates

Use of Estimates

The Company’s financial statements are prepared in accordance with GAAP, which requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to revenue recognition, stock-based compensation, and accrued research and development costs. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.
Cash, Cash Equivalents and Restricted Cash

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents include cash in readily available checking and money market accounts. Restricted cash represents cash held as collateral for the letter of credit required under the Company’s facility lease and is reported as a long-term asset in the accompanying balance sheets.
Marketable Securities

Marketable Securities

The Company’s marketable securities consist of corporate debt securities. The Company classifies its marketable securities as available-for-sale and records such assets at estimated fair value in the balance sheets, with unrealized gains and losses, if any, reported as a component of other comprehensive income (loss) within the statements of operations and comprehensive loss and as a separate component of stockholders’ equity. The Company classifies marketable securities with remaining maturities greater than one year as current assets because such marketable securities are available to fund the Company’s current operations. Realized gains and losses are calculated on the specific identification method and recorded as interest income. There were no realized gains and losses for the years ended December 31, 2021, 2020 and 2019.

At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. When the Company determines that a decline in the fair value below its cost basis is other-than-temporary, the Company recognizes an impairment loss in the period in which the other-than-temporary decline occurred. There have been no other-than-temporary impairments recognized for the years ended December 31, 2021, 2020 and 2019.
Concentration of Credit Risk

Concentration of Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments, credit quality, diversification, liquidity and maturities of investments, which are designed to maintain safety and liquidity.
Fair Value of Financial Instruments

Fair Value of Financial Instruments

Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:

 

•

Level 1—Quoted prices in active markets for identical assets or liabilities.

 

•

Level 2—Observable inputs, such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.

 

•

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

None of the Company’s non-financial assets are recorded at fair value on a non-recurring basis. The carrying amounts reflected in the Company’s balance sheets for prepaid and other assets and accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The carrying value of the Company’s previously outstanding debt approximated fair value due to the interest being reflective of then-current market rates for debt with similar terms and conditions. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. No transfers between levels have occurred during the periods presented.

See Note 3 (Fair Value Measurements) for information on assets and liabilities measured at fair value.
Property and Equipment

Property and Equipment

Property and equipment, including leasehold improvements, are stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recorded using the straight-line method over the estimated useful lives of the related assets, which ranges from three to five years. Leasehold improvements are amortized on a straight-line basis over the shorter of the estimated useful lives of the assets or the remaining lease term. Repairs and maintenance charges that do not increase the useful life of the assets are charged to operating expenses as incurred.
Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

Long-lived assets consist of property and equipment. An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. The Company has not recognized any impairment losses in any of the periods presented in these financial statements.
Segment Information

Segment Information

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by management in making decisions regarding resource allocation and assessing performance. The Company manages its operations as a single operating segment in the United States for the purposes of assessing performance and making operating decisions.

Revenue Recognition

Revenue Recognition

To date, all the Company’s revenue has been derived from collaboration and research agreements. The terms of these arrangements include the following types of payments to the Company: non-refundable, upfront license fees; development, regulatory and commercial milestone payments; payments for research and development services provided by the Company or for manufacturing supply services the Company provides through its contract manufacturers; and royalties on net sales of licensed products.

Effective January 1, 2019, the Company adopted Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, using the modified retrospective approach. This new standard requires a company to recognize revenues when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. An adjustment to retained earnings was not required upon adoption as the Company had no revenue generating agreements in effect on the date of adoption.

In accordance with Topic 606, the Company performs the following steps in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of these agreements: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as, the Company satisfies each performance obligation.

The Company receives payments from its collaborators based on billing schedules established in each contract. Upfront and other payments may require deferral of revenue recognition to a future period until the Company performs its obligations under its research and collaboration arrangements. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional.

See Note 5 (Collaboration, License and Research Agreements) for further information.

Research and Development Costs

Research and Development Costs

Research and development costs are expensed as incurred and include salaries, benefits and stock-based compensation associated with research and development personnel, third-party research and development expenses, license fees, laboratory supplies, facilities, overhead costs, and consultants. Nonrefundable advance payments for goods and services that will be used in future research and development activities are capitalized and recorded as expense in the period that the Company receives the goods or when services are performed.

Upfront and milestone payments to acquire contractual rights to licensed technology are recorded when incurred if there is uncertainty in the Company receiving future economic benefit from the acquired contractual rights.

Patent Costs

Patent Costs

Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.

Income Taxes

Income Taxes

The Company accounts for income taxes in accordance with Accounting Standards Codification (ASC) 740, Income Taxes, which provides for deferred taxes using the asset and liability method. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.

The Company is subject to taxation in the United States and various state jurisdictions. As of December 31, 2021, the Company’s tax years since conversion to a corporation in 2019 are subject to examination by taxing authorities.
Stock-Based Compensation

Stock-Based Compensation

Stock-based compensation expense for employee and non-employee stock option grants is recorded at the estimated fair value of the award as of the grant date and is recognized as expense on a straight-line basis over the requisite service period (usually the vesting period) of the stock-based award, and forfeitures are recognized as incurred. Stock-based compensation expense for employee stock purchases under the Company’s Employee Stock Purchase Plan (the ESPP) is recorded at the estimated fair value of the purchase as of the plan enrollment date and is recognized as expense on a straight-line basis over the applicable six-month ESPP offering period. The estimation of fair value for stock-based compensation requires management to make estimates and judgments about, among other things, the estimated life of options and volatility of the Company’s common stock. The judgments directly affect the amount of compensation expense that will be recognized.
Comprehensive Loss

Comprehensive Loss

Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on marketable securities. Comprehensive gains (losses) have been reflected in the statements of operations and comprehensive loss for all periods presented.
Net Loss Per Share/Unit

Net Loss Per Share/Unit

Basic net loss per share/unit is computed by dividing the net loss by the weighted-average number of common shares/units outstanding for the period, adjusted for the weighted-average number of common shares/units outstanding that are subject to repurchase or forfeiture. The Company has excluded 33,600, 123,285 and 217,524 weighted-average shares/units subject to repurchase or forfeiture from the weighted-average number of common shares/units outstanding for the years ended December 31, 2021, 2020 and 2019, respectively. Diluted net loss per share/unit is computed by dividing the net loss by the weighted-average number of common shares/units and dilutive common stock/unit equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For all periods presented, there is no difference in the number of shares/units used to calculate basic and diluted shares/units outstanding as inclusion of the potentially dilutive securities would be anti-dilutive.

Potentially dilutive securities not included in the calculation of diluted net loss per share/unit, because to do so would be anti-dilutive, are as follows (in common stock/unit equivalent shares; in thousands):

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Convertible preferred stock

 

 

—

 

 

 

—

 

 

 

17,666

 

Warrant to purchase convertible preferred stock

 

 

—

 

 

 

—

 

 

 

8

 

Warrant to purchase common stock

 

 

—

 

 

 

—

 

 

 

9

 

Common stock options issued and outstanding

 

 

5,778

 

 

 

3,788

 

 

 

1,667

 

Common stock subject to repurchase or

   forfeiture

 

 

15

 

 

 

69

 

 

 

195

 

ESPP shares pending issuance

 

 

3

 

 

 

1

 

 

 

—

 

Total

 

 

5,796

 

 

 

3,858

 

 

 

19,545

 
Recently Adopted and Issued Accounting Pronouncements

Recently Adopted Accounting Pronouncements

In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing certain separation models required under existing guidance. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and amends the diluted earnings-per-share (EPS) calculation guidance in certain areas to improve the consistency of EPS calculations. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020. The Company early adopted the new standard, effective January 1, 2021, on a modified retrospective basis. The adoption of ASU 2020-06 had no impact on the Company's financial statements and related disclosures.

Recently Issued Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. The Company

believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.
XML 37 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share/Unit

Potentially dilutive securities not included in the calculation of diluted net loss per share/unit, because to do so would be anti-dilutive, are as follows (in common stock/unit equivalent shares; in thousands):

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Convertible preferred stock

 

 

—

 

 

 

—

 

 

 

17,666

 

Warrant to purchase convertible preferred stock

 

 

—

 

 

 

—

 

 

 

8

 

Warrant to purchase common stock

 

 

—

 

 

 

—

 

 

 

9

 

Common stock options issued and outstanding

 

 

5,778

 

 

 

3,788

 

 

 

1,667

 

Common stock subject to repurchase or

   forfeiture

 

 

15

 

 

 

69

 

 

 

195

 

ESPP shares pending issuance

 

 

3

 

 

 

1

 

 

 

—

 

Total

 

 

5,796

 

 

 

3,858

 

 

 

19,545

 
XML 38 R23.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Summary of Cash Equivalents and Marketable Securities Measured at Fair Value

The following tables summarize the Company’s cash equivalents and marketable securities measured at fair value (in thousands):

 

 

 

 

 

 

 

Fair Value Measurements Using

 

As of December 31, 2021

 

Total

 

 

Quoted Prices in

Active Markets

for Identical

Assets (Level 1)

 

 

Significant

Other

Observable

Inputs (Level 2)

 

 

Significant

Unobservable

Inputs

(Level 3)

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

$

65,372

 

 

$

65,372

 

 

$

—

 

 

$

—

 

Negotiable certificates of deposit

 

 

3,873

 

 

 

—

 

 

 

3,873

 

 

 

—

 

Corporate debt securities

 

 

15,850

 

 

 

—

 

 

 

15,850

 

 

 

—

 

Total

 

$

85,095

 

 

$

65,372

 

 

$

19,723

 

 

$

—

 

 

 

 

 

 

 

 

Fair Value Measurements Using

 

As of December 31, 2020

 

Total

 

 

Quoted Prices in

Active Markets

for Identical

Assets (Level 1)

 

 

Significant

Other

Observable

Inputs (Level 2)

 

 

Significant

Unobservable

Inputs

(Level 3)

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Negotiable certificates of deposit

 

$

720

 

 

$

—

 

 

$

720

 

 

$

—

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

 

6,679

 

 

 

—

 

 

 

6,679

 

 

 

—

 

Total

 

$

7,399

 

 

$

—

 

 

$

7,399

 

 

$

—

 
Schedule of Reconciliation of Preferred Stock Warrant Liability Measured at Fair Value Using Level 3 Unobservable Inputs

The following table provides a reconciliation of the preferred stock warrant liability measured at fair value using Level 3 unobservable inputs (in thousands):

 

Balance at December 31, 2018

 

$

30

 

Change in fair value

 

 

15

 

Balance at December 31, 2019

 

 

45

 

Change in fair value

 

 

75

 

Reclassification of warrant liability

   to stockholders’ equity

 

 

(120

)

Balance at December 31, 2020

 

$

—

 
XML 39 R24.htm IDEA: XBRL DOCUMENT v3.22.0.1
Marketable Securities (Tables)
 12 Months Ended
Dec. 31, 2021
Investments Debt And Equity Securities [Abstract]  
Summary of Marketable Securities

The Company’s marketable securities, which consist of highly liquid marketable debt securities, are classified as available-for-sale and are stated at fair value. The following tables summarize the Company’s marketable securities (in thousands):

 

As of December 31, 2021

 

Maturity

(in years)

 

Amortized

Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Estimated

Fair Value

 

U.S. Treasury securities

 

1 or less

 

$

2,492

 

 

$

—

 

 

$

(1

)

 

$

2,491

 

Negotiable certificates of deposit

 

1 or less

 

 

1,190

 

 

 

—

 

 

 

(1

)

 

 

1,189

 

U.S. Treasury securities

 

1 - 2

 

 

63,034

 

 

 

—

 

 

 

(153

)

 

 

62,881

 

Negotiable certificates of deposit

 

1 - 2

 

 

2,687

 

 

 

—

 

 

 

(3

)

 

 

2,684

 

Corporate debt securities

 

1 - 2

 

 

15,879

 

 

 

—

 

 

 

(29

)

 

 

15,850

 

Total

 

 

 

$

85,282

 

 

$

—

 

 

$

(187

)

 

$

85,095

 

 

As of December 31, 2020

 

Maturity

(in years)

 

Amortized

Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Estimated

Fair Value

 

Corporate debt securities

 

1 or less

 

$

3,612

 

 

$

—

 

 

$

(2

)

 

$

3,610

 

Corporate debt securities

 

1 - 2

 

 

3,072

 

 

 

—

 

 

 

(3

)

 

 

3,069

 

Total

 

 

 

$

6,684

 

 

$

—

 

 

$

(5

)

 

$

6,679

 
XML 40 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaboration, License and Research Agreements (Tables)
 12 Months Ended
Dec. 31, 2021
Collaboration License And Research Agreements [Abstract]  
Summary of Reconciliation of Deferred Revenue Related to Lilly Agreement

A reconciliation of the closing balance of deferred revenue related to the Lilly Agreement is as follows (in thousands):

 

Balance at December 31, 2019

 

$

18,940

 

Revenue recognized

 

 

(3,100

)

Balance at December 31, 2020

 

 

15,840

 

Revenue recognized

 

 

(4,732

)

Balance at December 31, 2021

 

$

11,108

 
XML 41 R26.htm IDEA: XBRL DOCUMENT v3.22.0.1
Property and Equipment (Tables)
 12 Months Ended
Dec. 31, 2021
Property Plant And Equipment [Abstract]  
Schedule of Property and Equipment

Property and equipment consist of the following (in thousands):

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Laboratory equipment

 

$

4,775

 

 

$

2,928

 

Computers and software

 

 

116

 

 

 

58

 

Office furniture and equipment

 

 

1,398

 

 

 

44

 

Leasehold improvements

 

 

249

 

 

 

417

 

Property and equipment, gross

 

 

6,538

 

 

 

3,447

 

Less accumulated depreciation

 

 

(1,733

)

 

 

(1,979

)

Total property and equipment, net

 

$

4,805

 

 

$

1,468

 
XML 42 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]  
Schedule of ROU Assets and Liabilities Related to 2014 Lease and Temporary Lease

As of December 31, 2021, the Company’s ROU assets and liabilities related to the New Lease are as follows (in thousands):

 

ROU assets

 

$

10,784

 

 

 

 

 

 

Lease liabilities, current portion

 

$

1,769

 

Lease liabilities, net of current portion

 

 

9,960

 

Total lease liabilities

 

$

11,729

 
Schedule of Maturities of Lease Liabilities due under 2014 Lease and Temporary Lease

As of December 31, 2021, maturities of the lease liabilities due under the New Lease are as follows (in thousands):

 

Year ending December 31,

 

 

 

 

2022

 

$

1,769

 

2023

 

 

3,113

 

2024

 

 

3,207

 

2025

 

 

3,303

 

2026

 

 

3,111

 

Total lease payments

 

 

14,503

 

Less imputed interest

 

 

(2,774

)

Total operating lease liabilities

 

 

11,729

 

Less lease liabilities, current portion

 

 

(1,769

)

Lease liabilities, net of current portion

 

$

9,960

 
Supplemental Cash Flow Information Related to Cash Paid for Amounts Included in Measurement of Operating Lease Liabilities

Supplemental cash flow information related to cash paid for amounts included in the measurement of operating lease liabilities was as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Cash paid included in operating cash flows

 

$

234

 

 

$

163

 

 

$

382

 
Schedule of Rent Expense

Rent expense was as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Operating leases

 

$

946

 

 

$

453

 

 

$

302

 

Short-term leases

 

 

216

 

 

 

36

 

 

 

6

 

Total rent expense

 

$

1,162

 

 

$

489

 

 

$

308

 
XML 43 R28.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stockholders' Equity (Deficit) (Tables)
 12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Summary of Stock Option Activity

Stock option activity for employee and nonemployee awards and related information is as follows (in thousands, except per share and contractual term data):

 

 

 

Number of

Options

 

 

Weighted-

Average

Exercise

Price Per

Share

 

 

Weighted-

Average

Remaining

Contractual

Term

(in years)

 

 

Aggregate

Intrinsic

Value

 

Outstanding at December 31, 2020

 

 

3,788

 

 

$

9.06

 

 

 

 

 

 

 

 

 

Granted

 

 

2,671

 

 

 

23.23

 

 

 

 

 

 

 

 

 

Exercised

 

 

(172

)

 

 

5.42

 

 

 

 

 

 

 

 

 

Forfeited/expired

 

 

(509

)

 

 

22.99

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2021

 

 

5,778

 

 

$

14.49

 

 

 

8.5

 

 

$

58,950

 

Vested and expected to vest at

    December 31, 2021

 

 

5,778

 

 

$

14.49

 

 

 

8.5

 

 

$

58,950

 

Exercisable at December 31, 2021

 

 

1,885

 

 

$

8.91

 

 

 

7.8

 

 

$

29,226

 
Schedule of Assumptions used in Black-Scholes Model to Determine Fair Value of Stock/Unit Option Grants and Shares Purchasable under ESPP

The assumptions used in the Black-Scholes model to determine the fair value of stock/unit option grants and shares purchasable under the ESPP were as follows:

 

 

 

Year Ended December 31,

Stock/Unit Option Grants

 

2021

 

2020

 

2019

Risk-free interest rate

 

0.5% - 1.3%

 

0.3% - 1.5%

 

1.4% - 2.7%

Expected volatility

 

86% - 88%

 

88% - 92%

 

84% - 88%

Expected term (in years)

 

5.5 - 6.1

 

5.4 - 6.1

 

2.0 - 6.1

Expected dividend yield

 

—%

 

—%

 

—%

 

 

 

Year Ended December 31,

ESPP

 

2021

 

 

2020

 

2019

Risk-free interest rate

 

0.1%

 

 

0.1% - 0.2%

 

N/A

Expected volatility

 

69% - 75%

 

 

75% - 96%

 

N/A

Expected term (in years)

 

0.5

 

 

0.5

 

N/A

Expected dividend yield

 

—%

 

 

—%

 

N/A
Schedule of Allocated Stock-based Compensation Expense

The allocation of stock-based compensation expense was as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Research and development expense

 

$

9,228

 

 

$

1,895

 

 

$

84

 

General and administrative expense

 

 

7,828

 

 

 

2,415

 

 

 

322

 

Total stock-based compensation expense

 

$

17,056

 

 

$

4,310

 

 

$

406

 
Schedule of Common Stock Reserved for Future Issuance

Common stock reserved for future issuance consisted of the following (in thousands):

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Common stock options issued and outstanding

 

 

5,778

 

 

 

3,788

 

Equity awards available for future issuance

   under equity plans

 

 

2,575

 

 

 

2,852

 

Common stock authorized under the ESPP

 

 

639

 

 

 

296

 

Total

 

 

8,992

 

 

 

6,936

 
XML 44 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Reconciliation of Income Taxes Computed by Applying Statutory Federal Income Tax Rate

A reconciliation of income taxes to the amount computed by applying the statutory federal income tax rate to the net loss is summarized as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Income tax expense (benefit) at statutory rates

 

$

(24,784

)

 

$

(9,315

)

 

$

(5,194

)

State income tax, net of federal benefit

 

 

(7,868

)

 

 

(3,004

)

 

 

(1,057

)

Permanent items

 

 

210

 

 

 

1

 

 

 

14

 

Book income for pre-conversion period

 

 

—

 

 

 

—

 

 

 

527

 

Interest on convertible notes

 

 

—

 

 

 

—

 

 

 

445

 

Realized gain on conversion of convertible notes

 

 

—

 

 

 

—

 

 

 

958

 

Reserve for uncertain tax positions

 

 

1,170

 

 

 

398

 

 

 

140

 

Research and development tax credits

 

 

(4,792

)

 

 

(1,639

)

 

 

(584

)

Deferred taxes recognized upon conversion

 

 

—

 

 

 

—

 

 

 

(3,076

)

Valuation allowance

 

 

35,326

 

 

 

13,488

 

 

 

7,827

 

Other

 

 

738

 

 

 

71

 

 

 

—

 

Income tax expense (benefit)

 

$

—

 

 

$

—

 

 

$

—

 

 

 
Components of Deferred Tax Assets

Significant components of the Company’s deferred tax assets as of December 31, 2021 and 2020 are shown below (in thousands):

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Deferred tax assets:

 

 

 

 

 

 

 

 

Net operating loss carryforwards

 

$

41,443

 

 

$

11,277

 

Research and development tax credits

 

 

5,586

 

 

 

1,855

 

Deferred revenue

 

 

3,117

 

 

 

4,443

 

Accrued expenses

 

 

477

 

 

 

153

 

Intangibles and fixed assets

 

 

2,137

 

 

 

2,483

 

Lease liability

 

 

3,291

 

 

 

263

 

Stock-based compensation

 

 

3,668

 

 

 

969

 

Total deferred tax assets

 

 

59,719

 

 

 

21,443

 

Less valuation allowance

 

 

(56,693

)

 

 

(21,316

)

Net deferred tax assets

 

 

3,026

 

 

 

127

 

Deferred tax liabilities:

 

 

 

 

 

 

 

 

Right-of-use asset

 

 

(3,026

)

 

 

(127

)

Total deferred tax liabilities

 

 

(3,026

)

 

 

(127

)

Net deferred tax assets

 

$

—

 

 

$

—

 
Summarizes of Activity Related to Gross Unrecognized Tax Benefits

The following table summarizes the activity related to the Company’s gross unrecognized tax benefits for the years ended December 31, 2021 and 2020 (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Gross unrecognized tax benefits at the

   beginning of the year

 

$

671

 

 

$

156

 

Increases related to current year positions

 

 

1,283

 

 

 

446

 

Increases related to prior year positions

 

 

42

 

 

 

62

 

Other true up

 

 

—

 

 

 

7

 

Gross unrecognized tax benefits at the

   end of the year

 

$

1,996

 

 

$

671

 
XML 45 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1
Description of Business and Basis of Presentation - Additional Information (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended
Aug. 06, 2021
USD ($)
$ / shares
shares
Jul. 02, 2021
USD ($)
Jun. 16, 2020
USD ($)
$ / shares
shares
Jun. 04, 2020
Apr. 01, 2019
shares
Jun. 30, 2020
shares
Dec. 31, 2021
USD ($)
shares
Dec. 31, 2020
USD ($)
shares
Description Of Business And Basis Of Presentation [Line Items]                
Sale of stock number of shares issued in transaction             780,549,000  
Common stock, shares authorized     400,000,000       400,000,000 400,000,000
Preferred stock, shares authorized     40,000,000       40,000,000 40,000,000
Reverse stock split, description             On June 4, 2020, the Company effected a one-for-2.1095 reverse stock split of its common stock (the Reverse Stock Split).  
Stockholders' equity note, stock split, conversion ratio       2.1095        
Sale of common stock maximum aggregate offering price | $   $ 150,000            
Net proceeds from Issuance of common stock after deducting offering-related transaction costs and commissions | $             $ 19,600  
Accumulated deficit | $             184,549 $ 66,540
Cash, cash equivalents and marketable securities | $             $ 405,500  
Initial Public Offering                
Description Of Business And Basis Of Presentation [Line Items]                
Sale of stock number of shares issued in transaction     16,560,000          
Sale of stock, price per share | $ / shares     $ 18.00          
Proceeds from the IPO, net of underwriting discounts, commissions and offering costs | $     $ 274,100          
Outstanding shares of convertible preferred stock converted into common stock     17,921,069          
Series A Convertible Preferred Stock                
Description Of Business And Basis Of Presentation [Line Items]                
Preferred unit converted into convertible preferred stock         1      
Series B Convertible Preferred Stock                
Description Of Business And Basis Of Presentation [Line Items]                
Preferred unit converted into convertible preferred stock         1      
Undesignated Preferred Stock | Initial Public Offering                
Description Of Business And Basis Of Presentation [Line Items]                
Preferred stock, shares authorized     40,000,000          
Common Stock                
Description Of Business And Basis Of Presentation [Line Items]                
Common unit converted into common stock         1      
Outstanding shares of convertible preferred stock converted into common stock               17,921,000
Common Stock | Initial Public Offering                
Description Of Business And Basis Of Presentation [Line Items]                
Outstanding shares of convertible preferred stock converted into common stock           17,921,069    
Warrant to purchase of common stock     7,809          
Common stock, shares authorized     400,000,000          
Common Stock | Follow-on Public Offering                
Description Of Business And Basis Of Presentation [Line Items]                
Sale of stock number of shares issued in transaction 9,200,000              
Sale of stock, price per share | $ / shares $ 18.00              
Proceeds from the follow-on public offering, net of underwriting discounts, commissions and offering costs | $ $ 155,100              
XML 46 R31.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies - Additional Information (Details)
 12 Months Ended
Dec. 31, 2021
USD ($)
Segment
shares
Dec. 31, 2020
USD ($)
shares
Dec. 31, 2019
USD ($)
shares
Summary Of Significant Accounting Policies [Line Items]      
Realized gains and losses on marketable securities $ 0 $ 0 $ 0
Other-than-temporary impairments on marketable securities 0 $ 0 $ 0
Transfers of assets measured on recurring basis out of Level 1 into Level 2 0    
Transfers of assets measured on recurring basis out of Level 2 into Level 1 0    
Transfers of liabilities measured on recurring basis out of Level 1 into Level 2 0    
Transfers of liabilities measured on recurring basis out of Level 2 into Level 1 0    
Transfers of financial instrument classified as liability into level 3 0    
Transfers of financial instrument classified as liability out of level 3 0    
Transfers of financial instrument classified as asset into level 3 0    
Transfers of financial instrument classified as asset out of level 3 $ 0    
Number of operating segment | Segment 1    
Change in Accounting Principle, Accounting Standards Update, Adopted [true false] true    
Change in Accounting Principle, Accounting Standards Update, Adoption Date Jan. 01, 2019    
Weighted-average shares/units subject to repurchase or forfeiture | shares 33,600 123,285 217,524
Accounting Standards Update 2020-06      
Summary Of Significant Accounting Policies [Line Items]      
Change in Accounting Principle, Accounting Standards Update, Adopted [true false] true    
Change in Accounting Principle, Accounting Standards Update, Adoption Date Jan. 01, 2021    
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] true    
Change in Accounting Principle, Accounting Standards Update, Early Adoption [true false] true    
Minimum      
Summary Of Significant Accounting Policies [Line Items]      
Estimated useful lives of assets 3 years    
Maximum      
Summary Of Significant Accounting Policies [Line Items]      
Estimated useful lives of assets 5 years    
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share/Unit (Details) - shares
shares in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Total 5,796 3,858 19,545
Convertible Preferred Stock      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Total 0 0 17,666
Warrant | Common Stock      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Total 0 0 9
Warrant | Convertible Preferred Stock      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Total 0 0 8
Common Stock Options Issued and Outstanding      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Total 5,778 3,788 1,667
Common Stock Subject to Repurchase or Forfeiture      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Total 15 69 195
ESPP Shares Pending Issuance      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Total 3 1 0
XML 48 R33.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements - Summary of Cash Equivalents and Marketable Securities Measured at Fair Value (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Marketable securities $ 85,095 $ 6,679
Recurring    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total 85,095 7,399
Recurring | U.S. Treasury securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Marketable securities 65,372  
Recurring | Negotiable certificates of deposit    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Marketable securities 3,873  
Cash equivalents   720
Recurring | Corporate debt securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Marketable securities 15,850 6,679
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total 65,372 0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. Treasury securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Marketable securities 65,372  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Negotiable certificates of deposit    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Marketable securities 0  
Cash equivalents   0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Corporate debt securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Marketable securities 0 0
Recurring | Significant Other Observable Inputs (Level 2)    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total 19,723 7,399
Recurring | Significant Other Observable Inputs (Level 2) | U.S. Treasury securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Marketable securities 0  
Recurring | Significant Other Observable Inputs (Level 2) | Negotiable certificates of deposit    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Marketable securities 3,873  
Cash equivalents   720
Recurring | Significant Other Observable Inputs (Level 2) | Corporate debt securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Marketable securities 15,850 6,679
Recurring | Significant Unobservable Inputs (Level 3)    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total 0 0
Recurring | Significant Unobservable Inputs (Level 3) | U.S. Treasury securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Marketable securities 0  
Recurring | Significant Unobservable Inputs (Level 3) | Negotiable certificates of deposit    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Marketable securities 0  
Cash equivalents   0
Recurring | Significant Unobservable Inputs (Level 3) | Corporate debt securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Marketable securities $ 0 $ 0
XML 49 R34.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements - Schedule of Reconciliation of Preferred Stock Warrant Liability Measured at Fair Value Using Level 3 Unobservable Inputs (Details) - Significant Unobservable Inputs (Level 3) - Recurring - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Beginning Balance $ 45 $ 30
Change in fair value 75 15
Reclassification of warrant liability to stockholders? equity (120)  
Ending Balance $ 0 $ 45
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.22.0.1
Marketable Securities - Summary of Marketable Securities (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Schedule Of Available For Sale Securities [Line Items]    
Amortized Cost $ 85,282 $ 6,684
Unrealized Gains 0 0
Unrealized Losses (187) (5)
Marketable securities 85,095 6,679
U.S. Treasury Securities with 1 Year or Less Maturity    
Schedule Of Available For Sale Securities [Line Items]    
Amortized Cost 2,492  
Unrealized Gains 0  
Unrealized Losses (1)  
Marketable securities 2,491  
Corporate Debt Securities with 1 to 2 Years Maturity    
Schedule Of Available For Sale Securities [Line Items]    
Amortized Cost 15,879 3,072
Unrealized Gains 0 0
Unrealized Losses (29) (3)
Marketable securities 15,850 3,069
Negotiable Certificates of Deposit with 1 Year or Less Maturity    
Schedule Of Available For Sale Securities [Line Items]    
Amortized Cost 1,190  
Unrealized Gains 0  
Unrealized Losses (1)  
Marketable securities 1,189  
U.S. Treasury Securities with 1 to 2 Years Maturity    
Schedule Of Available For Sale Securities [Line Items]    
Amortized Cost 63,034  
Unrealized Gains 0  
Unrealized Losses (153)  
Marketable securities 62,881  
Negotiable Certificates of Deposit with 1 to 2 Years Maturity    
Schedule Of Available For Sale Securities [Line Items]    
Amortized Cost 2,687  
Unrealized Gains 0  
Unrealized Losses (3)  
Marketable securities $ 2,684  
Corporate Debt Securities with 1 Year or Less Maturity    
Schedule Of Available For Sale Securities [Line Items]    
Amortized Cost   3,612
Unrealized Gains   0
Unrealized Losses   (2)
Marketable securities   $ 3,610
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaboration, License and Research Agreements - Additional Information (Details)
 1 Months Ended 12 Months Ended
Nov. 30, 2019
shares
Apr. 30, 2019
USD ($)
Product
Dec. 31, 2021
USD ($)
Obligation
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Revenue recognized     $ 9,326,000 $ 6,787,000 $ 2,319,000
Lilly Note | Series C Convertible Preferred Stock          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Conversion of convertible note payable to preferred stock | shares 4,576,342        
Research Collaboration and License Agreement with Eli Lilly          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Upfront fees received   $ 20,000,000.0      
License agreement expiry period   10 years      
Number of performance obligation | Obligation     1    
Period for expects performance obligation     5 years    
Revenue recognized     $ 9,100,000 6,800,000 2,300,000
Deferred revenue     11,108,000 15,840,000 $ 18,940,000
Research Collaboration and License Agreement with Eli Lilly | Prepaid and Other Assets          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Collaboration receivables     900,000 1,200,000  
Research Collaboration and License Agreement with Eli Lilly | Maximum          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Rights to antibody oligonucleotide conjugates for messengers RNA targets. | Product   6      
Development milestone payment eligible to receive per target   $ 60,000,000.0      
Regulatory milestone payment eligible to receive per target   140,000,000.0      
Commercialization milestone payment eligible to receive   $ 205,000,000.0      
Research Collaboration with MyoKardia, Inc.          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Revenue recognized     $ 200,000 $ 0  
XML 52 R37.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaboration, License and Research Agreements - Reconciliation of Deferred Revenue Related to Lilly Agreement (Details) - Research Collaboration and License Agreement with Eli Lilly - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Balance $ 15,840 $ 18,940
Revenue recognized (4,732) (3,100)
Balance $ 11,108 $ 15,840
XML 53 R38.htm IDEA: XBRL DOCUMENT v3.22.0.1
Property,and Equipment - Schedule of Property and Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Property Plant And Equipment [Line Items]    
Property and equipment, gross $ 6,538 $ 3,447
Less accumulated depreciation (1,733) (1,979)
Total property and equipment, net 4,805 1,468
Laboratory Equipment    
Property Plant And Equipment [Line Items]    
Property and equipment, gross 4,775 2,928
Computers and Software    
Property Plant And Equipment [Line Items]    
Property and equipment, gross 116 58
Office Furniture and Equipment    
Property Plant And Equipment [Line Items]    
Property and equipment, gross 1,398 44
Leasehold Improvements    
Property Plant And Equipment [Line Items]    
Property and equipment, gross $ 249 $ 417
XML 54 R39.htm IDEA: XBRL DOCUMENT v3.22.0.1
Property and Equipment - Additional Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Property Plant And Equipment [Abstract]      
Depreciation expenses related to property and equipment $ 639 $ 373 $ 348
XML 55 R40.htm IDEA: XBRL DOCUMENT v3.22.0.1
Debt - Additional Information (Details)
 1 Months Ended 12 Months Ended
Jun. 17, 2020
shares
Jul. 01, 2019
Installment
Jun. 30, 2020
USD ($)
$ / shares
shares
Aug. 31, 2018
USD ($)
Jun. 30, 2017
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Debt Instrument [Line Items]                
Repayment of existing loan           $ 0 $ 4,683,000 $ 2,800,000
Proceeds from notes           $ 0 $ 0 $ 19,451,000
Common Stock                
Debt Instrument [Line Items]                
Warrant exercisable | shares     7,809          
Exercise price of warrant | $ / shares     $ 4.77          
Cashless exercise of warrants | shares 15,833              
SVB                
Debt Instrument [Line Items]                
Repayment of existing loan         $ 4,100,000      
Debt instrument final payments         400,000      
SVB | Convertible Notes                
Debt Instrument [Line Items]                
Proceeds from notes       $ 3,000,000.0        
SVB | Term C Loan | Common Stock                
Debt Instrument [Line Items]                
Warrant term     7 years          
Exercise price of warrant | $ / shares     $ 0.53          
SVB | Term C Loan | Common Stock | Maximum                
Debt Instrument [Line Items]                
Warrant to purchase common stock | shares     9,442          
SVB | Term A And Term B Loans | Series A Convertible Preferred Stock                
Debt Instrument [Line Items]                
Exercise price of warrant | $ / shares     $ 2.2615          
Warrant term     10 years          
SVB | Term A And Term B Loans | Series A Convertible Preferred Stock | Maximum                
Debt Instrument [Line Items]                
Warrant to purchase convertible preferred stock | shares     16,474          
SVB | LSA Amendment                
Debt Instrument [Line Items]                
Loan facility maximum borrowing capacity         7,000,000.0      
SVB | LSA Amendment | Term C Loan                
Debt Instrument [Line Items]                
Face amount of loans         5,000,000.0      
Debt instrument final payments         $ 300,000      
Maturity date         Jun. 01, 2021      
Basis spread on variable rate         0.20%      
Frequency of periodic payment principal           36 equal monthly    
Number of equal monthly installments of principal | Installment   36            
Frequency of periodic payment interest           monthly    
Debt instrument final payment percentage   6.50%            
SVB | LSA Amendment | Term D Loan                
Debt Instrument [Line Items]                
Face amount of loans         $ 2,000,000.0      
SVB | LSA Second Amendment | Term D Loan                
Debt Instrument [Line Items]                
Debt instrument final payments       $ 100,000        
Debt instrument final payment percentage       6.50%        
Proceeds from issuance of long-term debt       $ 2,000,000.0        
SVB | LSA | Term C And D Loans                
Debt Instrument [Line Items]                
Loans prepaid amount     $ 2,800,000          
Payment of final payment and accrued interest     $ 500,000          
XML 56 R41.htm IDEA: XBRL DOCUMENT v3.22.0.1
Convertible Notes - Additional Information (Details) - USD ($)
 1 Months Ended 12 Months Ended
Nov. 30, 2019
Apr. 30, 2019
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Debt Instrument [Line Items]            
Proceeds from issuance of convertible notes     $ 0 $ 0 $ 19,451,000  
Interest expense     $ 0 $ 209,000 7,387,000  
Convertible Notes | Series C Convertible Preferred Stock            
Debt Instrument [Line Items]            
Conversion of convertible notes payable to preferred stock 6,893,036          
Interest expense         6,900,000  
2018 Notes            
Debt Instrument [Line Items]            
Face amount of loans           $ 3,000,000.0
Convertible promissory notes accrued interest rate           8.00%
Convertible promissory notes conversion percentage on per share price paid by investors           85.00%
Qualified financing of convertible promissory notes converted into preferred equity           $ 10,000,000
2019 Notes            
Debt Instrument [Line Items]            
Face amount of loans         $ 4,500,000  
Convertible promissory notes accrued interest rate         10.00%  
Convertible promissory notes conversion percentage on per share price paid by investors         80.00%  
Qualified financing of convertible promissory notes converted into preferred equity         $ 10,000,000  
Lilly Note            
Debt Instrument [Line Items]            
Convertible promissory notes accrued interest rate   8.00%        
Proceeds from issuance of convertible notes   $ 15,000,000.0        
Maturity date   2020-10        
Lilly Note | Series C Convertible Preferred Stock            
Debt Instrument [Line Items]            
Conversion of convertible notes payable to preferred stock 4,576,342          
XML 57 R42.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies - Additional Information (Details) - USD ($)
 12 Months Ended
Dec. 18, 2020
Dec. 31, 2021
Commitments and Contingencies [Line Items]    
Operating lease, description   During the periods presented, the Company was party to various non-cancellable office and laboratory space operating leases and short-term leases. Currently, the Company is only party to a non-cancellable office and laboratory space operating lease. Under the relevant guidance, the Company recognizes operating lease right-of-use (ROU) assets and liabilities based on the present value of the future minimum lease payments over the lease term at the commencement date, using the Company’s assumed incremental borrowing rate of 5.5%, and amortizes the ROU assets and liabilities over the lease term. Lease expense for operating leases is recognized on a straight-line basis over the lease term. The Company’s short-term leases are not subject to recognition of an ROU asset or liability or straight-line lease expense requirements.
Incremental borrowing rate   5.50%
Weighted-average remaining term of operating leases   4 years 10 months 24 days
Loss contingencies accrued   $ 0
Lease Term through November 2017 | Office and Laboratory Space    
Commitments and Contingencies [Line Items]    
Operating lease, term of contract, description   In March 2014, the Company entered into a non-cancellable operating lease for office and laboratory space with a lease term through November 2017.
Lease Term through December 2021 | Office and Laboratory Space    
Commitments and Contingencies [Line Items]    
Operating lease, term of contract, description   In July 2017, the Company entered into an amendment to this lease to extend the lease term through December 2021.
New Lease | Office and Laboratory Space    
Commitments and Contingencies [Line Items]    
Operating lease, description On December 18, 2020, the Company entered into an amendment to the non-cancellable operating lease for its new headquarters location (as amended, the New Lease), which increased the square footage by adding adjacent space and extended the projected commencement date to November 1, 2021. Additionally, the non-cancellable temporary operating lease was amended (as amended, the Temporary Lease) to accommodate the projected commencement date of the New Lease. On June 1, 2020, the Company entered into a second amendment to its existing operating lease (as amended, the 2014 Lease) and entered into a new non-cancellable temporary operating lease in connection with a newly executed non-cancellable operating lease for its new headquarters location, with a projected commencement date of July 1, 2021.
Operating lease, lease payment under new lease $ 14,700,000  
Operating lease, term of contract 5 years  
Operating lease, renewal term 5 years  
Lessee, operating lease, existence of option to extend [true false] true  
Operating lease, initial monthly base rent $ 251,000  
Operating lease, monthly base rent for last year lease 282,000  
Letter of credit throughout the lease term $ 251,000  
Temporary Lease | Office and Laboratory Space    
Commitments and Contingencies [Line Items]    
Operating lease, expiration period, description The lease term under both the 2014 Lease and the Temporary Lease ends 15 days after the commencement date of the New Lease in November 2021.  
Operating lease expiration period 15 days  
XML 58 R43.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies - Schedule of ROU Assets and Liabilities Related to 2014 Lease and Temporary Lease (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]    
Right-of-use asset $ 10,784 $ 454
Lease liabilities, current portion 1,769 0
Lease liabilities, net of current portion 9,960 $ 938
Total lease liabilities $ 11,729  
XML 59 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies - Schedule of Maturities of Lease Liabilities due under 2014 Lease and Temporary Lease (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]    
2022 $ 1,769  
2023 3,113  
2024 3,207  
2025 3,303  
2026 3,111  
Total lease payments 14,503  
Less imputed interest (2,774)  
Total lease liabilities 11,729  
Less lease liabilities, current portion (1,769) $ 0
Lease liabilities, net of current portion $ 9,960 $ 938
XML 60 R45.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies - Supplemental Cash Flow Information Related to Cash Paid for Amounts Included in Measurement of Operating Lease Liabilities (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Commitments And Contingencies Disclosure [Abstract]      
Cash paid included in operating cash flows $ 234 $ 163 $ 382
XML 61 R46.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies - Schedule of Rent Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Commitments And Contingencies Disclosure [Abstract]      
Operating leases $ 946 $ 453 $ 302
Short-term leases 216 36 6
Total rent expense $ 1,162 $ 489 $ 308
XML 62 R47.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stockholders' Equity (Deficit) - Additional Information (Details) - USD ($)
 1 Months Ended 12 Months Ended
Aug. 06, 2021
Jul. 02, 2021
Jun. 16, 2020
Apr. 01, 2019
Jun. 30, 2020
Jan. 31, 2020
Nov. 30, 2019
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Jan. 31, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                      
Common stock shares authorized     400,000,000         400,000,000 400,000,000    
Preferred stock undesignated shares authorized     40,000,000         40,000,000 40,000,000    
Common stock par value per share     $ 0.0001         $ 0.0001 $ 0.0001    
Preferred stock par value per share     $ 0.0001         $ 0.0001 $ 0.0001    
Sale of stock number of shares issued in transaction               780,549,000      
Sale of common stock maximum aggregate offering price   $ 150,000,000.0                  
Termination notice period for sales agreement   10 days                  
Net proceeds from Issuance of common stock after deducting offering-related transaction costs and commissions               $ 19,600,000      
Reclassified accumulated deficit from predecessor deficit to additional paid in capital       $ 44,100,000              
Proceeds from issuance of Series C convertible preferred stock, net of issuance costs               0 $ 2,200,000 $ 72,623,000  
Issuance costs               $ 11,262,000 $ 24,026,000 0  
Shares of common stock reserved for future issuance               8,992,000 6,936,000    
Award vesting period               4 years      
Total intrinsic value of options exercised               $ 3,400,000 $ 500,000 $ 7,000  
Weighted-average grant date fair value of options granted               $ 16.78 $ 11.63 $ 3.46  
Stock options exercised were unvested               15,288 69,359    
Expected dividend yield               0.00% 0.00% 0.00%  
Time-based Options                      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                      
Unrecognized compensation cost               $ 46,900,000      
Weighted-average period of unrecognized compensation cost               2 years 7 months 6 days      
Maximum                      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                      
Expected term (in years)               6 years 1 month 6 days 6 years 1 month 6 days 6 years 1 month 6 days  
Minimum                      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                      
Expected term (in years)               5 years 6 months 5 years 4 months 24 days 2 years  
2013 Equity Incentive Plan                      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                      
Units initially reserved for issuance                     2,127,013
Increased to number of shares reserved under plan                     4,771,615
2013 Equity Incentive Plan | Maximum                      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                      
Expiration period               10 years      
2020 Incentive Award Plan                      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                      
Shares of common stock reserved for future issuance         3,900,000            
Percentage of shares of common stock outstanding on final day of immediately preceding calendar year         5.00%            
Number of remaining shares available for issuance               2,574,824      
2020 Incentive Award Plan | Maximum                      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                      
Expiration period               10 years      
Employee Stock Purchase Plan                      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                      
Participant maximum contribution as percentage of eligible compensation         15.00%            
Percentage of purchase price of shares of lower of fair market value         85.00%            
Shares of common stock available for issuance               638,563      
Shares issued under ESPP               33,147 28,979    
Expected term (in years)               6 months 6 months    
Expected dividend yield               0.00% 0.00%    
Unrecognized compensation cost               $ 200,000      
Weighted-average period of unrecognized compensation cost               6 months      
Employee Stock Purchase Plan | Accounts Payable and Accrued Liabilities                      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                      
Outstanding liability               $ 53,000      
Series A Convertible Preferred Stock                      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                      
Preferred unit converted into convertible preferred stock       1              
Series B Convertible Preferred Stock                      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                      
Preferred unit converted into convertible preferred stock       1              
Series C Convertible Preferred Stock                      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                      
Preferred stock, shares issued           537,232 17,915,525        
Stock issued price per share           $ 4.2812 $ 4.2812        
Proceeds from issuance of Series C convertible preferred stock, net of issuance costs           $ 2,200,000 $ 72,600,000        
Issuance costs           $ 100,000 $ 4,100,000        
Series C Convertible Preferred Stock | Convertible Notes                      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                      
Conversion of convertible note payable to preferred stock             6,893,036        
Common Stock                      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                      
Common unit converted into common stock       1              
Outstanding shares of convertible preferred stock converted into common stock                 17,921,000    
Shares issued under ESPP               33,000 29,000    
Public Offering                      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                      
Sale of stock number of shares issued in transaction     16,560,000                
Sale of stock, price per share     $ 18.00                
Proceeds from the IPO, net of underwriting discounts, commissions and offering costs     $ 274,100,000                
Outstanding shares of convertible preferred stock converted into common stock     17,921,069                
Public Offering | Common Stock                      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                      
Common stock shares authorized     400,000,000                
Outstanding shares of convertible preferred stock converted into common stock         17,921,069            
Follow-on Public Offering | Common Stock                      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                      
Sale of stock number of shares issued in transaction 9,200,000                    
Sale of stock, price per share $ 18.00                    
Proceeds from the follow-on public offering, net of underwriting discounts, commissions and offering costs $ 155,100,000                    
XML 63 R48.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stockholders' Equity (Deficit) - Summary of Stock Option Activity (Details)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2021
USD ($)
$ / shares
shares
Number of Options  
Outstanding at December 31, 2020 | shares 3,788
Granted | shares 2,671
Exercised | shares (172)
Forfeited/expired | shares (509)
Outstanding at December 31, 2021 | shares 5,778
Vested and expected to vest at December 31, 2021 | shares 5,778
Exercisable at December 31, 2021 | shares 1,885
Weighted-Average Exercise Price  
Outstanding at December 31, 2020 | $ / shares $ 9.06
Granted | $ / shares 23.23
Exercised | $ / shares 5.42
Forfeited/expired | $ / shares 22.99
Outstanding at December 31, 2021 | $ / shares 14.49
Vested and expected to vest at December 31, 2021 | $ / shares 14.49
Exercisable at December 31, 2021 | $ / shares $ 8.91
Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value  
Outstanding, Weighted- Average Remaining Contractual Term (in years) 8 years 6 months
Vested and expected to vest, Weighted - Average Remaining Contractual Term (in years) 8 years 6 months
Exercisable, Weighted- Average Remaining Contractual Term (in years) 7 years 9 months 18 days
Outstanding, Aggregate Intrinsic Value | $ $ 58,950
Vested and expected to vest, Aggregate Intrinsic Value | $ 58,950
Exercisable, Aggregate Intrinsic Value | $ $ 29,226
XML 64 R49.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stockholders' Equity (Deficit) - Schedule of Assumptions used in Black-Scholes Model to Determine Fair Value of Stock/Unit Option Grants and Shares Purchasable under ESPP (Details)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Risk-free interest rate, Minimum 0.50% 0.30% 1.40%
Risk-free interest rate, Maximum 1.30% 1.50% 2.70%
Expected dividend yield 0.00% 0.00% 0.00%
Employee Stock Purchase Plan      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Risk-free interest rate, Minimum   0.10%  
Risk-free interest rate, Maximum   0.20%  
Expected term (in years) 6 months 6 months  
Expected dividend yield 0.00% 0.00%  
Risk-free interest rate 0.10%    
Minimum      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Expected volatility 86.00% 88.00% 84.00%
Expected term (in years) 5 years 6 months 5 years 4 months 24 days 2 years
Minimum | Employee Stock Purchase Plan      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Expected volatility 69.00% 75.00%  
Maximum      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Expected volatility 88.00% 92.00% 88.00%
Expected term (in years) 6 years 1 month 6 days 6 years 1 month 6 days 6 years 1 month 6 days
Maximum | Employee Stock Purchase Plan      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Expected volatility 75.00% 96.00%  
XML 65 R50.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stockholders' Equity (Deficit) - Schedule of Allocated Stock-based Compensation Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]      
Total stock-based compensation expense $ 17,056 $ 4,310 $ 406
Research and Development Expense      
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]      
Total stock-based compensation expense 9,228 1,895 84
General and Administrative Expense      
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]      
Total stock-based compensation expense $ 7,828 $ 2,415 $ 322
XML 66 R51.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stockholders' Equity (Deficit) - Schedule of Common Stock Reserved for Future Issuance (Details) - shares
shares in Thousands
Dec. 31, 2021
Dec. 31, 2020
Class Of Stock [Line Items]    
Common stock reserved for future issuance 8,992 6,936
Common Stock Options Issued and Outstanding    
Class Of Stock [Line Items]    
Common stock reserved for future issuance 5,778 3,788
Equity Awards Available for Future Issuance under Equity Plans    
Class Of Stock [Line Items]    
Common stock reserved for future issuance 2,575 2,852
Common Stock Authorized under the ESPP    
Class Of Stock [Line Items]    
Common stock reserved for future issuance 639 296
XML 67 R52.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Additional Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Taxes Disclosure [Line Items]      
Provision for income taxes $ 0 $ 0 $ 0
Increase in the valuation allowance 35,400,000 13,500,000  
Accruals for interest or penalties 0 0  
Interest or penalties 0 $ 0  
Federal      
Income Taxes Disclosure [Line Items]      
Net operating loss (NOL) carryforwards $ 147,900,000    
Net operating loss available to offset against current taxable income percentage 100.00%    
Net operating loss available to offset against future taxable income percentage 80.00%    
Federal and state tax credit carryforwards $ 4,700,000    
Tax credit expiration beginning year 2039    
Federal | Orphan Drug Tax Credits      
Income Taxes Disclosure [Line Items]      
Federal and state tax credit carryforwards $ 700,000    
Tax credit expiration beginning year 2041    
State      
Income Taxes Disclosure [Line Items]      
Net operating loss (NOL) carryforwards $ 147,700,000    
Net operating loss carryforwards, expiration beginning year 2039    
Federal and state tax credit carryforwards $ 2,600,000    
XML 68 R53.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Reconciliation of Income Taxes Computed by Applying Statutory Federal Income Tax Rate (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Tax Disclosure [Abstract]      
Income tax expense (benefit) at statutory rates $ (24,784,000) $ (9,315,000) $ (5,194,000)
State income tax, net of federal benefit (7,868,000) (3,004,000) (1,057,000)
Permanent items 210,000 1,000 14,000
Book income for pre-conversion period 0 0 527,000
Interest on convertible notes 0 0 445,000
Realized gain on conversion of convertible notes 0 0 958,000
Reserve for uncertain tax positions 1,170,000 398,000 140,000
Research and development tax credits (4,792,000) (1,639,000) (584,000)
Deferred taxes recognized upon conversion 0 0 (3,076,000)
Valuation allowance 35,326,000 13,488,000 7,827,000
Other 738,000 71,000 0
Income tax expense (benefit) $ 0 $ 0 $ 0
XML 69 R54.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Components of Deferred Tax Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Deferred tax assets:    
Net operating loss carryforwards $ 41,443 $ 11,277
Research and development tax credits 5,586 1,855
Deferred revenue 3,117 4,443
Accrued expenses 477 153
Intangibles and fixed assets 2,137 2,483
Lease liability 3,291 263
Stock-based compensation 3,668 969
Total deferred tax assets 59,719 21,443
Less valuation allowance (56,693) (21,316)
Net deferred tax assets 3,026 127
Deferred tax liabilities:    
Right-of-use asset (3,026) (127)
Total deferred tax liabilities (3,026) (127)
Net deferred tax assets $ 0 $ 0
XML 70 R55.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Summarizes of Activity Related to Gross Unrecognized Tax Benefits (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Gross unrecognized tax benefits at the beginning of the year $ 671 $ 156
Increases related to current year positions 1,283 446
Increases related to prior year positions 42 62
Other true up 0 7
Gross unrecognized tax benefits at the end of the year $ 1,996 $ 671
XML 71 R56.htm IDEA: XBRL DOCUMENT v3.22.0.1
Subsequent Events - Additional Information (Details) - USD ($)
$ in Millions
 2 Months Ended 12 Months Ended
Mar. 01, 2022
Dec. 31, 2021
Subsequent Event [Line Items]    
Net proceeds from Issuance of common stock after deducting offering-related transaction costs and commissions   $ 19.6
Subsequent Event | Common Stock | Sales Agreement    
Subsequent Event [Line Items]    
Issuance of stock, net of issuance costs, Shares 1,100,000  
Net proceeds from Issuance of common stock after deducting offering-related transaction costs and commissions $ 16.9  
XML 72 rna-10k_20211231_htm.xml IDEA: XBRL DOCUMENT 0001599901 2021-01-01 2021-12-31 0001599901 2022-02-07 0001599901 2021-06-30 0001599901 2021-12-31 0001599901 2020-12-31 0001599901 2020-01-01 2020-12-31 0001599901 2019-01-01 2019-12-31 0001599901 rna:PreferredUnitsMember 2018-12-31 0001599901 rna:CommonUnitsMember 2018-12-31 0001599901 rna:PredecessorsDeficitMember 2018-12-31 0001599901 2018-12-31 0001599901 rna:PreferredUnitsMember 2019-01-01 2019-12-31 0001599901 rna:CommonUnitsMember 2019-01-01 2019-12-31 0001599901 rna:PredecessorsDeficitMember 2019-01-01 2019-12-31 0001599901 us-gaap:ConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001599901 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001599901 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001599901 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001599901 us-gaap:ConvertiblePreferredStockMember 2019-12-31 0001599901 us-gaap:CommonStockMember 2019-12-31 0001599901 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001599901 us-gaap:RetainedEarningsMember 2019-12-31 0001599901 2019-12-31 0001599901 us-gaap:ConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001599901 us-gaap:CommonStockMember us-gaap:IPOMember 2020-01-01 2020-12-31 0001599901 us-gaap:AdditionalPaidInCapitalMember us-gaap:IPOMember 2020-01-01 2020-12-31 0001599901 us-gaap:IPOMember 2020-01-01 2020-12-31 0001599901 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001599901 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001599901 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001599901 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001599901 us-gaap:CommonStockMember 2020-12-31 0001599901 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001599901 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001599901 us-gaap:RetainedEarningsMember 2020-12-31 0001599901 us-gaap:CommonStockMember us-gaap:IPOMember 2021-01-01 2021-12-31 0001599901 us-gaap:AdditionalPaidInCapitalMember us-gaap:IPOMember 2021-01-01 2021-12-31 0001599901 us-gaap:IPOMember 2021-01-01 2021-12-31 0001599901 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001599901 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001599901 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001599901 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001599901 us-gaap:CommonStockMember 2021-12-31 0001599901 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001599901 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001599901 us-gaap:RetainedEarningsMember 2021-12-31 0001599901 us-gaap:CommonStockMember 2019-04-01 2019-04-01 0001599901 rna:SeriesAConvertiblePreferredStockMember 2019-04-01 2019-04-01 0001599901 rna:SeriesBConvertiblePreferredStockMember 2019-04-01 2019-04-01 0001599901 us-gaap:IPOMember 2020-06-16 2020-06-16 0001599901 us-gaap:IPOMember 2020-06-16 0001599901 us-gaap:CommonStockMember us-gaap:IPOMember 2020-06-16 0001599901 rna:UndesignatedPreferredStockMember us-gaap:IPOMember 2020-06-16 0001599901 2020-06-04 2020-06-04 0001599901 us-gaap:CommonStockMember rna:FollowOnPublicOfferingMember 2021-08-06 2021-08-06 0001599901 us-gaap:CommonStockMember rna:FollowOnPublicOfferingMember 2021-08-06 0001599901 2021-07-02 2021-07-02 0001599901 srt:MinimumMember 2021-01-01 2021-12-31 0001599901 srt:MaximumMember 2021-01-01 2021-12-31 0001599901 us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001599901 us-gaap:WarrantMember us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001599901 us-gaap:WarrantMember us-gaap:ConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001599901 us-gaap:WarrantMember us-gaap:ConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001599901 us-gaap:WarrantMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001599901 us-gaap:WarrantMember us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001599901 us-gaap:WarrantMember us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001599901 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001599901 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001599901 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001599901 rna:CommonStockSubjectToRepurchaseOrForfeitureMember 2021-01-01 2021-12-31 0001599901 rna:CommonStockSubjectToRepurchaseOrForfeitureMember 2020-01-01 2020-12-31 0001599901 rna:CommonStockSubjectToRepurchaseOrForfeitureMember 2019-01-01 2019-12-31 0001599901 rna:EmployeeStockPurchasePlanSharesPendingIssuanceMember 2021-01-01 2021-12-31 0001599901 rna:EmployeeStockPurchasePlanSharesPendingIssuanceMember 2020-01-01 2020-12-31 0001599901 rna:EmployeeStockPurchasePlanSharesPendingIssuanceMember 2019-01-01 2019-12-31 0001599901 us-gaap:AccountingStandardsUpdate202006Member 2021-12-31 0001599901 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001599901 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001599901 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001599901 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001599901 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001599901 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001599901 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001599901 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001599901 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001599901 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001599901 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001599901 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001599901 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001599901 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001599901 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-01-01 2019-12-31 0001599901 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001599901 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-01-01 2020-12-31 0001599901 rna:USTreasurySecuritiesOneYearOrLessMaturityMember 2021-12-31 0001599901 rna:NegotiableCertificatesOfDepositOneYearOrLessMaturityMember 2021-12-31 0001599901 rna:USTreasurySecuritiesWithOneToTwoYearsMaturityMember 2021-12-31 0001599901 rna:NegotiableCertificatesOfDepositWithOneToTwoYearsMaturityMember 2021-12-31 0001599901 rna:CorporateDebtSecuritiesWithOneToTwoYearsMaturityMember 2021-12-31 0001599901 rna:CorporateDebtSecuritiesOneYearOrLessMaturityMember 2020-12-31 0001599901 rna:CorporateDebtSecuritiesWithOneToTwoYearsMaturityMember 2020-12-31 0001599901 srt:MaximumMember rna:ResearchCollaborationAndLicenseAgreementWithEliLillyAndCompanyMember 2019-04-01 2019-04-30 0001599901 rna:ResearchCollaborationAndLicenseAgreementWithEliLillyAndCompanyMember 2019-04-01 2019-04-30 0001599901 rna:ResearchCollaborationAndLicenseAgreementWithEliLillyAndCompanyMember 2021-01-01 2021-12-31 0001599901 rna:ResearchCollaborationAndLicenseAgreementWithEliLillyAndCompanyMember 2020-01-01 2020-12-31 0001599901 rna:ResearchCollaborationAndLicenseAgreementWithEliLillyAndCompanyMember 2019-01-01 2019-12-31 0001599901 rna:ResearchCollaborationAndLicenseAgreementWithEliLillyAndCompanyMember 2021-12-31 0001599901 rna:ResearchCollaborationAndLicenseAgreementWithEliLillyAndCompanyMember 2020-12-31 0001599901 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember rna:ResearchCollaborationAndLicenseAgreementWithEliLillyAndCompanyMember 2021-12-31 0001599901 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember rna:ResearchCollaborationAndLicenseAgreementWithEliLillyAndCompanyMember 2020-12-31 0001599901 rna:ResearchCollaborationAndLicenseAgreementWithEliLillyAndCompanyMember 2019-12-31 0001599901 rna:LillyConvertiblePromissoryNotesMember rna:SeriesCConvertiblePreferredStockMember 2019-11-01 2019-11-30 0001599901 rna:ResearchCollaborationWithMyoKardiaIncMember 2021-01-01 2021-12-31 0001599901 rna:ResearchCollaborationWithMyoKardiaIncMember 2020-01-01 2020-12-31 0001599901 rna:LaboratoryEquipmentMember 2021-12-31 0001599901 rna:LaboratoryEquipmentMember 2020-12-31 0001599901 us-gaap:ComputerEquipmentMember 2021-12-31 0001599901 us-gaap:ComputerEquipmentMember 2020-12-31 0001599901 rna:OfficeFurnitureAndEquipmentMember 2021-12-31 0001599901 rna:OfficeFurnitureAndEquipmentMember 2020-12-31 0001599901 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001599901 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001599901 rna:SiliconValleyBankMember rna:LoanAndSecurityAgreementAmendmentMember 2017-06-30 0001599901 rna:SiliconValleyBankMember rna:TermCLoanMember rna:LoanAndSecurityAgreementAmendmentMember 2017-06-30 0001599901 rna:SiliconValleyBankMember rna:TermDLoanMember rna:LoanAndSecurityAgreementAmendmentMember 2017-06-30 0001599901 rna:SiliconValleyBankMember 2017-06-01 2017-06-30 0001599901 rna:SiliconValleyBankMember rna:TermCLoanMember rna:LoanAndSecurityAgreementAmendmentMember 2017-06-01 2017-06-30 0001599901 rna:SiliconValleyBankMember rna:TermCLoanMember rna:LoanAndSecurityAgreementAmendmentMember 2021-01-01 2021-12-31 0001599901 rna:SiliconValleyBankMember rna:TermCLoanMember rna:LoanAndSecurityAgreementAmendmentMember 2019-07-01 2019-07-01 0001599901 rna:SiliconValleyBankMember rna:TermDLoanMember rna:LoanAndSecurityAgreementSecondAmendmentMember 2018-08-01 2018-08-31 0001599901 rna:SiliconValleyBankMember us-gaap:ConvertibleNotesPayableMember 2018-08-01 2018-08-31 0001599901 rna:SiliconValleyBankMember rna:TermCAndDLoansMember rna:AmendedAndRestatedLoanAndSecurityAgreementMember 2020-06-01 2020-06-30 0001599901 rna:SiliconValleyBankMember srt:MaximumMember rna:TermAAndTermBLoansMember rna:SeriesAConvertiblePreferredStockMember 2020-06-30 0001599901 rna:SiliconValleyBankMember rna:TermAAndTermBLoansMember rna:SeriesAConvertiblePreferredStockMember 2020-06-30 0001599901 rna:SiliconValleyBankMember rna:TermAAndTermBLoansMember rna:SeriesAConvertiblePreferredStockMember 2020-06-01 2020-06-30 0001599901 us-gaap:CommonStockMember 2020-06-30 0001599901 rna:SiliconValleyBankMember srt:MaximumMember rna:TermCLoanMember us-gaap:CommonStockMember 2020-06-30 0001599901 rna:SiliconValleyBankMember rna:TermCLoanMember us-gaap:CommonStockMember 2020-06-30 0001599901 rna:SiliconValleyBankMember rna:TermCLoanMember us-gaap:CommonStockMember 2020-06-01 2020-06-30 0001599901 us-gaap:CommonStockMember 2020-06-17 2020-06-17 0001599901 rna:TwoThousandAndEighteenConvertiblePromissoryNotesMember 2018-12-31 0001599901 rna:TwoThousandAndNineteenConvertiblePromissoryNotesMember 2019-12-31 0001599901 rna:TwoThousandAndEighteenConvertiblePromissoryNotesMember 2018-01-01 2018-12-31 0001599901 rna:TwoThousandAndNineteenConvertiblePromissoryNotesMember 2019-01-01 2019-12-31 0001599901 rna:LillyConvertiblePromissoryNotesMember 2019-04-01 2019-04-30 0001599901 us-gaap:ConvertibleNotesPayableMember rna:SeriesCConvertiblePreferredStockMember 2019-11-01 2019-11-30 0001599901 us-gaap:ConvertibleNotesPayableMember rna:SeriesCConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001599901 rna:LeaseTermThroughNovemberTwoThousandAndSeventeenMember rna:OfficeAndLaboratorySpaceMember 2021-01-01 2021-12-31 0001599901 rna:LeaseTermThroughDecemberTwoThousandAndTwentyOneMember rna:OfficeAndLaboratorySpaceMember 2021-01-01 2021-12-31 0001599901 rna:NewLeaseMember rna:OfficeAndLaboratorySpaceMember 2021-01-01 2021-12-31 0001599901 rna:NewLeaseMember rna:OfficeAndLaboratorySpaceMember 2020-12-18 2020-12-18 0001599901 rna:NewLeaseMember rna:OfficeAndLaboratorySpaceMember 2020-12-18 0001599901 rna:TemporaryLeaseMember rna:OfficeAndLaboratorySpaceMember 2020-12-18 2020-12-18 0001599901 2020-06-16 0001599901 2019-04-01 0001599901 rna:SeriesCConvertiblePreferredStockMember 2019-11-30 0001599901 rna:SeriesCConvertiblePreferredStockMember 2020-01-31 0001599901 rna:SeriesCConvertiblePreferredStockMember 2019-11-01 2019-11-30 0001599901 rna:SeriesCConvertiblePreferredStockMember 2020-01-01 2020-01-31 0001599901 us-gaap:CommonStockMember us-gaap:IPOMember 2020-06-01 2020-06-30 0001599901 rna:TwoThousandThirteenEquityIncentivePlanMember 2013-01-31 0001599901 rna:TwoThousandTwentyIncentiveAwardPlanMember 2020-06-30 0001599901 rna:TwoThousandTwentyIncentiveAwardPlanMember 2021-01-01 2021-12-31 0001599901 srt:MaximumMember rna:TwoThousandThirteenEquityIncentivePlanMember 2021-01-01 2021-12-31 0001599901 srt:MaximumMember rna:TwoThousandTwentyIncentiveAwardPlanMember 2021-01-01 2021-12-31 0001599901 rna:EmployeeStockPurchasePlanMember 2020-06-30 0001599901 rna:EmployeeStockPurchasePlanMember 2020-06-01 2020-06-30 0001599901 rna:EmployeeStockPurchasePlanMember 2021-12-31 0001599901 rna:EmployeeStockPurchasePlanMember 2021-01-01 2021-12-31 0001599901 rna:EmployeeStockPurchasePlanMember 2020-01-01 2020-12-31 0001599901 us-gaap:AccountsPayableAndAccruedLiabilitiesMember rna:EmployeeStockPurchasePlanMember 2021-12-31 0001599901 srt:MinimumMember 2020-01-01 2020-12-31 0001599901 srt:MinimumMember 2019-01-01 2019-12-31 0001599901 srt:MaximumMember 2020-01-01 2020-12-31 0001599901 srt:MaximumMember 2019-01-01 2019-12-31 0001599901 srt:MinimumMember rna:EmployeeStockPurchasePlanMember 2021-01-01 2021-12-31 0001599901 srt:MinimumMember rna:EmployeeStockPurchasePlanMember 2020-01-01 2020-12-31 0001599901 srt:MaximumMember rna:EmployeeStockPurchasePlanMember 2021-01-01 2021-12-31 0001599901 srt:MaximumMember rna:EmployeeStockPurchasePlanMember 2020-01-01 2020-12-31 0001599901 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001599901 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001599901 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001599901 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001599901 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001599901 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001599901 rna:TimeBasedOptionsMember 2021-12-31 0001599901 rna:TimeBasedOptionsMember 2021-01-01 2021-12-31 0001599901 rna:CommonStockOptionIssuedAndOutstandingMember 2021-12-31 0001599901 rna:CommonStockOptionIssuedAndOutstandingMember 2020-12-31 0001599901 rna:EquityAwardsAvailableForFutureIssuanceUnderEquityPlansMember 2021-12-31 0001599901 rna:EquityAwardsAvailableForFutureIssuanceUnderEquityPlansMember 2020-12-31 0001599901 rna:CommonStockAuthorizedUnderESPPMember 2021-12-31 0001599901 rna:CommonStockAuthorizedUnderESPPMember 2020-12-31 0001599901 us-gaap:DomesticCountryMember 2021-12-31 0001599901 us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0001599901 us-gaap:DomesticCountryMember 2021-01-01 2021-12-31 0001599901 us-gaap:StateAndLocalJurisdictionMember 2021-01-01 2021-12-31 0001599901 us-gaap:DomesticCountryMember rna:OrphanDrugTaxCreditsMember 2021-12-31 0001599901 us-gaap:DomesticCountryMember rna:OrphanDrugTaxCreditsMember 2021-01-01 2021-12-31 0001599901 us-gaap:CommonStockMember us-gaap:SubsequentEventMember rna:SalesAgreementMember 2022-01-01 2022-03-01 shares iso4217:USD iso4217:USD shares pure rna:Segment rna:Product rna:Obligation rna:Installment false 2021 FY --12-31 0001599901 1 true true true true true 1 P5Y P5Y P4Y 0 0 http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember P8Y6M P8Y6M P7Y9M18D 0.005 0.003 0.014 0.86 0.88 0.84 P5Y6M P5Y4M24D P2Y 0.013 0.015 0.027 0.88 0.92 0.88 P6Y1M6D P6Y1M6D P6Y1M6D 0.001 0.69 0.75 P6M P6M 0.002 0.75 0.96 10-K true 2021-12-31 false 001-39321 AVIDITY BIOSCIENCES, INC. DE 46-1336960 10578 Science Center Drive Suite 125 San Diego CA 92121 858 401-7900 Common Stock, par value $0.0001 per share RNA NASDAQ Yes No Yes Yes Large Accelerated Filer false false true false 798100000 47754677 243 BDO USA, LLP San Diego, California 320448000 321462000 85095000 6679000 5598000 3537000 411141000 331678000 4805000 1468000 251000 251000 10784000 454000 599000 47000 427580000 333898000 14085000 7745000 8940000 3152000 1769000 0 4864000 3690000 29658000 14587000 9960000 938000 6532000 12150000 46150000 27675000 0.0001 0.0001 40000000 40000000 0 0 0 0 0 0 0.0001 0.0001 400000000 400000000 47754000 47754000 37569000 37569000 5000 4000 566161000 372764000 -187000 -5000 -184549000 -66540000 381430000 306223000 427580000 333898000 9326000 6787000 2319000 101182000 37602000 14539000 26195000 13462000 5112000 127377000 51064000 19651000 -118051000 -44277000 -17332000 104000 206000 0 0 209000 7387000 0 75000 15000 -62000 0 0 42000 -78000 -7402000 -118009000 -44355000 -24734000 -182000 -5000 0 -118191000 -44360000 -24734000 -2.85 -2.05 -9.12 41428000 21663000 2713000 12459000 32693000 2842000 426000 -41555000 -41129000 106000 78000 38000 38000 17000 17000 -2549000 -2549000 -12459000 -32587000 12459000 32587000 -2920000 -481000 2920000 -43623000 44104000 4100000 17915000 72623000 6893000 29510000 69000 26000 26000 36000 36000 389000 389000 -22185000 -22185000 37267000 134720000 2989000 -43172000 -22185000 -65357000 100000 538000 2200000 24026000 16560000 2000 274052000 274054000 -37805000 -136920000 17921000 2000 136918000 136920000 120000 120000 16000 54000 22000 22000 29000 444000 444000 70000 70000 4310000 4310000 -44355000 -44355000 -5000 -5000 37569000 4000 372764000 -5000 -66540000 306223000 11262000 9980000 1000 174676000 174677000 172000 930000 930000 33000 709000 709000 26000 26000 17056000 17056000 -118009000 -118009000 -182000 -182000 47754000 5000 566161000 -187000 -184549000 381430000 -118009000 -44355000 -24734000 639000 373000 348000 17056000 4310000 406000 -179000 -9000 0 0 29000 71000 16000 0 0 0 110000 7027000 0 75000 15000 2510000 2444000 949000 6043000 5749000 436000 5788000 1838000 1010000 461000 289000 -80000 -4444000 -3100000 18940000 -94813000 -37117000 2490000 85357000 6693000 0 6580000 0 0 3740000 1092000 235000 -82517000 -7785000 -235000 185939000 298080000 0 11262000 24026000 0 930000 22000 65000 709000 444000 0 0 4683000 2800000 0 0 -106000 0 2200000 72623000 0 0 19451000 176316000 272037000 89233000 -1014000 227135000 91488000 321713000 94578000 3090000 320699000 321713000 94578000 0 571000 322000 12074000 936000 807000 220000 118000 43000 0 136920000 0 0 0 29510000 0 120000 0 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Description<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.5pt;"> </span>Business and <span style="letter-spacing:0.1pt;">Basis</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.5pt;"> </span>Presentation</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Description of Business</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Avidity Biosciences, Inc. (the Company or Avidity) is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs). The Company’s proprietary AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Formation and Conversion</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was formed under the laws of the State of Delaware in November 2012 as a Delaware limited liability company. In April 2019, pursuant to an Agreement and Plan of Conversion, Avidity Biosciences LLC (Avidity LLC) was converted into Avidity Biosciences, Inc., a Delaware corporation. The entire membership interests of Avidity LLC were converted into securities of Avidity Biosciences, Inc. as follows: (i) each outstanding common unit of Avidity LLC was converted into one share of Avidity Biosciences, Inc.’s common stock; (ii) each outstanding Series A convertible preferred unit of Avidity LLC converted into one share of Avidity Biosciences, Inc.’s Series A convertible preferred stock; and (iii) each outstanding Series B convertible preferred unit of Avidity LLC converted into one share of Avidity Biosciences, Inc.’s Series B convertible preferred stock. All the property, rights, privileges, powers and franchises of Avidity LLC vested in Avidity Biosciences, Inc., and all debts, liabilities and duties of Avidity LLC became debts, liabilities and duties of Avidity Biosciences, Inc. Outstanding convertible notes, warrants and stock awards under Avidity LLC’s employee benefit and incentive compensation plans continued on the same terms and conditions and became binding upon Avidity Biosciences, Inc.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Initial Public Offering</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 16, 2020, the Company completed its initial public offering (IPO) in which it sold 16,560,000 shares of common stock at an offering price of $18.00 per share. Proceeds from the IPO, net of underwriting discounts, commissions and offering costs, were $274.1 million.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, each of the following occurred in connection with the completion of the IPO:</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;font-family:Arial;color:#000000;">the conversion of all outstanding shares of convertible preferred stock into 17,921,069 shares of the Company’s common stock;</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;font-family:Arial;color:#000000;">the adjustment of an outstanding warrant to purchase convertible preferred stock into a warrant to purchase 7,809 shares of the Company’s common stock; and</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;font-family:Arial;color:#000000;">the amendment and restatement of the Company’s certificate of incorporation, authorizing 400,000,000 shares of common stock and 40,000,000 shares of undesignated preferred stock.</span></p></td></tr></table></div> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Reverse Stock Split</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 4, 2020, the Company effected a one-for-2.1095 reverse stock split of its common stock (the Reverse Stock Split). The par value and the authorized shares of the common stock were not adjusted as a result of the Reverse Stock Split. All issued and outstanding common stock and the conversion ratio of the convertible preferred stock have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Liquidity</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 6, 2021, the Company completed a public offering of 9,200,000 shares of its common stock at a public offering price of $18.00 per share. The net proceeds from the offering were $155.1 million, </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">after deducting underwriting discounts, commissions and offering costs. </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 2, 2021, the Company entered into a sales agreement (the Sales Agreement) with Cowen and Company, LLC (the Sales Agent), under which the Company may, from time to time, sell shares of its common stock having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150.0</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million through the Sales Agent. During the year ended </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company sold </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">780,549</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of its common stock pursuant to the Sales Agreement and received net proceeds of $</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.6</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million, after deducting offering-related transaction costs and commissions. </span><span style="color:#000000;">See Note 10 (Stockholders Equity (Deficit)) for more information</span><span style="color:#000000;"> on the Company’s public offerings</span><span style="color:#000000;">.</span></p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the Company has devoted substantially all of its resources to organizing and staffing the company, business planning, raising capital, developing its proprietary AOC platform, identifying potential product candidates, establishing its intellectual property portfolio, conducting research, preclinical and clinical studies, and providing other general and administrative support for these operations. In addition, the Company has a limited operating history, has incurred operating losses since inception and expects that it will continue to incur net losses into the foreseeable future as it continues the development of its product candidates and development programs. As of December 31, 2021, the Company had an accumulated deficit of $184.5 million and cash, cash equivalents and marketable securities of $405.5 million.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that existing cash, cash equivalents and marketable securities will be sufficient to fund the Company’s operations for at least 12 months from the date of the filing of this Form 10-K. The Company plans to finance its future cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. If the Company is not able to secure adequate additional funding, it may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or delay or reduce the scope of its planned development programs. Any of these actions could materially harm the Company’s business, results of operations and future prospects.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Basis of Presentation</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC). The financial statements reflect all adjustments which, in the opinion of management, are necessary for a fair statement of the results for the periods presented. All such adjustments are of a normal and recurring nature. The operating results presented in these financial statements are not necessarily indicative of the results that may be expected for any future periods.</p> 1 1 1 16560000 18.00 274100000 17921069 7809 400000000 40000000 On June 4, 2020, the Company effected a one-for-2.1095 reverse stock split of its common stock (the Reverse Stock Split). 2.1095 9200000 18.00 155100000 150000000.0 780549000 19600000 -184500000 405500000 <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Basis of Presentation</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC). The financial statements reflect all adjustments which, in the opinion of management, are necessary for a fair statement of the results for the periods presented. All such adjustments are of a normal and recurring nature. The operating results presented in these financial statements are not necessarily indicative of the results that may be expected for any future periods.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.85%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="font-weight:normal;color:#000000;"/><span style="font-size:10pt;font-family:Arial;color:#000000;">Summary</span><span style="font-size:10pt;font-family:Arial;letter-spacing:0.05pt;color:#000000;"> </span><span style="font-size:10pt;font-family:Arial;letter-spacing:0.15pt;color:#000000;">of</span><span style="font-size:10pt;font-family:Arial;letter-spacing:-0.45pt;color:#000000;"> </span><span style="font-size:10pt;font-family:Arial;color:#000000;">Significant</span><span style="font-size:10pt;font-family:Arial;letter-spacing:-0.5pt;color:#000000;"> </span><span style="font-size:10pt;font-family:Arial;color:#000000;">Accounting</span><span style="font-size:10pt;font-family:Arial;letter-spacing:0.05pt;color:#000000;"> </span><span style="font-size:10pt;font-family:Arial;letter-spacing:0.1pt;color:#000000;">Policies</span></p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s financial statements<span style="letter-spacing:-0.45pt;"> </span>are<span style="letter-spacing:-0.35pt;"> </span>prepared<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.1pt;">accordance</span><span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.15pt;"> GAAP, which</span><span style="letter-spacing:-0.45pt;"> </span>requires<span style="letter-spacing:-0.5pt;"> the Company </span>to<span style="letter-spacing:-0.2pt;"> </span>make<span style="letter-spacing:-0.3pt;"> </span>estimates <span style="letter-spacing:0.1pt;">and assumptions </span><span style="letter-spacing:0.15pt;">that </span><span style="letter-spacing:0.1pt;">impact </span><span style="letter-spacing:0.15pt;">the </span>reported <span style="letter-spacing:0.15pt;">amounts of </span>assets, <span style="letter-spacing:0.15pt;">liabilities, </span><span style="letter-spacing:0.1pt;">revenues and expenses and </span><span style="letter-spacing:0.15pt;">the </span><span style="letter-spacing:0.1pt;">disclosure </span><span style="letter-spacing:0.15pt;">of </span><span style="letter-spacing:0.2pt;">contingent </span>assets <span style="letter-spacing:0.1pt;">and </span><span style="letter-spacing:0.15pt;">liabilities in the financial statements and accompanying notes. The most significant estimates in the Company’s financial statements </span>relate <span style="letter-spacing:0.1pt;">to</span> revenue recognition, stock-based compensation, and accrued research and development costs. <span style="letter-spacing:0.15pt;">Although </span><span style="letter-spacing:0.1pt;">these </span>estimates are based <span style="letter-spacing:0.15pt;">on the </span><span style="letter-spacing:0.1pt;">Company’s</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.15pt;">knowledge</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.65pt;"> </span>current<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.15pt;">events</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.1pt;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">actions</span><span style="letter-spacing:-0.45pt;"> </span>it<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">undertake</span><span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">the</span><span style="letter-spacing:-0.3pt;"> </span>future,<span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:0.1pt;">actual</span><span style="letter-spacing:-0.2pt;"> </span>results<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.1pt;">ultimately</span><span style="letter-spacing:-0.15pt;"> </span>materially<span style="letter-spacing:-0.1pt;"> </span>differ<span style="letter-spacing:-0.65pt;"> </span>from<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.1pt;">these</span><span style="letter-spacing:-0.3pt;"> </span>estimates <span style="letter-spacing:0.1pt;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.1pt;">assumptions.</span></p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Cash, Cash Equivalents and Restricted Cash</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents include cash in readily available checking and money market accounts. Restricted cash represents cash held as collateral for the letter of credit required under the Company’s facility lease and is reported as a long-term asset in the accompanying balance sheets.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Marketable Securities</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s marketable securities consist of corporate debt securities. The Company classifies its marketable securities as available-for-sale and records such assets at estimated fair value in the balance sheets, with unrealized gains and losses, if any, reported as a component of other comprehensive income (loss) within the statements of operations and comprehensive loss and as a separate component of stockholders’ equity. The Company classifies marketable securities with remaining maturities greater than one year as current assets because such marketable securities are available to fund the Company’s current operations. Realized gains and losses are calculated on the specific identification method and recorded as interest income. There were no realized gains and losses for the years ended December 31, 2021, 2020 and 2019.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. When the Company determines that a decline in the fair value below its cost basis is other-than-temporary, the Company recognizes an impairment loss in the period in which the other-than-temporary decline occurred. There have been no other-than-temporary impairments recognized for the years ended December 31, 2021, 2020 and 2019.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments, credit quality, diversification, liquidity and maturities of investments, which are designed to maintain safety and liquidity.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;font-family:Arial;color:#000000;">Level 1—Quoted prices in active markets for identical assets or liabilities.</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;font-family:Arial;color:#000000;">Level 2—Observable inputs, such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;font-family:Arial;color:#000000;">Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></p></td></tr></table></div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None of the Company’s non-financial assets are recorded at fair value on a non-recurring basis. <span style="color:#000000;">The carrying amounts reflected in the Company’s balance sheets for prepaid and other assets and accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The carrying value of the Company’s previously outstanding debt approximated fair value due to the interest being reflective of then-current market rates for debt with similar terms and conditions. </span>The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. No transfers between levels have occurred <span style="color:#000000;">during the periods presented</span>.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 3 (Fair Value Measurements) for information on assets and liabilities measured at fair value.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Property and Equipment</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, including leasehold improvements, are stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recorded using the straight-line method over the estimated useful lives of the related assets, which ranges from three to five years. Leasehold improvements are amortized on a straight-line basis over the shorter of the estimated useful lives of the assets or the remaining lease term. Repairs and maintenance charges that do not increase the useful life of the assets are charged to operating expenses as incurred.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets consist of property and equipment. An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. The Company has not recognized any impairment losses in any of the periods presented in these financial statements.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Segment Information</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by management in making decisions regarding resource allocation and assessing performance. The Company manages its operations as a <span style="-sec-ix-hidden:F_000447">single</span> operating segment in the United States for the purposes of assessing performance and making operating decisions. </p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Revenue Recognition</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, all the Company’s revenue has been derived from collaboration and research agreements.<span style="color:#000000;"> The terms of these arrangements include the following types of payments to the Company: non-refundable, upfront license fees; development, regulatory and commercial milestone payments; payments for research and development services provided by the Company or for manufacturing supply services the Company provides through its contract manufacturers; and royalties on net sales of licensed products.</span></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January 1, 2019, the Company adopted Accounting Standards Update (ASU) No. 2014-09,<span style="font-style:italic;"> Revenue from Contracts with Customers (Topic 606),</span> which supersedes all existing revenue recognition requirements, using the modified retrospective approach. This new standard requires a company to recognize revenues when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. An adjustment to retained earnings was not required upon adoption as the Company had no revenue generating agreements in effect on the date of adoption.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with Topic 606, the Company <span style="color:#000000;">performs the following steps in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of these agreements: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as, the Company satisfies each performance obligation.</span></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company receives payments from its collaborators based on billing schedules established in each contract. Upfront and other payments may require deferral of revenue recognition to a future period until the Company performs its obligations under its research and collaboration arrangements. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note </span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (Collaboration</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> License </span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Research </span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) for further information. </span></p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Research and Development Costs</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred and include salaries, benefits and stock-based compensation associated with research and development personnel, third-party research and development expenses, license fees, laboratory supplies, facilities, overhead costs, and consultants. Nonrefundable advance payments for goods and services that will be used in future research and development activities are capitalized and recorded as expense in the period that the Company receives the goods or when services are performed.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront and milestone payments to acquire contractual rights to licensed technology are recorded when incurred if there is uncertainty in the Company receiving future economic benefit from the acquired contractual rights. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Patent Costs </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain. </p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Income Taxes</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes in accordance with Accounting Standards Codification (ASC) 740, <span style="font-style:italic;">Income Taxes</span>, which provides for deferred taxes using the asset and liability method. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to taxation in the United States and various state jurisdictions. As of December 31, 2021, the Company’s tax years since conversion to a corporation in 2019 are subject to examination by taxing authorities.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Stock-Based Compensation</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense for employee and non-employee stock option grants is recorded at the estimated fair value of the award as of the grant date and is recognized as expense on a straight-line basis over the requisite service period (usually the vesting period) of the stock-based award, and forfeitures are recognized as incurred. Stock-based compensation expense for employee stock purchases under the Company’s Employee Stock Purchase Plan (the ESPP) is recorded at the estimated fair value of the purchase as of the plan enrollment date and is recognized as expense on a straight-line basis over the applicable six-month ESPP offering period. The estimation of fair value for stock-based compensation requires management to make estimates and judgments about, among other things, the estimated life of options and volatility of the Company’s common stock. The judgments directly affect the amount of compensation expense that will be recognized.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Comprehensive Loss</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on marketable securities. Comprehensive gains (losses) have been reflected in the statements of operations and comprehensive loss for all periods presented.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Net Loss Per Share/Unit</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share/unit is computed by dividing the net loss by the weighted-average number of common shares/units outstanding for the period, adjusted for the weighted-average number of common shares/units outstanding that are subject to repurchase or forfeiture. The Company has excluded 33,600, 123,285 and 217,524 weighted-average shares/units subject to repurchase or forfeiture from the weighted-average number of common shares/units outstanding for the years ended December 31, 2021, 2020 and 2019, respectively. Diluted net loss per share/unit is computed by dividing the net loss by the weighted-average number of common shares/units and dilutive common stock/unit equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For all periods presented, there is no difference in the number of shares/units used to calculate basic and diluted shares/units outstanding as inclusion of the potentially dilutive securities would be anti-dilutive.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potentially dilutive securities not included in the calculation of diluted net loss per share/unit, because to do so would be anti-dilutive, are as follows (in common stock/unit equivalent shares; in thousands):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,666</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant to purchase convertible preferred stock</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant to purchase common stock</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options issued and outstanding</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,778</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,788</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,667</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock subject to repurchase or</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   forfeiture</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">195</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ESPP shares pending issuance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,796</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,858</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,545</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements<span style="font-size:12pt;font-style:normal;"> </span></p> <p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing certain separation models required under existing guidance. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and amends the diluted earnings-per-share (EPS) calculation guidance in certain areas to improve the consistency of EPS calculations. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020. The Company early adopted the new standard, effective January 1, 2021, on a modified retrospective basis. The adoption of ASU 2020-06 had no impact on the Company's financial statements and related disclosures.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. The Company </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s financial statements<span style="letter-spacing:-0.45pt;"> </span>are<span style="letter-spacing:-0.35pt;"> </span>prepared<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.1pt;">accordance</span><span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.15pt;"> GAAP, which</span><span style="letter-spacing:-0.45pt;"> </span>requires<span style="letter-spacing:-0.5pt;"> the Company </span>to<span style="letter-spacing:-0.2pt;"> </span>make<span style="letter-spacing:-0.3pt;"> </span>estimates <span style="letter-spacing:0.1pt;">and assumptions </span><span style="letter-spacing:0.15pt;">that </span><span style="letter-spacing:0.1pt;">impact </span><span style="letter-spacing:0.15pt;">the </span>reported <span style="letter-spacing:0.15pt;">amounts of </span>assets, <span style="letter-spacing:0.15pt;">liabilities, </span><span style="letter-spacing:0.1pt;">revenues and expenses and </span><span style="letter-spacing:0.15pt;">the </span><span style="letter-spacing:0.1pt;">disclosure </span><span style="letter-spacing:0.15pt;">of </span><span style="letter-spacing:0.2pt;">contingent </span>assets <span style="letter-spacing:0.1pt;">and </span><span style="letter-spacing:0.15pt;">liabilities in the financial statements and accompanying notes. The most significant estimates in the Company’s financial statements </span>relate <span style="letter-spacing:0.1pt;">to</span> revenue recognition, stock-based compensation, and accrued research and development costs. <span style="letter-spacing:0.15pt;">Although </span><span style="letter-spacing:0.1pt;">these </span>estimates are based <span style="letter-spacing:0.15pt;">on the </span><span style="letter-spacing:0.1pt;">Company’s</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.15pt;">knowledge</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.65pt;"> </span>current<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.15pt;">events</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.1pt;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">actions</span><span style="letter-spacing:-0.45pt;"> </span>it<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">undertake</span><span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">the</span><span style="letter-spacing:-0.3pt;"> </span>future,<span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:0.1pt;">actual</span><span style="letter-spacing:-0.2pt;"> </span>results<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.1pt;">ultimately</span><span style="letter-spacing:-0.15pt;"> </span>materially<span style="letter-spacing:-0.1pt;"> </span>differ<span style="letter-spacing:-0.65pt;"> </span>from<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.1pt;">these</span><span style="letter-spacing:-0.3pt;"> </span>estimates <span style="letter-spacing:0.1pt;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.1pt;">assumptions.</span></p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Cash, Cash Equivalents and Restricted Cash</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents include cash in readily available checking and money market accounts. Restricted cash represents cash held as collateral for the letter of credit required under the Company’s facility lease and is reported as a long-term asset in the accompanying balance sheets.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Marketable Securities</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s marketable securities consist of corporate debt securities. The Company classifies its marketable securities as available-for-sale and records such assets at estimated fair value in the balance sheets, with unrealized gains and losses, if any, reported as a component of other comprehensive income (loss) within the statements of operations and comprehensive loss and as a separate component of stockholders’ equity. The Company classifies marketable securities with remaining maturities greater than one year as current assets because such marketable securities are available to fund the Company’s current operations. Realized gains and losses are calculated on the specific identification method and recorded as interest income. There were no realized gains and losses for the years ended December 31, 2021, 2020 and 2019.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. When the Company determines that a decline in the fair value below its cost basis is other-than-temporary, the Company recognizes an impairment loss in the period in which the other-than-temporary decline occurred. There have been no other-than-temporary impairments recognized for the years ended December 31, 2021, 2020 and 2019.</p> 0 0 0 0 0 0 <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments, credit quality, diversification, liquidity and maturities of investments, which are designed to maintain safety and liquidity.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;font-family:Arial;color:#000000;">Level 1—Quoted prices in active markets for identical assets or liabilities.</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;font-family:Arial;color:#000000;">Level 2—Observable inputs, such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;font-family:Arial;color:#000000;">Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></p></td></tr></table></div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None of the Company’s non-financial assets are recorded at fair value on a non-recurring basis. <span style="color:#000000;">The carrying amounts reflected in the Company’s balance sheets for prepaid and other assets and accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The carrying value of the Company’s previously outstanding debt approximated fair value due to the interest being reflective of then-current market rates for debt with similar terms and conditions. </span>The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. No transfers between levels have occurred <span style="color:#000000;">during the periods presented</span>.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 3 (Fair Value Measurements) for information on assets and liabilities measured at fair value.</p> 0 0 0 0 0 0 0 0 <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Property and Equipment</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, including leasehold improvements, are stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recorded using the straight-line method over the estimated useful lives of the related assets, which ranges from three to five years. Leasehold improvements are amortized on a straight-line basis over the shorter of the estimated useful lives of the assets or the remaining lease term. Repairs and maintenance charges that do not increase the useful life of the assets are charged to operating expenses as incurred.</p> P3Y P5Y <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets consist of property and equipment. An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. The Company has not recognized any impairment losses in any of the periods presented in these financial statements.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Segment Information</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by management in making decisions regarding resource allocation and assessing performance. The Company manages its operations as a <span style="-sec-ix-hidden:F_000447">single</span> operating segment in the United States for the purposes of assessing performance and making operating decisions. </p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Revenue Recognition</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, all the Company’s revenue has been derived from collaboration and research agreements.<span style="color:#000000;"> The terms of these arrangements include the following types of payments to the Company: non-refundable, upfront license fees; development, regulatory and commercial milestone payments; payments for research and development services provided by the Company or for manufacturing supply services the Company provides through its contract manufacturers; and royalties on net sales of licensed products.</span></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January 1, 2019, the Company adopted Accounting Standards Update (ASU) No. 2014-09,<span style="font-style:italic;"> Revenue from Contracts with Customers (Topic 606),</span> which supersedes all existing revenue recognition requirements, using the modified retrospective approach. This new standard requires a company to recognize revenues when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. An adjustment to retained earnings was not required upon adoption as the Company had no revenue generating agreements in effect on the date of adoption.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with Topic 606, the Company <span style="color:#000000;">performs the following steps in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of these agreements: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as, the Company satisfies each performance obligation.</span></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company receives payments from its collaborators based on billing schedules established in each contract. Upfront and other payments may require deferral of revenue recognition to a future period until the Company performs its obligations under its research and collaboration arrangements. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note </span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (Collaboration</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> License </span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Research </span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) for further information. </span></p> 2019-01-01 <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Research and Development Costs</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred and include salaries, benefits and stock-based compensation associated with research and development personnel, third-party research and development expenses, license fees, laboratory supplies, facilities, overhead costs, and consultants. Nonrefundable advance payments for goods and services that will be used in future research and development activities are capitalized and recorded as expense in the period that the Company receives the goods or when services are performed.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront and milestone payments to acquire contractual rights to licensed technology are recorded when incurred if there is uncertainty in the Company receiving future economic benefit from the acquired contractual rights. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Patent Costs </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain. </p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Income Taxes</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes in accordance with Accounting Standards Codification (ASC) 740, <span style="font-style:italic;">Income Taxes</span>, which provides for deferred taxes using the asset and liability method. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to taxation in the United States and various state jurisdictions. As of December 31, 2021, the Company’s tax years since conversion to a corporation in 2019 are subject to examination by taxing authorities.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Stock-Based Compensation</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense for employee and non-employee stock option grants is recorded at the estimated fair value of the award as of the grant date and is recognized as expense on a straight-line basis over the requisite service period (usually the vesting period) of the stock-based award, and forfeitures are recognized as incurred. Stock-based compensation expense for employee stock purchases under the Company’s Employee Stock Purchase Plan (the ESPP) is recorded at the estimated fair value of the purchase as of the plan enrollment date and is recognized as expense on a straight-line basis over the applicable six-month ESPP offering period. The estimation of fair value for stock-based compensation requires management to make estimates and judgments about, among other things, the estimated life of options and volatility of the Company’s common stock. The judgments directly affect the amount of compensation expense that will be recognized.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Comprehensive Loss</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on marketable securities. Comprehensive gains (losses) have been reflected in the statements of operations and comprehensive loss for all periods presented.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Net Loss Per Share/Unit</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share/unit is computed by dividing the net loss by the weighted-average number of common shares/units outstanding for the period, adjusted for the weighted-average number of common shares/units outstanding that are subject to repurchase or forfeiture. The Company has excluded 33,600, 123,285 and 217,524 weighted-average shares/units subject to repurchase or forfeiture from the weighted-average number of common shares/units outstanding for the years ended December 31, 2021, 2020 and 2019, respectively. Diluted net loss per share/unit is computed by dividing the net loss by the weighted-average number of common shares/units and dilutive common stock/unit equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For all periods presented, there is no difference in the number of shares/units used to calculate basic and diluted shares/units outstanding as inclusion of the potentially dilutive securities would be anti-dilutive.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potentially dilutive securities not included in the calculation of diluted net loss per share/unit, because to do so would be anti-dilutive, are as follows (in common stock/unit equivalent shares; in thousands):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,666</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant to purchase convertible preferred stock</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant to purchase common stock</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options issued and outstanding</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,778</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,788</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,667</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock subject to repurchase or</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   forfeiture</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">195</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ESPP shares pending issuance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,796</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,858</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,545</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 33600 123285 217524 <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potentially dilutive securities not included in the calculation of diluted net loss per share/unit, because to do so would be anti-dilutive, are as follows (in common stock/unit equivalent shares; in thousands):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,666</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant to purchase convertible preferred stock</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant to purchase common stock</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options issued and outstanding</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,778</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,788</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,667</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock subject to repurchase or</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   forfeiture</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">195</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ESPP shares pending issuance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,796</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,858</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,545</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 0 0 17666000 0 0 8000 0 0 9000 5778000 3788000 1667000 15000 69000 195000 3000 1000 0 5796000 3858000 19545000 <p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements<span style="font-size:12pt;font-style:normal;"> </span></p> <p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing certain separation models required under existing guidance. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and amends the diluted earnings-per-share (EPS) calculation guidance in certain areas to improve the consistency of EPS calculations. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020. The Company early adopted the new standard, effective January 1, 2021, on a modified retrospective basis. The adoption of ASU 2020-06 had no impact on the Company's financial statements and related disclosures.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. The Company </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p> 2021-01-01 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.85%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="font-weight:normal;color:#000000;"/><span style="font-size:10pt;font-family:Arial;color:#000000;">Fair Value Measurements</span></p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines the fair value of its cash equivalents and marketable securities based on one or more valuations from its investment accounting and reporting service provider. The investment service provider values the securities using a hierarchical security pricing model that relies primarily on valuations provided by an industry-recognized valuation service. Such valuations may be based on trade prices in active markets for identical assets (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets, yield curves, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, and broker and dealer quotes, as well as other relevant economic measures.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the Company’s cash equivalents and marketable securities measured at fair value (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements Using</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices in</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Active Markets</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">for Identical</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Assets (Level 1)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Significant</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Other</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Observable</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Inputs (Level 2)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Significant</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unobservable</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,372</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,372</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Negotiable certificates of deposit</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,873</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,873</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,850</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,850</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.6%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,095</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,372</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,723</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements Using</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices in</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Active Markets</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">for Identical</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Assets (Level 1)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Significant</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Other</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Observable</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Inputs (Level 2)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Significant</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unobservable</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Negotiable certificates of deposit</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">720</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">720</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,679</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,679</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.6%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,399</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,399</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to completion of the IPO in June 2020, the Company had an outstanding warrant to purchase shares of its Series A convertible preferred stock. Since the underlying Series A convertible preferred stock was classified outside of permanent equity, the preferred stock warrant was classified as other long-term liabilities in the accompanying balance sheet. The preferred stock warrant liability was recorded at fair value utilizing the Black-Scholes model using significant unobservable inputs adjusted for the preferred stock warrant’s expected life and the fair value of the underlying convertible preferred stock. The Company adjusted the carrying value of the preferred stock warrant to its estimated fair value at each reporting date, with any related increase or decrease in the fair value recorded as an increase or decrease to other income (expense) in the statements of operations and comprehensive loss.<span style="color:#000000;"> In connection with the IPO, the preferred stock warrant was adjusted to become a warrant to purchase shares of the Company’s common stock and met the criteria to be classified within stockholders’ equity. Accordingly, the fair value of the warrant liability was reclassified to stockholders’ equity.</span> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of the preferred stock warrant liability measured at fair value using Level 3 unobservable inputs (in thousands):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2018</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of warrant liability</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   to stockholders’ equity</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(120</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr style="height:11.6pt;"> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the Company’s cash equivalents and marketable securities measured at fair value (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements Using</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices in</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Active Markets</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">for Identical</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Assets (Level 1)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Significant</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Other</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Observable</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Inputs (Level 2)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Significant</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unobservable</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,372</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,372</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Negotiable certificates of deposit</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,873</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,873</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,850</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,850</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.6%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,095</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,372</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,723</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements Using</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices in</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Active Markets</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">for Identical</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Assets (Level 1)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Significant</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Other</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Observable</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Inputs (Level 2)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Significant</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unobservable</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Negotiable certificates of deposit</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">720</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">720</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,679</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,679</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.6%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,399</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,399</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 65372000 65372000 0 0 3873000 0 3873000 0 15850000 0 15850000 0 85095000 65372000 19723000 0 720000 0 720000 0 6679000 0 6679000 0 7399000 0 7399000 0 <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of the preferred stock warrant liability measured at fair value using Level 3 unobservable inputs (in thousands):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2018</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of warrant liability</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   to stockholders’ equity</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(120</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr style="height:11.6pt;"> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 30000 15000 45000 75000 -120000 0 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="font-weight:normal;color:#000000;"/><span style="font-size:10pt;font-family:Arial;color:#000000;">Marketable Securities</span></p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s marketable securities, which consist of highly liquid marketable debt securities, are classified as available-for-sale and are stated at fair value. The following tables summarize the Company’s marketable securities (in thousands):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Maturity</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 or less</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,492</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,491</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Negotiable certificates of deposit</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 or less</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,190</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,189</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 - 2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,034</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(153</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,881</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Negotiable certificates of deposit</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 - 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,687</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,684</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 - 2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,879</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,850</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,282</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(187</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,095</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Maturity</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 or less</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,612</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,610</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 - 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,072</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,069</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,684</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,679</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;"> </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s marketable securities, which consist of highly liquid marketable debt securities, are classified as available-for-sale and are stated at fair value. The following tables summarize the Company’s marketable securities (in thousands):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Maturity</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 or less</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,492</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,491</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Negotiable certificates of deposit</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 or less</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,190</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,189</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 - 2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,034</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(153</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,881</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Negotiable certificates of deposit</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 - 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,687</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,684</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 - 2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,879</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,850</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,282</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(187</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,095</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Maturity</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 or less</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,612</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,610</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 - 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,072</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,069</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,684</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,679</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 2492000 0 1000 2491000 1190000 0 1000 1189000 63034000 0 153000 62881000 2687000 0 3000 2684000 15879000 0 29000 15850000 85282000 0 187000 85095000 3612000 0 2000 3610000 3072000 0 3000 3069000 6684000 0 5000 6679000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="font-weight:normal;color:#000000;"/><span style="font-size:10pt;font-family:Arial;color:#000000;">Collaboration, License and Research Agreements</span></p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Research Collaboration and License Agreement with Eli Lilly and Company</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2019, the Company entered into a Research Collaboration and License Agreement (the Lilly Agreement) with Eli Lilly and Company (Lilly) for the discovery, development and commercialization of AOC products directed against certain targets in immunology and other select indications on a worldwide basis. Under the Lilly Agreement, the Company granted Lilly an exclusive, worldwide, royalty-bearing license, with the right to sublicense (subject to certain conditions), under the Company’s technology to research, develop, manufacture and sell products containing AOCs that are directed to up to six mRNA targets. The Company retains the right to use its technology to perform its obligations under the Lilly Agreement and for all purposes not granted to Lilly. The Company agreed that it will not, itself or with a third party, research, develop, manufacture or commercialize or otherwise exploit any compound or product directed against targets subject to the Lilly Agreement.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration of the rights granted to Lilly under the Lilly Agreement, the Company received a one-time upfront fee of $20.0 million and is eligible to receive up to $60.0 million in development milestone payments, up to $140.0 million in regulatory milestone payments and up to $205.0 million in commercialization milestone payments per target. In addition, Lilly is obligated to reimburse the Company for research expenses, as defined in and incurred under the Lilly Agreement. Lilly is obligated to pay the Company a tiered royalty ranging from the mid-single to low-double digits on worldwide annual net sales of licensed products, subject to specified and capped reductions for the market entry of biosimilar products, loss of patent coverage of licensed products and for payments owed to third parties for additional rights necessary to commercialize licensed products in the territory. Lilly’s royalty obligations and the Lilly </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement will expire on a licensed product-by-licensed product and country-by-country basis on the later of </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ten years</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> from the date of the first commercial sale or when there is no longer a valid patent claim covering such licensed product in such country.</span></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has identified multiple promises to deliver goods and services, which include at inception of the agreement: (i) a license to technology and patents, information and know-how; and (ii) collaboration, including research services, technical and regulatory support provided by the Company. At inception and through December 31, 2021, the Company has identified one performance obligation for all the deliverables under the Lilly Agreement since the delivered elements are either not capable of being distinct or are not distinct within the context of the contract. Accordingly, the Company will recognize revenue for the fixed or determinable collaboration <span style="Background-color:#FFFFFF;color:#000000;">in an amount proportional to the collaboration expenses incurred and the total estimated collaboration expenses </span>over the <span style="-sec-ix-hidden:F_000555">five-year</span> period over which it expects to deliver its performance obligations. The Company periodically reviews and updates the estimated collaboration expenses, when appropriate, which adjusts the percentage of revenue that is recognized for the period. In connection with the Lilly Agreement, the Company recognized revenue of $9.1 million, $6.8 million and $2.3 million for the years ended December 31, 2021, 2020 and 2019, respectively, and had deferred revenue of $11.1 million and $15.8 million as of December 31, 2021 and 2020, respectively. Collaboration receivables related to the Lilly Agreement were $0.9 million and $1.2 million as of December 31, 2021 and 2020, respectively, which are included in prepaid and other assets on the balance sheets.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the closing balance of deferred revenue related to the Lilly Agreement is as follows (in thousands):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,940</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,100</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,840</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,732</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,108</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrently with the execution of the Lilly Agreement, the Company issued a convertible promissory note to Lilly (the Lilly Note). In connection with the Series C financing in November 2019, all outstanding principal and interest accrued under the Lilly Note converted into 4,576,342 shares of Series C convertible preferred stock. See Note 8 (Convertible Notes) for further discussion.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Research Agreement with MyoKardia, Inc.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, the Company entered into a research collaboration (the MyoKardia Agreement) with MyoKardia, Inc. (MyoKardia),<span style="font-size:12pt;font-family:Times New Roman;"> </span>a wholly-owned subsidiary of Bristol Myers Squibb, to demonstrate the potential utility of AOCs in cardiac tissue by leveraging MyoKardia’s genetic cardiomyopathy platform including, among other aspects, its novel target discovery engine and proprietary cardiac disease models. In connection with the MyoKardia Agreement, the Company recognized revenue of $0.2 million and $0 for the years ended December 31, 2021 and 2020, respectively.</p> 6 20000000.0 60000000.0 140000000.0 205000000.0 P10Y 1 9100000 6800000 2300000 11100000 15800000 900000 1200000 <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the closing balance of deferred revenue related to the Lilly Agreement is as follows (in thousands):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,940</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,100</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,840</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,732</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,108</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 18940000 3100000 15840000 4732000 11108000 4576342 200000 0 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">6</span><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Property and Equipment</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of the following (in thousands):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,775</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,928</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers and software</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office furniture and equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,398</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">417</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, gross</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,538</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,447</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,733</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,979</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, net</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,805</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,468</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense related to property and equipment was $0.6 million, $0.4 million and $0.3 million for the years ended December 31, 2021, 2020 and 2019, respectively.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of the following (in thousands):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,775</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,928</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers and software</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office furniture and equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,398</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">417</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, gross</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,538</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,447</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,733</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,979</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, net</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,805</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,468</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 4775000 2928000 116000 58000 1398000 44000 249000 417000 6538000 3447000 1733000 1979000 4805000 1468000 600000 400000 300000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">7</span><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Debt</p></td></tr></table></div> <p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Term Loan</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2017, the Company entered into an amendment (the LSA Amendment) to the Amended and Restated Loan and Security Agreement (as amended, the LSA) with Silicon Valley Bank (SVB). Pursuant to the LSA Amendment, SVB agreed to make loans of up to $7.0 million, comprising (i) a $5.0 million term loan, funded at the closing date (the Term C Loan), and (ii) subject to the achievement of a specified milestone relating to the Company’s research, an additional term loan totaling up to $2.0 million (the Term D Loan), of which $4.1 million was used to repay the Company’s existing loan with SVB, in addition to the final payments totaling $0.4 million. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Term C Loan was scheduled to mature on June 1, 2021 and bore interest at an adjustable annual rate of the prime rate per the Wall Street Journal plus one-fifth of one percent (0.20%). The LSA Amendment provided an extension of the interest only period through June 1, 2019, upon the Term D Loan advance. Beginning July 1, 2019, the Company was required to repay the principal amount in 36 equal monthly installments, in addition to the monthly interest payment. In addition, a final payment of 6.5% of the funded amount, or $0.3 million, was due on the maturity date. The final payment fee was accrued as interest expense over the term of the loan and recorded in long-term debt, net of current portion. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the Company entered into a second amendment to the LSA (the LSA Second Amendment). Pursuant to the LSA Second Amendment, SVB provided the Term D Loan of $2.0 million, upon the Company’s receipt of $3.0 million in convertible note financing. In addition, a final payment of 6.5% of the funded amount, or $0.1 million, was due on the maturity date. The Company accounted for the financing prospectively as a debt modification.  </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 30, 2020, the Company voluntarily prepaid the aggregate outstanding principal balance of $2.8 million and final payments and accrued interest of $0.5 million related to the Term C and Term D Loans, and the LSA was terminated.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In conjunction with the Term A and Term B Loans, the Company issued a warrant to SVB to purchase up to 16,474 shares of Series A convertible preferred stock at an exercise price of $2.2615 per share, exercisable at any time following the issuance, with a term of ten years. In connection with the completion of the IPO in June 2020, the preferred stock warrant was adjusted to become a warrant exercisable for 7,809 shares of common stock at an exercise price of $4.77 per share. In conjunction with the Term C Loan entered into in June 2017, the Company issued a warrant to SVB to purchase up to 9,442 shares of common stock at an exercise price of $0.53 per share, exercisable at any time following the issuance, with a term of seven years. The Company estimated the fair value of the warrants granted using the Black-Scholes model and recorded the fair value as debt discounts, which were being amortized to interest expense using the </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effective interest method over the term of the loans. On June 17, 2020, the warrants were cashless exercised for an aggregate of </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,833</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of common stock.</span></p> 7000000.0 5000000.0 2000000.0 4100000 400000 2021-06-01 0.0020 36 equal monthly 36 monthly 0.065 300000 2000000.0 3000000.0 0.065 100000 2800000 500000 16474 2.2615 P10Y 7809 4.77 9442 0.53 P7Y 15833 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">8.</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Convertible Notes</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018 and 2019, the Company issued convertible promissory notes in the aggregate principal amount of $3.0 million and $4.5 million, respectively (the 2018 Notes and 2019 Notes, respectively). The 2018 Notes and the 2019 Notes accrued interest at 8% and 10% per annum, respectively, and automatically converted into preferred equity in the next qualified financing of at least $10 million at 85% and 80%, respectively, of the per share price paid by the investors in such financing.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrently with the execution of the Lilly Agreement in April 2019, the Company issued the Lilly Note and received cash proceeds of $15.0 million. The Lilly Note accrued simple interest of 8.0% per annum and, if not converted, would have matured in October 2020. All unpaid principal and interest were due at maturity.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2018 Notes, 2019 Notes and the Lilly Note (collectively, the Notes) represented share settled debt that were accounted for at amortized cost by accreting the Notes to their redemption value over the life of the debt using the effective interest method.  In connection with the Series C financing in November 2019, all outstanding principal and interest accrued under the Notes converted into 6,893,036 shares of Series C convertible preferred stock. The Company recorded interest expense of $6.9 million for the year ended December 31, 2019 for the stated interest rate and the discount at which the Notes converted.</p> 3000000.0 4500000 0.08 0.10 10000000 10000000 0.85 0.80 15000000.0 0.080 2020-10 6893036 6900000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Commitments and Contingencies</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Lease Agreements</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted ASC 842, Leases, as of January 1, 2019. In accordance with ASC 842, the Company determines if an arrangement is a finance lease, operating lease or short-term lease at inception, or as applicable, and accounts for the arrangement under the relevant accounting literature. During the periods presented, the Company was party to various non-cancellable office and laboratory space operating leases and short-term leases. Currently, the Company is only party to a non-cancellable office and laboratory space operating lease. Under the relevant guidance, the Company recognizes operating lease right-of-use (ROU) assets and liabilities based on the present value of the future minimum lease payments over the lease term at the commencement date, using the Company’s assumed incremental borrowing rate of 5.5%, and amortizes the ROU assets and liabilities over the lease term. Lease expense for operating leases is recognized on a straight-line basis over the lease term. The Company’s short-term leases are not subject to recognition of an ROU asset or liability or straight-line lease expense requirements.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2014, the Company entered into a non-cancellable operating lease for office and laboratory space with a lease term through November 2017. In July 2017, the Company entered into an amendment to this lease to extend the lease term through December 2021.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 1, 2020, the Company entered into a second amendment to its existing operating lease (as amended, the 2014 Lease) and entered into a new non-cancellable temporary operating lease in connection with a newly executed non-cancellable operating lease for its new headquarters location, with a projected commencement date of July 1, 2021.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 18, 2020, the Company entered into an amendment to the non-cancellable operating lease for its new headquarters location (as amended, the New Lease), which increased the square footage by adding adjacent space and extended the projected commencement date to November 1, 2021. Additionally, the non-cancellable temporary operating lease was amended (as amended, the Temporary Lease) to accommodate the projected commencement date of the New Lease. The lease term under both the 2014 Lease and the Temporary Lease ends 15 days after the commencement date of the New Lease in November 2021. The remaining monthly rental payments under the 2014 Lease and the rent under the Temporary Lease were abated beginning on June 1, 2020, given the execution of the New Lease. The New </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a </span><span style="-sec-ix-hidden:F_000637"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">five</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-year</span></span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> term upon commencement </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n November 2021 and a renewal option for an additional </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">five years</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the New Lease, the initial monthly base rent of approximately $</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">251,000</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> will increase to approximately $</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">282,000</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> during the last year of the New Lease's initial term</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and the first year includes five months of rent abatement</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total lease payments under the </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">initial term of the </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New Lease of $</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.7</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million were allocated amongst the 2014 Lease, Temporary Lease and New Lease based on the relative standalone price of the separate lease components.</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Furthermore, pursuant to the terms of the New Lease, the Company is required to maintain a letter of credit totaling $</span>251,000<span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> throughout the lease term.</span></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2020, in accordance with the lease terms applicable at that time, the Company adjusted the ROU asset and liability of the 2014 Lease to conform to the modification terms and recorded an ROU asset and liability for the Temporary Lease upon occupancy. In December 2020, in connection with the lease amendments described above, the Company adjusted the ROU asset and liability of the 2014 Lease and Temporary Lease to conform to the modification terms. In November 2021, the Company recognized an ROU asset and liability related to the New Lease in connection with obtaining control of the asset upon occupancy of the new space.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the Company’s ROU assets and liabilities related to the New Lease are as follows (in thousands):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROU assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,784</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities, current portion</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,769</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities, net of current portion</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,960</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,729</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, maturities of the lease liabilities due under the New Lease are as follows (in thousands):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,769</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,113</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,207</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,303</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,111</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,503</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,774</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,729</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less lease liabilities, current portion</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,769</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities, net of current portion</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,960</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information related to cash paid for amounts included in the measurement of operating lease liabilities was as follows (in thousands):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid included in operating cash flows</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">234</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">382</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense was as follows (in thousands):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">946</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">453</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">302</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term leases</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">216</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total rent expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,162</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">489</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">308</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the weighted-average remaining term of the Company’s operating lease was 4.9 years.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Litigation</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. There are no matters currently outstanding for which any liabilities have been accrued.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Contractual Obligations</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into contracts in the normal course of business for contract research services, contract manufacturing services, professional services, and other services and products for operating purposes. These contracts may include certain provisions that could require payments for early termination. The amount of the termination payments vary depending on the timing of the termination and the specific terms of the contract.</p> During the periods presented, the Company was party to various non-cancellable office and laboratory space operating leases and short-term leases. Currently, the Company is only party to a non-cancellable office and laboratory space operating lease. Under the relevant guidance, the Company recognizes operating lease right-of-use (ROU) assets and liabilities based on the present value of the future minimum lease payments over the lease term at the commencement date, using the Company’s assumed incremental borrowing rate of 5.5%, and amortizes the ROU assets and liabilities over the lease term. Lease expense for operating leases is recognized on a straight-line basis over the lease term. The Company’s short-term leases are not subject to recognition of an ROU asset or liability or straight-line lease expense requirements. 0.055 In March 2014, the Company entered into a non-cancellable operating lease for office and laboratory space with a lease term through November 2017. In July 2017, the Company entered into an amendment to this lease to extend the lease term through December 2021. On June 1, 2020, the Company entered into a second amendment to its existing operating lease (as amended, the 2014 Lease) and entered into a new non-cancellable temporary operating lease in connection with a newly executed non-cancellable operating lease for its new headquarters location, with a projected commencement date of July 1, 2021. On December 18, 2020, the Company entered into an amendment to the non-cancellable operating lease for its new headquarters location (as amended, the New Lease), which increased the square footage by adding adjacent space and extended the projected commencement date to November 1, 2021. Additionally, the non-cancellable temporary operating lease was amended (as amended, the Temporary Lease) to accommodate the projected commencement date of the New Lease. The lease term under both the 2014 Lease and the Temporary Lease ends 15 days after the commencement date of the New Lease in November 2021. P15D P5Y 251000 282000 14700000 251000 <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the Company’s ROU assets and liabilities related to the New Lease are as follows (in thousands):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROU assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,784</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities, current portion</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,769</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities, net of current portion</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,960</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,729</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 10784000 1769000 9960000 11729000 <p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, maturities of the lease liabilities due under the New Lease are as follows (in thousands):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,769</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,113</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,207</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,303</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,111</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,503</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,774</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,729</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less lease liabilities, current portion</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,769</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities, net of current portion</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,960</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 1769000 3113000 3207000 3303000 3111000 14503000 2774000 11729000 1769000 9960000 <p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information related to cash paid for amounts included in the measurement of operating lease liabilities was as follows (in thousands):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid included in operating cash flows</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">234</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">382</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 234000 163000 382000 <p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense was as follows (in thousands):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">946</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">453</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">302</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term leases</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">216</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total rent expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,162</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">489</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">308</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 946000 453000 302000 216000 36000 6000 1162000 489000 308000 P4Y10M24D 0 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">10</span><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Stockholders’ Equity (Deficit) </p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Amended and Restated Certificate of Incorporation</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 16, 2020, the Company’s certificate of incorporation was amended and restated to authorize 400,000,000 shares of common stock and 40,000,000 shares of undesignated preferred stock, each with a par value of $0.0001 per share.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Common Stock</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 16, 2020, the Company completed its IPO in which it sold 16,560,000 shares of common stock at an offering price of $18.00 per share. Proceeds from the IPO, net of underwriting discounts, commissions and offering costs, were $274.1 million.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 2, 2021, the Company entered into the Sales Agreement with the Sales Agent, under which the Company may, from time to time, sell shares of its common stock having an aggregate offering price of up to $150.0 million through the Sales Agent. Sales of the Company’s common stock made pursuant to the Sales Agreement are made under the Company’s shelf registration statement on Form S-3, which became automatically effective upon filing on July 2, 2021 (the Shelf Registration Statement). In addition, the Sales Agreement may be terminated by the Company or the Sales Agent at any time upon ten days’ notice to the other party, or by the Sales Agent, with respect to itself, at any time in certain circumstances, including the occurrence of a material adverse change. During the year ended December 31, 2021, the Company sold 780,549 shares of its common stock pursuant to the Sales Agreement and received net proceeds of $19.6 million, after deducting offering-related transaction costs and commissions.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 6, 2021, the Company completed a public offering of 9,200,000 shares of its common stock at a public offering price of $18.00 per share. The net proceeds from the offering were $155.1 million, after deducting underwriting discounts, commissions and offering costs. The shares sold in the offering were registered pursuant to the Company’s Shelf Registration Statement.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Conversion</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 1, 2019, Avidity Biosciences LLC (Avidity LLC), a Delaware limited liability company, was converted into Avidity Biosciences, Inc., a Delaware corporation. The entire membership interests of Avidity LLC were converted into securities of Avidity Biosciences, Inc. as follows: (i) each outstanding common unit of Avidity LLC was converted into one share of Avidity Biosciences, Inc.’s common stock; (ii) each outstanding Series A convertible preferred unit of Avidity LLC converted into one share of Avidity Biosciences, Inc.’s Series A convertible preferred stock; and (iii) each outstanding Series B convertible preferred unit of Avidity LLC converted into one share of Avidity Biosciences, Inc.’s Series B convertible preferred stock. All the property, rights, privileges, powers and franchises of Avidity LLC vested in Avidity Biosciences, Inc., and all debts, liabilities and duties of Avidity LLC became debts, liabilities and duties of Avidity Biosciences, Inc. All references to the former members’ equity accounts in Avidity LLC have been adjusted to reflect the equivalent number of Avidity Biosciences, Inc.’s shares of common stock. Upon completion of the conversion, the Company reclassified an accumulated deficit of $44.1 million from predecessor deficit to additional paid-in capital.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Convertible Preferred Stock</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2019, the Company issued 17,915,525 shares of Series C convertible preferred stock, for cash, at a price of $4.2812 per share, for net proceeds of $72.6 million, net of issuance costs of $4.1 million. In addition, all outstanding principal and accrued interest under the Notes were automatically converted into 6,893,036 shares of Series C convertible preferred stock, at a stated discount pursuant to the original terms of the notes at issuance. In January 2020, the Company issued an additional 537,232 shares of Series C convertible preferred stock, for cash, at a price of $4.2812 per share, for net proceeds of $2.2 million, net of issuance costs of $100,000.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the completion of the IPO in June 2020, all of the outstanding shares of convertible preferred stock were converted into 17,921,069 shares of the Company’s common stock. Prior to conversion, the Company’s convertible preferred stock was classified as temporary equity in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities whose redemption is based upon certain change in control events outside of the Company’s control.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Equity Incentive Plans</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2013, the Company adopted the 2013 Equity Incentive Plan (the 2013 Plan). The 2013 Plan provided for the issuance of incentive units to employees and nonemployees of the Company and non‑statutory unit options, restricted unit awards, unit appreciation rights, and unit bonuses to directors, employees and consultants of the Company. Under the 2013 Plan, 2,127,013 units were initially reserved for issuance. Upon the conversion of the Company to a C corporation, the 2013 Plan continued on the same terms and conditions. In 2019, the number of shares reserved under the 2013 Plan was increased to 4,771,615 shares.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2020, the Company’s board of directors adopted, and the Company’s stockholders approved, the 2020 Incentive Award Plan (the 2020 Plan), which became effective in connection with the IPO. Pursuant to the 2020 Plan, the Company ceased granting awards under the 2013 Plan. Under the 2020 Plan, the Company may grant stock options, restricted stock, dividend equivalents, restricted stock units, stock appreciation rights, and other stock or cash-based awards to individuals who are then employees, officers, non-employee directors or consultants of the Company. A total of 3,900,000 shares of common stock were initially reserved for issuance under the 2020 Plan. In addition, the number of shares of common stock available for issuance under the 2020 Plan will be increased annually on the first day of each fiscal year during the term of the 2020 Plan, beginning with the 2021 fiscal year, by an amount equal to the lesser </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of (a) </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of the shares of common stock outstanding on the final day of the immediately preceding calendar year or (b) such smaller number of shares as determined by the </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company’s b</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">oard of </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">irectors. At </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,574,824</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares remain available for issuance under the 2020 Plan.</span></p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Stock Options</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted from the 2013 Plan and 2020 Plan are exercisable at various dates and will expire no more than ten years from their date of grant. Options generally vest over a <span style="-sec-ix-hidden:F_000706">four-year</span> period. Prior to the IPO, the exercise price of options was determined by the Company’s board of directors. Following the IPO, the Company grants options with an exercise price equal to the fair market value of the Company’s stock on the date of the option grant. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock option activity for employee and nonemployee awards and related information is as follows (in thousands, except per share and contractual term data):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Number of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Price Per</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Term</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,788</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.06</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,671</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.23</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(172</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.42</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/expired</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(509</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.99</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,778</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.49</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000721">8.5</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,950</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">    December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,778</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.49</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000722">8.5</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,950</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,885</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.91</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000723">7.8</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,226</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic values presented in the table above were calculated as the difference between the closing price of the Company’s common stock at December 31, 2021 and the exercise price of stock options that had strike prices below the closing price. The total intrinsic value of options exercised during the years ended December 31, 2021, 2020 and 2019 were $3.4 million, $0.5 million and $7,000, respectively. The total intrinsic values of options exercised were calculated as the difference between the fair value of the Company’s common stock/units at the time of the option exercise and the exercise price of that stock/unit option.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair value of options granted during the years ended December 31, 2021, 2020 and 2019 were $16.78, $11.63 and $3.46 per share/unit, respectively.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021 and 2020, 15,288 and 69,359, respectively, of the stock options exercised were unvested and subject to repurchase. </p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2020, the Company adopted the ESPP, which permits participants to contribute up to 15% of their eligible compensation during defined rolling six-month periods to purchase the Company’s common stock. The purchase price of the shares will be 85% of the lower of the fair market value of the Company’s common stock on the first day of trading of the offering period or on the applicable purchase date. The Company issued 33,147 and 28,979 shares of common stock under the ESPP during the years ended December 31, 2021 and 2020, respectively. The Company had an outstanding liability of $53,000 at December 31, 2021, which is included in accounts payable and accrued liabilities on the balance sheet, for employee contributions to the ESPP for shares pending issuance at the end of the offering period. As of December 31, 2021, 638,563 shares of common stock were available for issuance under the ESPP.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Stock-Based Compensation Expense</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used in the Black-Scholes model to determine the fair value of stock/unit option grants and shares purchasable under the ESPP were as follows:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Stock/Unit Option Grants</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000741">0.5% - 1.3%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000742">0.3% - 1.5%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000743">1.4% - 2.7%</span></p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000747">86% - 88%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000748">88% - 92%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000749">84% - 88%</span></p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000753">5.5 - 6.1</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000754">5.4 - 6.1</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000755">2.0 - 6.1</span></p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—%</p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">ESPP</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000763">0.1% - 0.2%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000765">69% - 75%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000766">75% - 96%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000769">0.5</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000770">0.5</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Risk-Free Interest Rate.<span style="font-style:normal;"> The Company bases the risk-free interest rate assumption for equity awards on the rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued.</span><span style="color:#FF0000;font-style:normal;"> </span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Expected Volatility.<span style="font-style:normal;"> Due to the limited trading history of the Company’s common stock, the expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology industry. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span><span style="color:#FF0000;font-style:normal;"> </span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Expected Term.<span style="font-style:normal;"> Due to its limited option exercise history not providing a reasonable basis for estimating expected term, the Company has estimated the expected life of its stock options using the simplified method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The expected life assumption for employee stock purchases under the ESPP is six months to conform with the six-month ESPP offering period.</span></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Expected Dividend Yield.<span style="font-style:normal;"> The Company’s expected dividend yield assumption is zero as it has never paid dividends and has no present intention to do so in the future.</span></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The allocation of stock-based compensation expense was as follows (in thousands):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,228</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,895</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expense</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,828</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,415</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">322</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,056</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,310</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">406</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the unrecognized compensation cost related to outstanding time-based options was $46.9 million, which is expected to be recognized over a weighted-average period of 2.6 years. As of December 31, 2021, the unrecognized compensation cost related to stock purchase rights under the ESPP was $0.2 million, which is expected to be recognized over a weighted-average period of 0.5 years.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Common Stock Reserved for Future Issuance </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved for future issuance consisted of the following (in thousands):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options issued and outstanding</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,778</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,788</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity awards available for future issuance</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   under equity plans</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,575</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,852</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock authorized under the ESPP</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">639</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">296</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,992</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,936</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 400000000 40000000 0.0001 0.0001 16560000 18.00 274100000 150000000.0 P10D 780549000 19600000 9200000 18.00 155100000 1 1 1 44100000 17915525 4.2812 72600000 4100000 6893036 537232 4.2812 2200000 100000 17921069 2127013 4771615 3900000 0.05 2574824 P10Y P10Y <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock option activity for employee and nonemployee awards and related information is as follows (in thousands, except per share and contractual term data):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Number of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Price Per</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Term</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,788</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.06</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,671</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.23</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(172</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.42</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/expired</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(509</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.99</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,778</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.49</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000721">8.5</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,950</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">    December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,778</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.49</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000722">8.5</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,950</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,885</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.91</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000723">7.8</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,226</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 3788000 9.06 2671000 23.23 172000 5.42 509000 22.99 5778000 14.49 58950000 5778000 14.49 58950000 1885000 8.91 29226000 3400000 500000 7000 16.78 11.63 3.46 15288 69359 0.15 0.85 33147 28979 53000 638563 <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used in the Black-Scholes model to determine the fair value of stock/unit option grants and shares purchasable under the ESPP were as follows:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Stock/Unit Option Grants</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000741">0.5% - 1.3%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000742">0.3% - 1.5%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000743">1.4% - 2.7%</span></p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000747">86% - 88%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000748">88% - 92%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000749">84% - 88%</span></p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000753">5.5 - 6.1</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000754">5.4 - 6.1</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000755">2.0 - 6.1</span></p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—%</p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">ESPP</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000763">0.1% - 0.2%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000765">69% - 75%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000766">75% - 96%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000769">0.5</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000770">0.5</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td> </tr> </table></div> 0 0 0 0.001 0 0 P6M 0 <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The allocation of stock-based compensation expense was as follows (in thousands):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,228</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,895</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expense</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,828</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,415</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">322</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,056</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,310</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">406</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 9228000 1895000 84000 7828000 2415000 322000 17056000 4310000 406000 46900000 P2Y7M6D 200000 P0Y6M <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved for future issuance consisted of the following (in thousands):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options issued and outstanding</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,778</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,788</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity awards available for future issuance</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   under equity plans</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,575</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,852</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock authorized under the ESPP</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">639</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">296</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,992</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,936</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 5778000 3788000 2575000 2852000 639000 296000 8992000 6936000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">11</span><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Income Taxes</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operated as a nontaxable partnership until its conversion on March 31, 2019. The Company had deferred tax assets in existence on March 31, 2019 when the Company became a taxable entity. Deferred tax assets were not recognized due to the uncertainty that such assets will be realized. The Company retained the valuation allowance on the deferred tax assets at December 31, 2019. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No provision for income taxes was recorded for the years ended December 31, 2021, 2020 and 2019. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of income taxes to the amount computed by applying the statutory federal income tax rate to the net loss is summarized as follows (in thousands):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense (benefit) at statutory rates</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,784</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,315</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,194</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income tax, net of federal benefit</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,868</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,004</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,057</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent items</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">210</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Book income for pre-conversion period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">527</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on convertible notes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">445</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realized gain on conversion of convertible notes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">958</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserve for uncertain tax positions</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,170</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">398</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,792</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,639</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(584</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred taxes recognized upon conversion</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,076</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,326</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,488</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,827</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">738</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense (benefit)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company’s deferred tax assets as of December 31, 2021 and 2020 are shown below (in thousands):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,443</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,277</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,586</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,855</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,117</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,443</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">477</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangibles and fixed assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,137</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,483</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,291</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">263</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,668</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">969</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,719</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,443</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56,693</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,316</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,026</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use asset</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,026</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(127</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,026</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(127</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has established a full valuation allowance against its net deferred tax assets due to the uncertainty that such assets will be realized. The Company periodically evaluates the recoverability of the deferred tax assets. At such time as it is determined that it is more likely than not that the deferred tax assets will be realizable, the valuation allowance will be released. The change in the valuation allowance was an increase of $35.4 million and $13.5 million for the years ended December 31, 2021 and 2020, respectively.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2021, the Company had federal and state net operating loss (NOL) carryforwards of $147.9 million and $147.7 million, respectively. On March 27, 2020, the CARES Act was signed into law in response to the economic challenges facing U.S. businesses.<span style="font-size:12pt;font-family:Times New Roman;"> </span>Under the CARES Act, the Internal Revenue Code of 1986, as amended (IRC) was amended to allow for federal NOLs to be carried back for five years to offset previous years’ income or carried forward indefinitely to offset 100% of taxable income for the tax year 2020 and 80% of taxable income for tax years 2021 and thereafter. The state NOLs begin to expire in 2039 unless previously utilized.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2021, the Company had federal and state research and development tax credits of $4.7 million and $2.6 million, respectively. The federal research and development tax credits begin to expire in 2039 unless previously utilized, and the state credits carry forward indefinitely. At December 31, 2021, the Company had federal orphan drug tax credits of $0.7 million, which begin to expire in 2041. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to IRC Section 382 and Section 383, the Company’s ability to use NOL and R&amp;D tax credit carryforwards (tax attribute carryforwards) to offset future taxable income is limited if the Company experiences a cumulative change in ownership of more than 50% within a three-year testing period. The Company has not completed an ownership change analysis pursuant to IRC Section 382. If ownership changes within the meaning of IRC Section 382 have occurred, the amount of remaining tax attribute carryforwards available to offset future taxable income and income taxes in future years may be significantly restricted or eliminated. Further, the Company’s deferred tax assets, along with the corresponding valuation allowance, associated with such tax attributes could be significantly reduced upon an ownership change within the meaning of IRC Section 382. Due to the existence of the valuation allowance, changes in the Company’s deferred tax assets from any such limitation will not impact the Company’s effective tax rate.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the activity related to the Company’s gross unrecognized tax benefits for the years ended December 31, 2021 and 2020 (in thousands):</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross unrecognized tax benefits at the</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   beginning of the year</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">671</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">156</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increases related to current year positions</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,283</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">446</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increases related to prior year positions</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other true up</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr style="height:26.9pt;"> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross unrecognized tax benefits at the</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   end of the year</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,996</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">671</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unrecognized tax benefit amounts are reflected in the determination of the Company’s deferred tax assets. If recognized, none of these amounts would affect the Company’s effective tax rate, since it would be offset by a corresponding adjustment to the deferred tax asset valuation allowance. The Company does not foresee material changes to its liability for uncertain tax benefits within the next twelve months.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties as of December 31, 2021 or 2020. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the Company’s tax years since conversion to a corporation in 2019 are subject to examination by U.S. federal and various state taxing authorities.</p> 0 0 0 <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of income taxes to the amount computed by applying the statutory federal income tax rate to the net loss is summarized as follows (in thousands):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense (benefit) at statutory rates</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,784</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,315</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,194</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income tax, net of federal benefit</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,868</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,004</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,057</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent items</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">210</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Book income for pre-conversion period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">527</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on convertible notes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">445</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realized gain on conversion of convertible notes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">958</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserve for uncertain tax positions</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,170</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">398</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,792</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,639</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(584</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred taxes recognized upon conversion</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,076</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,326</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,488</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,827</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">738</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense (benefit)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> -24784000 -9315000 -5194000 -7868000 -3004000 -1057000 210000 1000 14000 0 0 527000 0 0 445000 0 0 958000 1170000 398000 140000 4792000 1639000 584000 0 0 3076000 35326000 13488000 7827000 738000 71000 0 0 0 0 <p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company’s deferred tax assets as of December 31, 2021 and 2020 are shown below (in thousands):</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,443</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,277</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,586</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,855</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,117</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,443</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">477</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangibles and fixed assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,137</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,483</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,291</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">263</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,668</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">969</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,719</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,443</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56,693</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,316</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,026</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use asset</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,026</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(127</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,026</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(127</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 41443000 11277000 5586000 1855000 3117000 4443000 477000 153000 2137000 2483000 3291000 263000 3668000 969000 59719000 21443000 56693000 21316000 3026000 127000 3026000 127000 3026000 127000 0 0 35400000 13500000 147900000 147700000 1 0.80 2039 4700000 2600000 2039 700000 2041 <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the activity related to the Company’s gross unrecognized tax benefits for the years ended December 31, 2021 and 2020 (in thousands):</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross unrecognized tax benefits at the</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   beginning of the year</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">671</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">156</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increases related to current year positions</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,283</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">446</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increases related to prior year positions</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other true up</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr style="height:26.9pt;"> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross unrecognized tax benefits at the</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   end of the year</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,996</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">671</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 671000 156000 1283000 446000 42000 62000 0 7000 1996000 671000 0 0 0 0 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">COVID-19</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 outbreak in the United States has caused significant business disruption. The extent of the impact of COVID-19 on the Company’s operational and financial performance will depend on certain developments, including the continued spread of COVID-19 and the measures taken by the governmental authorities, and its impact on the Company’s preclinical studies and clinical trials, employees and vendors, all of which are uncertain and cannot be predicted, particularly as the Company advances its product candidates into and through clinical development. In December 2021, the Company began to transition to a hybrid model with its employees generally working both remotely and onsite, and the Company anticipates it will continue to use this model going forward. To date, the Company has not experienced material disruptions in its business operations. However, a prolonged outbreak could have a material adverse impact on the financial results and business operations of the Company, including the timing and ability of the Company to complete certain clinical trials and other efforts required to advance the development of its product candidates and raise additional capital.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">13.</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Subsequent Events</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From January 1, 2022 through March 1, 2022, the Company sold 1,100,000 shares of its common stock pursuant to the Sales Agreement and received net proceeds of $16.9 million, after deducting offering-related transaction costs and commissions.</p> 1100000 16900000 EXCEL 73 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( '""850'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !P@F%4'8N4[NX K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)O)VE!-'1[43PI""XHWD(RNQML_I",M/OVMG&WB^@#>,S,+]]\ M ]/I*'5(^)Q"Q$06\]7D!I^ECAMV((H2(.L#.I7K.>'GYBXDIVA^ICU$I3_4 M'J'A_!HGQI:Q;69]) M>8WSKVPE'2-NV'GR:WMWOWU@?<.;IN)MQ<6V$5+<2G'SOKC^\+L(NV#LSOYC MX[-@W\&ON^B_ %!+ P04 " !P@F%4F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M '""852AFS;^108 * : 8 >&PO=V]R:W-H965T&UL MI9E=;]LV%(:ONU]!&+UH@3C6AS_B(@F@V/'F-76\.&V1#;N@)=HF(HD>1<7) MO]^A+(MN01]IV$TBR3HO'QV2[R&ERYV0S]F&,45>DSC-KEH;I;:?.ITLW+"$ M9N=BRU+X925D0A6X_0[">5IZ_JRN#:7UY-8GT^BJY6@B%K-0:0D*_U[8B,6Q5@*. M?TK15M6F#CP^/JA/BH>'AUG2C(U$_)U':G/5NFB1B*UH'JL'L?N-E0_4TWJA MB+/B+]GM[^WU6R3,,R62,A@($I[N_]/7,A%' 5WO1(!7!G@_!;C=$P%^&> W M#>B6 =TB,_M'*?(PIHI>7TJQ(U+?#6KZH$AF$0V/SU/=[PLEX5<.<>IZ+,(< MNE$1FD;D-E5$YZ2+SR.X7)VV5'0N);HA&5# M-_N&O!,-N1[Y(E*UR:"5B$4_"G2 ND+W#N@W'JHX9N$Y\=TSXCF>:P$:X>$3 MMCPGSJ (]RSA8SS\]SR%UAU;ZS\\C5]UA%_H^2?T1N*%2?)7L,R4A,GP-R+9 MK22[A62WKF\?W[;,UF-XN.NT/R,4O8JBA\H$@! 5&).8KFT8>/R*QAE#./H5 M1[]9-N9,T1@RE@34Z-4#KQ?WKVKZ?Q!Q39HQC;A64AC\L2H)!.X:)UH MN%8-TD6%=/&?D,JLG83"U29/"-*P0AJB(J-CL;W2[.R'0V.L M;8(Y@B1*2. 4C/B5?&9O5E! MP<^9/5.X3IW!NL;I7=RJ2Z+;A,FU[KQ?04%MR$@D6YK:1]G_\W[7F+^+>_8A M61M88:) N$PMD'%\%[?I$FC"8RC[(W"PM9!V(ESGCLHU(T$8PE):@DRTE\08 M30EP<=<^S$J1)+ 47"@1/I]!"JED&;G/5:9@T0C];%M[E;+\^6'+M.$B8%]M?^BCI=(S_N\U\O]I&@H) MSE4LG<\*[V)$0/>*'!Q7)S*R%H4:]?$M!FG(VJ0!!%,,*RL\,!N8/[R'UJSQTNZ3J]P059A)RE M(2LJ'TRWL00;QXA-=? :50<[\>-.6(EQR47.8=2X7@\#-$7":U0D*L"1/H,A M^2AVJ14.EUO0E(PY>!4&9^J%UZA>5'#5A)E+\<*APZR$N.8HP-!,O? :U8L* M;2[ [6+R)]^>GL6XXM!S<;AH%%[CH76 @ICYX>'VX$\7. M8"-2S(EK1+K@Q(.A@SJ(J0T>;NN/7$%5$"N8/Q^6'\F"A;F$;%FQ:C8;/Q2] M+6PU7FB<,_+>.==K7[(%'\ET*<3V_J: ^+C%/TH:%W=@VIN[C?GQ@.CGO\?";\3WYN@C.R-W='.,QEN[C1GS@T<5&)\C* MA$M4JQ98_]"8KX1,.<5>L!K?[M:\KRGA)EPF9#JVOF3%%;RN;R/I'+W2U]OI MXM-(1D*]D]B_W:^N5I]?@N*C0\?&PO=V]R:W-H965T&ULG5C;;N,V M$/T5P@V*7<")1>J>. 9R0;$%NFV0[+;/C$Q'1"312U+)IE]?4E(D6:28I"^V M+F>&AR/.G"'7SXP_BIP0"7Z6127.%[F4^]/52F0Y*;$X87M2J3<[QDLLU2U_ M6(D])WC;&)7%"GE>M"HQK1:;=?/LAF_6K)8%K<@-!Z(N2\Q?+DG!GL\7_Q [HC\OK_AZF[5>]G2DE2"L@IPLCM?7,#3*Y1J@P;Q-R7/ M8G0-]%3N&7O4-[]OSQ>>9D0*DDGM JN_)W)%BD)[4CQ^=$X7_9C:<'S]ZOVW M9O)J,O=8D"M6_$.W,C]?) NP)3M<%_*6/7\AW81"[2]CA6A^P7.']18@JX5D M96>L&)2T:O_QSRX0(P,8S!B@S@"]U\#O#/QFHBVS9EK76.+-FK-GP#5:>=,7 M36P::S4;6NG/>">Y>DN5G=Q7K6,TX_B:9"? ATN / 0MYE?O-_<.S5=JBOT\43]/U/CS M9_Q=U9R32@(LA)KGJ<.CWWOT&X_!G$-* M9];3QD=>$"3KU=,X)C88#"+4PPZ8!CW3P,GT*^:/1.+[@@!!LII328F59>LF M' V?A%X:3DB:J"B*4SO%L*<8.BG><++'=-O$D\F<\.Y#V5B&QOAAF$XC:8+\ MT(_M)*.>9.0D^8U)7*BD'*\D&\'(&#N $ 9P0M&$^3Z,XL1.,NY)QF]$4I5X M+E^:4.I5N5=%5RY!1:2-:VQR3;SI%S=!:E'.\$QZGHF3YRT1DM-,DC:!;-P2 M8U@43H/HQAPP2WMFJ9N9KOS';'=<"])^91NYU(R)%R?!A)Z)"L+ 3@]Z0\GV MG 3_>B-!.O.##$G3"3,+*)C)#S@2$_B.#'$P@^:@* X3;TK.Q/F^GZ0S:PX. M*@#?)P,%Q?>T: JA2PO@( ;0K0876<9J5?S!'K\TE5:G'\XR7JL%/AK-&A7? MDE]>,LU""RR.@W F)(,X0+B?!C."!@< MY &Z]>$/HEJU<1R7?1W>,SY+V50!&$=&)I@H;X;OH!30+1779$<4O:WJ=)]( M59/WT;4(1Q)-2XH%Y4?I'.-!-J!;-P[%[:T5:RH"2J-P*L(6& S"9*[,#-(! MW=IA60U*W@#;O2O*IF2D:62L8PO*GRL_@[) M[28R^(#O$TMB4(?37E;= G! M<&9YH$%SD%MSVN7QQK) %DV)QH.W'"TP%$?Q3"5#@_H@M_I<%5O"Q:^_) C& M9TW+)E]A!YI"8Z\$\_SH!(I#M1NI29G -16 M-;T66/4_Y_VAB0?Q,@Z#!N7'RS!* 99 ;5])>:^ZM-<=[V67*O?%GC2G M%\6+-6*FA$Y; 0MDIJM$@\0BM\1>;+=4UQZ5YGHK=JRV_QG>4Y7V5I*675@4 MP6C:GUMP?JRR?8[NH+#(K;"J;:G+NL!Z ]'N&'4#PTFNCYB>E#HP8:]1IGP> MPY$D=;0MJ+GZ-$@L]F_\ 4$L#!!0 ( '""851<'WX#KP( #X) 8 M>&PO=V]R:W-H965T&ULG99=;]HP%(;_BA7M8I,Z\DV@@D@M M5;5=3$-%VRZF79CD0*PZ<68;Z/;K9SLA(X5 *!?$=L[[^CG.2>S)CO%GD0%( M])+30DRM3,KRUK9%DD&.Q8"54*@[*\9S+%67KVU174]AQG:.>8%%8\ M,6-S'D_81E)2P)PCL5:^X$GLLZD'K#C28G7L #YK9QSU;,; MEY3D4 C""L1A-;7NW-N9ZVB!B?A.8"<.VDBGLF3L67<^IU/+T41 (9': JO+ M%F9 J792'+]K4ZN94PL/VWOW1Y.\2F:)!%]>O, M9'XSF6\F"SHFFZMR!,XA1>H9)L\WJ,0<;3'=P*EUK+Q&QDN_>=O8&3B.HQ9M M>[A>%\-:J$&#&ER'6CUOA#O%L!;GJ.$<7<'9JU1'G17X>E7[1+:HQPWU^'KJ[DH='W-$41@< M Q\'^E$X''?RNL[_C<&YGOA"V=:6/;A/1': VP>;FSY9?,%\30J!**R4U!E$ MRH-7FW75D:PT^]V22;5[FF:F#CC =8"ZOV),[CMZ"VV.3/$_4$L#!!0 ( M '""851!D@@L404 /83 8 >&PO=V]R:W-H965T&UL MK5A=3BAXP94^@Y2W-Y.XF5VM]8E@QCEE%YS?$QVL=(OK.5B3W?LB:DO^P+?A!WER7>DI6PX_Z$?/D2W$UM;Q%(6*DU!X>/ 5BQ--1/8\5]-.FGF MU -/O[^P_U&*!S$;*MF*IU^32,6WD]D$16Q+BU0]\N-?K!;D:;Z0I[+\CXXU MUIZ@L)"*9_5@L"!+\NJ3/M>..!G@D($!I!Y +AW@U .<2P>X]0"W]$PEI?3# MFBJZ7 A^1$*C@4U_*9U9C@;Y2:[C_J0$_)K .+5\4E0QB*.2B&_1/WLFJ(Z' M1#2/T(IGD$RQCO*!H8]<2C1%7Y[6Z.V;=TC&5#")DAQ]CGDA 2^OT)NSYX6E MP$0]D176YMQ7YI !YQ&+S@DLT-8()"\"[\DHXYJ%U\C!5XC8 M!!L,6ET^W#8,7U\\',]'U#A-N)R2SQG@^Y"'/&.HB1KZ=K>12D#U?!]A=QMV MMV1W!]BA>%*ZX54*0%4?6%XP4Q KFJ"DT2O+83EWB+^P#J>.[8/\8!:<@]9] M$'&TIPX&&5XCPQN5\5@9CK:"9Y##>>D?J"L5HU5944QZSQ_8N*0 MA Q]>_^L=+)O4@;Y5V1U,7PWN6#LY ZDZ:]3,1M7\R7)P4EJ*H1&L[XFN M9MT*37HJ+N^T6'P\]SIR^BCLN'Y73A_E84S,:N:-FOFHFL]<@1;>B[M)R[QO M)0F_-/(<_L M$PLJ-2:@ZY*NZK61,'"<@?C@DVZ/QVM2Q4Q CRZ[R-LZ/N_&ZA*3EIN,>NM# MKACL"%1-;W04Z0?*=KM.ZH.([7<]U ?9 \YI>RMV+A-0^\6HP!F9M[:_#YD2 M>]X58$ %SDE_/!?1MG#\2@^/:;YC>ANVI8E !YI")X2M'6SDMDP(%J$C%8+" MUB%-Z"9)$_73J--]76;5Y7&8V'R^M-VE\"5 61W MS1^#G!O?MD7L7[)*&BO1J,7OV>#VI/0QTV#6%6,"N?;0HM)V9#S>DO^&XVD* M2Z71^,"\-';K864"NJ[C]1+*@"-NX+@#*MI.C&<7+(WAV9'G)3Q:W?@JV;9( M/-XCM;.*'([H:?(+BE$SPRD*MMMP[/[!%-5[3\G"0B0J,7=.W.]VT_ZFQH3J M^;*/&H>5FN=%?G\S*SK67?+9H;9W7B98/-KC.>G M?P."VS9.QMOXU_*JA$53>H ]#[22ZJ!?JH9$+914(!JV=Y>ZH-^I7>R26=<% MAJZ/?=_INL "[#3$6V=7(C *6Y77BQ)*.XB5]750?.VN;RZ*Z]L.N_O\)/D(0DP.UF3 M--F"INT^*S(3:]7%D^2D^?>C+A8EWJQX68%]:2WGD'QY?=Y#V\?/6?ZU6#-6 M@F])G!8GDW59;GZ9S8IPS9*@>)=M6,K_\I#E25#RQ_QQ5FQR%JSJ0DD\0X[C MSI(@2B>GQ_5[M_GI<;8MXRAEMSDHMDD2Y"\+%F?/)Q,XV;WQ,7I7.;\Z=95\LJ2EA:1%D*RYZKT'5E?LL M^UH]7*Y.)DZEB,4L+*LJ O[?$UNR.*YJXCK^;BN==&U6!?NO=[7_5G>>=^8^ M*-@RB_^,5N7Z9.)/P(H]!-NX_)@]7["V0[2J+\SBHOX7/+>QS@2$VZ+,DK8P M5Y!$:?-_\*T=B%X!B T%4%L R05<0P'<%L!C"Y"V !DKB;8%J%0 (4,!MRW@ MR@5\0P&O+>"-E>2W!?RQ+:.&4 MYQL95]1NPF$]X[-F+=8+^2PH@]/C/'L&>17/ZZM>U+NA+L_7;Y16&_>NS/E? M(UZN/+TK@Y+QC5@6('L RRQ]8GD9W<<,W/(=Q/*@/._MU'Y GXZ8P]1&)4_@RGX?'<&?OKA9U"L@YP5($K! MIW6V+7@EQ1'X8?!\/"MY=RI1L["5OFBD(X/T3UD9Q)IB2WNQV^U]'(7@CP?> MNRA]U%1PMJ>";F#J(=%4<&ZO8)DE"3^S3*5_V]O\BH6L*++\QP*T@ZVIYOT^ M$<:IUE1V,:I'IM*7XTOOGYTK>V6_KE91A80@!K=!M)KR-;8,-I%^J7PXM*[] M,J_W5!V&VV0;\\VW G^4:Y;SO9=P]*XK)CXQ<)T5NK5Q,[Y6[.A.R-0 M=T:@NE8R;L$?<5+&01JR(]">"25O+'P',#P"R(&^;DLU+="ZA/:D$88[8?@@8:,4-55[/448N7.L5T0Z1<2JJ#L,67T8'C)4YT09*N03I-=% M.UWT(%VC!%%EI AR]7K<3H]KU;,8W_S"59J?$@B16#O-J:D-HY3JA7J=4,\J M]"PJRCRZW]8NL\Q T@RD;D%YJ@#H&,;)[YKWK5A5-1_K=X&V:;2J66IKZPJ[ ]'\-Q7=X2OES_OY,__ _E'9K#.E5YX M!HG0$0[(L8K\G:=',3]NJ^E=\:.S$5O1L9: Z^MEI7W)5>>;+ ]*O>SSMMKA%O&AK%J-(@0Z9!AVI:T,N\AP M@$(!&VBGS9C>'8%/+*D>\I?N1+NK/:;6SJGPF0[ITQJF5T$*"DI!.Z8.ZY&V M)RJTIAA1WY-[HH-;/VS8$T$W:,?;N)X89^(-/YB:+RHD<@Y4<##XYV!<.LT)Y+[Z'*2 ^9-X/ M)+1S\HTD6^;D?:M@L.J].31P$PIP0CLY7RN]88(X>,4QW(2G66GH@ I>-*?0 MM%P$>N%X]KY9!ZPSH3+:]4V.% H&0SN$/[(P#HHBXNE O4$K7<]!G@[JK@H2W:A^^WHY%L8K9K->)8 MCW@RM6FRI\RF0'O<:-]":N[T::MSL[TNZIG&VV>;@."NWT M+9"*^YY-;JAICQGV2_@!9/<#;]@OR_*\:%4,EJ>!C:B76MII_X45)5\"E0P6 MY/%+3Z[9RR(5U%@9:6O,4*T@.;*3O+ZBF%87Q:MZ:?-DW>2V%FU5PW-5)@8&A4\17:> M6AM503A%"/IT.!PW2)-I#N.&X@0QD9V8JJ?M;@^:72FGRW,=1=I&!K/%O8AI M60D<(CL.C>K&J5*32XB)9S)U2- -V>FV>/T072 5+FAN6M%8\ 7;^6*XU-!) M6&!-;NA23*43XDH71S#TD+0H=7&618D%7/!XN+RQ:<9J"HF08U@16" %VY'R M'3PS5N%"37;::=+7[A=V9<@WC+=1Q]8!0KRB$.E[/U2%S<,^6"JRG 3 MB06?L)U/X[MIG(!+K"()NM0UK1T!)6R'TM+HWF7[&Z6R\?UWAA>KR(/857+C M]UC--*>ZP M-()(/%WV;T+22!6:Q';/?9QBM.U0#<^SY#I5'29O](F@8 <%R M;&?Y_S+IPJIU@/*ZNMH3-!POX2ZPW5TL@V(=LZ(8I"NZ+EI3%*QFT-!@^K%P M&/C5E]AOF39BC1E1-JHU9OA)E; KY+NEP[8Y(:HSH08?3X0K(8>FO.F*Y8!; MU3A[8:Q]XRU9D[HD:"A6F@QR>"1--)DP( MIG)2NC]N*$Z@G-A1WGPY(1Q\.<$H5@-=2>@UT63/)I&"ML1.6WL26-%)LT-T M>3(UW6@103)B)YD^"]1J6!#-I[*.BWJ?&[1:U>Q9.9TT57G("LT]UL4XW@NJ^?!7 MOF6YV!,T[(W *K5C]7^9*U#U>L TK8+8=/S-P!NX.JKBVG/DR^T]0<.>]+YN M-?ZCYC=T=52E/#9\/D@%X:F=\ >Y.JJB7OFPRQXS5"M03^VH?XVKHYI4U7.H MHG-?V%"J< +4[@1LOHYJ$ NA[\CK\V9$X%">@#&UP_@USHZJ">@4^M+Q>+TO M:OA508%3=]2]NLG=0=U.<55\$L\S)9ZNX*=KYZ?!W>DT+%P5D-B'1&;DA29. M&PO=V]R:W-H965T&ULK57+;MLP$/R5A5"@"=!&#RM*&]@&8CM%>PAJQ$U[IJ65180B'9** M$Z ?WR4EJ\[#;@Z]6%QR9[@[*X^&&Z5O385HX:$6THR"RMKU>1B:O,*:F1.U M1DDGI=(ULQ3J56C6&EGA0;4(DRC*PIIQ&8R'?F^NQT/56,$ESC68IJZ9?IR@ M4)M1$ ?;C6N^JJS;",?#-5OA NW->JXI"GN6@M_;T(+OG 6Y,PV2.D"MC7YOAM&4Y\RS.?N['<43BW._J\C(GW4UZ4M]I M7]_IP?KFS5+P'+Z7U#>7*_A-[W5=D\G\2X"LOR#['P),LI<"Q$F6/)5@^C(K M2:,D>Z9!N/,?KU&OO%<:NKN1MGW-^]W>CB^\"SW;GY!-MZ[ZEZ;U^"NF5UP: M$%@2971R1C+KUC?;P*JU=Y*ELN1+?EG1IP:U2Z#S4BF[#=P%_<=K_ =02P,$ M% @ <()A5-?) !DK"0 H"@ !@ !X;"]W;W)KU#W=[+5 ME:CY@XJ:=K_/U>M77LF7SS?DYOC@NWC::?-@=G]WR)_X(]=_'!X4?)L-O91B MS^M&R#I2?/OYY@OYM$[FIH%%_%OPE^;D,4+;;K( MX=\S7_&J,CW!./[L.[T9WFD:GGX^]OZK)0]D-GG#5[+ZCRCU[O--=A.5?)NW ME?XN7_[!>T)V@(6L&OLW>NFQ\4U4M(V6^[XQC& OZNY__K,WQ$D#LIAH0/L& MU&V03#1@?0-V;8.D;Y!8RW14K!W6N<[O[Y1\B91!0V_F@S6F;0WT16WF_5$K M^%5 .WW_J'/-81YU$\EMM,J;7?0K^$(3W49_/*ZC=[^\CWZ)1!W]:R?;)J_+ MYFZFX;6F\:SH7_&U>P6=> 6AT3=9ZUT3_:TN>7G>P0S&.PR:'@?]E09[7//B M8\3(AXC&E" #6EW?/$::KZ]N3I8!-FR8 F;[8Q/]6:-OK=&W2NXC6-,JUZ)^ MZA:%T((W@=M$1A-4I8,L#,"\X' /&BG+^5_83UTOJHE!)U"UH6H>%3WS,Q3\[DP M!GW7-KP$SWT?'91\%N!XT>85M>VG@'$7P]@60>.N.43=0N0FEF$&[EK/3RRR M8*YQ?0Q+F6-9!)-DN%G38>AI<.B/6A8_;DWL+*-"[B&A-)9&Q'^:SQRCDWK# M(&D\7SB$?%3"2.PP0D#Q F>4#8RR(*,O>ZFT^%_' J(:3,U>M/LF@O@5E:(I M9&OC70V!5/W@.M^ $S6\:)7UAP_&B3#6&<+:G40?XR#6/B+&Z2X'NLLWT1T9 M&KZ5S.M(-$V;UP6'"6XT&@&6@5%US'P$=:GYD)3@W$@\YJNG",CUTB#DG-E)YB7A@ SART0J M46NN>*-#"Z[O*C0_"(1XJPT!I3%-)ZC0D0H-4EGM\OJ)&YVPS86*GO.JY?W* MVW*E(+*\Y$KE-<1ID6]$)?0KRI)>9NE#4C?](!@RGZ X)FER(4M;BHWA>))$ MFH8?UUE/[$)"(6.Z)N%\_:#X(1>E[5SJ'5?]VU##);Z;T[D[^RL4EB2):S\$ MMDR6$Q89A^-4T8>E0_YJ0ZYAEA>%:OF9^5""9JX40I! M)6PBY9!1 )"P OC2$SE-H2@3/X7/TRQSF?@HDK',98*@8C(5F$9!0,**X)^# M?U<<9$&D3.UT*[>W(*DF7'XR9Q(DOR^(R]8'T&L-P;&4D-2EB^B&9#G!EHZR@,9O*II$_0PI].JBB8Y9FH:S]$.KBAVL EL? MHWH1LR+U\^QM-F=SQSHK#+=8+%W9C\"F+#CF;!K.V=]RW1-X&S,_N2[FF9MI M$)2[#H*0'9+.,U 'GB\BN#3-7'6%P:;IC>J AJM[=T%O10T5R_4+>DS4-)RH M'Y0L."^/<>-8&8'#0.K>0Z71F(+8&/C0;BI1P"^0(F @D.2>U,0&"L7R]7SI MU?@(CBZSV%T_:P0WM3C&M$[#:?TA?S4+P# ]KP+%_ 2* M^QA 4-Y(<<^\(.&#J!A0 MY:AJI4AI[^T.(B"_N$! $Y/-1C' PGL$O6?;+9U*UD^W4%#OHY)OT&C/+I;[ M*P1RFRPR-RUC,)K%4WQ&S<'"FF,M&JW$IK7>:5;EGN\W7*%.R2[O#%R&K!$( MI+:)HHB-&H.%-<:T3SY">($TO0+GA#2FM##*8]PNL&XYK,O+VU?L\LX! J'4 M4^<(*H7(QB8L<;+'?T&9!%;G:(!::MZ\A;8O-3S:%R%K!$*6R7QBZXZ-BH5= MJ5A.ZY#+>;VGYLL,DBZ8MWF'X&A*8^;6(0@N6U(V-;&C;F'A70U#\EW)"V5* MY?<@&[I/1C\8[A\Z"QCY^9Q7_+@K:_;[E"A,TC6_HP;PMRE@21*WZD1@E*:$ MN;(-P2U)DDT<'K!13K&PG%I=33+*=;3A3Z*NS>P;@0XQ0)8H=^2<@Y+4*T(1 M'#ANZNZ38-W%4S4H&P45"PNJMU'G9A\O2-J708S&BZ6;9E&<;YPU@CLWSCGM M45JQ+*C4']O#H;)GQGEE#QLJV;2JBV5'$0_NW]U)@ P6V@YEH[QA87ECZP.[ M(0H=#WOFJ!TOGV4@D'E*7/OY('8BYMDH0W+LZL9ZYQE&UE;5@X7+D$&3460D89'Q'=G5DQN= \R6E_QGT>WJ&WM+9TOPPG9M@IQ%T#AU M8Q<"6S*W.D! 63QQ8I&,RB2Y<&)A"Q^(UJW1&Q\B$%LF^UH/^V"#MZSK_F[* MB]"[02('MA9,=U5;=N;+_\)N=X)*%==XR"D'<2,? DHF4EXR:IDDK&565K$T M_7%C0,"992J=\N,@:[M'7O'C>:6 4DS 8G!*3]0PE_4. B%LL73-MPYV=6Z8 MDQL68<'SVQL%[M$:I^:4K6XT^(I9:YXT1&WB"QO/)A_\6\8+B4>/]_4$L#!!0 ( '""8533:QF (0L % = 8 >&PO M=V]R:W-H965T&ULO5G;K*LMNXJ2 MG<2)=Z6RLLE#*@_@#$ABC1G, AA1RM?G= ,S),7+[B:5O$CD#-#=Z#Y]NAN\ M7EKWS2^4"N*I,K5_?[0(H7D[&/ABH2KI<]NH&F]FUE4RX*N;#WSCE"QY4V4& MX^'P?%!)71]]N.9G]^[#M6V#T;6Z=\*W527=\XTR=OG^:'34/?BJYXM #P8? MKALY5P\J_-C<.WP;]%)*7:G::UL+IV;OCR:CMS>GM)X7_$VKI5_[+.@D4VN_ MT9?/Y?NC(1FDC"H"29#X]ZANE3$D"&;\G&0>]2IIX_KG3OH?^.PXRU1Z=6O- MWW49%N^/+H]$J6:R->&K7?Y)I?.B:+UP59I,RRH=!W_ MRZ?DA[4-E_LVC-.&,=L=%;&5'V60'ZZ=70I'JR&-/O!1>3>,TS4%Y2$XO-78 M%SY\5+YPNF$/V9FX:3T6>"]D78H;Z;6GI_=.>54'2:NN!P%J:?.@2"INHHKQ M'A6CL?C>UF'AQ:>Z5.6F@ 'L[8T>=T;?C ]*_*B*7+P996(\'(\.R'O3.^$- MRWNS1]ZD*&Q;!UW/Q;TUNM#*BW],ICXX@.:?!Q2<]@I.6<'I_]++AU6,\N]> M:ND$[],^>=2E#L_B1EN/,]>%\IGX7,.WQV&AQ*VM&ED_"^NZE2<" J68:MLL M)%*B4&W0A32B2$OQO](AJ%($B]PP2#A'7I6B1GX61GHVZ.L/$P$-3C8LP O( M,-@T00RFMGP6=T;/;=T61MF@2S*E_JF=RX"X'$_N;OU)+OZZLO#WO[L M>=$XVSBM MA%8)EHC S$6V1VJ;R>U]$RF#F%"\@&X1M5Z!EB#D? M,K6MC"V MQJ%DM(; L-1AP:M!?(7VR9%;QX!HZ)Z#2FFMLS;@9*U7M+C47H$]R$CUJ&WK MS;, YD"D04Z-BBI\6RPV1.8B<@\3&, "1\"E;,": \12>D$'Q?%:Y)AC_48N MV=OT^0&P4A$+>"R=$KH6/]A'54VQ>CQ$CDH*;?_:: 02XHR64VW(.2G&.1 B M)G"SH6U7F6A:YUOXBDXO\6KNE )K![;WWDAVUH$O)WRD M@G>1&;J&]+UXS=8M+ZQKK&.7193 %HWG%9_5+W1#TA22+;![UK2*I6(!&UJ] M*EJG \%@;?5VSG (#(JUP*=? MT($.:>VAGX2C7A3?WD'_+@,>D(PXQ:13I0EW@.-,.39"F]*MN7Z"3)4U7(2OWZ/=N(OML [\H? MM0VT!MF&8X4HCSTC* -+GSAHS9C>OZIJC'U6"M;5:J8C26CHK*DY8XY!PQ?Y M#NQ=B=S6X;>\"S^(.MH/K[=HJR M+^YFLUBO[FKQYQ;(&9USCS',Q'I!)"N-XK#A]#K):*(,V\DX_GQ_=T*!72XT M8(VS>FM*$GEV/LR&PV'$)<=@/7N%)*^LY !2!:/WU>@RQRX@+N[,T3'80BDX M?.9LQ29"9X9:RUG!45@2=4$*R@_W.#@Y%VGO>Y?UF@KKZ3V3X*OQQ6D^0L=I M#!,I2%^6T=%9RM-862+GT79;@"A=!#.B4J>^NZ^=R6VI>"9KWWY'V!B?O_LN M+NG+&Y80Y-?98-U?>[,SIOWH(KL:C[+A^=7:KK"C9=C@S0U;9/D3VF^N9&1+ MO6%*PC[5/-2_8H'*_LM&R9W;+K++X6^RDH*V:2F,+/N22X4-Q;XS?*;IK%>&/>BY)F;+%H5\519HZ$Q+R MT(";^K0[W95U"C M2)0D4G^-=N?U.!\-K\YPXB@JVN-9%!TK;#HN=K4[]*9N MLI%./$K3*CX2.S9Y@JS>B,^&6,X7<&)"#%E(K1268S+L=NQ0&^L(,I'(C1-Q MNUE8N?A%>G"P5N;L1]Y"/A+;*AJA@[-Q"D;OV1L++&(+3P-*JH,A=?],]MI%=$;]+.(51$UASM8TVYQ94XQU4VWD+05@2)&K4P.SN].F3R^GRRPZ6),PN% MM"@WP4*0$J.K_'P_,+JSOW88/SB;P.]>QLK'($A-2H^3'#VFPN@%QXV&XIBS M;(&C4*OX":F$1#K^J'@@/3GAQ*LLCVNS?A!,C=#6]+N9%UZ 8-+\_\*3FXY$ M%<*)'BV9[]LI41 U-,015("C2^%=BXJE>,BU;B[K6"!B[R=GLRZ"18?(:7?- M0'U@@349JE;$-/2,E^^;W3.B2.L39,\,,EM:QY7*6 @%Y M(,U2VKB#.W8(<1"-H&;<0:9P$JU)U.6,!WV#UJ[@ MBP!$L/OB0TM7 K$IASCJ+0D(-+4+X!FS>]PARPI;Z Z)6UO?-J23(XJU="D M2SB@_D5[]3(XLI_&TQ;H U,'Z^!F6H "'CNOU7MC/4T;GGIK;K";_@Y!/37P M!@*Y )V"W)< =]]F4WA9'*="DL(,%9L]\I#B"XM9&UH D]2'?KOG92FL70N2 M0OLB5'$,65N))7,G*_^K85LR#Z'KK-J8?&7,FU0+3O.SGGLXA-(CL/17*"0: M2KWJII=*NF\JWL-LCONO3H=G*S$;MTXHJD;#_.1(]82(1'#_1C7L_RDA9$;F MJTA5LS85_9=IOH)-+,N(DI(HNJ,Q75[1-6M?Y,K4X''H,/W%2LM5GJZ50$"O M_[)YICASD7I=2X8.3$^1YB/5S(P=E:M(6#WE9#QNILW,0; PID;*>9%H)".4 MF;;<3.@"PX2@[HAU(I/@R^6"^HT&>47=&K/(P%)%,9)O6EE;NIDL M$.H^?XA$U=Z$J9]3G,$K,EF+)L40YF!9I'.ZL]T)J8ZJL]2T,O37<,97&!$$ MT.F9/O+=%]>,)N1DU$#136!@ZDQSB5_K2D&T:+SCU$C[7,FX8T?^F#_D':=2 M.2J(QJB!7-W7HUY >$,E_?B/D\G]2=\LN]8DX*!/(8+@HW3WH:OTHQ6?GC"+ M 4WDF52H49H_W:;)8.<1NJ:9BN1J5O2QV2)XQSX3Q2V-LY6L900LPDXC _C- M>ZIUG,=B)K436[-;%Y%4-W:UX#1&\,WQNAGIRDLB$= WF*[-09T@MV$H:[L& M>54T.EV]['0*O\<%,@T^W4DT@D07+T4L>2].P#298::#!JAJW#_.+L M*%[A=5^";?@WLZD-P5;\<:' 'XX6X/W,@K/2%U+0_XCZX=]02P,$% @ M<()A5% 1SE?4%0 I#\ !@ !X;"]W;W)KO8'FK=NTJ6;X[]U0Y3G).MC(3;YR<>=C:!XJ$)(PI0@.0EC6_ M?K_N!D"0DIS)GMW:%R>BB$;?^^L&]'IE[+V;*]5DCXNJ=F_VYTVS?'E\[(JY M6N1N;):JQC=38Q=Y@X]V=NR65N4E+UI4QVJ M=MK4F573-_O7IR_?7=#[_,(_M%JYY/\923(QYIX^?"K?[)\00ZI214,42Z!6F!C7Z#XO*J\&J&&?GIZ/L[.3L] EZYU'Z%C&S_[R> MN,;"6_[KB0TNX@87O,'%_XEZGZ9]-M[[Z^2S[T[1:Q]/!MKK(;LUCF M]?I?_^7YV>FS5RZ;ZCJO"YU7F6OP$H*O<0BOB!^'#%0Z7RB*]V IQ&B^D'5+9@A NH1 MF<;Y#[2JU*ZHC&LM)4U(XG^9<4U)CLNFKFIIVQ5DC1VU??UV95J7+&\I#HD3]16XLPL4U^KT1I M1=-B(Z07YJE:>^(#98^SF]S-1_PW^_!'JQ_R*E+^"HFL+AI5RO>)T4FA3F-# MO%E5V1SI"UM4&A1*B/^ E2+>2C?SS%@]@^P5.HX%0F8W^%78*2HVM*OT50'\E*#S_PA MUU4^J?#-7!7W9%A:#T[4&CS:>]2S7,( ]!,U,"&K4,$<;\"?YZHBG4(E506> M+>1$O6,9*M7@ 3N@5:5NL!;LX;]BK>U>DA?DFM"FRKW!M*--C246L%&>5::> M'8'R@FP)9KW#]5QUDE<<=IS>(<8O+!=+?:>*8(9M@;SHWG3=FVQQN#Q'DP4W M9)]239KDI7'?1RIPA^B@B&AVD25Y@CF.H+[<*L MA*:TS6#K5@4%]&4>B?>U->Q>Z3^Q8@:@(;Z-U. HB>@I/JY' _V2&N$,-4MK M0-GR(ZOFA"@>:#]\5MD!D3GD;3P'2633TB7<0<*3';1'@];Z>,263BUS5FEO M;Y3PXGYN*HHT;Q_V\&:]4]7;U? M(-U2%91[,^0A9'?*PHS5%@KIM$Q<2*RJ:T@)Y_&V8_V![HK^U";;Z2,QF$DO M+E.$1C)@";680&L!3_#?$UYV=G+Z8IQ=PU-S:*KGDIS41OWJ1WNPD)M1D*@6 M[@7S)*[,WK,T3K/,T'6I*"&@S*/$*G99VF:X JF$_?F(S(T4LJ! MO"FW^"6 M/<8B/5^1NO*;F?7\53^#VU_8V#QNA'/ MIC"^D>S_5;O[[&-$ ?"SQK8>!I"*ET 7\&14U#7";/*[\@@H* M63@%'D6[C MTBI#^X1\O;1(EY;*'KW U7ZC4'+UVQ;2_2Q#V:/A\"@5NQY;:*I**GK8 -^T M5-RF/1%UTPJ#>%<]%E3DP&,=H8NZB@!&/7&W(& M/\6NG:XHC1%80'(H2Z9$\O?C@01&DH(9-#(&LA$ E:HX"JV:Y;9DL+)<6O.@ M>DAK%(S_!W ?ZL,("/@!52/FQ9&'9P0MQ-XI%NM1$NZ)W5*1OD1SP?J9RZ?* M$XDDQ]E'2@?_X'0 >IV7?TJ\_(80*J4R7\T'4%SRO(6A2ZKT28(1N$0=A-_( MEWWR1!A(,CSI$0Z&P 9(AML72L)J9=J*W(("6^D'']:Y9X.0)V*?140LU6Z* MG?+(USH[R,EO=2,D#V-2LB@D>@D)08";@;Q\@%?E,V7:4(9C HE;=70EI5-] ML@3/:6O!\F"U65&R\C0 #!I-6S&JD-T7 (>(&DZ55%3&K'I).(TJYC4, XVV MWNO]ZZE*%RU87N2/B+H_I6=HI$@?42%F*]<_+:C/-=(-.@A$!+X MLJL@4VVA@69EQ.]\0T/XHA,J=)-@B9-)\E8J_,L]0C9G5Z_V/A,7V2D#G;-7 M_]$: BSL.%+#>8[D#2O00M!+T>DK<1+*P /29Y[TEZ'F1P$H(P/\>%<'8U:, M\[;L.=HD$=8*%&#(U 2Z?2E^3!R?!5-[]XHT$\7C':1H=@=CK9EPNX$@7JJ?4//:-+)Q;;HF$ *&A-DM2TI( KS$%7NN MYYUQAQZD/:5EI&>&Y0;)WHW8YZF@A99S2O!*<*VIS$S[.4?0JCZ49^L2H!^KVD0I-;7F0)T5AIBX&*1$V4B+A5#A,FJZ8T\)54 MLVW_?G_)CH^&CJL'V4.\.DE[$91Y&>N(MN OMO-8N0E]<"QZ"8HG"*)Y0,59HV'%YHWT2#SL@BNT"]_5EC16@E_+>0/YR0*& MUG_R@S&ZCB>^[L= ZX(&:19-)PM'W!7YQAAL"2;I)BFHY].V@FX>5*R@5@E? MHKL "BV!JSBEH[I+;3YY +=(X^SS5A7(:$ XEKR1#YB3GC'RQEXNH[,?L]KE M5V$\3#ED@D9^1M,%:O!"JT..7',H R[:6>AQ2\-U#0:ULE2PCFPX'>9SA@V\ MG#&6GV5@WVX8S3-(WXI^ZII;T/E,([S/C$:OA1P_J?B)WR 9N2VW^AXZB2U- ML^M<@<=;)4T$ZG1F7&@+QZ/PE_)>4H_@T;+?>T&FH?HKY#T8DY'"MO+D$AL) MCINI6L6J+:U0HCCV?YXY-9NI6!3=K=C>%"9].E>HA@?T)M>8VF@UEEI'8O*;W0CMO1KF^$X*:U<'KTG:9( M4@G/H!B(*,O;PB^&K3_M(8/<=*K)HTNL!&-?Y3P&_[)9F/HWXT=>=$JPK2#Y M0QRV*0]H *ZE1:,,PR-UQGZ!5;(=@9 LGR'Y>$,1HU)-Q-2D9LN9:M$[!QBT M#>NEI! 4YW@6D_#XTB,'&F*2YD=9NP17Y%Y Q36YC5+N%3@&[#&^%D#9E,]I M)N GO@MEV: H>H@0 C=AOU?=SF343C3J>CJB&>%7QN&43W49 JHS#A83 =BH MG=+!#U=0 K$#VT?/(DH[N:CRX3.LJ"25:[6>>5S KJK$9AI_FD M/Y)C75"O8,JV('-\F$X]*OAW4*+I&H_(3E\,)I^E65(4)@>.=P1(!F[" WGF<_X+[A,V\ZE3KX9I:ZR*Y.K@Y'".#T M')+?C%_W>?+^[P:NXAJUY'0RQ/J,F1#8Q&N7NH)32QY,TQ0/I5!.IKJJ?#!- M*CW+DR,\&1MWCAS]_&5VH ^'P^Z0VZ ,35:8&4IQU(,%NWLH&ZS["E1 )@@2 MJ:1#XR>H4;)+DD3*?@J$$FIK&22ACN'K)F5'/3:!_QYW8"_M2?PKZ8"$^])T M/T^#(04MJ0'E8!4^XO,M.S-)]!\.T_RWBWI(!CN$E; X "V;I+O$]E1RN=7- M7=_%' @X/JEA0V^GWT^^?F[EDGQ!SB]!&S*DL4E7!HA;L>,6MBXE:+?!V.+6G8IBP=<":"IO)#9SGV/*)IY7KW^P$;CWI5%)^"%Z^E8J+T7J46@<75LU.?O"KZ;NBK4,8PO5+[&2SUCPKBS2A!CA0JFZ]6-&[\([ MA?!SH6YFO=2-/V4;'CMZ>0='6;QKLRW$Z6%,N^RRVW(O]1-IS&Z""X[%0L(V MQ#G="&%GYV]CY>;Q$'9*[?PAQX\;[H(D+^A(^6.LPJW-I:M=2UC5UF1D_,4 9\.\H+T))6@ MWI(*N>/SLX<80NEMHGXX >860@V>&(;X=$9/8U=>@4P!B5U/0^C[Y*[ M_RQ M?]^B2U(RL>"W&GY+;P*6K2CIQI0=% !6NCG,GEV#^8CHIE;[DODJCDI/KHU>%].7E!VX]^3]_++:2\YN:-@5&(&;J0 M)(US'C&)Q[C8CRW=HA^T\=Y#'[[DS$B*8%*F.;A_R$.<:;9+/]64J2J-M($H M=1.G#:D&:.N5JBKI^M+J$48%7=_&,'6C^^Y7>AJ5AH-?0SOY4B09I2E8 MPU,U(D4HATZ;N&W-?@?R=^CE_2CMFEG>K$(6PY+9WL:S,6DF,4G,6'W = M0V/*2V:63\K2.8CWRZUWAX*E5@@ILJ/_S%3D%EJ\@Y4"^<#8CV=9C)[@+RJD M\E %#EK7\A$XO47GK[X%QW>'@8VT0C.+4OF@CJGRZ28DN:3)B$.GG].KJ#'< MN'-/W%+[$);P!MEMN*1W6R&V#FC%A[O;V\.?-4*\[-?985GQ ,4";\73SG_6 M(KY&\%T'_7C$5Q"986P*A-N90:+3<^S#.N&:3])V:=B#9I?.9_@8_5XE=T5) MDM_;,LR2:#HTHE82+!B?SL".[R$ZU85QI%EVU\L>#.IC+$O;K$;C"'#&+(MH MW=8E>"T:NAW)[;OH*;:T6WVGAYTZ6XQYW^ZBVV>:2O8?A4'EX/3>G]U3?\*7 MW,)I0!XB1K!#UZNYI&/9.=_D190NS K5/Y,96*]=?>**('G3CJLQ?9%DX8&L M.DRN'&V<*OWL'4&^K0 E;PPP@7E5(^J]A6!W&(G- MW[:U]@?9BV7K9[,E\%KLHN,:7W]7_-,$51[EA'I@G+KE:B(^P=Y$A!U3=KU3 MI7#W0?B&5Y>_MZY);E7]$[23,]Q8?ZR*Z4,F8CY#;DZ/U2-W165V?CZZ.@%@ M.CT['YT]OY0[7*?/1I=G%YO<]9CY"_MV2/=_08D_4O;V&7@E?P+#0CSM\N9?Z]A[Y-OTYV2.WWKL1VVI*Q# B MS:*4GV'L^?L>\5\$\=75U=YO/"_B,(U!6OP$F><[*'2";2PA/KNO8X76:'+\ M?"#QA[W+T;-GS_?.1\^>/]\[!T=XOKK#W\TOL_6)T>7&Y]U71E5+XT_7F=/[6HI.G M1E)JUZS5I MO 3OXW6"FZY1(=U^82SPQ2O]X*Z=-#SJOWAVV/"\A3[_794S M[.])=V<*<,T/X"RY-O-E5?.% +H6&$D_/[T\NC@Y?)F*0@DL==?T%B1MV=LD M?V*?+F8]T4DU-H3H )'%\.=4\5R9=NR 41HJ M>B!",1!!]44 V(H_5;CS5_7EOBN,&FR:BC40B>^;>-_U/^':RLJ$)A8+PR.G MH 9_L,J_!N K5<,?WO#8@U;0_5HY[:1#(G\M5WR9V&3*=&$ M1'W$H9X=?+B].^PE]B 562:PGE.Y)![\O8QX9@)-H.AQSP!"*1V:(22V0IE4 M\6B/A]G:T7A$H,E$(8;X8"R?TLV-F,A/+P-(83_$RY4__./#%BKL34"%/T7Q MI _L$L*J]-AEE3F?4T8)[[UC26*,.\8%#],4C6\;:P)^2B^,1::AJE0Q\YS& M$>$WB_W?[_W;KA]&\IS87_V)OU7DG\'X#/QI(S\.$O!'AI=Z(6=5^'?$$B=Q MM.POX)L*0M6C.Z+;@'I5TMQV!15DPFH1PV+:K M_'SNWE8;O1B/ :/!Q]M^SGN<_')ZH>R,?Q].4!K:EQ]1QZ?Q)^C7\LOK[G7Y M_?HON9U1^UBI*9:>C)]=[LLD/'Q I>'?84],TY@%_Y<.0Y2E%_#]U +^@^T M0?QA_MO_!E!+ P04 " !P@F%4Q=17#*P& &$@ &0 'AL+W=O^$>YG<& MJV[-)9&9R*W4.3-B>MZ^[)]>'=)Y?^"3%$O;>&:DR43K1UK<).?M'@$22L2. M.'#\+<2U4(H8 <;GDF>[%DF$S>>*^SNO.W29<"NNM?I=)BX];Q^W62*FO%#N M@U[^)$I]1L0OULKZ7[8,9X>';187UNFL) :"3.;AGW\I[= @..[M(!B4! ./ M.PCR*-]RQR_.C%XR0Z?!C1Z\JIX:X&1.3KEW!KL2=.[B'9>&?>*J$.Q6<%L8 M 8L[>]9U8$Y'NG')Z"HP&NQ@U!^P6YV[U+(?\T0DFPRZ0%5#&U30K@9[.;X5 M<8<-^Q$;] ;]/?R&M:I#SV_XLJIOI8V5)FTM^^-R8IU!=/RY1\9A+>/0RSC\ M[^;W@Q3ZF@EWK;,[S%>+/"8.P@!X.KZ=$LO D>LHD#L? M>FJ>)X@?\R@9XR7PCK M" R2*M9%[F0^\XR-F&OC5U:8A8P%FQN]D(DP'0^[0;E](, .:C1 %=;S9JD4 MAILXE3%7U?X*Q#*F_4PG0H&4.T!01(<=:"G5BA1J*%&*2]AD!<0 E"#'S.J- M$;&>Y?(K=NK3%<8.NR_BM,DEXRLV$6N+(7X2X=$(,D]9:TH[PW*P)H3"3H2> M6TLO7_\B%@#=Q_EYX>P!F7PMVFM4J1].!/TXG*(GA,S[3T@8S+!$0@%'VAK2 MJ5J5,@:5C C%%YIPRSX7V@%["9D 6IE)Q4T)+V(K*52"$F3@LH@MM (P14:? M0CMM\"XV(I'P9.@&454,F>&.2)!@%B9<"')51)P,.3X8Q8=+C()!F5? *@TD M% (%BHA1JZ ]/%2$V,=N(B8N\N03HQ^A.STF N%M@E80#067*/3TK[U]$!5B MP2$=;LYU)F.6A92R(3"G6J$]D32?%K9L4H@'CZ9,M^^_.Q[TQS_\HZPJY20, MOFNDYVM$B4MU84%I#TYW)OL#!4#KTE(^HR"*; )MJJ+8^J@=5ZW?@B_OZO"[ M#.%WVPB_FSK\+C?#[Z!U+Q'X4^S!/.^]M=ZOX^LFA%X52)NG'W*]Z^3PH'7[ MG#U.6P^=>]C<>"57C9W6J];1*!J.!\T';_'!#XVG7\5,.^FYQ@*UAJ# YV2? M!-7'2M<:1L?C84VPN;K6!B4*%#Z.FN+[H^AXU*L/;BV#I5^UCD=1[V34A-@_ MB<:#80/AOW%E[__MRNNM>#_]%C>\:HVA5].'F^L=\;';0T?1T?BD)M]<5?X9 M1\.3DTVA6V]@6ZHQ&M4GFROAJRU04YK?W+TGF_]H#NA'S";H%X$<.@T)'V.P8#G5'')<52!B?]3^J#!%I^Z M<"J=S][0C,$4O$T-0(; )&;4_;UM".Z$*TY:^%DT5-5=PBI6*R^66J])GE3( M@MK-5U^2P>I*\?CQS7V<:JK.H=^'YF@;45PTH[CLFCSY"RT>[*O6L@-57=S% MESFZ)[:5G I?V9^.5ENNVNOOQ(H0*>$"+8 MU1DZ&MDMM^*@XH@JM/X.B*=WN4-YH5.B@[) A\_*^YK&7 M6?ER[*X-JS&9>4#\A?1\MK'K+*/!S_/W31VCBO<5:A#RD0?^S50AG+(D070B M)FS)KDR\#HHXF1-N4646/@VFG:FQ%@3)^X0\,\94TR[,XUV:QV#-FQ7OY0S= M,;^$W"L;Q+-YMSWA7)7U 7RVNE__&.5YV&M=ISR?^7!<"T(?WD=YTCHOVV M_LAQ&>[VZ^/A"PD:Y@S#,%-B"M)>9SQJ,Q.^.H2%TW-_TY]HYW3F'U.,YL+0 M >Q/-::+&PO=V]R:W-H965TQ:&F!90"1RH+=2TDBM="4-3O0EQJT%D#E25(8^B M25@)6?O+N;-=Z^5<-::4-5QKADU5";T_AU+M%G[L/Q@^RTUAK"%F%DE:Z7N[.1#MO CFQ"4 MD!K+(.AU#Q=0EI:(TOA^X/2[D!;8'S^POW/:2]PT#.V?*DJT3W9KO4=1SY+&S2J.H I@TK6[5O\.-2A!TA> O #@+N\ MVT NRTMAQ'*NU8YIZTUL=N"D.C0E)VN[*3=&TZHDG%E^%/H.C%B7P&X@;;0T M$G >&J*V#F%ZH#EO:?@+-#%G'U5M"F17=0;94X*00#M@P M#AB/>'R$;]@)'3J^X0M\'^I[0$/'R2"[A+5AJSIC5]\;:?8]Y>S;:HU&TUGY MZTC,41=SY&*._FMQC].,!MY/F=B7 MB%JK:BWO_V*N'Q]"W2V>@\L?,,V*Z0 M:<%215\3&J9R5M!Q+?>LE%2"K(_*;''Z4*&!I:5 E+F$C EDXE[(TCJ?TJUP MBH)0@JII'=$(8YT,RX74[%Z4#0Q MJD&*AR=GW@JM%CHK4*U!=^>%ZF4L9.\ >Q :3[Q5I;2A]W+S8J8T(V'HO?9X,)IQ M>CLY_"V-WL3>R6$A]C[!1AGIQ*5 2>4RI3!.2P9;A=+TV.(@GD4=D^,A4S([ MELDIX]YD&$3#40\X'A)TPH,D^<4,+ L/)LGTD<126-/(NU!ZJS2!GI^8 S > M!\ET]HCD,YLX&<>1]T4945(UDG' D^=UHG G[5HT&[^PP]'_NN&:' M]-$WM6D[0F?M^NFJ;2./[FTSIOMF0Q4CK3E!H\%T[#/=-KAV8M36-96U,M2B MW+"@?P+0UH'6&PO=V]R:W-H965T@E*F4 M747KR_+8X[5=)7LWE:UD)E.>[.XAE0-$MB3$(,$%0,O*K\]K@*1(6U)V#WNQ M*1#]];K[-<#;C;'/;DWDQ6NN"WC0=CS^.GQ 8%H+3(/?T5#P\GOIY?VM-1MA>3>T\4,(-4C#.55P4KYY MB[<*T6BY,%8R1HGXNTH!. E99.*)'$F;KL5\98F0".]N1QXV67*4UOH? MHO[I ?V3J?AL"K]VXHTK2)*E3*C"&R%_G\535A2MM8MGQ_PX#4MG I06G,B42\T+V6V" M?GX!3Y5!+XND)L_)IDIJ]=_H@UF*^3\>16E-5J4 )U,6! /7Y0H4Z+Q(R7H\ M"2_MBK !CRK/J\)HLXI^&!@%+P9FPNM,I4&U$QPBLYC.0 +$;*/<4/R$QHF. MO@FR#^'*RH+]:.(5])KJRH'SDIW.1%BSE=IOSQ< 6!4KH2.>202,%5HF,H$\ MN&I1OQ6G>/X/NXOE)L#4P/7@^%DBJM;)VI\__^EZ.KGZS@E/Z;H.'L*VSFP+ M=0(V*ZHE.JJRL00!C-[A"RMLC5T%[E"WEDB-I1WPT%J5P5_U*O*G+_,&^J'X M9P4DV?7*EL:1$X7Q;5:@ M-X=B$,J8$(H8_Z \Z]S@2(-]+B[H02R*V\F$Z'HXQ';5N6$(Y0DQDNUQ1E1M:3R1661XBY\7)5-O7#NN9T1DG1\=L&\8,Z- MD!5I99F##^9E>, P'.Z91+6JP.8UUPAD?L4-C*3E86>NLG.'E9@=' S/,U-Q MKC+DS & M/FZ('\?09VA%:,@@M"Z4<0J)D+:C5QL73)8(%_41)@6.JWN]:'F@S:'91(QV M_:LH.M"D$Z'5'5*@2IW#T3BP;*^#WUOB"8,0,#:MX@JLD]/2;H-]E[_8NWWL M%7@'M:&8/'@&O35WOMB>OUVKYV/%X/'[^C%.+5;#EM =J"4F BK$%D7H=D60 MX5W#$4ME>72V,8=,!_I;4] $SQ0S*M)1K*!2BA<@D[59T5+E,3=<:*Y"L;]S M&)"%%[6G?2I>HR-0;86/A9/C5*]*^ #A7#&;(R<9. 46Q,J8S-6SRK[ #,ID MLU90C2;2%=,XY0N TAS)^^S]!M; ;W&Z2JCK5&<[/D-I1*#E@MO]\-1U[%)7 M !9PJJKI%R5#*ARU>!"#!5A=:'-B>'#J\Y#W7&6\ES>U:SQUZP[C PB]^B:+ M_)//_X D38UEI/6V'W-H)XPE,\!0\R; NI8^:6/$ H&&LBM*2;F; O76A@R=RG0?@.Q3#R>3Z^33;'SRU)JJX(L:%U]O=H9E>*:VZ>!T]TRCGJG"B =(H6Q_.*9%I'+<+7IPU1ZVB_K+1.O$-[(=D/B*=!2+A= 'D+V#%$$N\=G&/F"HDSX/L8NBQFMQ^MC9R&LNWM"6E0U-S+>TRO''H.&>6VH$X?/6_$VB M)V4"B-* 4YM)KH*CE\Z6+_L]$M!O%;^[8KXU>=HNX%:T[QO!J/.Q!M-N%3Y) MN3B4XG>;=K7]ZC6/'WMVV^,GL\\X'/*51M,2HN/AU>4@GB6:']Z4X=//PGAO M\O"X)HF$\@:\7QK@7/]@ ^VWP/O_ 5!+ P04 " !P@F%44\!<&OH" "' M!@ &0 'AL+W=O>B$YPYDW"S5/ MBYW2OTT-8.EC(Z19!K6U[644F:*&AIF1:D'B3:5TPRR*>AN95@,KO5,CHC2. M)U'#N Q6"Z];Z]5"=59P"6M-3=JW$SZ6RR!V"8& MPCH$AML#W( 0#@C3^'/ #(:0SO'T?$1_[VO'6C;,P(T2/WAIZV4P"V@)%>N$ M_:QV'^!0S]CA%4H8O])=;YO' 2TZ8U5S<,8,&B[[G3T>^G#B,'O-(3TXI#[O M/I#/\AVS;+70:D>ULT8T=_"E>F],CDOW*%^LQEN.?G:UUOB^VNXIDR6]_=/Q M%CMN%Y%%;&<1%0>F]DK8V]%:64#X'B#"I(;/TF-EU^B;B.RA& M-$M"FL9I\@9>-E2:>;SL7Y6N!9.67IW62W]>;8S5^(G\>B-2/D3*?:3\OWOZ M-LZ$CLC+6/29&@9UH7!:C*6JHK8&6BF!0\?EEIYSB1K5&;0W%Y<$FPO-!K1K M,'$-=DM,[MA&:6:5WC^!DC.2A]/I&/3Y%((.9%$77=()9*'$FD9X*SMS4D_,DG&89N7"'^72. MAZ_*,D';5_ E] 7/8E=P$N:3&3;K"9#"(_*A 22D/II5KV#1'3/T+!Y-<&R% M0-?02?E1\L:HR 8%,JQ_M3TP["VX,:*G[^0'P:^Q=T[C9!YB'J8%3VUB/WKI MXXU.R*$!O?44:/!3Z:3M>6+0#BQ[U9/+DWE/T?=,;[DT5$"%KO%H.@ZH[FFO M%ZQJ/=5LE$7B\L<:_Q2@G0'>5TK9H^ "#/^>U5]02P,$% @ <()A5"#< M#(*5!@ A! !D !X;"]W;W)K&ULK5C;;ALW M$'WO5Q"J4\2 HKLMI[4-2':+)D@0(TJ3AZ(/U"Y7RYA+*B37LOOU/4/N38[M M-$ >$NUR9X8S9V;.D#[=&7OM]W/OMK\.A2W)1<#[<4RNS. M>N->O?!>;G)/"\/STRW?B)7P?VVO+-Z&C954%D([:32S(COK+<:_+F^X4?#RDGM^?FK-CEF2AC5Z"*$&;3@G M-25EY2V^2NCY\TNQ]J=##TOT/DPJK674FCRB-9ZPMT;[W+'?=2K2?0-#N-#X M,:G]6$Z>M'@ID@&;COML,IJ,G[ W;>*:!GO3)^)BE](ERKC2"O;W8NV\10W\ M\X3Q66-\%HS/OA.TI[7F;/!3<.N#L 5[8[AFKS1[76J!H,?S/O.Y8!>FV')] MQX3VPHJ42>T-@R1'(Z3XY]ES$GNS6K!%O73(($.K805*7*?LO7">>[R$C6AE M)9+22G_'%ALK1+3%7;0LTK@][!ZB GW.5E+)!&WSD2LE[MB2ZVOV?/5Q>3A@ M5Z5U)8=ZM>V>,WT&(<9IBY0$"GXMF((/CIF,E5M:.Y@/1BAFI="7?98@9"N= MU!OV7!XRS@Z.VL_,$UBDWV=9&:/S85?*+.FDB#*"$G"]" $?]D/(SR4,NG+] M&1Q0>\N37(J;&#\\XLQM12(S"MMU#T7)&%*N1))Z;6V\O:6WBRRV62LX/98-P([I"?TD4@ MK=CRNP>=$;?2!6?#QC%['Y=]U$[C6AU')LE+&*+P7>ODP6@PJW<=L _[8 8W M:!RDI:J3ZJFI3%6^5=L&R-<&'V2H7N4F[P0W?ME'(@G'_,\ABJ2"JA4VI M :)2(74/9K<5K(*J$CT@HJF%4;+[94!0' ^.GM60U&T6'$%E6JJ.:=NO%$5: MANR'3:D6B%:H$2/^^^8S(8(.3Q);DF'7.BAN<;IPL'5393XT4.6(JIG+BL38 M-+ A%O7F19!*P:5]ID4( -1F0[*-]:&&$?&BW*#L* \G3Y$KO"\6Z; IP?OE \^[S- ILJ\9)Q%R&V(]F':X!)!@1\#G)?67 M-C[BCW+2FQ^0^/'W)+X&&*DF&S"&8V-#/,$EPH(8EPYC*%6JBY!)%&\*%DYX M3-^[BEJFH\ MH_T$WA@%\]Q*ZEGJ(AFAY1O,G4W@EM*C670:=ZR;:\T5=6L% M^TD#(A79/6JDI;IB6Y+(")*C1B^,B=C+G0%$JITDNSB+Z@HA%*E^L1U40X:0 MP,^ECL?40-^-L45K;%D;ZP(AG0LM!:O65J5(!8>?;8GYA/-J-8#&Q_W9?,9< MSA$)!;("U^%IL5<^ #,3EGH#XP4UV-B!;W *%S@A*^0]ZOKMY1 M_5='J+I([L=00Q,X*$RBF+$U6A7^M=AU(Z"ZG?=/1B\[B$$<#/LM9&:#^;S% MY1OYK0;L'B')1P^%_S_;+_NSV>2[74=I3W]@2AV.64U2N_2 5I)%;!RB!BXM MN^&J;$X$57B.;>@'8J6K-ULJGER_6"6YP5&-.$.H_1%QSR)1%K%+BJL 41+Z M)YZS=@ <)4!V07@H_W]C57PUFMJ]199%WFJ%"N%S'!@>'5^N93)*9END38C! MCX2['/&X)BF1.&G\M8R6L?%1_V0Z?22M@X+-LQ>/]_"VW..$XID0&U=%@?M1C-MYYXXLWVW#/7!N/6VMXS 5/A24! M?,\,9E/U0ALT?W@X_P]02P,$% @ <()A5$ZQ)9Q6! XPD !D !X M;"]W;W)K&ULI59+;^,V$+[W5PR$!-@%#$FVDZRS M< PX28LNL(]@LVT/10^T-+*(4*1"4G'<7]\9ZF$EV>32BRV2,]]\\R27.V/O M7(GHX;%2VEU$I??UQR1Q68F5<+&I4=-)86PE/"WM-G&U19$'I4HELS0]2RHA M=;1:AKT;NUJ:QBNI\<:":ZI*V/TE*K.[B*91O_%=;DO/&\EJ68LMWJ+_H[ZQ MM$H&E%Q6J)TT&BP6%]%Z^O'RA.6#P)\2=V[T#>S)QI@[7GS*+Z*4":'"S#." MH+\'O$*E&(AHW'>8T6"2%1$M(LBQ$(WRW\WN M=^S\.66\S"@7?F'7RLX^1) USINJ4R8&E=3MOWCLXC!26*2O*,PZA5G@W1H* M+*^%%ZNE-3NP+$UH_!%<#=I$3FI.RJVW="I)SZ^NC'Y Z^5&(7PU'MTR\03+ MATG605RV$+-7(*8S^&*T+QW\JG/,GP(DQ&<@->M)7<[>1+S&+(;Y= *S=#9] M V\^.#D/>/-7\38>KJ7+E'&-1?A[O7'>4D'\\P;XR0!^$L!/_D\$WX98Q+^\ M0(%/FMR?+D#HG#_.)^!+A"M3U4+O03K78 [92*VVIJ)M8_>@ X+4045LMQ:W MPK.$U)FLA0)1F49[, 4.4"DNIT"-DZ^@D/NTW)M1WKL;0.6H/[Q@ND&HI M]M3:Y5/A]S'\>"G= 9SW6UEFV0VI/9*R!^%A<1PDI^DQU&CI6S?54^A)$! - M]8;P,A.*J'6!:+$,>8H%6DM+O&^DW_>QT/CHX;X12A:2#@NI!45$;SD29%NA M(!)'TU%$B-!IRVB1'C_G05J,RCQ=*6R(<$:_0N:PV8KXN#%@8 M(=&FFA&NY&+)$',72F!Z>JB!-FUCW2Y'3E:UPD.J2'$1CY/$5B8@"ZZ^0SXF M-)8;E4,I'I &EV]LR!%\R[S9D"JU>!K#6BEH=(C;J$CUJ#)V] =Y@YR1 $-9 M?5YBDR>UI5^$X1U-2W7('I\&V?<4'*H81[%E1T,F'7JO:)7S[/"EZ!A0-+AS MN':,92[42=1__X9>))J4=0X8>BZJP0!02=)"6C*48U6'Y#X(1>X8"E,0I)+$ M/N'!:.-Z#"R*EO4A'!7ZTN0Q3PD*M>[NN*&$;M%*,GLUJG"*^5=G;0!#90TTGLZIOC>I+[*[ M-HE]_5*5&IN/1P(^T@/$A= P MW ?Q]OGS1=BMU(Y&4$&J:?SA- +;/BG:A3=UN,8WQM/@"Y\EO<+0L@"=%X8( M=PLV,+SK5O\!4$L#!!0 ( '""850C(8=4VPD + ; 9 >&PO=V]R M:W-H965T,9Q]F= M9B?99/)HI]/I!XB$).R2! . EM5?WW,O0(JB;"6=S0?+(@A5R].3UVZ4H5T(U.I$F\6QA;2X]$N3UUEE7%=R MJ3XI_Z7Z8/%TVDK)=*%*ITTIK%J\/+J=O'@UH_D\X1]:K5WGNR!-YL;\3@]O MLI='8P*DDA=WOC?2?67?H,I=.W9G\GSKS MJY='ET?8AWFGB5'(JV=-T5<# 2%+L-_^1!Y MZ"RX'#^Q((D+$L8=-F*4KZ67-]?6K(6EV9!&7UA57@UPNB2C?/(6;S76^9L[ M4Q3:@V7OA"PS<6=*K\NE*E.MW/6IQQ8T\32-XEX%< <)*R=^*C.5 M[0HX!;868-( ?)496)VT]WXG*6#,-L-Q32";,0O\BR1H *)GUR-1)O*'I28S-9I@H. MZE?;I;XC-U->63@I]M<+@!+26@E(A$!HP!0+7;*,G#8<"N06*PEU&! &Z6)E MK#\A.7%,8BF65!3$0YH!D+*J0X9I#NAJTE+9"E&U-VXAB>&48MD<"\Q M%.?SQMH3!EA\)%[7EH9H*H!IDSF!3.<@1&6[FJX!HI+6;X0WXEYB;NU$:YH'$_9U=R-Q5UN+_?/-[OX@TY3Y9HM! M_I'=1^++/D?+6K.]=S>V*C7+4O\7B/O&LY0 3\SBI,;#\,)E=P$7S;W$6P89\+@)C22 M(BH0 L'RF?2 7[O&J%&)O_SI,IE<_,T1O+H $OB7Y14R%V *L4TKH!SC.1N= M_3FZ60'[L.XD#1H^I> C $_X;"2*X3=^0B:3AL6\THW!J]-AR=.VCR'8VL^EKK MP*/CG/%.VG1%*62VZT,43Y9I?]QQ>W[%3!UP9LY'LNL+?F5-O5R)7T%4,0=7 MP'#!D'ZI$33T= @1:(<2&;L0GOT*E$?I!MIZO.M[7[,CJE6S8S(9B?>T(X@* MY6M\D 8',["/=;;6\"WUH!VST>?EF!(AS6Z2$S$=O.PY,]7G&2U2GVNOB@IL M@LN^=%TBELHR-D^18X@ ?^I!I375C^^Q'*E .Z_0,7Y%60$DL&E2&?)Y%%Q9 M0^X(F7L!S!6)S!9[ &:UY7ER^6UJ]^RI_CCR??9_Q=1 /K1::7@^IQ5.=?3> MD0R2;#RZ73&G,IS1CC+[#6X,;,&=V7+L9''A(6Z@3NOD+3^WD$L89=Z4C>\W M^WJKUKZ*G]METAINM#@ *'!:5PJB2;(3W7Z!MG%[Z(*_:*HJ6-I0.>6_,F!D>(#+U_$ME=T#T;A)Z0/G31 M@XFBV%8&%?FW>LM#6.H?SF$NMGA.,.4+^AU! [_N( MOX<6UF,G\3QQL#C(&?MV<*V];-ZGQ,Q]3.5XXZW)&VV"X%V:FW=4\+D.HXRR MK[?4-W<0.[#;3OO 8>!)S-0.2#JS(OK73AQKBE\<)"' /7\QV(H!)/@HZ/L>#SZ+CB5T2,ISMMDGRNSGX%Z5G^#-9L;OS #LGK:IXF ZFP\ED M2E]G^)J,+^CK&;Y.QSQZSA,F.VHVZ7N $\H9IKU5#N6BJ+BYU=Q#.C\X3H87 M%[/!\[BTWS%UN8I,L9R]M_NF.@[PG_\?MGH6K?6I1IIKSJRI="NQ ($ '>YI MPY5IZW<\H9(Z"W6]")R1JB%H@:(.!SC:^H"BH4W\AMGX!G#/:A/Z& _H M8FEPU\+J0MGNV^I%7IA,9V3P\RD^IY?)X"/!;,Z>/P;/^]YYG-B>G>-S=L:[ MCI/!I_Z)>I!,X%KG@_/H'K8#BQUT;W M\SQ2L'NURB=/%PZ>:9SOF@ K*381KN E]()SNINB9$$XFNF"+L3XZL0I>X^^ MC3)'\ZZ09;T@#-S[;B> RP4$A59].]PQ1ASC(EVZ=!PU?9?C:$2IQ M9]@H4,A-$Z,B599;.@BYUXX98 -"K3QKNK]M:TQ;0!T0'RZ'F;302D=C1J?N MO-ZNOJ,GKE(I=2"[36NCT.BQ*_W3SJ\HA;)+_JV( M@@,8PP\J[6C[<]1M^!5F.SW\EO5.6ASNJ 8LL'0\NC@["M>CS8,W%?\F@Z.N M-P5_I6L&96D"WM,M0?- &[0_TMW\#U!+ P04 " !P@F%4RT*QQ+(1 !1 M- &0 'AL+W=OO*"CV MC0505).]S]@&9%N3.$AF!&MF@B"X#]5D=7?%7#I<)&M^?;YSJHI+;[*3( ^V MV$W6J;-^9RGVZ\>B_%QME:K%ERS-JS<7V[K>?7=]7<5;E M3>AY?N!7K1ZKWK4@259%\9D^?$S>7(R((96JN"8*$G\>U'N5ID0(;/S3TKQH MMZ2%_6M'_0>6';*L9*7>%^E?=5)OWUPL+D2BUK))ZT_%XQ^5E6=*].(BK?A_ M\6B>'6/'N*GJ(K.+\3G3N?DKOU@]]!8L1B<61'9!Q'R;C9C+#[*6;U^7Q:,H MZ6E0HPL6E5>#.9V34>[K$G_%[3\;73^)5Q_46L>Z MOGQ]76,/>O(ZMO3>&7K1"7IA)/Y2Y/6V$K=YHI(A@6LPUW(8.0[?16A[3R7B(0D](/$H*R%[&Y=NX[H0LJFW M1:E_4V(R&ODC\T]46XF'B%)<9!E(5"0<+YX<>ZH![4IO=F)MERK:4=>5^'CW M$\06CUN-S70M*EB"%DYGYT6J(16^!<*E*MSF(]NW,L4@MUL2J5@Y-IHNG\#7_J&0:N> M/KE,/OE6)* WN03]]060..TIC50\4-Q6/I 84)[<8.N-\;Q]-38[HO@BG,+2 M3CYL7Q;-YH#'P'[ LJ,NWM\]DXD2NZ:L&@F)3R@"O)L'C>S'B *)TS4"8J,) M73A:.#9X/3Y0*A'W5V/?:FZE8D0214V!%(-X2V$F!;$Y6T%*X 5KDQF$D1(1T6J;0Q .@5(EX*_,- M O!#4[HU3PHP8@ -^49E*W#L+*M;DNY7X\Y_?BU?N!CY<0G)X9RH?"8=2G6DR5ZKE"OA0&Q."'9_3 M<\R[U0[6C]#WJ2X(!C1[.=YH!XQKPCP.B&JK=T1-4;IG#^@Q9Y2UMVNE$(DP MBQH\?<"# +_K(D5_4'TG7NE+D]_105" )\9@[&9-KNN#?0^%+7)KU[.['LT# MWV/_8PSI6J7EURC+'_C*EG-K3,DE>#X3,-"IVA#A70%W,D&[!K3%6UVI X][@!LRKV>]&R20 M4X$6*]K$10MQ2K>29M\[B;)-RE^]YM"C24P6W82R!0SJH8%<-IQQ MP:V^0,0,ZB(%CA1E\G\TE2VS03SE7$E1"@(H@2FKY VGKJ\RV/$"-A"_[#B+ M<#X@M++E4]SBUS!S((FE$BB[UMP-D!Q-UIB\E)@VA>%_TJM(#=+#.1)DP*HJ MRO9)ZB!LP8*,O9,ZN:)\+W>ZEJD#4>-;=ZUOF>(>M?0@I\^C?DZW M93ZQ156,3=N&7*]R'Q1PY,C]& <+>:QW5-J0F\=QV9C@98CN5:D_%C7D8X@> M5II[(3_S%\NQ/QK/OEDYK!+;!;H4?) PT1=N--F5RLVV+L^9.1!PNF"I_R3S M1I9/1]HT:TF9]SUE.I[[T3CZGQLU"J*OL6EHJB>6#/SD=B;5=E:'X6;;3VY7 MC0[8^N9FWPGZ87Q2T*/IF6(!=>!HUB]DG^N4J&_5U!04IQ"AM^P,/Y2V>[@! MC%09%1\PN05$S5A2E GKTK3[9K@ -Z/F:--H]0N5Q6U2*[V4[IJ(K'OLEIM5I.Q#N(;@G*?*Z+%*A M'A2A-YE&)^JT*OGIP$UR@,C$$*2Y2U'##ST_' \]7R;%CO%_J_CN<2*F,>3[ M]/'2E'+M9_)?Y :0<6IK_=4,>BPIJA XT(#@ TD,<4&JQ-)B+ )85:[*H1JSZ3R[8<=/"76QH"N-""Z?'=5Y$UE\FF" MPC0&==P>,@@-5TV*Z*CW^4-J:Q&Q50I5/E@U=5! M%&?)85[<5P?E,L:?MJKVAWNS-^BYFG)[76]1B,;U)C< M/!I7/*;#H>\<)4:C%*9D(>Z8P]NLDVB*0"BM*]V./&?\T7?=]:G(,/,5NZ?) M9E<&L:PX-$_)>HEHVPK^2EF(J7;HL3LO<+A58"JI>L! S_6:82^)6"E.1B MRK3*!,HLPD\6".V,&(:'%$.,^"[]2' M7-)-14F WV](EKR,%, ]!QY+* M5?N?]V/J"E<;[*Y^'JN0* MG2C$0JUT:[1(C1L5V7=X_IX('WGT$YN9W/!];\.?:4/BDC5ZZ=VTYP0?\9#. M*QV+7^DHR/NIY_;RT+5&WMB?+Q;>"V\9C&;>'XPO>)$_FX=>- ZBL>>83;Q7 MX3SR+KUI,(F\'XIRK6CL=FV,C;O3T1)WHRA8+I_;-O2FR+NT;3@))DMO$4QQ M/5WXR^G(^]5,,TC)H*UBV^>S*WPKK=NAOQZN#?W%@IY?!,O0FP=$)EKZ433S MJ%3LSE]TJU<^8JL('RJ5V[$+PYS99 5OM3V&3&/;_5-1OZ4$LK:#$*!?_4B3 M#%.L%]5@0/SL&0W\7[R,(&AQ6!,N+0#[G$PZ;K(%Z-@V@Y*Z,$7.N M:NKK<.I'BP5_,5OZX^ER2,)OL_K A?=LV>0/'694S>H?]NRL5+NF1']:P8MO M728PR>/.WC"I[63-/V@T;^_O[EP-OJ/D#D/389ZFR5-N6D1."WK5U,H>T(93 M5YG ."K5&QX"T)1#Y95)/M8R-/BC<@%-,9]R5OK+549OD-!FNC#EJQ/H*Z83 MY"[MXP-LL26$J_$6+8LBI7&S^\#^E,GRLZJ_/@".EH=(7(D]/QN<*QG!J*:R MJU#:ISIF)&U9)]\VTNS-O<9C/YS,C3,![N?+4[5?5PV1";\Z$GIN>@@XCA<" M4GK-H9?PNH,H&GA-QUS^'X-LYTRZL@>W)INT\^^=?#))I3?3[,_@K=)6,N6B MC]]]\H=U4.N/!OJ+3@OTF-477)$9;\M'"U^*CPJ/F>QD:/MB-E[X4V#$N7[G MV:J5.+0%Z]4[;C_>]R/F]@M=*S:$Q.K,XD)3=?GX72JQ^#Y&TPTVLB)1W#NT M=?D1<#_ 7 .>IFQTNC)NRKM@7.9]YFN?Z%]3)$HN/"J M/"Y)N"PCZ/4^Z>KSU;I4JIMDEP@&#VGQI;@283!^B>NQN9Z^],)@0M=1,'_I MW;K2Z:% EF-W]!8SNKU8O/3P#U?+"%<3]UV[HMZK+J?(PE=B%H14^MFK*!C9 MJW99V\H_:94F'J-#]/W+(Q>G]$):_'H=A"_Y/[ Q"B#(C]+>F1.=0S M9ZTM9WO/[HL+[?*_P4//"H>G!?/Z _'ZT?'ZZ0"\:"!A"H[RN&@]CS:Q;$_% M3 =C8[[DCHMN_Q+<8X.2I[M/XC=5%E> #YK)K0JT+Z:[1IOCQKJ51D4E2X,% M-.&U$:X&^K!?\J;($13Y'":(_%8GO[9*IC=(VK=DA+:T<5=X MN29F\<3 XX9E%Q#6/:F2H5.D>JV<.,.JL*F*YF(=$6U=56J*IDD182KU]NCNX,)P*#0MZ^-#';:#VR7I-OWI+C@J?;S MBJ:@_2(R\S:Q*3+)Y-W@K"L5><%!LFYM^L'!V-\(Q@8^V0:D.HYY>R%(0$/) M3M=LK%P]\*MMNEMFTB;?+%R[S$B7,PW*Q86H"A-M MK=J?RJSHA+#=T4[J#II45^>O!9W\E&8DSZI]0_U>D MH?F$E6;P=O6G_A3_!W9L\=%5N>_[Y?!@WF]"H']JGE>:&UO7D;&'D\GV??R$ M8P_VA;S9>.E%RYD)#@_MW#+R9OYR/#OVHX3KWL\\,E5N^,-S^V^8LL >=(;FJ-I:-@/KTP/N0^U,6.?S2R*NJZR/ARJR1X MIP=P?UT@W=L/M$'[*Z*W_P)02P,$% @ <()A5/3#%@JM"0 )AH !D M !X;"]W;W)K&ULK5EM;]LX$OZN7T'D>HL44&U+ M\FN;!DC;W;L"W;9(NGLX'.X#+=,VMY+H(ZDXOE]_SXQ>(B=RFRT.*%);(H?S M\LPS,_3%WMBO;JN4%W=Y5KC79UOO=R^'0Y=N52[=P.Q4@3=K8W/I\=5NAFYG ME5SQICP;QJ/1=)A+79Q=7O"SS_;RPI0^TX7Z;(4K\US:PQN5F?WKL^BL>7"M M-UM/#X:7%SNY43?*_[;[;/%MV$I9Z5P53IM"6+5^?785O7PSIO6\X'>M]J[S M69 E2V.^TI?WJ]=G(U)(92KU)$'BOUOU5F49"8(:_ZEEGK5'TL;NYT;Z+VP[ M;%E*I]Z:[!]ZY;>OS^9G8J76LLS\M=G_7=7V3$A>:C+'?\6^6ILD9R(MG3=Y MO1D:Y+JH_I=WM1\Z&^:C$QOB>D/,>E<'L9;OI)>7%];LA:75D$8?V%3>#>5T M04&Y\19O-?;YR_=%:G(EOL@[Y2Z&'A+I^3"M=[^I=LQ^-44?NO$S\5* MK8X%#*%*JT_V=2$UQBX<$=_S[5=IT6SLS6@R.!&_E MBL"KK(5P",4!3D&"+H2ZT\ZK(E6/98C]5A7"=^0L52JAN12-8@K*^,- O.L1 MOE?P?6$\LCDUFT+_%Z]7I1+>L,P29UH/(O$'?)<>3(&SF[TZRW :MLJ,-AZ; M8Q7MH]/P\%9FI:QR/@/IR-H4>M5G,@X"ZE2^5+;CK(]&[*RYU>Q,D!\\PS'R M'*,]XD%&6*">WY+P@Y+6P0'T[('$N/H[$K)8U0=$Z?%V$23:J/DS!:T-,;3WK?VQ&R\G!0 M8V(M/CB?A?/I'#O.DW THJWG43B:S/#ALP)I%X C,D/E+HBC41 %T3AX@Q+1 MR*;0H9B]Z"0.,DZ;5?#37^9Q%+]J_Y_$,QCJ@6#G"4W5#J\)\X TS'JX8SR> M!-Y;K*6NR,3'FE+ M49A-(>+WQRD8)),PB:=!E(3C^3Q X.#13P"F#68)OD>ME&_A"2AIEO5]NM'0 M=*U366>,(0 X_2A]Z\2E# :'N:W9%P A3'N4-"#9[6F@GX60.3X?SR>3^ M8(O%18DXA%$T"\8L]BI-;8EWM9]=,,81T20AJ,MB0\!T?-):WS%7D-Y!'$;) M#'_'\R3XH- 3"7#8$D3F#Y >+V#R-$$2F_3K"VJ95AP+',"0P)(I2M%(@U[PNXM+73W-C"5U?5<;*%MP^\/M3Y?S8 NI)PI-= MP?W:C&!<6YOBG V5G]/[J!TKJ(A8AC^L?99,!F-TZ%G&2Y$RSZ)D,&F?/*E) M:%DFA$INIWADR0[LLIZ.PC]HZ)KJ2%(-[>RL7Q(/I*0<0 M5)JCGG3 4FT(4X;85EL&6#Q*%DC(C/@-?.6/4#?Y^JV%>KPGC:" ^E]:55'7Q[OWU M6W%33]W)/&8;[K\G86\M;H@#^XE[ 5+>=_V3S'>OWG5T>P#=EN2A M[LOG),VLU^ %L*>GR:\94^K^#PR3Z5Q37ZV/>@2NB%;3&$235UKF928I\AUV M0 ]03V#P%A,5,]1D]%<0B]]B!<:BK57J!26] %-R%E8D^G <<\QL5"7?:VP/Q?OUHIVL4(@MS)0O2 TH_C-16PD"3IB61:M@=/[#8 M*KKDX;'CM,N%O)4Z8Q=_S_<4WJ.!!_K5*RN2S"7-E\PA=4^7T:2'R5VGY"(P MJJ+H%30A#\0OI:5NLA]>/94"R9496$.NX3T8YRIR6I&1/;P?TDZ3:I[(>5M5 MQ[KNH"&\S%9]BJ_*M.FA^Z+[I!!AL+ZOY)U)?7VJ5H4M!'3QY"9X;4TN")=L M'V=()98+)@%50TCJ>P6J];HBR78"K;F2I\P*/P2#=@:M&@B^GR,&0#%F!]=& M/A2_L53%RJ(SEM Y]8#@_F2A_8&9]V_?4:#N39@JFR@V"J'9FV+203<_F=*< MP^V#ZYK,N8>$8\KHSGDBEGN!NG6KVKWV[N.)V&1^NS\PI$NQ M!O].M6?N.0DE0_&)* V1L)1+T'S?I'!-8'3G\H >Y.J/TOFJQIL3S6A?/A[S M_LJHBOB!6JB/S(T1P>W M;MB93*<'JH,XJ'4K-6S530>R8DAW) JEA^:;+N@Z]TQ0&QN88_2CZ?WQS6-A MD.Z8/&%G=;76W*MT3SHUB6,1Y2$ZG?X%_06 ]*DHH8IRYR(&IG!T=\96P>*N M)EI4HWZY_(,Q1#V/; $+1'!WVNTU;\%F()*Z5\.!C),2[&)Y-AST738/.W?W MN;(;_H6"BTCAJVO\]FG[(\A5=?=_O[SZ!07M."@'6%%K;$7W-CD3MOI5HOKB MS8Y_"5@:[TW.'[=*P@!:@/=K8WSSA0YH?QJZ_!]02P,$% @ <()A5-E: MG=04! ^0@ !D !X;"]W;W)K&ULG59-<]LV M$+WW5V"8F9Y<4:*=Q$UES?@CG?B0J2>NTT.G!Y!8D1B# . DO7O^Q:D:-EC M^Y"+37SLVWV[;Q=:;IV_#PU1% ^ML>$L:V+L/N5YJ!IJ99BYCBQ.ULZW,F+I MZSQTGJ1*1JW)B_G\0]Y*;;/5,NW=^-72]=%H2S=>A+YMI=]=D'';LVR1[3>^ MZ;J)O)&OEIVLZ9;B77?CL+$[Z?+GS7M T'WX*9 ME,[=\^):G65S#H@,59$1)/YMZ)*,82"$\6/$S":7;'CXO4?_,W$'EU(&NG3F M'ZUB<]XE3,A_17;X>[)<2:J/D37CL:(H-5V^"\? MQCP<&)S.7S$H1H,BQ3TX2E%>R2A72^^VPO-MH/%'HIJL$9RV7)3;Z'&J81=7 MEW]]O[[Z;?'[,H] X[V\&BTO!LOB%)(%/-B\0;>\<3M..$=OX+W^2%ZZ;S2%G(3YU:).]N'7AIQ':D- MXM_S,N!&%?][P]G)Y.PD.3OYB42^;;D0A9C]LK<7?SX"$$H'7S?L?IG"98>(N'BD MC[KJC?1F)U"[@[B$5!O.8DBA=]ZI'K$#16F5:JUM=&-*O.OKYC'0@P3/Q+45 M:"-J2_*IC8Z>."FIEDB' SF)N9KF(L.*9E=ZK43K%/$$BDT*XY%Z3182, B; MARR7KW2XY*EUD9A,JCD0Z6BJV\0,-:YT-["(@TSVA6?OT"_NZS!ZKQW#0U5; MZ15TZP0GX"D/%CZGEQX@0$W(&V+'+2[9@>HY:XG(U!&3DL-,?'%;9,XC8,ZW M<;8&RM1PE>N-@J,-X7S"1I7(!WJFK<=^@$SQ' Q2><'IOO5&'L_;(>J6/]E8 MEMKHN'MFP.FJ\&DHTM1@SQ0[U )&7M ::40TGG[T&C),M1YTEE /E,..7E$> MXWFIP5HJI<]?/A.7N\/OPH M^"I]K9$W0VN8SF&PO=V]R:W-H965T MRAZ MH*71@I HA!U3BYI72C)*.!Z:*K:M05&$)"7C+$E.8R4:'2UF8>[.+&;4.=EHO#-@ M.Z6$>5FAI.T\2J/]Q'U3UQ0.E:!1JVY &@^4\6J87 MJZF/#P'?&MS:@S[X2C9$#W[PN9A'B1>$$G/G"8*;)[Q$*3V(93SNF-&PI4\\ M[._I-Z%VKF4C+%Z2_-X4KIY'9Q$46(I.NGO:?L)=/2>>EY.TX0O;/C8[CR#O MK".U2V8%JM%]*YYWYW"0<):\D9#M$K*@N]\HJ+P23BQFAK9@?#33?">4&K)9 M7*/]3UD[PZL-Y[G%NMM8?.Q0.[A^XJ^=Q8ZQ?C'.=XA5C\C>0*09W))VM85K M76#Q.R!F/8.H;"]JE1TE7F$^ADDZ@BS)TB.\R5#D)/ F_UHD_%ANK#-\)7X> MP4\'_#3@I_]SAL<1Z63\[D^5-X84?!&Z8[M ?QP9N-I05]5P*TQ>[V='/(UP M2:H5^@4LR8)7TB09)4D"MA8&+5 )#4-S4HKMP#4 M:+CSP: 4CO/YP+45O1MSLJS%X[V>QGJ3V_'??D9\<+D5FBI8V)?1:=??\V%V M>"66O3E^A?=/#!]9U6@+$DM.3<8?3R(PO6W[@:,V6&5#CHT7NC6_=&A\ *^7 M1&X_\!L,;^?B%5!+ P04 " !P@F%4/0-Y L@7 "2P &0 'AL+W=O MO(#S C W(LB7'2U; <9*Y M&:2[/7'G]L-@'J@J2F*[5%235;;5OW[.PJWD4J6=OL"\)+94/#P\/,MWEO*; M!V/OW%*I1CRNJMJ]W5\VS?K5\;$KEFHEW=BL50W?S(U=R09^M8MCM[9*EK1H M51U/3T[.CU=2U_OOWM!G-_;=&],VE:[5C16N7:VDW;Q7E7EXNS_9#Q]\U8ME M@Q\J=II4PNKYF_WKR:OWD]/< $]\4^M'ESV ML\"CS(RYPU\^EV_W3Y C5:FB01(2_KM7UZJJD!+P\89OICFTF4_&3J9NE$Q_K4I5= L? "^= M=BCG&ZN:ZEG6A924 MB9E2M0 +7DNK2J%K6F=+>%J![C5+\6U\.Q8+52LKJVJ#7ZMU X_*)*&UU4!\ M7:%6_.?5UZ(FT=@33O5=UZO44QUL[_@JM*[8K* MN)8OOS!D)*A-^$!&)ZAG/_=UV35AN&/E6%E6QC7"9?Y91>EXDG])0(T!K6V6 MIETLO8*9_M5WM7FH5+F@\^#1(W\LMA:U>M\4#FNI0,KQW_%QS]:?2^KR-M7D(G5I-[X?9_B_:MHYRJ)U^TTB,.1 M3UH""@ !5!HHH"'?J^BAT+<:JQ=P,Q589!-<(1FL57C+%"'!-L&'PA5:LV+U M J'B4^O6@L,$P<(]@C47R(E*G(Z9-^1W^RM@I*C:TJ_1B*=DB7Y#WDM=R5D% MWRQ5<8=JA^N!$[4!'NT=X$+O]X%^)@8B!$&$?9;CWY>JPAL'D53@^3%^1 =: MJ08^(/. L*,;6 OL800B7>K785F@X8 TE?3JI#$"K(VE> 02%Y6I%T= >86: M!LQZ<^@8TDQ6Y!0()0VJX454PXM!5?F))$-R2S&M3^-^@$ROOUNE)UUZDE3/ M->QT+(@%%:54LR9[:-Q5U@K$!$X$'4>SBRP*-NC%$5S@D0,M"J$,/*SS<0\% M#H\F;U1R- 6E:U6XB:[P1VP&;0T*6.D_8<4",@)2CKO&;]JE@6N]VX(M'6(D M%&EG;X#DQ=W25&CR_G[(U)K-3E'WBYDD816F3JBEF4=8@'0:,@H)&*968J.D M)<,"($%QA44_4X5LP3+H.G;<)<2D9.3@..:M#UK;*A9H)P&AP>^X):);R*I MB ??^SCB %]@B!+@$"$(S@F3P'B8P>D BBE06M]E>@7 >OSS"ZP9?MD)# MMJ!-OX%:=AB+]#QPD?!)@4XE HMD?C-,N,G("P0/,TH;=FS5/3[>$""-/PG@ M$#C2EK QL,K7P,H!,NBS,RU ML]^5!Z[A\D#KK"%S M+169 FG,7)4^FX1O6HSZ\\X1==,R@_"L>L2T!CEYNJK2*]UL[0B(B-(A1.56 M*SAO2;F-=Q5 D:.51S%T$# .#; 6@R#:A%]N'"S=$B#)"6Y(!XSCG0>C2!QN8% B->K0C4$ MK+%0;.T/IJU06]'_*7T?,W3#QVLT55C0"7QMQ(-&<=,,D#Z/O MYNH-G! (4&HIRWM0=KE0I@UH)?K9N%6BRY$/P[C%9 ^WYLP06&T>T*=[&H"? M&HU;$?CBW5< YL&8*:)@[!V3Z-D/-JI8UJ O(-'6&Z-_/!?IJG58TG@$9_ G M9Z MUPS,S"E[3_Y)U^LV>"W 5]M/MO639\?9S>^XY?X;QKOW&5F ? QU?%F M"SH(X[Q3F$-Z9![02CGOJ\ 55;%(EE%>:O!_D/.!I<*7*=#.M04)- ^&] L#I^>N]+\B%F! >G+[^[]8@KB/%8:A#Y7-_ ML8S &.0525Z9DF!@V"(]]:1_V9;\*.03X)B^OZN#RZP(#O?L.7I*(JQEQ.1K M9YYN]Q3?)PZ_<^KAU2O2S 0/ST#D('4PUIH9965@Q)O\(6\?H/]R6TRG7DS? MGJIHVL^U:Y\5<8<YTLJI <@29*R$C MRM.^/CM"0\ >3DQ8@#O,/WBQH<239>TK@VY;9%N4,P[&XN?,QK>SJ]K41_,G M_L6J+!_J.!5L6-&B5#TF",]B0D=$I8U0K_1E\5@[?K)_-PTGQ:<>@&97Q5J= MN;T(E]9R$_T)?&A;M17Y$&@\4OJ/&\,!TBERD(15]B6H+!=K\DIX/$Q'\[8/ M -S>:PA/"%+!%!K@!]=0M2/CH5."R"!:3#5GBFON)*]4+Z^/0O[K##,*A&XLE .\ZL!*Z1O9Z>WX_0DAT/E;AX]RI M4+T/2RR8 R*,]:"37%A#MRP;SFNI4@IZV:Y\):+$FB08&?=\46E7H'7Z3_I@ M#)GBP-==@VQ=N$YL F)W]X@R65_, +88(*7J%X"+>5O!1=TKE_HPS!=?9 #. M%I%>+/$B",#2#*HCI;5C\:57!%S.88[9BFQ(H1)>4@'T:IJ\BN 7>TBU"5*0T$6+M3R4@9>O.%\.[@0AJ'E!/A2 M8RSU6:B S>6#(17/FMZ30DA$0=09]0N'W7J'"($1A\AZO M^JU:$$>?D\_N59UG4Q&_1"-P_"W+-915E6^S^+*T M8^@B\. 6$!F*=@91TCN;6,?&J[6 ^3K5E[2ISBJ>%(O4?[7?1UK\:GR5&3N$ M?>#&MY=)^:DF"HD:I_L8(*B=1GE$D"3NAH!6R 7$#M9HDB,C$[8)U )+@6;5 MZ0%NI:";-4< 'JQ2YSQ^,JC4.P;H&*,1+L&KM .(<.JT;Z4X3Y7T )"]I4E9Z\W&HVE(:F:[+YHUL$MQ+[ M;-_6U/L]N+K]=@CP<8SK7QR= (F@9J0@UYYGWU.ZIK$Q[$@?_&K6NA#G)^>' M(_ O3T9]XM==GKQYNBU5<8U:D]_=SAL)?X/?05Z3CP]*S0$C]^=4=P4T,-=5 MY6U]5NF%S(8+N%.3%#GJ^2MQH ^W^TLA"( P--["PF LP'P^W+M/B\+MO@8J M0"8<)%+)^S0#U"0/S00?EK.?X]B,VH9KI1#PX>LF9T<]QJFC#G? 7I[?^D?R M8AO5./+]/ U"A+BDAK0 ;H7:^[[\0TPB_?O#W#WOHAZ4U&>N<"L(9(X=<**O G3K"2XE\2PZ4H2'K:9BBD&$"8'WCJH@*&CK MF.;*:IQ2V3-Q<-WA:B2^^)C@AV:8_:M@O,()3G+GK?5EM(@^QF(HLJ.377&8?LO!Q#=EB/[ ?)+@KR _M(K[NBF$%?8W7Y'.;,L]M>,+%1VD(+6"[ M6&R; =2>:P_N:?K@B#4<\1\0\1KAG,&\%C[W@P4[> #%[G0Q8VZ@1\^"T8W(:#+/'J1W:X6 I)Z%+)DD\]"O42'$N4I+8_FSKA"NY! M%*J+!MCUTL%3!,?&"%@V1I765]>]M>T\A"^'IE;-6C>^![\]E.#/N]7HIEV; M/F^$'\8(0=;5%R:P\9V[EZO;*'OV'S3=.CD^'ASQO9 M#!OKX/)^8\UI^G]#48:*+E68>ENWUK64GO *B5I=A!1DR[?Z 6E.;$H$0X[: M[/?1MO-9T:Z=0R93,#4PD=!4P]$B;(/0"O"V([!AJN8]%1#3_7,F/>BW6M3)D@'F/?Z4%R\.$'@FFU)0S%1 M)KA#;+JC[<(M[)QF(80#SP>]1M#36>[!#B RO/YH\N%Y[L:N#!8X]!W/N;[O\A#['.W: M=SJXTX)M+L@,=!.+?KD$<.L'A9/U;@L%A(I=*@]0NO&DW-1%;-@^"3,J!G?R MD((Y^@9P"2OC#57:D12B5>Q 4YU&_ X9G"MUXW-S^-Q+B//CZ1[6%94-+<#X.)#Q=V_$ATV:$M./1S353@S#II XI6M@ M9^$Y]EXFXYJ:_;LD[',QEU%=CQ MJ6D276A2F'4:%+XW^#)3B-1]MX95+N",6.:CI:U+X+5H<.">JD(LIU@IZ=6= M#LY-=S'H==(LX^1[XX?YV/,7X_JAP'.)B.Y'H6.Q->GDYYPP_Z:YZ= YE<%T M&7"F6H3+,O*=C0Y:A'[+/ R$UR"[I1C!J;.4:UW3#=VC\0+#WC583;%^J0# M_]RQV7>.9]JWJTZ:=@^GP1H+)5D-T<)) M>#8 9PEW6?,H)>6U 38Q).+0 E#31^&)L;CYSCK?^&=5#V5NS[3?OAQ6C5%\KP5'U QX M\AW,\$"(=+Y% 6X9]ANZ;R^AU\P79!H@'W?X:B_7[3W4;?SG9 _5>N^:[U9C M6(!+Q,JO\F6X/3^I%_\'(SX_/]_[C:JS9*;12(MGD+G<02$=[,D2Y#-]'8&+ MAE34E[@R?=@[&UU<7.Z=CBXN+_X3L6+"" M*A>@<+@O1N6]T[U)Y/%7T\@*]WYY#GM?GL'>+T=G+\Z&_AA &EJ:#L\:?57X MG@/HY)7OI^&9/_/Q\U?[K:D-5@]VCHH_=Y^=Q+'?=M4N<%89M8DQ9AHQ[JV MO#>8)AU\NKI]?Q@N[_N-021_A#V\#VK6>&E_B$-KURGU19G\0BCJ%Z\@![?M MK*$FX(N+DZ/IR:&O:%NPF(;*F_C[/U2Y@/T]Z=1M!#/Z")QEPYF_/-0TZ87# MYY'TY>3LZ,7)X:O\*.AL<]/*9^UQR\XFUC_TX*ZS*R291Q,CX2QE%DW^L(HY$).,5=*#%F/4EB G]#;Z;,-_& M9=1$X0K T/1VT#H;W@.'PQ<>@@I %NQ+NR,(*D?DEL3!QYO;PTX0"J?"FPFL M2PSMR(,?N(O=5) $!&A*^X!03@>K4ME=04A7L>E/;2[ML.#&,&JFP(:H92[G M.)(7@\[D+ JTD-XN/)C =2&11#2! 3[+(HG71":$5:EQUD/PGF?,LIX[PPL M(&.4]*^H/*NP6])8$[!>/I81 M;!")RO0["'=K,B756_P+LJBG4=K\$DQ^4_'UM%B"#J*;4[N&CN\9=3$F=%YP MV "V2EM0&0$_IGQ5XHM=8%CH!>.5(&;L>X_-QK\DTLUBJ; <+[PW1SW._BS1 M2MD%_?$EA/T@??X+1?'3^ >>KOC/&J7'^:]#_23M A/O2LUAZ.9J9IS(I^Q-ZCLO@ ?#\W@%O]+[A!_+-7[_X/4$L#!!0 ( '"" M853K1>I52 , \' 9 >&PO=V]R:W-H965T-;6 O*1J@*8PX:1Z*/-#4R&*6(AU>ULG?=TC) M6B^ZN\B+Q-N<M;FS-:*#'XU4=I76SATNL\SR&AMF+_0!%>U4VC3, MT=3L,WLPR,IHU,BL& ZG6<.$2M?+N+8QZZ7V3@J%&P/6-PTS/Z]1ZN,JS=/3 MPD>QKUU8R-;+ ]OC%MWGP\;0+.M12M&@LD(K,%BMTJO\\GH!,.;CB7'OEA-K#1DO!!5IX_8GM)-HWR\P1<3#/>$=RW9(4SY#D M!7S0RM46WJD2R\< &2GN91PA:Y-\(% M8J4=O%=<>HH5" 4W3'(O6Q?VEK8H(%MS0QFGY5P3UW/R]K. M]90G/?:Q'G&FQ]4(_+&FLM.D2),,F@ZDR49-GC0-8(><>8O@-)0:K*9B];*D M9:!T$[^?: = )L L5%I2OZ"D(SZNFX9HJ!;X780#_.[%/9.DNB6Q;UM=VENF M2OOF,J$$P69'(BA)DI DX3.D3[Y(;K2Z1^,$93-0)ZO0&)(>X9-7O\V+O'C; M__/98#J=)E^8,:$N2/[!&UY3'R!9OPXS?P;AP;'_F02=#]N@#R'6%H2UGFC( M3: >:QT-*&N3R6 VFR>CP6P^3W*2/'ML;?WN&_7!P&ZPY]>&XFPJ%,X;3/)) M,ETD^6*2O-MN-EU@Z2(C0>1EBF,R2O)>XR?MF SCK=/Q0=F]H)B(;$BT^'%;)*":=MO.W'Z M$%O>3CMJH'%8TXN%)AR@_4I3RG>30-"_@>O_ %!+ P04 " !P@F%4,\&: M; $$ #M"@ &0 'AL+W=O['YF,?WS0Q',]Y(]:)3 $-^9ESHZU9J3#[R?1VGD%%](7,0>+.4*J,& MMVKEZUP!39Q2QOVPV[WR,\I$:S)V9P]J,I:%X4S @R*ZR#*J7F^ R\UU*VB] M'3RR56KL@3\9YW0%I:0, A-M8"Q;\US(!S:PAA_*ALMFJ75K&Y?K/^T7%'+@NJ M82;Y=Y:8]+HU:)$$EK3@YE%N/D'%QP&,)=?NEVPJV6Z+Q(4V,JN4$4'&1/E/ M?U9Q^!6%L%(('>[2D4-Y2PV=C)7<$&6ET9I=.*I.&\$Q89,R-PIO&>J9R4?* M%/E&>0'D'J@N%&#$C2;G3W3!0;?'OD$O5M:/*XLWI<7PB,4@)/=2F%23#R*! M9-> C_!JC.$;QIOPI,5;B"](%'1(V V#$_:BFG/D[$7_SOF6Z9A+2UN3/Z8+ M;126R9\G?%S6/BZ=C\LC/N9ED1.Y)#.J4_+A1\'6E+O84I&0>ZI>P-@8DSG$ MA6*&(80J!0FAAFQ1'LK!:>]/*9"EY/CBF%@1YT97[X[]!<3@]4QF.16OO[T; MA$'_O2:Q10E[*+,M2KU%F350+BW*M8OE.1-H618:-75[Y!TKK6>-H+RIMK'! MU$*V %6GUWN2AG+O]T(:=/"@6(P.T?#4O=XJ;!K)*7*7H#D64TZF6MO#\\^P M!DZ"MC=G*\&6>"<,^8IL%?FZT*#6CLF=R(NM=+@K_2SD,[Z8 M7Y GY4B^-FZ\,^^JUXGZ87/A(AZ^;ZR^P$H:YJS&H(R#8L#%)X%<:F:\J#/H M1[7"[FXF52X5:J#TPC3=![W.H->M!?>V9:3/O$&OTQWVFA"#8:7WDUTTT@.MC>1*KEF"J:(X)^R#M\TNKPEH1V!3$> U M@2,]K=@A4#0)L*JB]KK>#>54Q&#M[+V(8( IB[K>+*5B9?4;CO!MGM(<>I>] MPWK]GH?YXE3KLEXKTO\D:&3)/94\ :6KON]>@'GUS@.LX_8)",TR/U1O?F,$ MR4"MW*"%7Q59"%-.(_5I/K*U_WZ#BE'5H+8 MW9>^6.)PSIESAA3IV5:J)\P!-/M1%A5>NKG6FPO?QR2'DF-?;J"BF4RJDFL: MJK6/&P4\M:"R\*,@&/LE%Y4[G]G8O9K/9*T+4<&]8EB7)5>[*RCD]M(-W9? M5['.M0GX\]F&KV$)^G%SKVCDMRRI**%"(2NF(+MT%^'%U=#DVX1O K;8>6?& MR4K*)S/XE%ZZ@1$$!23:,'!Z/,,U%(4A(AG?]YQN6]( N^\O[!^M=_*RX@C7 MLOA3I#J_=&.7I9#QNM!?Y?8/V/L9&;Y$%FA_V;;)'04N2VK4LMR#24$IJN;) M?^S[T '$QP#1'A!9W4TAJ_*&:SZ?*;EERF03FWFQ5BV:Q(G*+,I2*YH5A-/S M.ZZ>0/-5 6P)2:V$%H#L[,%$L#?S-=4PF7ZRY[MJ^*(C?&'$[F2E%5]%)QAM(^FP0>BP*HO $WZ!U/+!\@R-\GZIG0$W[2B.[@95F MBRIEM]]KH7?=%ORU6*%6M&G^/E%SV-8]"V>!Q@OM#BA7H-H=XMQQ;2 [ M"]@!5]AS%J54FLJE5 NU\UC1^578\>]T;F$W\%DB CJWJ$5I_7PT9KX9,\YC M?TF&*!5K6LR#-B=D4C$RALZO3N0-IQ$]K9WH [V=A4YO/Q$Z7V MM;#F$B!1 MF4BHC/62PD:BT!VVT NG02@43T\I.6>1,QYXP6#8 8X&!!U'7AS_I +# M$GGC>'(@,10F-'2NI=I(1:"W.V8/#$=>/)D>D-'4"*?@*' >I.8%=2,>>5'\ MMD]4KM?,!=/1D14._L\5/N7LL,0#;QR^D1Y9X68B^,_VT.),HM=]I=!XVO9F M;+O\BG]D^6EB,GWO//([-T ):FWO.:2/OJYT&ULC51-;]LP#+W[5PC&#BT0U%_IFA9)@*3=L $K4*3[. P[R#)M M"Y6E3)+K=K]^E.RX6=$$NUBB3+[W2(F<=TH_F!K DJ=&2+,(:VNW5U%D6 T- M-6=J"Q+_E$HWU**IJ\AL-=#"!S4B2N/X?=10+L/EW)_=Z>5:F+9I MJ'Y>@U#=(DS"W<&&5[5U!]%ROJ45W(/]MKW3:$4C2L$;D(8K2324BW"57*VG MSM\[?.?0F;T]<9GD2CTXXW.Q"&,G" 0PZQ H+H]P#4(X()3Q>\ ,1TH7N+_? MH7_TN6,N.35PK<0/7MAZ$ #LC63(A M:9PF1_"RL129Q\O^IQ1C)58'*O%SE1NK\5'].D(]':FGGGIZ@/J^;PFB2N1B M2C(N>"\#3VZ@!*W!R7@$V0*N@EJTK4*50CR_R'KK6HXSK["S7A/:&@@3RG!9 MX8L75#)PQ\5.AQYTZ!<=+N25%L(-H8:46%75XGS@%"?+,WKK<:*_=&M"5'RJ&,-5*VW?>>#K.K57?KB_N_="[I;KBTA ! M)8;&9Q?G(='](.D-J[:^>7-E<13X;8VS%[1SP/^E4G9G.()QFB__ E!+ P04 M " !P@F%4X9VU$+\" #6!0 &0 'AL+W=OM7",8.+6#4\4>^BB1 TG;8@!8+VFX[##LH-AT+E257 MDIOVWX^R$SZ.T.'OFZL.X@F$TJMH8GL#^KI<9=T*%DO 1IN))40S[UYN'U(G'^C<,O M#ANS9U.G9*74B]M\SZ9>SQ$" :EU" R7-[@!(1P0TGC=8GI=2A>X;^_0OS;: M4UL(]J\PVV>OH.+U7"-%^Z:7V3GD?3VEA5;H.1 M0B.:.1VD0C.2[=HSQ9 MC;<!Q23.-4BW@(L6,#H!&$;T M04E;&'HG,\@. 0)DUU&,=A07T5G$6TBO:!SZ-.I%X1F\N),<-WCQ_R0O!4.I M\P/A?^8K8S7^*W_/9$JZ3$F3*3F1Z0E;**L%4)73XX4^5M_SF 5EI=4;N&M#HF1,DG!(C@OTZ5HK8\C [\-1S@D,_ M&8R._0+!7J^5H-?-1#%8_UK:MNVZTVYHS=M>_71O)]X#TVLN#1608VCO:MCW MJ&ZG2+NQJFHZ=Z4LSH'&+'#P@G8.>)\K97<;EZ ;Y;-_4$L#!!0 ( '"" M853K3-NM$ 0 $,+ 9 >&PO=V]R:W-H965TZ6K93QX#C[*(!DDV09%L411]H:6P3*Y%:DJJ3O]\A M)14G8D".'Y9 M"IE3C5NY,]Z83>W8OIQ-1ZHQQN)=$E7E.Y"OS. M8*-::V(\60CQU6RNTXN>9PA!!HDV"!1?_\ 4KF@FO&5\ 3!HJS M\RNFDDRH4@+Y:[906F+Y_-UA-6JL1M9J](K51^RJM,R B"5YN/M"9DI!'?H; M1AXH9BV*PY3T+3C&0_:AD\! S&'3D=-#D=O#FGMU27L@H0[BJR[<2F)9 2.T+^ MA[QVLW@UK_D>)9.K@VBT:+TKEW\"E01XBGVS9]E!RT&3,MR$3MCW_= L(UP& MWM L![@,/7L:6P%_+UT%?;'MZ?A1?X!B-Z 487E1FK)C7(,$I9V3H#\<1LYI MK8J_*TE-(Q_)>97Q"N?@ZV')G53T3]]1)L90$/\ MK@G308T>*[UW<$T,E:7AREI<6[>%%2BV7&G-E;6XFAK,]_EVI)5LL$+_K4CM M7^B@1GWS\/#ACYUY0ZM-96>W\S+#7YLKHAH-+8(HV,Q=%N#30YR9<4OEBG'3]TM4])O*:F2K-EH4=DQ:"(U#EUVN<&PO=V]R:W-H965T MVN21M M;[?; R/!-B^2J)*4G>RO'TC)RH_93O9@F9* #Q] (2.5U+=Z06 H?=E4>F3 MP<*8^F@XU-D"2JY]64.%;V92E=S@K9H/=:V YTZI+(8L"";#DHMJ<'KLGEVJ MTV/9F$)4<*FH;LJ2JX16RCM[\RD_&026$!20&8O \6\) M[Z$H+!#2^-EA#GJ35O'I>HW^P?F.OMQR#>]E\4/D9G$R2 8TAQEO"G,E5W] MYT]D\3)9:'>EJTXV&-"LT4:6G3(R*$75_O/[+@YO46"= G.\6T..Y3DW_/18 MR1555AK1[,*YZK21G*CLIEP;A6\%ZIG3:R.SNX4L90$+=^"->M='#F^T!:]S]J_IK38*L^/O'9CC'G/L,,?;PMGF M-I4SZB)+O]8N^:8V^=#:ICB^@NA@9/V8PY8T5B.%LB[D P#E54XK63W>K[C* MM7NLH. &MR)B C+TX2\BM)_6!"/BI>H7G"O$D<$C;RV8BLR>9D M/XP9.2"1/V8$RW\& F6'<%\+9=]&08IO&?/3]#6S(8F\.+9FP[$_3DGB1[B. M$B^- O(=M-T>&V3$QDZ%-T;2)3[^WU@=>5NPFW5#+TFL?.*G(8E]"\-2C[') MCL2/^L2/=JMFH;,%;?QOL,8I>7%]>;JJPW=1O M%ABO#90-/G].NUS3SGO:5FAFJ2_7U+6CWECJ7=7.'ZGKEGK]'^H6Q]*G*[!% MU]?G$?D3T[[MH<^VE&P+$7%[[?*=!6%*KH2^.YPI[ L"\UW9S%)8/23PHSUZ M2$-_M(?K4;N.]DCHC^V:^?$>IE27DTN)?404V'I(,K&ODV2/X ]7*/VL MUS ORC;R(Q29^*&MJ6[%_*!;]6HY]K<<,%(/ HJ<_/9+PD+V^]Z&Q;:XV"B^ M/0;AGKL@C2%[$MW,;KN]TSH5>=0>D!I5=IV%0XN^VXPFGQ+,X43HGG6+W"GOMV*.SU8B]!+>:-PXB,&",WTJ#":UY9,[$71!-AH3%>367::;Q_VG_+3-L1_E&\_1#Z MS-4W>M M+\Y48RLAX5HST]0UUYM+J-3Z?! ,MB]NQ&)IZ<7HXFS%%W +]O/J6N/3J/=2 MBAJD$4HR#?/SP31X?9G2?#?ABX"UV1LSBF2FU%=Z^%">#\8$""HH+'G@>+N' MMU!5Y AA_-OY'/1+DN'^>.O]G8L=8YEQ V]5]:R-6O\& M73P)^2M49=R5K;NYXP$K&F-5W1DC@EK(]LX?NCQ\CT'8&80.=[N00WG%+;\X MTVK--,U&;S1PH3IK!"76:OPJT,Y>?)"%JH'=\0 A&M4^N 6,7L$ABO52,M*_9@\2TL^FYZ:/,.VLX+TPAMZTBB=F ^#1.F M([?X#_UQP^:J0M9C8PF),U5CN"S-R6OO+^"Z[12&=89Z!IIJ[5&MZ3+&2Y![ M'W;KP0/*D $VG(&$N; GC-L]A 3'>#][PS#VLTGLG= X]Z,@:8>)'^3TEM(- M>W'X#CPF:!MBY]X;9OXDG:#%,/+'8S(=!OXXR7!P#:@&$C!UPD)MO# 8>X$7 MQ-XE:L_6-\HE0Y4\Q4+<@W82M@(M5.G]\M,D#,(W_3T),PS4@@:#2"1K+:Q M)C*I**RG%G&<>#? *Y?E!0KOSLQT]?ZVDSR9H!,#^KX%V\@"#<@9I7NEC*#> M,5[@!]G8B_()1CAV%EP72X:%1/&[1U%?U90*,BHTE,(:;X@UR,,V96F4TR!Q M-;F".6BE"NBB:U:,0GJ&E*F0INOC"JZ;M:DZMQ1&U%R5^%*9>$/GQ M9.)AX3"C?V!C:B^+\#GHO1SK)^R2[;0#HR/JD/3JD!RE)=%?4=L8*E"?"N+Y MU!BPYA#3C[N\%9B^N2AX1^.=>Z(E+W MKKS$0\91),U2K24R _/]C,DOT/?J^5JOO=^):L@"K!]*C%.,@FN]P?9;YAAR M&J&RJ.+K*1T02E<+7,#U*4Y)44CR-/?NE$6%.5 &+\G]#/4N;*/_")B9^P.- M/DQ2/\TC(A1.C0(B!"7UD$LD#'$"J?"H%EOH K @[@AVJN:G#0;E[!S1PM1Q M-R2Q.X!YS\6SZ2^A^3%*I3VETN/]O]UL7!=/Z8"'16$W4'':T'![>J^IRS[+ M/:DAPEVVI#](N>-+WBVAV]7<-DGGI=V>9]I]=8M#[W [99/F/KC>^S[;P# '9;6G\%"2$GA=L)"@+".*2HK$C5)25;0 ML KF:#I^E:&NZ_9_H7VP:N7.Z#-E\<3OADO\Q0)-$_#[7.$FWCW0 OU/V\7_ M4$L#!!0 ( '""853LC/CMC 8 "0> 9 >&PO=V]R:W-H965T M6RN5OQT,9+1F*96G/&<9/%ERD5(%MV(UD+E@=%$*I-YPD-(XZUVV15+$JT)<'PR2GOUFEJP>;W5_JXT'HRYIY)=\>1CO%#K\]ZXAQ9L28M$ M?>";]\P8%&I]$4]D^8LV9J[70U$A%4^-,"!(XZSZ3S^;C6@(^*,. 6($R)X MP1T"OA'PCUTA, +!G@ ..@1"(Q#N0^HR>F@$AL<*C(S :$^@!QY=H6DB8("6BV0)-J8RE'KT13+),T7+6";I<+&)]21,TSZI\TP]>SYBB M<2+?H%=H@.2:@A2*,W27Q4KV81"N_USS0H)N>390@%YC&$0&Z;1"2CJ07A:K M4^0-^XAX!-_=SM#K5V_L0M5OB]8KM]9?BP2TDAVM+5IF3VG)3A&NL'G'8_OY M"*U>4&EM$7_WQ(;E L2Q%L>33@R_'('!]RH,G4K>NY7,6 1*\,XF=^J:'Z_+ M<^@:0"+4V4#J;""E]GP]V\P \T52^4_#@!^#< O 00= M &YIPG3&0=Y'#R@KTGLFRGN335(6;*$320F:25H6C#9_5*N$Y2JZWCU>C,9> M&$P\#P+IL05@4 ,,G "O>)J"V26^_A86+=2:B_A?MFA+G> 2^"9OQI+A?KH MF?-C9N[8%];VA4[[P+E+)@1L\M>8&';"V;/PV(GS(R;NV#>L[1LZ[?O 'IF0 MS 28S)-8]:$YJ,.^+9C<&J\S!"3!D.&I/E)KAB!,DVJG=CY$XWK6_- MDP5H_PFQ3T6LOJ",*];?W:"(9QI V>#IO&_C\FHE[#5<5IG:[K!Q#7%\%"/L M; HT '%:I(BN5H*MJ-(S(&SC;(5R$4<,_8=>M=7":JE1 R(.NV-J4D.<."'^ M 3UY+GC$V$*BI> IF@-/T2PZ!$Z7"@AMP18%4!>@W<(^$2RA.DX:O :24E6= MB-8!W >#LL.T]Y-#TR;#+LNP9]LCSVG;9105:5%A@QXZCB!,.Q 83, M2'RF9BK7$*KP6T;R(P1.9O8/SC$/T)S=0RA)%A4" MVC?6N9-FF=$.]X1AYU[:XHJ)$^ <&L$8FL:;XCZ)(RBEE>\=>8QMW<3^RU1N M;"LC=I?&[U2[9_BPN.%A..S.4VR+&W97MQV(?<,5.< L,>J J)O65F3A89*- M.S#9@H3=]>-FASDTV\]OKOLH8V4]*#+@YHT.6&"+12PC7F3Z--%D!!WA-?]5 MI-$>VC,#I6D &06XZ*A#+&<3 M]V'G^SKC\,C3Y0S+Z,3-Z'= /C)>967UWW,"4,S7US-BF9J$+^0>2\SD*6)^ MSE'(*#W^Y$(LR1(WR9JSYY,Y8)F/C%]HDRTG$G?O;&QJ3P!G27AG-!\1\;[E M1]_-CS^ZCLW]%LXLZUA7>/B6.OTG^M]&>#PK.WU+GOY+O2=JO"ARD^>/]M0O M?@NA.CL.W_*J[^;5CU1 "ZP0H,@+$:VI/#@IME&+?]@8C\9>%QI+M;Z[*7[& M*RV_^_5,5QA;VO7=M+L7QN]XDO#-"8Q\12!;2O5'+Q3(EH3]XUYP?..Q:6J6 M:?ID0EP>L1SMNSGZVTY-4[_EU43'J2FP1!T\U, G0] 9XO.5?;&_T)K/XP?/$_4$L#!!0 ( '""852/K[;J_00 )T6 M 9 >&PO=V]R:W-H965T& ))#R0MKWZN97J F-G+]825/^DIMZ;#@@<6&LRFIC1)") MO/KGMW4B-@RBX0X#5ANP1P9LO,,@J@VBO@;#VF!89J:B4N9AQBV?3K2Z(=J- M1F_NHDQF:8WT1>[F?6XUOA5H9Z?S:KZ)2LE<+'.1BICGEIS$L2IR*_(EN5)2 MQ (,V2,G22+<;'%)+O*JYMS+8C/&7D4N5V M9D\ZIC,=]V3^>DMVI(+"YGY[(D\;"(/ MR\C#'9'? Y?B;TC($K<:0WB>$*F,P4!8'XCI"U;(0@(Q$!<::VAKZDZK&.,R MAMNPKJ?A)+C>G*C.$3/?B ?41@VUD9?:.[L"O6=7/-_#;*V5=AD6V9H+71;5 M?V)8A1IY&(XZ&?I&/&!XT# \\#+\0_/<8-W_'1XV29>N@WON"_>PP;O M87^\4O"%D&6!_,@D'_8%?=2 /GIBT-V9/NH+FH:MG(7]8:85NVH7^[.4.B6@(EZT#;@&H_%6L+KS:=SBSK/=6+(AW7"K7N9 MJ+7%A'[") -)N33P>2MP/P9G[6E*:"MLU*]LWT_&];?86,-6%O[@O_%\G]#7 M/[UXX7H]'Y]6^*A?^3Z6GS&0[/%K+!1D5K6.09$+U$!3+/["SRF"JTW#NM#Q M"C^(B-($6_44A,5=&^MI9^=Z2K]5OB@Z"!]W*%N&41:QP]&C/F7+.$;'(S;< M4:*MG%*_GGIFK6S1]\(#7[9;!:1'S]Q.LU;'F%_'GF49=F#H6(:LE3GFE[FG M788=P3>7(:,^/JT,,K\,?A>?"RPJ"]JIT7F:NO7:.4U^-%W3U&HF\VOF=]$Z MYUK>M9/5RWVS@Z?.\WMEL_\7SW_ M*\U^EZ/=:0XVSNTRT,OR_-.0DF=UXM4\;!00 (<0 9 >&PO=V]R:W-H965T M.O8K.V4CK0_?J^=-.$CA(HG7DKBG'-S[SGQ36Y'6ZF>=4JI0:\9%WK< M28W9?/ \':943]NJ-<;L<=W'E;>&+KU-@%;S+:D#5=4/-M,U=PYE51$I91 MH9D42-'5N'.+/\R"P!(B%!>T1IS1^ :%^ \4^ %N2&CZ?KK?0)^]FXZ'+=6$U?,0 MNGCAB7BWX&G28.?]:VGE1R4S-)79)C>%F8\K=$^4@$=EQT3TXQ,$1@^&9OIG M2UK=*JVN2ZM[(JVOTA#>Y'9!ZSF:[7$ODUY_&(V\EUT'CD'AH#?8!\V.07C8 MZ_8JU%[>O2KO7FO>4RE>J#)L"9MF#AV-*@4:+HR,GUM4B:KHT369U:_2ZE]F M5O](8O_ J;.(V3$"]Z,H:K9I4&4\:,WX.U'*MKW_K%@9Z'3.H6$5>'A-#F&_ M;OO^91Z5O#:3SD-F#9!ALT5XYTV%WVW2);L*!_6=@JMRK6[..+S0M?"\:V/&[9U[=T.AQXU52Z,'K7.0$5[AZ#$WVL !2-^JO*M[ M-8XN]"YJ>(?U!X?V':/"_N#P)=: PE'4/V%BW=!Q>T??,W&1+_^!KW9D)'JB MFUS%*7QW(ZD0?(BO*#.YHFV"U3T9#Z[*R;JGX^&%3@Z/U>\=^GB,B8:'+C;$ M&9[X$@GJEA^TM_S[Q7Q>2&+5<3O.;40BXC;#@KI!!_B:# OJ?AX$EQE6\O8V MU8%?#1!\8%<#Q#\PR]N9T#*JUF[2U<@-6<6H4:U6T_2MFR$/UN]@RBYFXCI, M,:)_)FK-H+=RNH*0_DT?\E'%U%N<&+EQ<^!2&I@JW6%*24*5!<#UE821KCRQ M-ZC^]S#Y'U!+ P04 " !P@F%4/>@[+Q8% !G(@ &0 'AL+W=O9!E%XZ!Q-EB Z1- M-DZZ%XN]H&W:)BJ)+DG;+="'7TI61"6R&-51%[J)=9@9#><7OZ$4#7="?E$K MQC3X%H6Q.N^LM%Z_]SPU6[&(JC.Q9K$YLQ RHMKLRJ6GUI+1>>H4A1[J=GM> M1'G<&0W38W=R-!0;'?*8W4F@-E%$Y?=+%HK=>0=VG@[<\^5*)P>\T7!-EVS" M]./Z3IH]+X\RYQ&+%1^GSBD%I\YVZG"-DB&,A7B2[)S/3_O M=).,6,AF.@E!S<^6C5D8)I%,'E^SH)W\FHEC MG7?Z'3!G"[H)];W8_I;&<_"1 MRB],TVG(P(3--I)KSM13D#F@&A1BGUP94QZJ4Q/X<7(%3MZ=@G> Q^!A)3;* MA%-#3YOA)$EYLRSURWWJJ"+U*S8[ QC^!E 7P0/NX_KNW>?NGBEB7DF45Q*E M\?#KE;Q0BIDJ79@JW7 ZY>&+VMS&X#XIF>3Q,K7Z)&*9'[BDBBOPSXV)#ZXU MB]2_CNQPGAU.LR,5V1744KE:AVJ^#Q.D81(&;$=]OSOPA]ZV6-JR5:\7#'*C M9RF2/$7B3#$OB6.X?A[+;Z$8O3R[GG.D#T+3\%#Q]V[^*\4O6P5X4%'\($\I MJ%=\\ ,\GDW.P(-,"_2]\G9Y=IE^?IE^"W49Y-D-FIDD@Y("/1\'Z+ $L&M9 MW*TMPB>V%)JGN&5+0U@3A^9F& NY%M+H;[2?ZGI3 M$EI6PC;"$EI:0CNJEG2PC:B%EK60C=L*YL@ M?(VNF8IELXHYARR 47T OTW"X]HHLMQ&;>0V*BR&&^(V*G/;T4N1!3=R@[M1 M*=_4C)%%/B)M%-4V"N0W)*I?>V[:+H#<7:!.)T9ELE==UV(=_5]8/[*1(XM\ MU$;D(XM\U-#Z&KG8GDE=&__8XA_7Q_^$+^-TGL<:W.H5D^!VJICB ML:4Y;B/-L:4Y;HCFN#;-L:4Y=M/\+:J]J1MC"WX9V&C,N4KGPT)I;3Y!=Q^L@.3"S#21L93BS#24/+I0^8.5X$ M6Z:3XYC^&(LJ<;&K"9/".^@V0IM8:!,WM"N;,'%!.A.K-L>)Y3@YCN-.I8[K MO,22F[21W,22FS1$;E(F=Y5B%MO$C>UC%7M3U_4MV_UN"[7S+>%]V(QV69P: MVOD6W[X;WW5:KE]&&ULC57;;MLP#/T5PNA#"ZRUX]RV(LG0 MI!M6H,6"9FT?ACTH-A,+E:54DI/V[T?)CI?FUKTDDDP>'AZ*8F^E]+/)$"V\ MYD*:?I!9N[@,0Y-DF#-SH18HZJ=]%1A!98[2<"5!XZP?7#4N1UUG[PT>.:[,QAI<)E.EGMWF)NT'D2.$ A/K$!C]+7&$ M0C@@HO%2809U2.>XN5ZC?_>Y4RY39G"DQ!-/;=8//@>0XHP5PMZKU0^L\FD[ MO$0)XW]A5=E& 22%L2JOG(E!SF7YSUXK'38<&IT##G'E$&\[M XX-"N'ID^T M9.;3NF:6#7I:K4 [:T)S"Z^-]Z9LN'15G%A-7SGYV<%WQC4\,E$@W"$SA48J MD35P#A.Z,&DA$-0,[C%1,N&",Z\]G8Q);=0:4YA8E3S#$].:20NWG$W)SKZM MX5)@%C:B/!@NYW"+2Q30A >II@;UDDTIT(U<%!3Z]!HMX\*<.1)\+OF,)PYZ MKVT%Y&R)9*&U0S^'A\DUG)Z.UX,/X*.(U)A?0;'R".(JC/81&_^W>^'*$3K.N M?]/C-3^N_Y4Q2)+6=?LI-R0=,L/-GA)L7XW?MQ0 ;BSFYL\1>JV:7LO3:QV@ M-\0YE[(D()A,<%\)2XBNAW"OUG+0:O?"Y::HNR;-J#9YQZQ=,VL?93;*F)RC MNUXS)^'22;B/7(G2WHCNJ@X5=8=: M!<8U;Z9$BMI\!7PIZ'Q?%IT=BN>-^(""W9ID]RA)ZJ@/"MO=J5JT)=VN16M; MNG#C<O3>BQ=^==XZWQ(XZJ<+O]@REEWQS1=4P,"9P09 M771)*%W.CW)CU<(_P5-EZ4'WRXQ&+FIG0-]G2MGUQ@6HA_C@+U!+ P04 M" !P@F%4=DFKXJ $ !7& &0 'AL+W=OW#KM0AL9T;*T":#6J[TK0=+3NMJJH/ 0Q$D\34-L-N M?WV=D(D#3DRF(%Z&7,[-)^=\\/#/!= MEL7L^R>2TOW8@M;KA2_)>B.*"_9DM(W79$;$T_:1R3.[MK),,I+SA.: D=78 MNH+F8>3:2>F/P2LV'@#LP.CQ70%6@7>3^5UY*4?Y#"3[,I>/_N W@'DAQ\W= =C_,E']E"!EBX ML1=5,)\.P:".8*9D,0 8_@"0@V"+>M1?W3E6MV5:ZMR@.C>HM(<[[,UDSRQW MI"CX+DO&_#8YQ[1B7CMT.Q_<992+YERQ! M1+EHR^-!/RCUBTY]F80>"M'(?FFF2Y?R_="MA8YB<^O87&-L3[FD15H&]Y.D M1.M3/ECP&GZ=D\A,$D=A>7587M^P'BCGI#4N3_-Z!\/@)+06(:\]-K^.S3?& MUF@@7M=,6WR^YCKTG*%W$J NY?O!L#W$H XQ,*=O,!N KS*%?">;OE'9^T1L M 1_DI@!6?@/A',)!%'<_FZH]+#V&]ZVQ8:UX^&%+3;4THS<(6I/,W04;IV+ MVZKVZH8PYZ80,CU0M7%\-.T-4%"HC0 M3,1>7:!S[O0M8A0Y#DV!$)XA8:]&"?1&05KN6H1P1WB*ES"\4C>%;0_8TU*H MBV''[WB;0$57:,;KKV1-15*&&1%9BJMD(3N0%]O)*=E2GHC_^V9!"K7(N6W_ M(45;9*;M^?Y#.FHA''94+VKL6,VP[=-82.=LEU\%662&;*^NJ6ST>;T@15ED MWH_V;@BD[SDA##LJ'2G4HC,;SS,[I[>]79!"*/)O7-T*D>M$ZRIOA3-DQEF_\M9WC'?0ZR ^5AC#YAUC[P+'^K;11V'8 MT6%8P0R;8=:?Y6^K=:RHAF\]B#.%=?PY7,V[CU&8\4S M?(5!&K<,R5V%KHB&KS0F5W:"XXQWP 4KK&$SULX."F_=JF#%-7SC,1@KM.$+ M!^$(ZUS#/NR8 5S%-??B23AR>T_"KL*9>_DD'+DMDW#7BA7&W.M,PE%E)SC. M^.G*[<97W^*3NS2_EGD$*5E)-6<0R.C9X2OVX430;?DA>$Z%H%EYN"'QDK!" M0-Y?42I>3XIOR_7_$B;_ 5!+ P04 " !P@F%4J*!8-4L% "D%0 &0 M 'AL+W=O6B!]:"3YWJ-S/W@/ MQ?&]5-_T&L"0ARS-]5EK;4QQVF[K> T9UR>R@!Q_64J5<8.W:M76A0*>.*W:C)6&Y,*G*X441OLHRKW3FD\OZL15N/#V[%:FWL@_9D M7/ 5W('Y6MPHO&M7*(G((-="YD3!\JPUI:<7;& =G,4? N[UWC6QH2RD_&9O M+I.S5F0900JQL1 <_VQA!FEJD9#'OQZT5;W3.NY?/Z)?N. QF 77,)/IGR(Q MZ[/6L$426/)-:F[E_6_@ ^I9O%BFVOU/[KUMU"+Q1AN9>6=DD(F\_,L??"+V M'-@Q!^8=V'.'X1&'CG?H/'/HT",.7>_0??Z&8PX][]![K4/?._1=[LMDN4S/ MN>&3L9+W1%EK1+,7KES.&Q,L@&6K,PR+10-Y/$:4"Y>C5*%&$A_I^K)CH/MO-R36R!3I7B^\OTWQ;Z\EGE\S(+\ MCI>:NZFER5^?$9E<&LCTWP%>W8I7U_'J'N%U"UO(-X #-9:K7'QO;M828^ P M[%S?3D8=UH^B:-S>[A?HT*X_& X.["X.[5B'CO;MG@33JX+I!8/Y+-)TA[DT M0/XC=Z $:#(C,YEO01FQ2('?G.WE[ANKU!O]-ES84;5F2' M+W2A'\M/1K>;V(_3NQK8*"9F33ZF@KAR!U(UJMX^>E,EI%$M9%$P+U^+I4(9 M($O 3L8E"OCZI@4Z\SA/5E14_FNN#-T34_K"HO+R614 '@JA=J3 !2:;V801 M:41V6&X=2A&KZ;$@V/4F6X"R/8Y\G';G,1!9Z0BV19/AEAS>5DM4BPL4G,<1JDL7)(R@5UH9.[V8*6>8A3";\:\ MR%NY\'P;.;+#C790[EDM72PL+[>PVJ3<2!3X'\*T<[ADNF&JM7JQL'K-9):! MB@5/Q?=RO;R*<2/-AB^2J!>D64L2"TO2D;7M5O'53G[B*A'\ [G,XY/0.JGU M@KVM+Q)6RP4+?Y.\;KOA00[WLL^F<8/=\UJU]PZ1L%56[KA/XYC8Y*;\=J^> M5D>*4W>0]NSY.3V=T8;G45+@F!24QAB:^*3@;8)*H\$BQO MC"S<$=9"&B,S=[D&GH"R!OC[4N)WFK^Q+Z@.9B?_ U!+ P04 " !P@F%4 MQ5X;1L8" &!P &0 'AL+W=ORAZH*651(0B79*VDGY]EY2LV*[M M%KU()+4SG)VEEH-*JA== !CR6G*AAUYAS.+:]W520$GUI5R P"^95"4U.%6Y MKQ<*:.I )?>C(.CY)67"&PW32<";@7A&]+$NJWB; 937T0F^]\,#R MPM@%?S18T!P>P3PO[A7._)8E924(S:0@"K*A-PZOIST;[P*^,JCTQIC83.92 MOMC)YW3H!580<$B,9:#X6L$4.+=$*.-GP^FU6UK@YGC-_M'ECKG,J8:IY-]8 M:HJAU_=("AE=\ (&H T2Z@

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end XML 74 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 75 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 76 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 214 473 1 false 73 0 false 8 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Balance Sheets Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Balance Sheets (Parenthetical) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Statements of Operations and Comprehensive Loss Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 100040 - Statement - Statements of Convertible Preferred Stock/Units and Stockholders'/Members' Equity (Deficit) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit Statements of Convertible Preferred Stock/Units and Stockholders'/Members' Equity (Deficit) Statements 5 false false R6.htm 100050 - Statement - Statements of Convertible Preferred Stock/Units and Stockholders'/Members' Equity (Deficit) (Parenthetical) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficitParenthetical Statements of Convertible Preferred Stock/Units and Stockholders'/Members' Equity (Deficit) (Parenthetical) Statements 6 false false R7.htm 100060 - Statement - Statements of Cash Flows Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows Statements of Cash Flows Statements 7 false false R8.htm 100070 - Disclosure - Description of Business and Basis of Presentation Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation Description of Business and Basis of Presentation Notes 8 false false R9.htm 100080 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 100090 - Disclosure - Fair Value Measurements Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 100100 - Disclosure - Marketable Securities Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureMarketableSecurities Marketable Securities Notes 11 false false R12.htm 100110 - Disclosure - Collaboration, License and Research Agreements Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreements Collaboration, License and Research Agreements Notes 12 false false R13.htm 100120 - Disclosure - Property and Equipment Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment Property and Equipment Notes 13 false false R14.htm 100130 - Disclosure - Debt Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebt Debt Notes 14 false false R15.htm 100140 - Disclosure - Convertible Notes Notes http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureConvertibleNotes Convertible Notes Notes 15 false false R16.htm 100150 - Disclosure - Commitments and Contingencies Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 100160 - Disclosure - Stockholders' Equity (Deficit) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficit Stockholders' Equity (Deficit) Notes 17 false false R18.htm 100170 - Disclosure - Income Taxes Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 18 false false R19.htm 100180 - Disclosure - COVID-19 Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCOVID19 COVID-19 Notes 19 false false R20.htm 100190 - Disclosure - Subsequent Events Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 20 false false R21.htm 100200 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 21 false false R22.htm 100210 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 22 false false R23.htm 100220 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurements 23 false false R24.htm 100230 - Disclosure - Marketable Securities (Tables) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesTables Marketable Securities (Tables) Tables http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureMarketableSecurities 24 false false R25.htm 100240 - Disclosure - Collaboration, License and Research Agreements (Tables) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsTables Collaboration, License and Research Agreements (Tables) Tables http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreements 25 false false R26.htm 100250 - Disclosure - Property and Equipment (Tables) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment 26 false false R27.htm 100260 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies 27 false false R28.htm 100270 - Disclosure - Stockholders' Equity (Deficit) (Tables) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitTables Stockholders' Equity (Deficit) (Tables) Tables http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficit 28 false false R29.htm 100280 - Disclosure - Income Taxes (Tables) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxes 29 false false R30.htm 100290 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Details) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails Description of Business and Basis of Presentation - Additional Information (Details) Details 30 false false R31.htm 100300 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Summary of Significant Accounting Policies - Additional Information (Details) Details 31 false false R32.htm 100310 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share/Unit (Details) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareUnitDetails Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share/Unit (Details) Details 32 false false R33.htm 100320 - Disclosure - Fair Value Measurements - Summary of Cash Equivalents and Marketable Securities Measured at Fair Value (Details) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueDetails Fair Value Measurements - Summary of Cash Equivalents and Marketable Securities Measured at Fair Value (Details) Details 33 false false R34.htm 100330 - Disclosure - Fair Value Measurements - Schedule of Reconciliation of Preferred Stock Warrant Liability Measured at Fair Value Using Level 3 Unobservable Inputs (Details) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfReconciliationOfPreferredStockWarrantLiabilityMeasuredAtFairValueUsingLevel3UnobservableInputsDetails Fair Value Measurements - Schedule of Reconciliation of Preferred Stock Warrant Liability Measured at Fair Value Using Level 3 Unobservable Inputs (Details) Details 34 false false R35.htm 100340 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails Marketable Securities - Summary of Marketable Securities (Details) Details 35 false false R36.htm 100350 - Disclosure - Collaboration, License and Research Agreements - Additional Information (Details) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails Collaboration, License and Research Agreements - Additional Information (Details) Details 36 false false R37.htm 100360 - Disclosure - Collaboration, License and Research Agreements - Reconciliation of Deferred Revenue Related to Lilly Agreement (Details) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsReconciliationOfDeferredRevenueRelatedToLillyAgreementDetails Collaboration, License and Research Agreements - Reconciliation of Deferred Revenue Related to Lilly Agreement (Details) Details 37 false false R38.htm 100370 - Disclosure - Property,and Equipment - Schedule of Property and Equipment (Details) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails Property,and Equipment - Schedule of Property and Equipment (Details) Details 38 false false R39.htm 100380 - Disclosure - Property and Equipment - Additional Information (Details) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails Property and Equipment - Additional Information (Details) Details 39 false false R40.htm 100390 - Disclosure - Debt - Additional Information (Details) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails Debt - Additional Information (Details) Details 40 false false R41.htm 100400 - Disclosure - Convertible Notes - Additional Information (Details) Notes http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails Convertible Notes - Additional Information (Details) Details 41 false false R42.htm 100410 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 42 false false R43.htm 100420 - Disclosure - Commitments and Contingencies - Schedule of ROU Assets and Liabilities Related to 2014 Lease and Temporary Lease (Details) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfROUAssetsAndLiabilitiesRelatedTo2014LeaseAndTemporaryLeaseDetails Commitments and Contingencies - Schedule of ROU Assets and Liabilities Related to 2014 Lease and Temporary Lease (Details) Details 43 false false R44.htm 100430 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Lease Liabilities due under 2014 Lease and Temporary Lease (Details) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnder2014LeaseAndTemporaryLeaseDetails Commitments and Contingencies - Schedule of Maturities of Lease Liabilities due under 2014 Lease and Temporary Lease (Details) Details 44 false false R45.htm 100450 - Disclosure - Commitments and Contingencies - Supplemental Cash Flow Information Related to Cash Paid for Amounts Included in Measurement of Operating Lease Liabilities (Details) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSupplementalCashFlowInformationRelatedToCashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilitiesDetails Commitments and Contingencies - Supplemental Cash Flow Information Related to Cash Paid for Amounts Included in Measurement of Operating Lease Liabilities (Details) Details 45 false false R46.htm 100460 - Disclosure - Commitments and Contingencies - Schedule of Rent Expense (Details) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRentExpenseDetails Commitments and Contingencies - Schedule of Rent Expense (Details) Details 46 false false R47.htm 100470 - Disclosure - Stockholders' Equity (Deficit) - Additional Information (Details) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails Stockholders' Equity (Deficit) - Additional Information (Details) Details http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitTables 47 false false R48.htm 100480 - Disclosure - Stockholders' Equity (Deficit) - Summary of Stock Option Activity (Details) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails Stockholders' Equity (Deficit) - Summary of Stock Option Activity (Details) Details http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitTables 48 false false R49.htm 100490 - Disclosure - Stockholders' Equity (Deficit) - Schedule of Assumptions used in Black-Scholes Model to Determine Fair Value of Stock/Unit Option Grants and Shares Purchasable under ESPP (Details) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesModelToDetermineFairValueOfStockUnitOptionGrantsAndSharesPurchasableUnderESPPDetails Stockholders' Equity (Deficit) - Schedule of Assumptions used in Black-Scholes Model to Determine Fair Value of Stock/Unit Option Grants and Shares Purchasable under ESPP (Details) Details http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitTables 49 false false R50.htm 100500 - Disclosure - Stockholders' Equity (Deficit) - Schedule of Allocated Stock-based Compensation Expense (Details) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAllocatedStockBasedCompensationExpenseDetails Stockholders' Equity (Deficit) - Schedule of Allocated Stock-based Compensation Expense (Details) Details http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitTables 50 false false R51.htm 100510 - Disclosure - Stockholders' Equity (Deficit) - Schedule of Common Stock Reserved for Future Issuance (Details) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails Stockholders' Equity (Deficit) - Schedule of Common Stock Reserved for Future Issuance (Details) Details http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitTables 51 false false R52.htm 100520 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 52 false false R53.htm 100530 - Disclosure - Income Taxes - Reconciliation of Income Taxes Computed by Applying Statutory Federal Income Tax Rate (Details) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesComputedByApplyingStatutoryFederalIncomeTaxRateDetails Income Taxes - Reconciliation of Income Taxes Computed by Applying Statutory Federal Income Tax Rate (Details) Details 53 false false R54.htm 100540 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails Income Taxes - Components of Deferred Tax Assets (Details) Details 54 false false R55.htm 100550 - Disclosure - Income Taxes - Summarizes of Activity Related to Gross Unrecognized Tax Benefits (Details) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummarizesOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails Income Taxes - Summarizes of Activity Related to Gross Unrecognized Tax Benefits (Details) Details 55 false false R56.htm 100560 - Disclosure - Subsequent Events - Additional Information (Details) Sheet http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails Subsequent Events - Additional Information (Details) Details 56 false false All Reports Book All Reports rna-10k_20211231.htm rna-20211231.xsd rna-20211231_cal.xml rna-20211231_def.xml rna-20211231_lab.xml rna-20211231_pre.xml rna-ex1012_82.htm rna-ex231_8.htm rna-ex311_9.htm rna-ex312_6.htm rna-ex321_10.htm rna-ex322_7.htm gsua0c5v34oe000001.jpg gsua0c5v34oe000002.jpg gsua0c5v34oe000003.jpg http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 79 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "rna-10k_20211231.htm": { "axisCustom": 0, "axisStandard": 24, "contextCount": 214, "dts": { "calculationLink": { "local": [ "rna-20211231_cal.xml" ] }, "definitionLink": { "local": [ "rna-20211231_def.xml" ] }, "inline": { "local": [ "rna-10k_20211231.htm" ] }, "labelLink": { "local": [ "rna-20211231_lab.xml" ] }, "presentationLink": { "local": [ "rna-20211231_pre.xml" ] }, "schema": { "local": [ "rna-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 582, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 43, "http://www.aviditybiosciences.com/20211231": 1, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 49 }, "keyCustom": 86, "keyStandard": 387, "memberCustom": 45, "memberStandard": 28, "nsprefix": "rna", "nsuri": "http://www.aviditybiosciences.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Fair Value Measurements", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Marketable Securities", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureMarketableSecurities", "shortName": "Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Collaboration, License and Research Agreements", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreements", "shortName": "Collaboration, License and Research Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Property and Equipment", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Debt", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "rna:ConvertibleNotesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Convertible Notes", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureConvertibleNotes", "shortName": "Convertible Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "rna:ConvertibleNotesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Commitments and Contingencies", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Stockholders' Equity (Deficit)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficit", "shortName": "Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Income Taxes", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - COVID-19", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCOVID19", "shortName": "COVID-19", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Balance Sheets", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets", "shortName": "Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Subsequent Events", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Marketable Securities (Tables)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesTables", "shortName": "Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Collaboration, License and Research Agreements (Tables)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsTables", "shortName": "Collaboration, License and Research Agreements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Property and Equipment (Tables)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "rna:LesseeLeaseAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "rna:LesseeLeaseAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Stockholders' Equity (Deficit) (Tables)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitTables", "shortName": "Stockholders' Equity (Deficit) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Income Taxes (Tables)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Balance Sheets (Parenthetical)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical", "shortName": "Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20211231", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Details)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "shortName": "Description of Business and Basis of Presentation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "us-gaap:MarketableSecuritiesPolicy", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:MarketableSecuritiesPolicy", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share/Unit (Details)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareUnitDetails", "shortName": "Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share/Unit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Fair Value Measurements - Summary of Cash Equivalents and Marketable Securities Measured at Fair Value (Details)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueDetails", "shortName": "Fair Value Measurements - Summary of Cash Equivalents and Marketable Securities Measured at Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231", "decimals": "-3", "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Fair Value Measurements - Schedule of Reconciliation of Preferred Stock Warrant Liability Measured at Fair Value Using Level 3 Unobservable Inputs (Details)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfReconciliationOfPreferredStockWarrantLiabilityMeasuredAtFairValueUsingLevel3UnobservableInputsDetails", "shortName": "Fair Value Measurements - Schedule of Reconciliation of Preferred Stock Warrant Liability Measured at Fair Value Using Level 3 Unobservable Inputs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231", "decimals": "-3", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails", "shortName": "Marketable Securities - Summary of Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Collaboration, License and Research Agreements - Additional Information (Details)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails", "shortName": "Collaboration, License and Research Agreements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_us-gaapTypeOfArrangementAxis_rnaResearchCollaborationAndLicenseAgreementWithEliLillyAndCompanyMember_20190401_20190430", "decimals": "-5", "lang": null, "name": "rna:UpfrontFeesReceived", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_us-gaapTypeOfArrangementAxis_rnaResearchCollaborationAndLicenseAgreementWithEliLillyAndCompanyMember_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Collaboration, License and Research Agreements - Reconciliation of Deferred Revenue Related to Lilly Agreement (Details)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsReconciliationOfDeferredRevenueRelatedToLillyAgreementDetails", "shortName": "Collaboration, License and Research Agreements - Reconciliation of Deferred Revenue Related to Lilly Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_us-gaapTypeOfArrangementAxis_rnaResearchCollaborationAndLicenseAgreementWithEliLillyAndCompanyMember_20210101_20211231", "decimals": "-3", "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Property,and Equipment - Schedule of Property and Equipment (Details)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails", "shortName": "Property,and Equipment - Schedule of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Property and Equipment - Additional Information (Details)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails", "shortName": "Property and Equipment - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Statements of Operations and Comprehensive Loss", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss", "shortName": "Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": "-3", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RepaymentsOfLongTermDebt", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Debt - Additional Information (Details)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "shortName": "Debt - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200630", "decimals": "INF", "lang": null, "name": "rna:ClassOfWarrantExercisableForCommonStock", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromConvertibleDebt", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Convertible Notes - Additional Information (Details)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails", "shortName": "Convertible Notes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "rna:ConvertibleNotesDisclosureTextBlock", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_us-gaapLongtermDebtTypeAxis_us-gaapConvertibleNotesPayableMember_us-gaapStatementClassOfStockAxis_rnaSeriesCConvertiblePreferredStockMember_20190101_20191231", "decimals": "-5", "lang": null, "name": "us-gaap:InterestExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Commitments and Contingencies - Schedule of ROU Assets and Liabilities Related to 2014 Lease and Temporary Lease (Details)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfROUAssetsAndLiabilitiesRelatedTo2014LeaseAndTemporaryLeaseDetails", "shortName": "Commitments and Contingencies - Schedule of ROU Assets and Liabilities Related to 2014 Lease and Temporary Lease (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Lease Liabilities due under 2014 Lease and Temporary Lease (Details)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnder2014LeaseAndTemporaryLeaseDetails", "shortName": "Commitments and Contingencies - Schedule of Maturities of Lease Liabilities due under 2014 Lease and Temporary Lease (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "rna:LesseeCashFlowInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Commitments and Contingencies - Supplemental Cash Flow Information Related to Cash Paid for Amounts Included in Measurement of Operating Lease Liabilities (Details)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSupplementalCashFlowInformationRelatedToCashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilitiesDetails", "shortName": "Commitments and Contingencies - Supplemental Cash Flow Information Related to Cash Paid for Amounts Included in Measurement of Operating Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "rna:LesseeCashFlowInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "rna:ScheduleOfLeaseRentExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Commitments and Contingencies - Schedule of Rent Expense (Details)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRentExpenseDetails", "shortName": "Commitments and Contingencies - Schedule of Rent Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "rna:ScheduleOfLeaseRentExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20200616", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Stockholders' Equity (Deficit) - Additional Information (Details)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "shortName": "Stockholders' Equity (Deficit) - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20200616", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Stockholders' Equity (Deficit) - Summary of Stock Option Activity (Details)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails", "shortName": "Stockholders' Equity (Deficit) - Summary of Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "rna:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Stockholders' Equity (Deficit) - Schedule of Assumptions used in Black-Scholes Model to Determine Fair Value of Stock/Unit Option Grants and Shares Purchasable under ESPP (Details)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesModelToDetermineFairValueOfStockUnitOptionGrantsAndSharesPurchasableUnderESPPDetails", "shortName": "Stockholders' Equity (Deficit) - Schedule of Assumptions used in Black-Scholes Model to Determine Fair Value of Stock/Unit Option Grants and Shares Purchasable under ESPP (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "rna:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_us-gaapPlanNameAxis_rnaEmployeeStockPurchasePlanMember_20210101_20211231", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_us-gaapPartnerCapitalComponentsAxis_rnaPreferredUnitsMember_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PreferredUnitsOutstanding", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Statements of Convertible Preferred Stock/Units and Stockholders'/Members' Equity (Deficit)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit", "shortName": "Statements of Convertible Preferred Stock/Units and Stockholders'/Members' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_us-gaapPartnerCapitalComponentsAxis_rnaPreferredUnitsMember_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PreferredUnitsOutstanding", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Stockholders' Equity (Deficit) - Schedule of Allocated Stock-based Compensation Expense (Details)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAllocatedStockBasedCompensationExpenseDetails", "shortName": "Stockholders' Equity (Deficit) - Schedule of Allocated Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "rna:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Stockholders' Equity (Deficit) - Schedule of Common Stock Reserved for Future Issuance (Details)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails", "shortName": "Stockholders' Equity (Deficit) - Schedule of Common Stock Reserved for Future Issuance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "rna:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_us-gaapStatementClassOfStockAxis_rnaCommonStockOptionIssuedAndOutstandingMember_20211231", "decimals": "-3", "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxExpenseBenefit", "us-gaap:IncomeTaxExpenseBenefit", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Income Taxes - Additional Information (Details)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "shortName": "Income Taxes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": "-5", "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Income Taxes - Reconciliation of Income Taxes Computed by Applying Statutory Federal Income Tax Rate (Details)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesComputedByApplyingStatutoryFederalIncomeTaxRateDetails", "shortName": "Income Taxes - Reconciliation of Income Taxes Computed by Applying Statutory Federal Income Tax Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails", "shortName": "Income Taxes - Components of Deferred Tax Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Income Taxes - Summarizes of Activity Related to Gross Unrecognized Tax Benefits (Details)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummarizesOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails", "shortName": "Income Taxes - Summarizes of Activity Related to Gross Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20191231", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Subsequent Events - Additional Information (Details)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "shortName": "Subsequent Events - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_rnaSalesAgreementMember_20220101_20220301", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "rna:StockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Statements of Convertible Preferred Stock/Units and Stockholders'/Members' Equity (Deficit) (Parenthetical)", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficitParenthetical", "shortName": "Statements of Convertible Preferred Stock/Units and Stockholders'/Members' Equity (Deficit) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "rna:StockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Statements of Cash Flows", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows", "shortName": "Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100070 - Disclosure - Description of Business and Basis of Presentation", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation", "shortName": "Description of Business and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rna-10k_20211231.htm", "contextRef": "C_0001599901_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 73, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r573", "r574", "r575" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm Id", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r573", "r574", "r575" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r573", "r574", "r575" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r573", "r574", "r575" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "verboseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r571" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "verboseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r571" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r571" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r579" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r571" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r571" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r571" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r571" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well Known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r573", "r574", "r575" ], "lang": { "en-us": { "role": { "label": "Icfr Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r570" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r572" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "rna_AmendedAndRestatedLoanAndSecurityAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amended and restated loan and security agreement.", "label": "Amended And Restated Loan And Security Agreement [Member]", "terseLabel": "LSA" } } }, "localname": "AmendedAndRestatedLoanAndSecurityAgreementMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rna_CashlessExerciseOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cashless exercise of warrants.", "label": "Cashless Exercise Of Warrants", "terseLabel": "Cashless exercise of warrants" } } }, "localname": "CashlessExerciseOfWarrants", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "rna_CashlessExerciseSharesOfCommonStockWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cashless exercise shares of common stock warrants.", "label": "Cashless Exercise Shares Of Common Stock Warrants", "terseLabel": "Cashless exercise of common stock warrants, Shares" } } }, "localname": "CashlessExerciseSharesOfCommonStockWarrants", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "sharesItemType" }, "rna_CashlessExerciseValueOfCommonStockWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cashless exercise value of common stock warrants.", "label": "Cashless Exercise Value Of Common Stock Warrants", "terseLabel": "Cashless exercise of common stock warrants" } } }, "localname": "CashlessExerciseValueOfCommonStockWarrants", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "rna_ClassOfWarrantExercisableCommonStockWarrantExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant exercisable common stock warrant exercise price.", "label": "Class Of Warrant Exercisable Common Stock Warrant Exercise Price", "terseLabel": "Exercise price of warrant" } } }, "localname": "ClassOfWarrantExercisableCommonStockWarrantExercisePrice", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "rna_ClassOfWarrantExercisableForCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant exercisable for common stock.", "label": "Class Of Warrant Exercisable For Common Stock", "terseLabel": "Warrant exercisable" } } }, "localname": "ClassOfWarrantExercisableForCommonStock", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "rna_ClassOfWarrantNumberOfSecuritiesCalledByEachWarrantToPurchaseCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant number of securities called by each warrant to purchase common stock.", "label": "Class Of Warrant Number Of Securities Called By Each Warrant To Purchase Common Stock", "terseLabel": "Warrant to purchase common stock" } } }, "localname": "ClassOfWarrantNumberOfSecuritiesCalledByEachWarrantToPurchaseCommonStock", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "rna_ClassOfWarrantNumberOfSecuritiesCalledByEachWarrantToPurchaseConvertiblePreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant number of securities called by each warrant to purchase convertible preferred stock.", "label": "Class Of Warrant Number Of Securities Called By Each Warrant To Purchase Convertible Preferred Stock", "terseLabel": "Warrant to purchase convertible preferred stock" } } }, "localname": "ClassOfWarrantNumberOfSecuritiesCalledByEachWarrantToPurchaseConvertiblePreferredStock", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "rna_ClassOfWarrantOrRightTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right term.", "label": "Class Of Warrant Or Right Term", "terseLabel": "Warrant term" } } }, "localname": "ClassOfWarrantOrRightTerm", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "rna_CollaborationLicenseAndResearchAgreementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration, license and research agreements.", "label": "Collaboration License And Research Agreements [Abstract]" } } }, "localname": "CollaborationLicenseAndResearchAgreementsAbstract", "nsuri": "http://www.aviditybiosciences.com/20211231", "xbrltype": "stringItemType" }, "rna_CollaborationReceivablesCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaboration receivables current.", "label": "Collaboration Receivables Current", "terseLabel": "Collaboration receivables" } } }, "localname": "CollaborationReceivablesCurrent", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rna_CommercializationMilestonePaymentEligibleToReceivePerTarget": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Commercialization milestone payment eligible to receive per target.", "label": "Commercialization Milestone Payment Eligible To Receive Per Target", "terseLabel": "Commercialization milestone payment eligible to receive" } } }, "localname": "CommercializationMilestonePaymentEligibleToReceivePerTarget", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rna_CommitmentsAndContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and Contingencies.", "label": "Commitments And Contingencies [Line Items]", "terseLabel": "Commitments and Contingencies [Line Items]" } } }, "localname": "CommitmentsAndContingenciesLineItems", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rna_CommitmentsAndContingenciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies", "label": "Commitments And Contingencies [Table]", "terseLabel": "Commitments And Contingencies [Table]" } } }, "localname": "CommitmentsAndContingenciesTable", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rna_CommonStockAuthorizedUnderESPPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock authorized under ESPP.", "label": "Common Stock Authorized Under E S P P [Member]", "terseLabel": "Common Stock Authorized under the ESPP" } } }, "localname": "CommonStockAuthorizedUnderESPPMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "rna_CommonStockOptionIssuedAndOutstandingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock option issued and outstanding.", "label": "Common Stock Option Issued And Outstanding [Member]", "terseLabel": "Common Stock Options Issued and Outstanding" } } }, "localname": "CommonStockOptionIssuedAndOutstandingMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "rna_CommonStockSubjectToRepurchaseOrForfeitureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock subject to repurchase or forfeiture.", "label": "Common Stock Subject To Repurchase Or Forfeiture [Member]", "terseLabel": "Common Stock Subject to Repurchase or Forfeiture" } } }, "localname": "CommonStockSubjectToRepurchaseOrForfeitureMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareUnitDetails" ], "xbrltype": "domainItemType" }, "rna_CommonUnitConvertedIntoCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common unit converted into common stock.", "label": "Common Unit Converted Into Common Stock", "terseLabel": "Common unit converted into common stock" } } }, "localname": "CommonUnitConvertedIntoCommonStock", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "rna_CommonUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common units.", "label": "Common Units [Member]", "terseLabel": "Common Units" } } }, "localname": "CommonUnitsMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "domainItemType" }, "rna_ConvertibleNotesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible notes disclosure.", "label": "Convertible Notes Disclosure [Text Block]", "terseLabel": "Convertible Notes" } } }, "localname": "ConvertibleNotesDisclosureTextBlock", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureConvertibleNotes" ], "xbrltype": "textBlockItemType" }, "rna_ConvertiblePromissoryNotesConversionPercentageOnPerSharePricePaidByInvestors": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible promissory notes conversion percentage on per share price paid by investors.", "label": "Convertible Promissory Notes Conversion Percentage On Per Share Price Paid By Investors", "terseLabel": "Convertible promissory notes conversion percentage on per share price paid by investors" } } }, "localname": "ConvertiblePromissoryNotesConversionPercentageOnPerSharePricePaidByInvestors", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "rna_CorporateDebtSecuritiesOneYearOrLessMaturityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Corporate debt securities with one year or less maturity.", "label": "Corporate Debt Securities One Year Or Less Maturity [Member]", "terseLabel": "Corporate Debt Securities with 1 Year or Less Maturity" } } }, "localname": "CorporateDebtSecuritiesOneYearOrLessMaturityMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "rna_CorporateDebtSecuritiesWithOneToTwoYearsMaturityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Corporate debt securities with one to two years maturity.", "label": "Corporate Debt Securities With One To Two Years Maturity [Member]", "terseLabel": "Corporate Debt Securities with 1 to 2 Years Maturity" } } }, "localname": "CorporateDebtSecuritiesWithOneToTwoYearsMaturityMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "rna_DebtInstrumentAccruedInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument accrued interest rate.", "label": "Debt Instrument Accrued Interest Rate", "terseLabel": "Convertible promissory notes accrued interest rate" } } }, "localname": "DebtInstrumentAccruedInterestRate", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "rna_DebtInstrumentFinalPaymentPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument final payment percentage.", "label": "Debt Instrument Final Payment Percentage", "terseLabel": "Debt instrument final payment percentage" } } }, "localname": "DebtInstrumentFinalPaymentPercentage", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "rna_DebtInstrumentFinalPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt instrument final payments.", "label": "Debt Instrument Final Payments", "terseLabel": "Debt instrument final payments" } } }, "localname": "DebtInstrumentFinalPayments", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rna_DebtInstrumentFrequencyOfPeriodicPaymentInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument frequency of periodic payment interest", "label": "Debt Instrument Frequency Of Periodic Payment Interest", "terseLabel": "Frequency of periodic payment interest" } } }, "localname": "DebtInstrumentFrequencyOfPeriodicPaymentInterest", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rna_DebtInstrumentFrequencyOfPeriodicPaymentPrincipal": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument frequency of periodic payment principal.", "label": "Debt Instrument Frequency Of Periodic Payment Principal", "terseLabel": "Frequency of periodic payment principal" } } }, "localname": "DebtInstrumentFrequencyOfPeriodicPaymentPrincipal", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rna_DebtInstrumentMaturityMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument maturity month and year.", "label": "Debt Instrument Maturity Month And Year", "terseLabel": "Maturity date" } } }, "localname": "DebtInstrumentMaturityMonthAndYear", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "rna_DebtInstrumentMinimumQualifiedFinancingOfConvertiblePromissoryNotesConvertedIntoPreferredEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt instrument minimum qualified financing of convertible promissory notes converted into preferred equity.", "label": "Debt Instrument Minimum Qualified Financing Of Convertible Promissory Notes Converted Into Preferred Equity", "terseLabel": "Qualified financing of convertible promissory notes converted into preferred equity" } } }, "localname": "DebtInstrumentMinimumQualifiedFinancingOfConvertiblePromissoryNotesConvertedIntoPreferredEquity", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rna_DeferredTaxAssetsIntangiblesAndFixedAssets": { "auth_ref": [], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "order": 10100.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets, intangibles and fixed assets.", "label": "Deferred Tax Assets Intangibles And Fixed Assets", "terseLabel": "Intangibles and fixed assets" } } }, "localname": "DeferredTaxAssetsIntangiblesAndFixedAssets", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "rna_DeferredTaxAssetsLeaseLiability": { "auth_ref": [], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "order": 10110.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets lease liability.", "label": "Deferred Tax Assets Lease Liability", "terseLabel": "Lease liability" } } }, "localname": "DeferredTaxAssetsLeaseLiability", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "rna_DeferredTaxLiabilitiesRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "order": 10030.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities right-of-use asset.", "label": "Deferred Tax Liabilities Right Of Use Asset", "negatedLabel": "Right-of-use asset" } } }, "localname": "DeferredTaxLiabilitiesRightOfUseAsset", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "rna_DescriptionOfBusinessAndBasisOfPresentationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of business and basis of presentation.", "label": "Description Of Business And Basis Of Presentation [Line Items]", "terseLabel": "Description Of Business And Basis Of Presentation [Line Items]" } } }, "localname": "DescriptionOfBusinessAndBasisOfPresentationLineItems", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rna_DescriptionOfBusinessAndBasisOfPresentationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of business and basis of presentation.", "label": "Description Of Business And Basis Of Presentation [Table]", "terseLabel": "Description Of Business And Basis Of Presentation [Table]" } } }, "localname": "DescriptionOfBusinessAndBasisOfPresentationTable", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rna_DevelopmentMilestonePaymentEligibleToReceivePerTarget": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Development milestone payment eligible to receive per target.", "label": "Development Milestone Payment Eligible To Receive Per Target", "terseLabel": "Development milestone payment eligible to receive per target" } } }, "localname": "DevelopmentMilestonePaymentEligibleToReceivePerTarget", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rna_DistributionsToMembers": { "auth_ref": [], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10090.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Distributions to members.", "label": "Distributions To Members", "terseLabel": "Distributions to members" } } }, "localname": "DistributionsToMembers", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rna_EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee stock purchase plan.", "label": "Employee Stock Purchase Plan [Member]", "terseLabel": "Employee Stock Purchase Plan" } } }, "localname": "EmployeeStockPurchasePlanMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesModelToDetermineFairValueOfStockUnitOptionGrantsAndSharesPurchasableUnderESPPDetails" ], "xbrltype": "domainItemType" }, "rna_EmployeeStockPurchasePlanSharesPendingIssuanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ESPP shares pending issuance.", "label": "Employee Stock Purchase Plan Shares Pending Issuance [Member]", "terseLabel": "ESPP Shares Pending Issuance" } } }, "localname": "EmployeeStockPurchasePlanSharesPendingIssuanceMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareUnitDetails" ], "xbrltype": "domainItemType" }, "rna_EquityAwardsAvailableForFutureIssuanceUnderEquityPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity awards available for future issuance under equity plans.", "label": "Equity Awards Available For Future Issuance Under Equity Plans [Member]", "terseLabel": "Equity Awards Available for Future Issuance under Equity Plans" } } }, "localname": "EquityAwardsAvailableForFutureIssuanceUnderEquityPlansMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "rna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfPreferredStockWarrantLiabilityToStockholdersEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability reclassification of preferred stock warrant liability to stockholders equity.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reclassification Of Preferred Stock Warrant Liability To Stockholders Equity", "terseLabel": "Reclassification of warrant liability to stockholders? equity" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfPreferredStockWarrantLiabilityToStockholdersEquity", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfReconciliationOfPreferredStockWarrantLiabilityMeasuredAtFairValueUsingLevel3UnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "rna_FollowOnPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Follow-on public offering.", "label": "Follow On Public Offering [Member]", "terseLabel": "Follow-on Public Offering" } } }, "localname": "FollowOnPublicOfferingMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rna_IncomeTaxReconciliationBookIncomeLossForPreConversionPeriod": { "auth_ref": [], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesComputedByApplyingStatutoryFederalIncomeTaxRateDetails": { "order": 10040.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation book income (loss) for pre-conversion period.", "label": "Income Tax Reconciliation Book Income Loss For Pre Conversion Period", "terseLabel": "Book income for pre-conversion period" } } }, "localname": "IncomeTaxReconciliationBookIncomeLossForPreConversionPeriod", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesComputedByApplyingStatutoryFederalIncomeTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "rna_IncomeTaxReconciliationDeferredTaxRecognizedUponConversion": { "auth_ref": [], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesComputedByApplyingStatutoryFederalIncomeTaxRateDetails": { "order": 10090.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation deferred tax recognized upon conversion.", "label": "Income Tax Reconciliation Deferred Tax Recognized Upon Conversion", "negatedLabel": "Deferred taxes recognized upon conversion" } } }, "localname": "IncomeTaxReconciliationDeferredTaxRecognizedUponConversion", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesComputedByApplyingStatutoryFederalIncomeTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "rna_IncomeTaxReconciliationInterestOnConvertibleNotes": { "auth_ref": [], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesComputedByApplyingStatutoryFederalIncomeTaxRateDetails": { "order": 10050.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation interest on convertible notes.", "label": "Income Tax Reconciliation Interest On Convertible Notes", "terseLabel": "Interest on convertible notes" } } }, "localname": "IncomeTaxReconciliationInterestOnConvertibleNotes", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesComputedByApplyingStatutoryFederalIncomeTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "rna_IncomeTaxReconciliationPermanentItems": { "auth_ref": [], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesComputedByApplyingStatutoryFederalIncomeTaxRateDetails": { "order": 10030.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation permanent items.", "label": "Income Tax Reconciliation Permanent Items", "terseLabel": "Permanent items" } } }, "localname": "IncomeTaxReconciliationPermanentItems", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesComputedByApplyingStatutoryFederalIncomeTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "rna_IncomeTaxReconciliationRealizedGainOnConversionOfConvertibleNotes": { "auth_ref": [], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesComputedByApplyingStatutoryFederalIncomeTaxRateDetails": { "order": 10060.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation realized gain on conversion of convertible notes.", "label": "Income Tax Reconciliation Realized Gain On Conversion Of Convertible Notes", "terseLabel": "Realized gain on conversion of convertible notes" } } }, "localname": "IncomeTaxReconciliationRealizedGainOnConversionOfConvertibleNotes", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesComputedByApplyingStatutoryFederalIncomeTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "rna_IncomeTaxReconciliationReserveForUncertainTaxPositions": { "auth_ref": [], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesComputedByApplyingStatutoryFederalIncomeTaxRateDetails": { "order": 10070.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation reserve for uncertain tax positions.", "label": "Income Tax Reconciliation Reserve For Uncertain Tax Positions", "terseLabel": "Reserve for uncertain tax positions" } } }, "localname": "IncomeTaxReconciliationReserveForUncertainTaxPositions", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesComputedByApplyingStatutoryFederalIncomeTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "rna_IncomeTaxesDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income taxes disclosure.", "label": "Income Taxes Disclosure [Line Items]", "terseLabel": "Income Taxes Disclosure [Line Items]" } } }, "localname": "IncomeTaxesDisclosureLineItems", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rna_IncomeTaxesDisclosureTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income taxes disclosure.", "label": "Income Taxes Disclosure [Table]", "terseLabel": "Income Taxes Disclosure [Table]" } } }, "localname": "IncomeTaxesDisclosureTable", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rna_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet": { "auth_ref": [], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10260.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in operating lease right-of-use assets and liabilities, net.", "label": "Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net", "terseLabel": "Operating lease right-of-use assets and liabilities, net" } } }, "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rna_IncreasedToNumberOfSharesReservedUnderPlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increased to number of shares reserved under plan.", "label": "Increased To Number Of Shares Reserved Under Plan", "terseLabel": "Increased to number of shares reserved under plan" } } }, "localname": "IncreasedToNumberOfSharesReservedUnderPlan", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "rna_IssuanceOfConvertiblePreferredStockUponConversionOfConvertibleNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of convertible preferred stock upon conversion of convertible notes.", "label": "Issuance Of Convertible Preferred Stock Upon Conversion Of Convertible Notes", "terseLabel": "Issuance of Series C convertible preferred stock upon conversion of outstanding convertible notes" } } }, "localname": "IssuanceOfConvertiblePreferredStockUponConversionOfConvertibleNotes", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rna_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laboratory equipment.", "label": "Laboratory Equipment [Member]", "terseLabel": "Laboratory Equipment" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "rna_LeaseRentExpense": { "auth_ref": [], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRentExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lease rent expense.", "label": "Lease Rent Expense", "totalLabel": "Total rent expense" } } }, "localname": "LeaseRentExpense", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRentExpenseDetails" ], "xbrltype": "monetaryItemType" }, "rna_LeaseTermThroughDecemberTwoThousandAndTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease term through December 2021.", "label": "Lease Term Through December Two Thousand And Twenty One [Member]", "terseLabel": "Lease Term through December 2021" } } }, "localname": "LeaseTermThroughDecemberTwoThousandAndTwentyOneMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rna_LeaseTermThroughNovemberTwoThousandAndSeventeenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease term through November 2017.", "label": "Lease Term Through November Two Thousand And Seventeen [Member]", "terseLabel": "Lease Term through November 2017" } } }, "localname": "LeaseTermThroughNovemberTwoThousandAndSeventeenMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rna_LesseeCashFlowInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, cash flow information.", "label": "Lessee Cash Flow Information Table [Text Block]", "terseLabel": "Supplemental Cash Flow Information Related to Cash Paid for Amounts Included in Measurement of Operating Lease Liabilities" } } }, "localname": "LesseeCashFlowInformationTableTextBlock", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "rna_LesseeLeaseAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, lease assets and liabilities.", "label": "Lessee Lease Assets And Liabilities Table [Text Block]", "terseLabel": "Schedule of ROU Assets and Liabilities Related to 2014 Lease and Temporary Lease" } } }, "localname": "LesseeLeaseAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "rna_LesseeOperatingLeaseExpirationPeriodAfterCommencementOfNewLease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease expiration period after commencement of new lease.", "label": "Lessee Operating Lease Expiration Period After Commencement Of New Lease", "terseLabel": "Operating lease expiration period" } } }, "localname": "LesseeOperatingLeaseExpirationPeriodAfterCommencementOfNewLease", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "rna_LesseeOperatingLeaseExpirationPeriodDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease expiration period description.", "label": "Lessee Operating Lease Expiration Period Description", "terseLabel": "Operating lease, expiration period, description" } } }, "localname": "LesseeOperatingLeaseExpirationPeriodDescription", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rna_LesseeOperatingLeaseInitialMonthlyBaseRent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease, initial monthly base rent.", "label": "Lessee Operating Lease Initial Monthly Base Rent", "terseLabel": "Operating lease, initial monthly base rent" } } }, "localname": "LesseeOperatingLeaseInitialMonthlyBaseRent", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rna_LesseeOperatingLeaseLeasePaymentUnderNewLease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease, lease payment under new lease.", "label": "Lessee Operating Lease Lease Payment Under New Lease", "terseLabel": "Operating lease, lease payment under new lease" } } }, "localname": "LesseeOperatingLeaseLeasePaymentUnderNewLease", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rna_LesseeOperatingLeaseMonthlyBaseRentForLastYearLease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease, monthly base rent for last year lease.", "label": "Lessee Operating Lease Monthly Base Rent For Last Year Lease", "terseLabel": "Operating lease, monthly base rent for last year lease" } } }, "localname": "LesseeOperatingLeaseMonthlyBaseRentForLastYearLease", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rna_LesseeOperatingLeaseTermOfContractDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, operating lease, term of contract, description.", "label": "Lessee Operating Lease Term Of Contract Description", "terseLabel": "Operating lease, term of contract, description" } } }, "localname": "LesseeOperatingLeaseTermOfContractDescription", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rna_LicenseAgreementExpiryPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement expiry period.", "label": "License Agreement Expiry Period", "terseLabel": "License agreement expiry period" } } }, "localname": "LicenseAgreementExpiryPeriod", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "rna_LillyConvertiblePromissoryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lilly convertible promissory notes.", "label": "Lilly Convertible Promissory Notes [Member]", "terseLabel": "Lilly Note" } } }, "localname": "LillyConvertiblePromissoryNotesMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rna_LoanAndSecurityAgreementAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan and security agreement amendment.", "label": "Loan And Security Agreement Amendment [Member]", "terseLabel": "LSA Amendment" } } }, "localname": "LoanAndSecurityAgreementAmendmentMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rna_LoanAndSecurityAgreementSecondAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan and security agreement second amendment.", "label": "Loan And Security Agreement Second Amendment [Member]", "terseLabel": "LSA Second Amendment" } } }, "localname": "LoanAndSecurityAgreementSecondAmendmentMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rna_NegotiableCertificatesOfDepositOneYearOrLessMaturityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Negotiable certificates of deposit one year or less maturity.", "label": "Negotiable Certificates Of Deposit One Year Or Less Maturity [Member]", "terseLabel": "Negotiable Certificates of Deposit with 1 Year or Less Maturity" } } }, "localname": "NegotiableCertificatesOfDepositOneYearOrLessMaturityMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "rna_NegotiableCertificatesOfDepositWithOneToTwoYearsMaturityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Negotiable certificates of deposit with one to two years maturity.", "label": "Negotiable Certificates Of Deposit With One To Two Years Maturity [Member]", "terseLabel": "Negotiable Certificates of Deposit with 1 to 2 Years Maturity" } } }, "localname": "NegotiableCertificatesOfDepositWithOneToTwoYearsMaturityMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "rna_NetIncomeLossExcludingConversion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net income loss excluding conversion.", "label": "Net Income Loss Excluding Conversion", "terseLabel": "Net loss" } } }, "localname": "NetIncomeLossExcludingConversion", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "rna_NetIncomeLossToDateOfConversion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net income (loss) to date of conversion.", "label": "Net Income Loss To Date Of Conversion", "terseLabel": "Net loss to date of conversion" } } }, "localname": "NetIncomeLossToDateOfConversion", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "rna_NetOperatingLossCarryForwardAvailableForOffsettingAgainstFutureTaxableIncomePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net operating loss carry forward available for offsetting against future taxable income percentage.", "label": "Net Operating Loss Carry Forward Available For Offsetting Against Future Taxable Income Percentage", "terseLabel": "Net operating loss available to offset against future taxable income percentage" } } }, "localname": "NetOperatingLossCarryForwardAvailableForOffsettingAgainstFutureTaxableIncomePercentage", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "rna_NetOperatingLossCarryForwardAvailableForOffsettingAgainstTaxableIncomePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net operating loss carry forward available for offsetting against taxable income percentage.", "label": "Net Operating Loss Carry Forward Available For Offsetting Against Taxable Income Percentage", "terseLabel": "Net operating loss available to offset against current taxable income percentage" } } }, "localname": "NetOperatingLossCarryForwardAvailableForOffsettingAgainstTaxableIncomePercentage", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "rna_NetOperatingLossCarryforwardsExpirationBeginningYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net operating loss carryforwards expiration beginning year.", "label": "Net Operating Loss Carryforwards Expiration Beginning Year", "terseLabel": "Net operating loss carryforwards, expiration beginning year" } } }, "localname": "NetOperatingLossCarryforwardsExpirationBeginningYear", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "gYearItemType" }, "rna_NewLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New lease.", "label": "New Lease [Member]", "terseLabel": "New Lease" } } }, "localname": "NewLeaseMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rna_NoncashInterestExpense": { "auth_ref": [], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10210.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash interest expense.", "label": "Noncash Interest Expense", "terseLabel": "Noncash interest expense" } } }, "localname": "NoncashInterestExpense", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rna_NumberOfMonthlyInstallmentsOfPrincipal": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of monthly installments of principal.", "label": "Number Of Monthly Installments Of Principal", "terseLabel": "Number of equal monthly installments of principal" } } }, "localname": "NumberOfMonthlyInstallmentsOfPrincipal", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "rna_NumberOfPerformanceObligation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of performance obligation.", "label": "Number Of Performance Obligation", "terseLabel": "Number of performance obligation" } } }, "localname": "NumberOfPerformanceObligation", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "rna_NumberOfRemainingSharesAvailableForFutureIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of remaining shares available for future issuance.", "label": "Number Of Remaining Shares Available For Future Issuance", "terseLabel": "Number of remaining shares available for issuance" } } }, "localname": "NumberOfRemainingSharesAvailableForFutureIssuance", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "rna_OfficeAndLaboratorySpaceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office and laboratory space.", "label": "Office And Laboratory Space [Member]", "terseLabel": "Office and Laboratory Space" } } }, "localname": "OfficeAndLaboratorySpaceMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rna_OfficeFurnitureAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office furniture and equipment.", "label": "Office Furniture And Equipment [Member]", "terseLabel": "Office Furniture and Equipment" } } }, "localname": "OfficeFurnitureAndEquipmentMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "rna_OrphanDrugTaxCreditsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Orphan drug tax credits.", "label": "Orphan Drug Tax Credits [Member]", "terseLabel": "Orphan Drug Tax Credits" } } }, "localname": "OrphanDrugTaxCreditsMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rna_PartnersCapitalUnitsIssuedDuringPeriodSharesUnitOptionsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Partners capital units issued during period shares unit options exercised.", "label": "Partners Capital Units Issued During Period Shares Unit Options Exercised", "terseLabel": "Issuance of common units upon exercise of unit options, Units" } } }, "localname": "PartnersCapitalUnitsIssuedDuringPeriodSharesUnitOptionsExercised", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "sharesItemType" }, "rna_PartnersCapitalUnitsIssuedDuringPeriodValueUnitOptionsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Partners capital units issued during period value unit options exercised.", "label": "Partners Capital Units Issued During Period Value Unit Options Exercised", "terseLabel": "Issuance of common units upon exercise of unit options" } } }, "localname": "PartnersCapitalUnitsIssuedDuringPeriodValueUnitOptionsExercised", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "rna_PaymentOfFinalPaymentAndAccruedInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment of final payment and accrued interest.", "label": "Payment Of Final Payment And Accrued Interest", "terseLabel": "Payment of final payment and accrued interest" } } }, "localname": "PaymentOfFinalPaymentAndAccruedInterest", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rna_PercentageOfSharesOfCommonStockOutstandingOnFinalDayOfImmediatelyPrecedingCalendarYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of shares of common stock outstanding on final day of immediately preceding calendar year.", "label": "Percentage Of Shares Of Common Stock Outstanding On Final Day Of Immediately Preceding Calendar Year", "terseLabel": "Percentage of shares of common stock outstanding on final day of immediately preceding calendar year" } } }, "localname": "PercentageOfSharesOfCommonStockOutstandingOnFinalDayOfImmediatelyPrecedingCalendarYear", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "rna_PeriodForExpectsPerformanceObligation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period for expects performance obligation.", "label": "Period For Expects Performance Obligation", "terseLabel": "Period for expects performance obligation" } } }, "localname": "PeriodForExpectsPerformanceObligation", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "rna_PredecessorsDeficitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Predecessor's deficit.", "label": "Predecessors Deficit [Member]", "terseLabel": "Predecessor's Deficit" } } }, "localname": "PredecessorsDeficitMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "domainItemType" }, "rna_PreferredUnitConvertedIntoConvertiblePreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred unit converted into convertible preferred stock.", "label": "Preferred Unit Converted Into Convertible Preferred Stock", "terseLabel": "Preferred unit converted into convertible preferred stock" } } }, "localname": "PreferredUnitConvertedIntoConvertiblePreferredStock", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "rna_PreferredUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred units.", "label": "Preferred Units [Member]", "terseLabel": "Preferred Units" } } }, "localname": "PreferredUnitsMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "domainItemType" }, "rna_PreferredUnitsValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Preferred units, value.", "label": "Preferred Units Value", "periodEndLabel": "Preferred Units, balance", "periodStartLabel": "Preferred Units, balance" } } }, "localname": "PreferredUnitsValue", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "rna_ProceedsFromIssuanceOfCommonStockInPublicOfferingGross": { "auth_ref": [], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10040.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock in public offering, gross.", "label": "Proceeds From Issuance Of Common Stock In Public Offering Gross", "terseLabel": "Proceeds from issuance of common stock in public offerings, gross" } } }, "localname": "ProceedsFromIssuanceOfCommonStockInPublicOfferingGross", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rna_ProceedsFromIssuanceOfFollowOnPublicOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of follow on public offering.", "label": "Proceeds From Issuance Of Follow On Public Offering", "verboseLabel": "Proceeds from the follow-on public offering, net of underwriting discounts, commissions and offering costs" } } }, "localname": "ProceedsFromIssuanceOfFollowOnPublicOffering", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rna_ReclassificationOfWarrantLiabilityToEquityDueToAdjustmentFromPreferredStockWarrantToCommonStockWarrantUponCompletionOfInitialPublicOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reclassification of warrant liability to equity due to adjustment from preferred stock warrant to common stock warrant upon completion of initial public offering.", "label": "Reclassification Of Warrant Liability To Equity Due To Adjustment From Preferred Stock Warrant To Common Stock Warrant Upon Completion Of Initial Public Offering", "terseLabel": "Reclassification of warrant liability to equity due to adjustment from preferred stock warrant to common stock warrant upon completion of initial public offering" } } }, "localname": "ReclassificationOfWarrantLiabilityToEquityDueToAdjustmentFromPreferredStockWarrantToCommonStockWarrantUponCompletionOfInitialPublicOffering", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "rna_RegulatoryMilestonePaymentEligibleToReceivePerTarget": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Regulatory milestone payment eligible to receive per target.", "label": "Regulatory Milestone Payment Eligible To Receive Per Target", "terseLabel": "Regulatory milestone payment eligible to receive per target" } } }, "localname": "RegulatoryMilestonePaymentEligibleToReceivePerTarget", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rna_ResearchCollaborationAndLicenseAgreementWithEliLillyAndCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research collaboration and license agreement with Eli Lilly and company", "label": "Research Collaboration And License Agreement With Eli Lilly And Company [Member]", "terseLabel": "Research Collaboration and License Agreement with Eli Lilly" } } }, "localname": "ResearchCollaborationAndLicenseAgreementWithEliLillyAndCompanyMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsReconciliationOfDeferredRevenueRelatedToLillyAgreementDetails" ], "xbrltype": "domainItemType" }, "rna_ResearchCollaborationWithMyoKardiaIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research collaboration with MyoKardia, Inc.", "label": "Research Collaboration With Myo Kardia Inc [Member]", "terseLabel": "Research Collaboration with MyoKardia, Inc." } } }, "localname": "ResearchCollaborationWithMyoKardiaIncMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rna_RetainedEarningsAccumulatedDeficitReclassifiedToAdditionalPaidInCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Retained earnings accumulated deficit reclassified to additional paid in capital.", "label": "Retained Earnings Accumulated Deficit Reclassified To Additional Paid In Capital", "terseLabel": "Reclassified accumulated deficit from predecessor deficit to additional paid in capital" } } }, "localname": "RetainedEarningsAccumulatedDeficitReclassifiedToAdditionalPaidInCapital", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rna_RightsToAntibodyOligonucleotideConjugatesForMessengersRNATargets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rights to antibody oligonucleotide conjugates for messengers RNA targets.", "label": "Rights To Antibody Oligonucleotide Conjugates For Messengers R N A Targets", "terseLabel": "Rights to antibody oligonucleotide conjugates for messengers RNA targets." } } }, "localname": "RightsToAntibodyOligonucleotideConjugatesForMessengersRNATargets", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "rna_SaleOfCommonStockMaximumAggregateOfferingPrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sale of common stock maximum aggregate offering price.", "label": "Sale Of Common Stock Maximum Aggregate Offering Price", "terseLabel": "Sale of common stock maximum aggregate offering price" } } }, "localname": "SaleOfCommonStockMaximumAggregateOfferingPrice", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rna_SalesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales agreement.", "label": "Sales Agreement [Member]", "terseLabel": "Sales Agreement" } } }, "localname": "SalesAgreementMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rna_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of common stock reserved for future issuance.", "label": "Schedule Of Common Stock Reserved For Future Issuance Table [Text Block]", "terseLabel": "Schedule of Common Stock Reserved for Future Issuance" } } }, "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitTables" ], "xbrltype": "textBlockItemType" }, "rna_ScheduleOfLeaseRentExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of lease rent expense.", "label": "Schedule Of Lease Rent Expense Table [Text Block]", "terseLabel": "Schedule of Rent Expense" } } }, "localname": "ScheduleOfLeaseRentExpenseTableTextBlock", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "rna_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of share based payment award stock options and employee stock purchase plan valuation assumptions.", "label": "Schedule Of Share Based Payment Award Stock Options And Employee Stock Purchase Plan Valuation Assumptions Table [Text Block]", "terseLabel": "Schedule of Assumptions used in Black-Scholes Model to Determine Fair Value of Stock/Unit Option Grants and Shares Purchasable under ESPP" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitTables" ], "xbrltype": "textBlockItemType" }, "rna_SeriesAConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A convertible preferred stock.", "label": "Series A Convertible Preferred Stock [Member]", "terseLabel": "Series A Convertible Preferred Stock" } } }, "localname": "SeriesAConvertiblePreferredStockMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rna_SeriesBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B convertible preferred stock.", "label": "Series B Convertible Preferred Stock [Member]", "terseLabel": "Series B Convertible Preferred Stock" } } }, "localname": "SeriesBConvertiblePreferredStockMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rna_SeriesCConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C convertible preferred stock.", "label": "Series C Convertible Preferred Stock [Member]", "terseLabel": "Series C Convertible Preferred Stock" } } }, "localname": "SeriesCConvertiblePreferredStockMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, number of shares available for issuance.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Issuance", "terseLabel": "Shares of common stock available for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "rna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnvestedSharesEarlyExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award number of unvested shares early exercised.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Unvested Shares Early Exercised", "terseLabel": "Stock options exercised were unvested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnvestedSharesEarlyExercised", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "rna_ShortTermLeaseRentExpense": { "auth_ref": [], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRentExpenseDetails": { "order": 10020.0, "parentTag": "rna_LeaseRentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Short-term lease rent expense.", "label": "Short Term Lease Rent Expense", "terseLabel": "Short-term leases" } } }, "localname": "ShortTermLeaseRentExpense", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRentExpenseDetails" ], "xbrltype": "monetaryItemType" }, "rna_SiliconValleyBankMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Silicon valley bank.", "label": "Silicon Valley Bank [Member]", "terseLabel": "SVB" } } }, "localname": "SiliconValleyBankMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rna_StockIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Stock issuance costs.", "label": "Stock Issuance Costs", "terseLabel": "Stock issuance costs" } } }, "localname": "StockIssuanceCosts", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "rna_StockIssuedDuringPeriodSharesStockOptionsExercisedNetOfRepurchases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares stock options exercised net of repurchases.", "label": "Stock Issued During Period Shares Stock Options Exercised Net Of Repurchases", "terseLabel": "Issuance of common stock upon exercise of stock options, net of repurchases, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisedNetOfRepurchases", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "sharesItemType" }, "rna_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfRepurchases": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value stock options exercised net of repurchases.", "label": "Stock Issued During Period Value Stock Options Exercised Net Of Repurchases", "terseLabel": "Issuance of common stock upon exercise of stock options, net of repurchases" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedNetOfRepurchases", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "rna_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies line items.", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rna_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies table.", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rna_TaxCreditCarryforwardsExpirationBeginningYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax credit carryforwards expiration beginning year.", "label": "Tax Credit Carryforwards Expiration Beginning Year", "terseLabel": "Tax credit expiration beginning year" } } }, "localname": "TaxCreditCarryforwardsExpirationBeginningYear", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "gYearItemType" }, "rna_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity stock issued during period shares conversion of units.", "label": "Temporary Equity Stock Issued During Period Shares Conversion Of Units", "terseLabel": "Conversion from LLC to C corporation, Temporary equity, Shares" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodSharesConversionOfUnits", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "sharesItemType" }, "rna_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity stock issued during period shares new issues.", "label": "Temporary Equity Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of Series C convertible preferred stock, net of issuance costs, Shares" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "sharesItemType" }, "rna_TemporaryEquityStockIssuedDuringPeriodSharesUponConversionOfConvertibleNotes": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity stock issued during period shares upon conversion of convertible notes.", "label": "Temporary Equity Stock Issued During Period Shares Upon Conversion Of Convertible Notes", "terseLabel": "Issuance of Series C convertible preferred stock upon conversion of convertible notes, Shares" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodSharesUponConversionOfConvertibleNotes", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "sharesItemType" }, "rna_TemporaryEquityStockIssuedDuringPeriodValueConversionOfUnits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Temporary equity stock issued during period value conversion of units.", "label": "Temporary Equity Stock Issued During Period Value Conversion Of Units", "terseLabel": "Conversion from LLC to C corporation, Temporary equity" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodValueConversionOfUnits", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "rna_TemporaryEquityStockIssuedDuringPeriodValueUponConversionOfConvertibleNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Temporary equity stock issued during period value upon conversion of convertible notes.", "label": "Temporary Equity Stock Issued During Period Value Upon Conversion Of Convertible Notes", "terseLabel": "Issuance of Series C convertible preferred stock upon conversion of convertible notes" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodValueUponConversionOfConvertibleNotes", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "rna_TemporaryLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary lease.", "label": "Temporary Lease [Member]", "terseLabel": "Temporary Lease" } } }, "localname": "TemporaryLeaseMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rna_TermAAndTermBLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term A and term B loans.", "label": "Term A And Term B Loans [Member]", "terseLabel": "Term A And Term B Loans" } } }, "localname": "TermAAndTermBLoansMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rna_TermCAndDLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term C and D loans.", "label": "Term C And D Loans [Member]", "terseLabel": "Term C And D Loans" } } }, "localname": "TermCAndDLoansMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rna_TermCLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term C loan.", "label": "Term C Loan [Member]", "terseLabel": "Term C Loan" } } }, "localname": "TermCLoanMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rna_TermDLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term D loan.", "label": "Term D Loan [Member]", "terseLabel": "Term D Loan" } } }, "localname": "TermDLoanMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rna_TerminationNoticePeriodForSalesAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination notice period for sales agreement.", "label": "Termination Notice Period For Sales Agreement", "terseLabel": "Termination notice period for sales agreement" } } }, "localname": "TerminationNoticePeriodForSalesAgreement", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "rna_TimeBasedOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Time based options.", "label": "Time Based Options [Member]", "terseLabel": "Time-based Options" } } }, "localname": "TimeBasedOptionsMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rna_TwoThousandAndEighteenConvertiblePromissoryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and eighteen convertible promissory notes.", "label": "Two Thousand And Eighteen Convertible Promissory Notes [Member]", "terseLabel": "2018 Notes" } } }, "localname": "TwoThousandAndEighteenConvertiblePromissoryNotesMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rna_TwoThousandAndNineteenConvertiblePromissoryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand nineteen convertible promissory notes.", "label": "Two Thousand And Nineteen Convertible Promissory Notes [Member]", "terseLabel": "2019 Notes" } } }, "localname": "TwoThousandAndNineteenConvertiblePromissoryNotesMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rna_TwoThousandThirteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2013 equity incentive plan.", "label": "Two Thousand Thirteen Equity Incentive Plan [Member]", "terseLabel": "2013 Equity Incentive Plan" } } }, "localname": "TwoThousandThirteenEquityIncentivePlanMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rna_TwoThousandTwentyIncentiveAwardPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 incentive award plan.", "label": "Two Thousand Twenty Incentive Award Plan [Member]", "terseLabel": "2020 Incentive Award Plan" } } }, "localname": "TwoThousandTwentyIncentiveAwardPlanMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rna_USTreasurySecuritiesOneYearOrLessMaturityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U . S treasury securities one year or less maturity.", "label": "U S Treasury Securities One Year Or Less Maturity [Member]", "terseLabel": "U.S. Treasury Securities with 1 Year or Less Maturity" } } }, "localname": "USTreasurySecuritiesOneYearOrLessMaturityMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "rna_USTreasurySecuritiesWithOneToTwoYearsMaturityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U.S. treasury securities with one to two years maturity.", "label": "U S Treasury Securities With One To Two Years Maturity [Member]", "terseLabel": "U.S. Treasury Securities with 1 to 2 Years Maturity" } } }, "localname": "USTreasurySecuritiesWithOneToTwoYearsMaturityMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "rna_UndesignatedPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Undesignated preferred stock.", "label": "Undesignated Preferred Stock [Member]", "terseLabel": "Undesignated Preferred Stock" } } }, "localname": "UndesignatedPreferredStockMember", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rna_UnitsInitiallyReservedForIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Units initially reserved for issuance.", "label": "Units Initially Reserved For Issuance", "terseLabel": "Units initially reserved for issuance" } } }, "localname": "UnitsInitiallyReservedForIssuance", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "rna_UnrecognizedTaxBenefitsOtherTrueUpAdjustment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unrecognized tax benefits other true up adjustment.", "label": "Unrecognized Tax Benefits Other True Up Adjustment", "terseLabel": "Other true up" } } }, "localname": "UnrecognizedTaxBenefitsOtherTrueUpAdjustment", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummarizesOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "rna_UpfrontFeesReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Upfront fees received.", "label": "Upfront Fees Received", "terseLabel": "Upfront fees received" } } }, "localname": "UpfrontFeesReceived", "nsuri": "http://www.aviditybiosciences.com/20211231", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r49", "r51", "r105", "r106", "r233", "r269" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r232", "r268", "r313", "r314", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r528", "r529", "r567", "r568" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesModelToDetermineFairValueOfStockUnitOptionGrantsAndSharesPurchasableUnderESPPDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r232", "r268", "r313", "r314", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r528", "r529", "r567", "r568" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesModelToDetermineFairValueOfStockUnitOptionGrantsAndSharesPurchasableUnderESPPDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r232", "r268", "r304", "r313", "r314", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r528", "r529", "r567", "r568" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesModelToDetermineFairValueOfStockUnitOptionGrantsAndSharesPurchasableUnderESPPDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r232", "r268", "r304", "r313", "r314", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r528", "r529", "r567", "r568" ], "lang": { "en-us": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesModelToDetermineFairValueOfStockUnitOptionGrantsAndSharesPurchasableUnderESPPDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r50", "r51", "r105", "r106", "r233", "r269" ], "lang": { "en-us": { "role": { "label": "Repurchase Agreement Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate202006Member": { "auth_ref": [ "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.", "label": "Accounting Standards Update202006 [Member]", "terseLabel": "Accounting Standards Update 2020-06" } } }, "localname": "AccountingStandardsUpdate202006Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10120.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable And Accrued Liabilities Current", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Accounts Payable And Accrued Liabilities [Member]", "terseLabel": "Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r88" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10180.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion Amortization Of Discounts And Premiums Investments", "negatedLabel": "Amortization of premiums and discounts on marketable securities, net" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r34", "r204" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": { "order": 10020.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r27", "r55", "r56", "r57", "r520", "r537", "r541" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10070.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r54", "r57", "r64", "r65", "r66", "r109", "r110", "r111", "r406", "r532", "r533", "r585" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r25", "r352", "r478" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10060.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid In Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r109", "r110", "r111", "r349", "r350", "r351", "r422" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r113", "r114", "r115", "r116", "r125", "r176", "r177", "r193", "r194", "r195", "r196", "r198", "r199", "r217", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r385", "r386", "r387", "r388", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r446", "r475", "r494", "r495", "r496", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r581", "r582", "r583", "r584", "r585" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Adjustments For New Accounting Pronouncements [Axis]", "terseLabel": "Accounting Standards Update" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options", "terseLabel": "Vesting of early exercise options" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r315", "r317", "r355", "r356" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r317", "r341", "r354" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAllocatedStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r87", "r252", "r259", "r260", "r458" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10190.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization Of Financing Costs And Discounts", "terseLabel": "Amortization of discounts and loan issuance costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Total" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareUnitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareUnitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareUnitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareUnitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsReconciliationOfDeferredRevenueRelatedToLillyAgreementDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r101", "r155", "r164", "r170", "r188", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r402", "r407", "r437", "r476", "r478", "r499", "r519" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r9", "r10", "r48", "r101", "r188", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r402", "r407", "r437", "r476", "r478" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10160.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r425" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Fair Value Disclosure", "totalLabel": "Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r184" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": { "order": 10010.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax", "terseLabel": "Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r185" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": { "order": 10020.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax", "negatedLabel": "Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r182", "r200" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Amortized Cost Basis", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r179", "r183", "r200", "r504" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueDetails": { "order": 10010.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": { "order": 10030.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Securities Debt Securities", "terseLabel": "Marketable securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r319", "r343" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r411", "r412" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis Of Accounting Policy Policy [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r6", "r108", "r149" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description And Basis Of Presentation [Text Block]", "terseLabel": "Description of Business and Basis of Presentation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r92", "r93", "r94" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred But Not Yet Paid", "terseLabel": "Costs incurred, but not paid, in connection with purchases of property and equipment included in accounts payable and accrued liabilities" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalUnits": { "auth_ref": [ "r544" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.", "label": "Capital Units", "periodEndLabel": "Members' equity, balance", "periodStartLabel": "Members' equity, balance" } } }, "localname": "CapitalUnits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalUnitsOutstanding": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Number of capital units or capital shares outstanding. This element is relevant to issuers of face-amount certificates and registered investment companies.", "label": "Capital Units Outstanding", "periodEndLabel": "Members' equity, balance, Units", "periodStartLabel": "Members' equity, balance, Units" } } }, "localname": "CapitalUnitsOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r7", "r31", "r89" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10210.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueDetails": { "order": 10040.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash And Cash Equivalents Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r12", "r90", "r498" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy", "terseLabel": "Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r31" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash Cash Equivalents And Short Term Investments", "terseLabel": "Cash, cash equivalents and marketable securities" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r83", "r89", "r95" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r83", "r447" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental schedule of noncash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates Of Deposit [Member]", "terseLabel": "Negotiable certificates of deposit" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "auth_ref": [ "r0", "r1", "r109", "r110", "r112", "r176", "r177", "r189", "r190", "r191", "r193", "r194", "r217", "r345", "r346", "r347", "r385", "r413", "r414", "r415", "r438", "r440", "r441", "r442", "r445", "r446", "r461", "r475", "r494", "r495", "r530", "r531", "r581" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether accounting standards update was adopted.", "label": "Change In Accounting Principle Accounting Standards Update Adopted", "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "auth_ref": [ "r0", "r1", "r109", "r110", "r119", "r176", "r177", "r189", "r190", "r191", "r193", "r194", "r217", "r345", "r346", "r347", "r385", "r413", "r414", "r415", "r416", "r419", "r438", "r440", "r441", "r442", "r445", "r446", "r461", "r475", "r494", "r495", "r530", "r531", "r581" ], "lang": { "en-us": { "role": { "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.", "label": "Change In Accounting Principle Accounting Standards Update Adoption Date", "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adoption Date" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption": { "auth_ref": [ "r4", "r112", "r177", "r189", "r192", "r195", "r217", "r348", "r386", "r413", "r416", "r419", "r439", "r440", "r443", "r444", "r446", "r461", "r496", "r530", "r531", "r563" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether accounting standards update was early adopted.", "label": "Change In Accounting Principle Accounting Standards Update Early Adoption", "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Early Adoption [true false]" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": { "auth_ref": [ "r113", "r124", "r178", "r197", "r352", "r389" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.", "label": "Change In Accounting Principle Accounting Standards Update Immaterial Effect", "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r99", "r101", "r127", "r128", "r129", "r131", "r133", "r137", "r139", "r140", "r188", "r218", "r222", "r223", "r224", "r227", "r228", "r266", "r267", "r270", "r271", "r437", "r577" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class Of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareUnitDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class Of Stock [Line Items]", "terseLabel": "Class Of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1", "terseLabel": "Exercise price of warrant" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights", "terseLabel": "Warrant to purchase of common stock" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r397", "r398", "r400" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaboration, License and Research Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]", "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsReconciliationOfDeferredRevenueRelatedToLillyAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r43", "r213", "r505", "r524" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10020.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "verboseLabel": "Commitments and contingencies (Note 9)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r210", "r211", "r212", "r215", "r562" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments And Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Shares of common stock reserved for future issuance", "verboseLabel": "Common stock reserved for future issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r109", "r110", "r422" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareUnitDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock, par value", "verboseLabel": "Common stock par value per share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized", "verboseLabel": "Common stock shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r24", "r273" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r24", "r478" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10050.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Common stock, $0.0001 par value; authorized shares \u2013 400,000; issued and outstanding shares \u2013 47,754 and 37,569 at December 31, 2021 and 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components Of Deferred Tax Assets [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "ComponentsOfDeferredTaxAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components Of Deferred Tax Liabilities [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r59", "r61", "r62", "r69", "r507", "r526" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income Policy Policy [Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computers and Software" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r143", "r516" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk Credit Risk", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract With Customer Asset And Liability Table [Text Block]", "terseLabel": "Summary of Reconciliation of Deferred Revenue Related to Lilly Agreement" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r285", "r286", "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract With Customer Liability", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsReconciliationOfDeferredRevenueRelatedToLillyAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r285", "r286", "r298" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10150.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract With Customer Liability Current", "terseLabel": "Deferred revenue, current portion" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r285", "r286", "r298" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10110.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract With Customer Liability Noncurrent", "terseLabel": "Deferred revenue, net of current portion" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r299" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract With Customer Liability Revenue Recognized", "negatedLabel": "Revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsReconciliationOfDeferredRevenueRelatedToLillyAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockAmountIssued1": { "auth_ref": [ "r92", "r93", "r94" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion Of Stock Amount Issued1", "terseLabel": "Conversion of convertible preferred stock into common stock upon completion of initial public offering" } } }, "localname": "ConversionOfStockAmountIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r16", "r500", "r518", "r543" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]", "terseLabel": "Convertible Notes" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r266", "r267", "r270" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]", "terseLabel": "Convertible Preferred Stock" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareUnitDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r305", "r312", "r542" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r92", "r94" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion Converted Instrument Shares Issued1", "terseLabel": "Conversion of convertible note payable to preferred stock", "verboseLabel": "Conversion of convertible notes payable to preferred stock" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r98", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r246", "r253", "r254", "r256", "r261" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r16", "r17", "r18", "r100", "r107", "r229", "r230", "r231", "r232", "r233", "r234", "r236", "r242", "r243", "r244", "r245", "r247", "r248", "r249", "r250", "r251", "r252", "r257", "r258", "r259", "r260", "r459", "r500", "r502", "r518" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument Basis Spread On Variable Rate1", "terseLabel": "Basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r229", "r257", "r258", "r457", "r459", "r460" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument Face Amount", "terseLabel": "Face amount of loans" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r41", "r232", "r429" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument Maturity Date", "terseLabel": "Maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r42", "r100", "r107", "r229", "r230", "r231", "r232", "r233", "r234", "r236", "r242", "r243", "r244", "r245", "r247", "r248", "r249", "r250", "r251", "r252", "r257", "r258", "r259", "r260", "r459" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r42", "r100", "r107", "r229", "r230", "r231", "r232", "r233", "r234", "r236", "r242", "r243", "r244", "r245", "r247", "r248", "r249", "r250", "r251", "r252", "r255", "r257", "r258", "r259", "r260", "r274", "r277", "r278", "r279", "r456", "r457", "r459", "r460", "r515" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Debt Instrument [Table]", "terseLabel": "Debt Instrument [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "auth_ref": [ "r186" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities Available For Sale Realized Gain Loss", "terseLabel": "Realized gains and losses on marketable securities" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities Available For Sale [Table]", "terseLabel": "Debt Securities Available For Sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationLiabilityCurrent": { "auth_ref": [ "r302", "r303" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10130.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.", "label": "Deferred Compensation Liability Current", "terseLabel": "Accrued compensation" } } }, "localname": "DeferredCompensationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.", "label": "Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent", "terseLabel": "Outstanding liability" } } }, "localname": "DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r19", "r20", "r373", "r501", "r517" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "order": 10020.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Income Tax Liabilities", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Income Taxes [Abstract]" } } }, "localname": "DeferredIncomeTaxesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsDeferredIncome": { "auth_ref": [ "r381", "r382" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "order": 10080.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.", "label": "Deferred Tax Assets Deferred Income", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredTaxAssetsDeferredIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r374" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "order": 10040.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r376" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets Liabilities Net", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r376" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "order": 10010.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets Net", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r381", "r382" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "order": 10060.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r379", "r381", "r382" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets Tax Credit Carryforwards", "terseLabel": "Federal and state tax credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r379", "r381", "r382" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "order": 10070.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Deferred Tax Assets Tax Credit Carryforwards Research", "terseLabel": "Research and development tax credits" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r381", "r382" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "order": 10120.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost", "terseLabel": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r381", "r382" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "order": 10090.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r375" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "order": 10050.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets Valuation Allowance", "negatedLabel": "Less valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r87", "r202" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10160.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation", "verboseLabel": "Depreciation expenses related to property and equipment" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Country [Member]", "terseLabel": "Federal" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Basic And Diluted", "terseLabel": "Net loss per share/unit, basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r134", "r135" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share Policy [Text Block]", "terseLabel": "Net Loss Per Share/Unit" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAllocatedStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r342" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized", "terseLabel": "Unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1", "terseLabel": "Weighted-average period of unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Common Stock Options Issued and Outstanding" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareUnitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r64", "r65", "r66", "r109", "r110", "r111", "r114", "r121", "r123", "r136", "r196", "r273", "r280", "r349", "r350", "r351", "r387", "r388", "r422", "r448", "r449", "r450", "r451", "r452", "r453", "r532", "r533", "r534", "r585" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareUnitDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ExtinguishmentOfDebtAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of debt extinguished.", "label": "Extinguishment Of Debt Amount", "terseLabel": "Loans prepaid amount" } } }, "localname": "ExtinguishmentOfDebtAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ExtraordinaryAndUnusualItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Extraordinary And Unusual Items [Abstract]" } } }, "localname": "ExtraordinaryAndUnusualItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r87", "r262" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10220.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10070.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment Of Warrants", "negatedLabel": "Change in fair value of preferred warrant liability", "terseLabel": "Change in fair value of preferred warrant liability" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r425", "r426", "r427", "r433" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": { "auth_ref": [ "r427" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.", "label": "Fair Value Assets Level1 To Level2 Transfers Amount", "terseLabel": "Transfers of assets measured on recurring basis out of Level 1 into Level 2" } } }, "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": { "auth_ref": [ "r427" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.", "label": "Fair Value Assets Level2 To Level1 Transfers Amount", "terseLabel": "Transfers of assets measured on recurring basis out of Level 2 into Level 1" } } }, "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r425", "r426" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value Assets Measured On Recurring Basis [Text Block]", "terseLabel": "Summary of Cash Equivalents and Marketable Securities Measured at Fair Value" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfReconciliationOfPreferredStockWarrantLiabilityMeasuredAtFairValueUsingLevel3UnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r430", "r433" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfReconciliationOfPreferredStockWarrantLiabilityMeasuredAtFairValueUsingLevel3UnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r425", "r433" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Fair Value By Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r244", "r257", "r258", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r426", "r482", "r483", "r484" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfReconciliationOfPreferredStockWarrantLiabilityMeasuredAtFairValueUsingLevel3UnobservableInputsDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r425", "r426", "r428", "r429", "r434" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Fair Value By Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfReconciliationOfPreferredStockWarrantLiabilityMeasuredAtFairValueUsingLevel3UnobservableInputsDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r244", "r305", "r306", "r311", "r312", "r426", "r482" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r244", "r257", "r258", "r305", "r306", "r311", "r312", "r426", "r483" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r244", "r257", "r258", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r426", "r484" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfReconciliationOfPreferredStockWarrantLiabilityMeasuredAtFairValueUsingLevel3UnobservableInputsDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount": { "auth_ref": [ "r427" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.", "label": "Fair Value Liabilities Level1 To Level2 Transfers Amount", "terseLabel": "Transfers of liabilities measured on recurring basis out of Level 1 into Level 2" } } }, "localname": "FairValueLiabilitiesLevel1ToLevel2TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount": { "auth_ref": [ "r427" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.", "label": "Fair Value Liabilities Level2 To Level1 Transfers Amount", "terseLabel": "Transfers of liabilities measured on recurring basis out of Level 2 into Level 1" } } }, "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r430", "r433" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]", "terseLabel": "Schedule of Reconciliation of Preferred Stock Warrant Liability Measured at Fair Value Using Level 3 Unobservable Inputs" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfReconciliationOfPreferredStockWarrantLiabilityMeasuredAtFairValueUsingLevel3UnobservableInputsDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": { "auth_ref": [ "r431" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3", "terseLabel": "Transfers of financial instrument classified as liability into level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": { "auth_ref": [ "r431" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3", "terseLabel": "Transfers of financial instrument classified as liability out of level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": { "auth_ref": [ "r431" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3", "terseLabel": "Transfers of financial instrument classified as asset into level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": { "auth_ref": [ "r431" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3", "terseLabel": "Transfers of financial instrument classified as asset out of level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease", "terseLabel": "Change in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfReconciliationOfPreferredStockWarrantLiabilityMeasuredAtFairValueUsingLevel3UnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r430" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfReconciliationOfPreferredStockWarrantLiabilityMeasuredAtFairValueUsingLevel3UnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r244", "r257", "r258", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r482", "r483", "r484" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfReconciliationOfPreferredStockWarrantLiabilityMeasuredAtFairValueUsingLevel3UnobservableInputsDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r432", "r434" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfReconciliationOfPreferredStockWarrantLiabilityMeasuredAtFairValueUsingLevel3UnobservableInputsDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r435", "r436" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value Of Financial Instruments Policy", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r87" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10200.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain Loss On Sale Of Property Plant Equipment", "negatedLabel": "Gain on disposal of property and equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r72" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10120.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General And Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "terseLabel": "General and Administrative Expense" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAllocatedStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "I P O [Member]", "terseLabel": "Public Offering", "verboseLabel": "Initial Public Offering" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r201", "r207" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment Or Disposal Of Long Lived Assets Policy [Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r206", "r209" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAllocatedStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAllocatedStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r102", "r364", "r371", "r378", "r390", "r392", "r394", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r103", "r122", "r123", "r154", "r362", "r391", "r393", "r527" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesComputedByApplyingStatutoryFederalIncomeTaxRateDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense Benefit", "terseLabel": "Provision for income taxes", "totalLabel": "Income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesComputedByApplyingStatutoryFederalIncomeTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r63", "r360", "r361", "r371", "r372", "r377", "r383" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax Policy [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r363" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesComputedByApplyingStatutoryFederalIncomeTaxRateDetails": { "order": 10100.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance", "terseLabel": "Valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesComputedByApplyingStatutoryFederalIncomeTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r363" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesComputedByApplyingStatutoryFederalIncomeTaxRateDetails": { "order": 10010.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate", "terseLabel": "Income tax expense (benefit) at statutory rates" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesComputedByApplyingStatutoryFederalIncomeTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r363" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesComputedByApplyingStatutoryFederalIncomeTaxRateDetails": { "order": 10110.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Income Tax Reconciliation Other Adjustments", "terseLabel": "Other" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesComputedByApplyingStatutoryFederalIncomeTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r363" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesComputedByApplyingStatutoryFederalIncomeTaxRateDetails": { "order": 10020.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "Income Tax Reconciliation State And Local Income Taxes", "terseLabel": "State income tax, net of federal benefit" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesComputedByApplyingStatutoryFederalIncomeTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "auth_ref": [ "r363" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesComputedByApplyingStatutoryFederalIncomeTaxRateDetails": { "order": 10080.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Income Tax Reconciliation Tax Credits Research", "negatedLabel": "Research and development tax credits" } } }, "localname": "IncomeTaxReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesComputedByApplyingStatutoryFederalIncomeTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r86" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10240.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase Decrease In Accounts Payable And Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r86" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10270.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase Decrease In Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r86" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10250.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase Decrease In Employee Related Liabilities", "terseLabel": "Accrued compensation" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r86" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10230.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r67", "r153", "r455", "r458", "r508" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10060.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r81", "r84", "r91" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid Net", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNonoperating": { "auth_ref": [ "r73" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10050.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.", "label": "Investment Income Nonoperating", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeNonoperating", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investment Type Categorization [Member]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments Debt And Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r187", "r497", "r512", "r560", "r578" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureMarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]", "terseLabel": "Lease Contractual Term" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]", "terseLabel": "Lease Contractual Term" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LegalCostsPolicyTextBlock": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.", "label": "Legal Costs Policy [Text Block]", "terseLabel": "Patent Costs" } } }, "localname": "LegalCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDescription": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Description of lessee's operating lease.", "label": "Lessee Operating Lease Description", "terseLabel": "Operating lease, description" } } }, "localname": "LesseeOperatingLeaseDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to extend operating lease.", "label": "Lessee Operating Lease Existence Of Option To Extend", "terseLabel": "Lessee, operating lease, existence of option to extend [true false]" } } }, "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r473" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee Operating Lease Liability Maturity Table [Text Block]", "terseLabel": "Schedule of Maturities of Lease Liabilities due under 2014 Lease and Temporary Lease" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r473" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnder2014LeaseAndTemporaryLeaseDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnder2014LeaseAndTemporaryLeaseDetails2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee Operating Lease Liability Payments Due", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnder2014LeaseAndTemporaryLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r473" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnder2014LeaseAndTemporaryLeaseDetails": { "order": 10010.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnder2014LeaseAndTemporaryLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r473" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnder2014LeaseAndTemporaryLeaseDetails": { "order": 10050.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Five", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnder2014LeaseAndTemporaryLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r473" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnder2014LeaseAndTemporaryLeaseDetails": { "order": 10040.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnder2014LeaseAndTemporaryLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r473" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnder2014LeaseAndTemporaryLeaseDetails": { "order": 10030.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnder2014LeaseAndTemporaryLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r473" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnder2014LeaseAndTemporaryLeaseDetails": { "order": 10020.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnder2014LeaseAndTemporaryLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r473" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnder2014LeaseAndTemporaryLeaseDetails2": { "order": 10010.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee Operating Lease Liability Undiscounted Excess Amount", "negatedLabel": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnder2014LeaseAndTemporaryLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Renewal Term", "terseLabel": "Operating lease, renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Term Of Contract", "terseLabel": "Operating lease, term of contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters Of Credit Outstanding Amount", "terseLabel": "Letter of credit throughout the lease term" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r38", "r101", "r165", "r188", "r218", "r219", "r220", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r403", "r407", "r408", "r437", "r476", "r477" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r30", "r101", "r188", "r437", "r478", "r503", "r522" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r40", "r101", "r188", "r218", "r219", "r220", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r403", "r407", "r408", "r437", "r476", "r477", "r478" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10090.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r36" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line Of Credit Facility Maximum Borrowing Capacity", "terseLabel": "Loan facility maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Longterm Debt Type [Axis]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r42", "r216" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Longterm Debt Type [Domain]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r213" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual At Carrying Value", "terseLabel": "Loss contingencies accrued" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r8", "r39" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10220.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities Current", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities Policy", "terseLabel": "Marketable Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "auth_ref": [ "r71" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10020.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in marketable security.", "label": "Marketable Securities Unrealized Gain Loss", "terseLabel": "Net unrealized losses on marketable securities" } } }, "localname": "MarketableSecuritiesUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_MembersEquity": { "auth_ref": [ "r137", "r138", "r139", "r140", "r280" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of ownership interest in limited liability company (LLC), attributable to the parent entity.", "label": "Members Equity", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "localname": "MembersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r83" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10030.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r83" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r83", "r85", "r88" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash (used in) provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r5", "r58", "r60", "r66", "r68", "r88", "r101", "r113", "r117", "r118", "r119", "r120", "r122", "r123", "r130", "r155", "r163", "r166", "r169", "r171", "r188", "r218", "r219", "r220", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r424", "r437", "r506", "r525" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10010.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements Policy Policy [Text Block]", "terseLabel": "Recently Adopted and Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r73" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10040.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income Expense", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income Expense [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number Of Operating Segments", "terseLabel": "Number of operating segment" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10100.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r155", "r163", "r166", "r169", "r171" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10030.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r464" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRentExpenseDetails": { "order": 10010.0, "parentTag": "rna_LeaseRentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease Expense", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfRentExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r463" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnder2014LeaseAndTemporaryLeaseDetails2": { "order": 10020.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfROUAssetsAndLiabilitiesRelatedTo2014LeaseAndTemporaryLeaseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease Liability", "totalLabel": "Total lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnder2014LeaseAndTemporaryLeaseDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfROUAssetsAndLiabilitiesRelatedTo2014LeaseAndTemporaryLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r463" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfROUAssetsAndLiabilitiesRelatedTo2014LeaseAndTemporaryLeaseDetails": { "order": 10020.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10140.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease Liability Current", "negatedLabel": "Less lease liabilities, current portion", "terseLabel": "Lease liabilities, current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnder2014LeaseAndTemporaryLeaseDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfROUAssetsAndLiabilitiesRelatedTo2014LeaseAndTemporaryLeaseDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r463" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfROUAssetsAndLiabilitiesRelatedTo2014LeaseAndTemporaryLeaseDetails": { "order": 10010.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10100.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liability Noncurrent", "terseLabel": "Lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnder2014LeaseAndTemporaryLeaseDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfROUAssetsAndLiabilitiesRelatedTo2014LeaseAndTemporaryLeaseDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r465", "r469" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease Payments", "terseLabel": "Cash paid included in operating cash flows" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSupplementalCashFlowInformationRelatedToCashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r462" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10190.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset", "terseLabel": "Right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfROUAssetsAndLiabilitiesRelatedTo2014LeaseAndTemporaryLeaseDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r472", "r474" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease Weighted Average Discount Rate Percent", "terseLabel": "Incremental borrowing rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r471", "r474" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease Weighted Average Remaining Lease Term1", "terseLabel": "Weighted-average remaining term of operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r379" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss (NOL) carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10200.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r52", "r53", "r55" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax", "terseLabel": "Other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r74" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10080.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income Expense", "terseLabel": "Other expense" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": { "auth_ref": [ "r181" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).", "label": "Other Than Temporary Impairment Loss Debt Securities Available For Sale", "terseLabel": "Other-than-temporary impairments on marketable securities" } } }, "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PartnerCapitalComponentsAxis": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Information by partner capital components which are allocated for example, but not limited to accumulated other comprehensive income or comprehensive income.", "label": "Partner Capital Components [Axis]", "terseLabel": "Partner Capital Components" } } }, "localname": "PartnerCapitalComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_PartnerCapitalComponentsDomain": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Partner capital components are the parts of the total Partners' Capital balance including that which is allocated to accumulated other comprehensive income, comprehensive income.", "label": "Partner Capital Components [Domain]", "terseLabel": "Partner Capital Components" } } }, "localname": "PartnerCapitalComponentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PartnersCapitalAccountDistributions": { "auth_ref": [ "r280", "r283" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total distributions to each class of partners (i.e., general, limited and preferred partners).", "label": "Partners Capital Account Distributions", "negatedLabel": "Distribution to members" } } }, "localname": "PartnersCapitalAccountDistributions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r80" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10050.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments Of Stock Issuance Costs", "negatedLabel": "Payment of issuance costs related to public offerings", "terseLabel": "Issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r180" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10120.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments To Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r76" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10140.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r319", "r343" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesModelToDetermineFairValueOfStockUnitOptionGrantsAndSharesPurchasableUnderESPPDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesModelToDetermineFairValueOfStockUnitOptionGrantsAndSharesPurchasableUnderESPPDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r23", "r266" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock Par Or Stated Value Per Share", "terseLabel": "Preferred stock, par value", "verboseLabel": "Preferred stock par value per share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "verboseLabel": "Preferred stock undesignated shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r23", "r266" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r23", "r478" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10040.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock Value", "terseLabel": "Preferred stock, $0.0001 par value; authorized shares \u2013 40,000; issued and outstanding shares \u2013 none" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredUnitsOutstanding": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "The number of preferred units outstanding.", "label": "Preferred Units Outstanding", "periodEndLabel": "Preferred Units, balance, Units", "periodStartLabel": "Preferred Units, balance, Units" } } }, "localname": "PreferredUnitsOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssets": { "auth_ref": [], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10230.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.", "label": "Prepaid Expense And Other Assets", "terseLabel": "Prepaid and other assets" } } }, "localname": "PrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses And Other Current Assets [Member]", "terseLabel": "Prepaid and Other Assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r78" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10110.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds From Convertible Debt", "positiveTerseLabel": "Proceeds from issuance of convertible notes", "terseLabel": "Proceeds from issuance of convertible notes, net of issuance costs", "verboseLabel": "Proceeds from notes" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r77" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds From Issuance Initial Public Offering", "terseLabel": "Proceeds from the IPO, net of underwriting discounts, commissions and offering costs", "verboseLabel": "Proceeds from the IPO, net of underwriting discounts, commissions and offering costs" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r77" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock", "terseLabel": "Net proceeds from Issuance of common stock after deducting offering-related transaction costs and commissions" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r77" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10100.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds From Issuance Of Convertible Preferred Stock", "terseLabel": "Proceeds from issuance of Series C convertible preferred stock, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r78" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds From Issuance Of Long Term Debt", "verboseLabel": "Proceeds from issuance of long-term debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10130.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds From Sale And Maturity Of Marketable Securities", "terseLabel": "Maturities of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r77", "r344" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10060.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds From Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock/unit options, net of repurchases" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r77" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10070.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds From Stock Plans", "terseLabel": "Proceeds from issuance of common stock under employee stock purchase plan" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r5", "r58", "r60", "r66", "r82", "r101", "r113", "r122", "r123", "r155", "r163", "r166", "r169", "r171", "r188", "r218", "r219", "r220", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r401", "r404", "r405", "r409", "r410", "r424", "r437", "r509" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10150.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit Loss", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property Plant And Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r34", "r205" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r208", "r564", "r565", "r566" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property Plant And Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r33", "r203" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": { "order": 10010.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property Plant And Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r13", "r14", "r205", "r478", "r513", "r523" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10170.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "terseLabel": "Property and equipment, net", "totalLabel": "Total property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r32", "r205", "r564", "r565" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property Plant And Equipment Policy [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r13", "r205" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property Plant And Equipment [Text Block]", "terseLabel": "Schedule of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r13", "r203" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property Plant And Equipment Useful Life", "terseLabel": "Estimated useful lives of assets" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r79" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10080.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments Of Long Term Debt", "negatedLabel": "Payments on long-term debt", "terseLabel": "Repayment of existing loan" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r358", "r492", "r569" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10110.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and Development Expense" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAllocatedStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research And Development Expense Policy", "terseLabel": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r11", "r15", "r95", "r561" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10180.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r26", "r280", "r352", "r478", "r521", "r536", "r541" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10080.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r109", "r110", "r111", "r114", "r121", "r123", "r196", "r349", "r350", "r351", "r387", "r388", "r422", "r532", "r534" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r151", "r152", "r162", "r167", "r168", "r172", "r173", "r174", "r296", "r297", "r493" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10090.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue From Contract With Customer Excluding Assessed Tax", "positiveTerseLabel": "Revenue recognized", "terseLabel": "Collaboration revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r97", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r301" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue From Contract With Customer Policy [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.", "label": "Revenue From Contract With Customer Product And Service Extensible List", "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]" } } }, "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r470", "r474" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale Of Stock Number Of Shares Issued In Transaction", "terseLabel": "Sale of stock number of shares issued in transaction" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale Of Stock Price Per Share", "terseLabel": "Sale of stock, price per share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareUnitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]", "terseLabel": "Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share/Unit" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule Of Available For Sale Securities [Line Items]", "terseLabel": "Schedule Of Available For Sale Securities [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule Of Available For Sale Securities Reconciliation Table [Text Block]", "terseLabel": "Summary of Marketable Securities" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]", "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsReconciliationOfDeferredRevenueRelatedToLillyAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]", "terseLabel": "Components of Deferred Tax Assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]", "terseLabel": "Reconciliation of Income Taxes Computed by Applying Statutory Federal Income Tax Rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r317", "r340", "r354" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAllocatedStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r317", "r340", "r354" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Schedule of Allocated Stock-based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r34", "r205" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule Of Property Plant And Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r319", "r343" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesModelToDetermineFairValueOfStockUnitOptionGrantsAndSharesPurchasableUnderESPPDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r324", "r330", "r333" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r44", "r99", "r137", "r139", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r274", "r275", "r276", "r277", "r278", "r279", "r280" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule Of Stock By Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r370", "r384" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]", "terseLabel": "Summarizes of Activity Related to Gross Unrecognized Tax Benefits" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r156", "r157", "r158", "r159", "r160", "r161", "r173" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting Policy Policy [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r86" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10170.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Allocation And Classification In Financial Statements [Abstract]" } } }, "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1", "terseLabel": "Award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesModelToDetermineFairValueOfStockUnitOptionGrantsAndSharesPurchasableUnderESPPDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesModelToDetermineFairValueOfStockUnitOptionGrantsAndSharesPurchasableUnderESPPDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesModelToDetermineFairValueOfStockUnitOptionGrantsAndSharesPurchasableUnderESPPDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum", "terseLabel": "Risk-free interest rate, Maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesModelToDetermineFairValueOfStockUnitOptionGrantsAndSharesPurchasableUnderESPPDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum", "terseLabel": "Risk-free interest rate, Minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesModelToDetermineFairValueOfStockUnitOptionGrantsAndSharesPurchasableUnderESPPDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesModelToDetermineFairValueOfStockUnitOptionGrantsAndSharesPurchasableUnderESPPDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate", "terseLabel": "Participant maximum contribution as percentage of eligible compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract]", "terseLabel": "Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number", "terseLabel": "Exercisable at December 31, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price", "terseLabel": "Exercisable at December 31, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r332" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value", "terseLabel": "Total intrinsic value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period", "negatedLabel": "Forfeited/expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair value of options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r343" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value", "terseLabel": "Outstanding, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r326", "r343" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "periodEndLabel": "Outstanding at December 31, 2021", "periodStartLabel": "Outstanding at December 31, 2020" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward", "terseLabel": "Number of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "periodEndLabel": "Outstanding at December 31, 2021", "periodStartLabel": "Outstanding at December 31, 2020" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward", "terseLabel": "Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r333" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value", "terseLabel": "Vested and expected to vest, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number", "terseLabel": "Vested and expected to vest at December 31, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest at December 31, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r316", "r322" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price", "terseLabel": "Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price", "terseLabel": "Forfeited/expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r319", "r323" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share Based Compensation Option And Incentive Plans Policy", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r335", "r353" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesModelToDetermineFairValueOfStockUnitOptionGrantsAndSharesPurchasableUnderESPPDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r343" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1", "terseLabel": "Exercisable, Aggregate Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1", "terseLabel": "Exercisable, Weighted- Average Remaining Contractual Term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2", "terseLabel": "Outstanding, Weighted- Average Remaining Contractual Term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1", "terseLabel": "Vested and expected to vest, Weighted - Average Remaining Contractual Term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent", "terseLabel": "Percentage of purchase price of shares of lower of fair market value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "auth_ref": [ "r284", "r357" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).", "label": "Shareholders Equity And Share Based Payments [Text Block]", "terseLabel": "Stockholders' Equity (Deficit)" } } }, "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued Price Per Share", "terseLabel": "Stock issued price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares Outstanding", "periodEndLabel": "Balance, Shares", "periodStartLabel": "Balance, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r96", "r108" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State And Local Jurisdiction [Member]", "terseLabel": "State" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r22", "r23", "r24", "r99", "r101", "r127", "r128", "r129", "r131", "r133", "r137", "r139", "r140", "r188", "r218", "r222", "r223", "r224", "r227", "r228", "r266", "r267", "r270", "r271", "r273", "r437", "r577" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Statement Class Of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareUnitDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r47", "r64", "r65", "r66", "r109", "r110", "r111", "r114", "r121", "r123", "r136", "r196", "r273", "r280", "r349", "r350", "r351", "r387", "r388", "r422", "r448", "r449", "r450", "r451", "r452", "r453", "r532", "r533", "r534", "r585" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareUnitDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r109", "r110", "r111", "r136", "r493" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r46", "r247", "r273", "r274", "r280" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period Shares Conversion Of Convertible Securities", "terseLabel": "Conversion of convertible preferred stock into common stock upon completion of initial public offering, Shares", "verboseLabel": "Outstanding shares of convertible preferred stock converted into common stock" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "auth_ref": [ "r23", "r24", "r273", "r274", "r280" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Stock Issued During Period Shares Conversion Of Units", "terseLabel": "Conversion from LLC to C corporation, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r23", "r24", "r273", "r280" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period Shares Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock under employee stock purchase plan, Shares", "verboseLabel": "Shares issued under ESPP" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r23", "r24", "r273", "r280" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of stock, net of issuance costs, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r23", "r24", "r273", "r280" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Stock Issued During Period Shares Share Based Compensation", "terseLabel": "Stock-based compensation, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r23", "r24", "r273", "r280", "r328" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "negatedLabel": "Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r47", "r273", "r280" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period Value Conversion Of Convertible Securities", "terseLabel": "Conversion of convertible preferred stock into common stock upon completion of initial public offering" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "auth_ref": [ "r47", "r273", "r280" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Stock Issued During Period Value Conversion Of Units", "terseLabel": "Conversion from LLC to C corporation" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r23", "r24", "r273", "r280" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period Value Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock under employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r23", "r24", "r273", "r280" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period Value New Issues", "terseLabel": "Issuance of stock, net of issuance costs, Value" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r23", "r24", "r280", "r318", "r331" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock Issued During Period Value Share Based Compensation", "terseLabel": "Stock-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r47", "r273", "r280" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period Value Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r24", "r28", "r29", "r101", "r175", "r188", "r437", "r478" ], "calculation": { "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10030.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders Equity Note Stock Split Conversion Ratio1", "terseLabel": "Stockholders' equity note, stock split, conversion ratio" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Stockholders Equity Reverse Stock Split", "terseLabel": "Reverse stock split, description" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r454", "r480" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r454", "r480" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r454", "r480" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r454", "r480" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r479", "r481" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Subsidiary Sale Of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit", "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r218", "r222", "r223", "r224", "r227", "r228" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Carrying Amount Attributable To Parent", "periodEndLabel": "Temporary equity, balance", "periodStartLabel": "Temporary equity, balance" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Shares Outstanding", "periodEndLabel": "Temporary equity, balance, Shares", "periodStartLabel": "Temporary equity, balance, Shares" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of new stock classified as temporary equity issued during the period.", "label": "Temporary Equity Stock Issued During Period Value New Issues", "terseLabel": "Issuance of Series C convertible preferred stock, net of issuance costs" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockUnitsAndStockholdersMembersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r113", "r114", "r115", "r116", "r125", "r176", "r177", "r193", "r194", "r195", "r196", "r198", "r199", "r217", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r385", "r386", "r387", "r388", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r446", "r475", "r494", "r495", "r496", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r581", "r582", "r583", "r584", "r585" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Type Of Adoption [Member]", "terseLabel": "Accounting Standards Update" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type Of Arrangement [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCollaborationLicenseAndResearchAgreementsReconciliationOfDeferredRevenueRelatedToLillyAgreementDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r104", "r305", "r312", "r510" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "U S Treasury Securities [Member]", "terseLabel": "U.S. Treasury securities" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r359", "r367" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Gross unrecognized tax benefits at the end of the year", "periodStartLabel": "Gross unrecognized tax benefits at the beginning of the year" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummarizesOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r365" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued", "terseLabel": "Accruals for interest or penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r365" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Expense", "terseLabel": "Interest or penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r369" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions", "terseLabel": "Increases related to current year positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummarizesOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r368" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions", "terseLabel": "Increases related to prior year positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummarizesOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an event or transaction that is unusual in nature or infrequent in occurrence, or both.", "label": "Unusual Or Infrequent Items Disclosure [Text Block]", "terseLabel": "COVID-19" } } }, "localname": "UnusualOrInfrequentItemsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureCOVID19" ], "xbrltype": "textBlockItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r141", "r142", "r144", "r145", "r146", "r147", "r148" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r376" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance Deferred Tax Asset Change In Amount", "verboseLabel": "Increase in the valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrant" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareUnitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number Of Share Outstanding Basic And Diluted", "terseLabel": "Weighted-average shares/units outstanding, basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).", "label": "Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation", "terseLabel": "Weighted-average shares/units subject to repurchase or forfeiture" } } }, "localname": "WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aviditybiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r108": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2646-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70258-108054" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r149": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563" }, "r187": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r208": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r212": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751" }, "r215": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r261": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.F)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770" }, "r284": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r301": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19512-108361" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20028-108363" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r357": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r396": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r481": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r497": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803" }, "r512": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04.16(a))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r560": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=123877278&loc=SL120174030-210619" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r570": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r571": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r572": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r573": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r574": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r575": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r576": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r577": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r578": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r579": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r580": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r6": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "220", "URI": "http://asc.fasb.org/subtopic&trid=114868817" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" } }, "version": "2.1" } ZIP 80 0001564590-22-008049-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-008049-xbrl.zip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�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౰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